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ABSTRACT

Monocytes were isolated from the peripheral blood of healthy adult donors,
seronegative for human cytomegalovirus (HCMV), and challenged in vitro under
mycoplasma-free conditions with a laboratory-adapted (AD169) or a clinical
(p72) strain of H C M V .

The ability of challenged monocytes to function as

efficient i m m u n e accessory cells for antigen presentation and cytokine
secretion w a s compared to that of control, mock-challenged monocytes.
HCMV-challenged monocytes demonstrated a reduced ability to present antigen
to autologus T cells and expressed decreased levels of M H C class II HLA-DR
molecules particularly in the presence of augmenting stimuli such as interferon
gamma.

It is proposed that the drop in H L A - D R expression contributed to

decreased antigen presenting ability. Supernatants harvested from H C M V challenged monocytes contained suppressor factors.

O n separation, two

suppressor fractions were obtained which were suppressive for antigenspecific T cell proliferation and for the T cell mitogenic response. Inhibitory
activity w a s detected in fractions of molecular weight 130-180 kDa from
culture supernatants of both control and virus-challenged cells, but the levels
were elevated in the latter. In addition there was a novel suppressor activity
in the fraction of molecular weight 75-100 kDa from the virus-challenged
cultures. This suppressive fraction specifically inhibited T cell interleukin 2
(II2) responsiveness, decreasing the detectable levels of the low affinity p55
( T A C / a chain) component of the high affinity II2 receptor (II2R).

T cells

exposed to this fraction retained the capacity to respond to IL2, only when the
lymphokine w a s added at high levels, apparently through the selective
retention of the intermediate affinity, p75 (p chain) component of the IL2R.
HCMV-challenged monocyte supernatants also contained elevated amounts of
interleukin 1 (IL1), and tumour necrosis factor alpha (TNF a), while levels of
interleukin 6 (IL6) remained unchanged.

At times later than 48h post virus

challenge, increased IL1 levels (as recorded by ELISA) could not be detected in
an IL1 biological activity assay due to the masking influence of the suppressor
factors. Because IL1 and T N F a are potent mediators of the inflammatory
response, elevated levels of these cytokines induced in response to H C M V in
vivo could be associated with the immunopathology associated with H C M V
infection.

Production of suppressor factors active against the T cell

proliferative response could provide a means whereby H C M V has a general
effect on cell mediated immunity and causes generalized immunosuppression in
vivo.
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1.0

INTRODUCTION

1.1 HUMAN CYTOMEGALOVIRUS
1.1.1.

Historical

background.

Cytopathic effects characteristic of cytomegalovirus infection were first
reported in 1904 when enlarged cells containing inclusion bodies were detected in
the kidneys of a stillborn child. Intranuclear and cytoplasmic inclusion bodies were
subsequently detected in the salivary glands, lungs, liver and kidneys of infants that
had died from a variety of causes. Similar cytopathic effects were observed in the
salivary glands of guinea pigs which were subsequently used to establish the viral
aetiology of the disease (reviewed by Apperly and Goldman 1988). In 1956 the
virus was independently isolated by three separate groups giving rise to three of
the most widely used laboratory strains : Smith (Smith 1956), Davis (Weller et al
1957) and A D 169 (Rowe et al 1956). Only one of these isolates was derived from
salivary gland tissue (Smith 1956) and the name of the virus was thus changed
from the original "salivary gland virus" to "cytomegalovirus" , a name taken from
the Greek ('kytos': hollow container or cell and 'megalos': large) to describe the
characteristic cytopathic effect induced in infected cells.

1.1.2. Classification
The cytomegaloviruses belong to the family Herpesviridae, subfamily
Betaherpesvirinae and as a group they show a high degree of morphological
similarity with other members of the Herpesviridae (Wright et al 1964). C o m m o n
features include a central core consisting of double stranded DNA, an icosahedral
protein capsid of 162 capsomeres surrounding the core, an outer lipoprotein
envelope and an amorphous globular tegument layer between the capsid and outer
envelope (Apperley and Goldman 1988). To differentiate between the various
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herpesviruses and between the cytomegaloviruses themselves, more specific
physical and biological characteristics must be defined.

1.1.3. Characteristics of human cytomegalovirus
1.1.3.1. Morphology
The human cytomegalovirus ( H C M V ) genome consists of a ds D N A of 150155 x 1 0 6 daltons (230-240 kbp) with a G + C ratio of 5 6 % which is packaged into a
fibrillar spool to give a core 64 n m in diameter. The icosahedral nucleocapsid is 90
- 110 n m in diameter while the size of the mature enveloped virion ranges from
180 - 250 nm. The D N A consists of a long and a short segment of unique nucleotide
sequences each flanked by a pair of inverted (terminal and internal) repeat
sequences (Stinski et al 1981). During replication the virus undergoes internal
rearrangement to form four different isomers, each of which is found in equimolar
concentrations (Weststrate et al 1980). The H C M V genome has the capacity to code
for about 200 proteins (Rasmussen 1989) although their characterization is
incomplete. The literature on H C M V proteins is extensive and often contradictory
but has recently been thoroughly reviewed by Landini and Michaelson (1988) and
Rasmussen (1989). Viral proteins can be broadly divided into structural proteins
which are largely (but not universally) transcribed after viral D N A synthesis and
non-structural proteins which are transcribed prior to D N A synthesis and which are
responsible for the establishment of infection. These include D N A binding proteins
and enzymes such as D N A polymerase, DNase and protein kinases .

1.1.3.2. Physical properties
H C M V is sensitive to low pH, lipid solvents, heat and ultra-violet light. It
has a half-life of 60 minutes at 37°C. The virus is more stable at 36°C than at 4°C
(Vonka and Benyesh-Melnick 1966)

3
1.1.3.3. Epidemiology
Cytomegalovirus is endemic throughout the world and it has been estimated
that between 2 8 % and 1 0 0 % of a given population over 35 years old will be
seropositive for H C M V (Apperly and Goldman 1988). Variations in seropositivity
can generally be correlated with socio-economic factors, with prevalence
increasing as socio-economic status declines. H C M V can be transmitted in body
fluids such as blood, saliva, urine, semen and vaginal secretions and via blood and
bone marrow products used in transfusions and marrow transplants. Donor organs
such as kidneys and hearts have also been identified as sources of infectious virus.
The risk of acquiring infectious H C M V through transplantation is dependent on the
serostatus of both the donor and the recipient before transplantation. (Reviewed by
Griffiths and Grundy 1988 & Herschman and Cost 1988)

1.1.3.4. Disease characteristics
Primary infection is usually asymptomatic in individuals with normal
immunity but can produce a mononucleosis-like syndrome. Following initial
infection, the virus establishes a persistent yet inapparent infection in a variety of
cells throughout the body (Huang and Pagano 1977). Host immune mechanisms may
be involved in the control of persistence, since immune suppression can lead to
reactivation of the virus. In the immunocompromised individual, primary infection
or reactivation of a previously latent infection can lead to symptomatic and often
life-threatening disease. Immunosuppressed individuals w h o are commonly at risk
include pregnant w o m e n , foetuses, transplant recipients, patients receiving
chemotherapy and other immunosuppressive drugs and victims of the aquired
immunodeficiency syndrome (AIDS) (Hershmann and Cost 1988). Disease sequalae
include interstitial pneumoniltis, colitus, hepatitis, cyctitis, retinitis,
oesophagogastritis, pancreatitis,encephalitis and a variety of haematological
disorders such as atypical lymphocytosis, thrombocytopaenia and neutropaenia
(Weller 1971a & 1971b). Infection of the foetus in utero can lead to congenital
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malformation and severe d a m a g e to the foetal central nervous system. H C M V has
also been associated with the development of a variety of cancers, including
carcinomas (Huang and Roche 1978) and sarcomas (Giraldo et al 1980) and
following the frequent detection of H C M V in AIDS patients (Skolnick et al 1988), the
virus has been implicated in the develoment of the syndrome.

1.1.3.5. Sites of infection
The cellular receptor for H C M V has not been identified to date but proposals
have been put forward. Grundy et al (1987) have shown that H C M V in body fluids is
coated with B 2 microglobulin (B 2 M), the light chain of class I histocompatibility
linked (HLA) molecules, and have suggested that B 2 M bound to H C M V can displace
3 2 M bound to the heavy chain of Class I H L A expressed on the cell surface and
trigger virus internalisation via receptor-mediated endocytosis. If Class I H L A
molecules are the major cellular receptors for H C M V , then the majority of
nucleated cells in the body are potential targets for infection. In vivo , H C M V has
been regularly isolated from organs, body fluids and individual cell types. Organs
include salivary gland, kidney, liver, brain, retina and colon ; body fluids include
blood, urine, semen, vaginal secretions and saliva; cell types include monocytes,
granulocytes, T cells, natural killer (NK) cells, fibroblasts, endothelial cells,
epithelial cells and bone marrow precursor cells (Griffiths and Grundy 1988). In
vitro , fibroblasts, endothelial cells, monocytes, T lymphocytes, N K cells and bone
marrow precursor ceils have all been infected with laboratory adapted and
clinically isolated strains of H C M V . Although endothelial cells have been recently
shown (Waldman et al 1989) to support a full replication cycle and yield infectious
virus, the majority of studies on H C M V replication have been performed using
h u m a n fibroblasts.

5
1.1.3.6 Virus replication cvcle
After adsorption to an as yet unidentified receptor on the cell surface, the
virus enters the cell either via pinocytosis or fusion of viral and cell membranes
within three minutes (Smith and de Harven 1973). Virus replication occurs inside
the nucleus and, after the rapid internalization of the virus, is a relatively slow
process. Host cell R N A polymerase is responsible for transcribing the first viral
genes. The protein products, the alpha or immediate early (IE) proteins, are
required for subsequent viral gene expression including the production of the B or
early (E) proteins expressed prior to - and the g a m m a or late (L) proteins
expressed after - viral D N A replication. Expression of alpha proteins occurs within
2 hours of infection and is controlled by sequences proximal to the promotor which
are cis -activated probably by a trans -acting structural protein (Spaete and
Mocarski 1985). Expression of B proteins is required for viral D N A replication.
About 25 different B proteins with molecular weights ranging from 12-145 kDa
have described by various authors (reviewed by Landini and Michelson 1988) and
m a n y have been characterized as glycoproteins, phosphoproteins, D N A binding
proteins and enzymes (protein kinases and a D N A polymerase). It has not been
conclusively established if all these proteins are novel virus-induced proteins;
s o m e m a y be host cell glycoproteins that are required for viral D N A synthesis
(Radsak et al 1985). D N A replication c o m m e n c e s at about 12 hours post infection,
followed by expression of the g a m m a proteins which are the structural proteins of
the capsid or the spike proteins expressed on the infected cell surface. S o m e
structural proteins m a y also be expressed prior to viral D N A synthesis
(Rassmussen 1989). Capsid assembly occurs after approximately 3 days of
infection. Assembled capsids enter the cytoplasm, migrate to the region of the Golgi
apparatus and are then transported to the cell surface in vesicles. The virion
envelope is aquired intracellular^ but the exact origin of the envelope is uncertain.
It is generally thought that the envelope is aquired upon budding through the nuclear
membrane (Smith and de Harven 1973) but it has also been proposed (Severi et al
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1979) that it is aquired during budding into cytoplasmic membranes. Cell death
occurs about 8 days after infection. The virus is spread predominantly to
contiguous cells resulting in little cell free virus.

1.1.3.7. Pathogenesis
It is important to note that although H C M V m a y be recovered from a
particular disease site, it m a y not be the underlying cause of the clinical symptom.
Griffiths and Grundy (1988) have defined five potential mechanisms whereby H C M V
m a y cause disease in the infected host :
i)

Direct viral lysis of target cells

ii) Lysis of infected cells by cytotoxic T cells (CTC) reactive to viral antigen
expressed on the cell surface. This could occur whether or not the virus proceeded
through the full replication cycle.
iii) Synergism between H C M V and another virus either due to one virus activating
the other or immunosuppression induced by the one virus favouring the survival of
the other virus in the infected host. Synergy has been reported between the human
immunodeficiency virus (HIV) and H C M V .
iv) Activation of host oncogenes by mechanisms such as transactivation, promotor
or enhancer insertion or g e n o m e translocation.
v) Triggering of autoimmunity through induction of C T C responses against host
antigens and expansion of self reactive clones due to polyclonal activation of B or T
cells.

Only the first criterion requires the virus to undergo a full replication cycle. Thus,
a variety of mechanisms exist whereby H C M V pathogenesis can be induced through
persistent infection of a host cell type. Persistence also provides a m e a n s whereby
immune surveillance m a y be largely avoided. Harbouring a persistent infection
could have two potential outcomes : either reactivation to an acute infection stage,
or subtle perturbation ofthe normal functioning of the latently infected cell. The
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criteria listed above m a y be related to disease induced in a variety of body tissues.
Additional mechanisms of pathogenesis include the direct infection of immune
response cells and the consequent perturbation of their functions. Pathogenesis in
this case would be characterised by a generalized immunosuppression and an
increased susceptibility to secondary infection from a range of opportunistic
pathogens. Again, this could be mediated just as well through latent infection of a
cell lineage as by direct ablation of that lineage as a result of cell lysis due to a
productive infection.

1.1.3.8. Immunosuppression
The question of H C M V and immunosuppression is important for two reasons:
Firstly, the consequences of infection are largely dependent on the immune status of
the host at the time of infection. While healthy individuals experience few if any
symptoms, immunosuppressed patients m a y experience a range of clinical
symptoms from a mild febrile illness to severe and often fatal disease syndromes
disseminated to organs throughout the body. Secondly, H C M V is suppressive in its
own right, resulting in increased susceptibility to infection by opportunistic
pathogens such as fungi, protozoa or bacteria and creating favourable conditions for
the reactivation of other viruses that m a y have remained latent in the body due to
host immune surveillance mechanisms.

1.1.4. Infection of immunocompetent cells by HCMV

1.1.4.1. introduction
Functional immune response cells include the leucocytes or white blood
cells in the peripheral blood, their precursors in the bone marrow and the tissue
counterparts of certain peripheral blood lineages. H C M V has been frequently
isolated from the peripheral blood leucocytes of patients with clinical H C M V
infection (Armstrong 1971, Fiala et al 1975, Gadler et al 1982, Garnett 1982,
Lang and Noren 1968, Rinaldo et al 1977, Saltzman et al 1988 & Turtinen et al
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1987) and normal leucocytes have been experimentally infected in vitro by a
number of investigators (Dudding and Garnett 1987, Einhorn and Ost 1984, Kapasi
and Rice 1986, Rice et al 1984, Rodgers et al 1985, Scott et al 1989 & Turtinen
1989). W h e n reviewing the literature pertaining to these investigations, it is
important to note the distiction between :
i) Leucocytes infected in vitro as opposed to those taken from patients with a
clinical illness associated with H C M V infection, and
ii) In vitro infection of leucocytes as a whole as opposed to separate infection of
different functional subsets with subsequent assay of cell-cell interactions.

1.1.4.2. Cell types susceptible to in vitro infection
The experimental techniques use to detect the presence of H C M V in potentially
infected cells have included immunohistochemical methods for the detection of H C M V
specific proteins, or in situ hybridization for H C M V D N A or R N A . It should be
appreciated that these techniques, in particular staining for HCMV-specific protein
products, may not be sensitive enough to fully predict the extent to which a cell
population is infected. It has also been reported (Einhorn and Ost 1984 & Rice et al
1984) that H C M V stocks recently isolated from patients were much more effective
in inducing H C M V specific proteins than the laboratory adapted strain A D 169. This
has led to the suggestion that the established laboratory adapted strains such as A D
169, T o w n e and Davis m a y have developed preferential tropisms for fibroblasts due
to the many in vitro passages through these cells and thus the degree of affinity
that they show for peripheral blood or bone marrow leucocytes m a y not be truly
representative of the cell tropism of the virus in vivo .

The following review has been sub-divided into reports describing the experimental
infection of peripheral blood mononuclear cells ( P B M C ) and peripheral blood
polymorphonuclear cells as heterogeneous cell populations; cells of the monocyte, T
cell and B cell lineages individually; and bone marrow cells. All detection methods
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involved immunohistochemical staining for H C M V immediate early (IE) , early (E) or
late (L) viral antigen.

a) Infection of PBMC:
Einhorn and Ost (1984) reported that when recently isolated P B M C were infected
with A D 169, a m a x i m u m of 0.01% of cells were EA positive as determined by
anticomplement immunofluorescence. This rose to 0.04% if the cells were
precultured for six days before infection. Using certain clinical virus strains,
greater than 2 % of cells were E A positive. Rice et al (1984), using indirect
immunofluorescence to detect expression of the major 72 kDa IE antigen, reported
that depending on the clinical isolate used, from less than 1 % up to 1 5 % of cells
were IE positive. N o late antigen staining could be detected. The majority of the
infected P B M C were monocytes with a small percentage being identified as T cells,
B cells or N K cells. Kapasi and Rice (1986) reported that 3 % of experimentally
infected P B M C expressed IE antigens as detected by indirect immunofluorescence
and that the majority of these cells were monocytes. E and L antigens were not
detected nor w a s infectious virus produced. Scott et al (1989) reported that only
0.2-0.5% of experimentally infected P B M C expressed the major 72 kDa IE antigen.

b) Infection of polymorphonuclear cells:
Einhorn and Ost (1984) reported that no more than 0.1% of an experimentally
challenged population of polymorphonuclear cells expressed H C M V E antigens and
that this w a s due primarily to mononuclear cell contamination.

c) Infection of monocytes:
Following observations that the monocyte appeared to be the mononuclear leucocyte
most frequently infected, several studies investigated in vitro challenge of these
cells using purified or monocyte-enriched populations. Rodgers et al (1985)
reported that even when monocytes were infected at a multiplicity of infection

(moi) as high as 10, no IE, E or L antigens could be detected by immunofluorescence
and no productive virus replication occured. Dudding and Garnett (1987) reported
the detection of low levels (0.01%-0.1% ) of expression of H C M V IE when using A D
169 for monocyte infection, with an increase of 7 % - 9 % of cells IE positive when a
recent clinical isolate was used. Buchmeier and Cooper (1989) on the other hand
were unable to detect H C M V antigens in monocytes infected for 1-7 days with
laboratory adapted or patient-derived virus strains using immunofluorescent
techniques and M A B directed against IE, E and L antigens. Turtinen et al (1989)
found that approximately 0.6% of a population of infected THP-1 cells (a
myelomonocyfic cell line ) expressed H C M V IE as determined by immunoperoxidase
labelling and that approximately 1 % of the cells contained radiolabeled virus
particles. Wahren et al (1986) infected monocytes isolated from the blood of
donors seropositive as well as seronegative for H C M V . Using anticomplement
immunofluorescence for virus antigen detection, they found that the greatest
percentage of monocytes that could be infected from a seronegative donor was 1 2 %
whereas with seropositive donors, as many as 2 5 % of a monocyte population could
be infected.

d) Infection of T and B cells:
Rice et al (1984) reported that although the majority of P B M C expressing H C M V
antigens were monocytes, a small percentage of B cells, N K cells and T cells of the
helper and suppressor phenotype were also infected. W h e n purified T cells were
infected, up to 1 5 % of the cells were positive for the major 72 kDa IE antigen but,
as for monocytes, the infection appeared to be restricted with no expression of L
antigens and no production of infectious virus. T cells have also been separately
infected in vitro by Einhorn and Ost (1984), Schrier et al (1986) and Sing and
Garnett (1984). Braun and Reiser (1986) demonstrated C M V replication in T cells
after allogeneic or IL 2-induced stimulation.
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Furukawal (1979) report a persistently infected B lymphoid cell line with the
continuous release of infectious virus and the presence of C M V positive L antigen
cells. Joncas et al (1981) also detected C M V antigen expression on B
lymphoblastoid cell lines.

e) Infection of bone marrow cells:
Einhorn and Ost (1984) infected freshly isolated bone marrow cells with A D 169
and found that only 0.01%-0.02% of cells were positive for H C M V E antigens using
anticomplement immunofluorescence. This rose to 2 % when the cells were cultured
for 6 days prior to infection. In addition, they found that of the E antigen positive
cells, the majority appeared to be of a mature phenotype and were monocyte- or
macrophage-like.

1.1.4.3. Infection in clinical disease
Attempts have also been m a d e to predict the extent of the interaction
between H C M V and peripheral blood cells by analysing cells isolated from individuals
with clinical disease associated with H C M V infection. The majority of these studies
have shown H C M V to be associated primarily with polymorphonuclear cells with
virus being recovered less frequently or in lesser amounts from mononuclear cells
(Carney and Hirsch 1981, Fiala et al 1975, Fiala et al 1977, Gadler et al 1982,
Howell et al 1979, Rinaldo et al 1982 & Zaia et al 1984). Recent studies indicate
that H C M V exists in different forms within the two cell fractions and that virus
interactions with mononuclear cells m a y be more complex. In 1987 for example,
Turtinen et al recorded the use of in situ hybridization to analyze HCMV-leucocyte
interactions in immunosuppressed individuals with persistent H C M V viremia. They
found that the monocyte was the predominant mononuclear cell harbouring the virus
while on morphological criteria, other infected cells appeared to be small
lymphoctes or large granular lymphocytes. H C M V D N A and IE R N A were detected in
both the cytoplasm and the nuclei of infected cells although infectious virus was not

produced. In the polymorphonuclear cell fraction, neutrophils were identified as the
predominant cell type infected. However, in the infected neutrophils viral D N A was
cytoplasmic only and viral R N A w a s not detected although cells were a source of
infectious virus. This was taken as evidence that neutrophils phagocytose m a n y
virus particles and harbour them in phagosomes for dissemination to secondary
sites. In monocytes on the other hand, the viral D N A is probably released from the
nucleocapsid and subsequently persists. The authors proposed that the life cycle of
H C M V in monocytes in vivo is restricted to early events in the replication cycle
just as it is in vitro . Saltzman et al (1988), using dot-blot hybridization to probe
leucocytes from patients with H C M V viremia, reported that while viral D N A could
be detected in 1 0 0 % and 9 4 % of polymorphonuclear and mononuclear cells
respectively, only 4 7 % of samples enriched for mononuclear cells yielded
infectious virus as compared to 9 4 % of the samples enriched for polymorphonuclear
cells. In addition, although viral D N A was found in mononuclear cells with almost the
s a m e frequency as in polymorphonuclear cells, the amount of D N A w a s significantly
less. The authors interpret these observations as evidence that C M V can exist
within polymorphonuclear cells in a mature infectious form. A recent report by
Danker et al (1989) suggests that H C M V is actively expressed in polymorphonuclear
cells and that these cells m a y be important for dissemination of H C M V in
immunocompromised individuals. These workers also identify monocytes as
important sites of H C M V infection.

Thus, regarding HCMV infection of mononuclear leucocytes, the following
conclusions can be drawn : only a low percentage of cells appear to be infected (at
least as far as current detection techniques would suggest); of the infected cell
population, the monocyte appears to be the predominant cell type; viral replication
appears to be restricted, resulting in a persistent or latant infection; recent
clinical isolates of H C M V appear to be more efficient in establishing infection than
the laboratory adapted strains.
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1.1.5.

HCMV

infection and leucocyte function

A variety of functional defects have been associated with the isolation of
H C M V from the peripheral blood leucocytes of patients with clinical C M V infections

1.1.5.1. Effect on Ivmphocvte blastoaenesis
The peripheral blood leucocytes of patients with C M V mononucleosis show
an impaired proliferative response to mitogen or antigen stimulation (Carney and
Hirsch 1981, Levin et al 1979 & Rinaido et al 1980). Rinaldo et al (1980) showed
that it was adherent mononuclear cells, identified as belonging to the
monocyte/macrophage lineage, that suppressed the concanavalin A (con A)
responses of autologous lymphocytes. This was confirmed in a later report (Carney
and Hirsch, 1981) where the decreased con A responsiveness of unseparated P B M C
from mononucleosis patients could be reproduced by incubating monocytes from
mononucleosis patients with normal lymphocytes.

Attempts have been made to investigate these phenomena in vitro. It has been
demonstrated (Rice et al 1984 & Wahren et al 1986) that in vitro infection of
peripheral blood leucocytes results in decreased mitogen and antigen responsiveness
and that reduced lymphocyte responsiveness is due primarily to a monocyte defect.
Sing and Garnett (1984) have shown that T cells directly infected with H C M V have a
decreased mitogen responsiveness. Carney and Hirsch (1981) and Schrier et al
(1986) demonstrated that monocytes separately infected in vitro showed a
decreased ability to support the proliferative responses of normal T cells. Kapasi
and Rice (1988) further investigated the question of T cell histogenesis by
infecting monocytes or lymphocytes separately as well as infecting the P B M C
population as a whole. They found that when the whole P B M C population was
experimentally infected, the suppression of T cell proliferation ranged from 2 3 % 9 2 % depending on the seronegative donor. To determine the cell type responsible

for immunosuppression, monocytes or lymphocytes were separately infected for
three days and then co-cultured with the uninfected counterpart. Suppression was
observed in both systems but w a s greater when lymphocytes were infected.
Monocytes and T cells were separated purely on the basis of adherence, so it is
possible that a percentage of contaminating monocytes in the lymphocyte-enriched
population m a y have contributed to the immunosuppressive effect.

1.1.5.2. Effect on NK and CTLL activity
Rice et al (1984), Kapasi and Rice (1986) and Schrier et al (1986) have all
reported that P B M C infected in vitro with H C M V show reduced N K activity. Using
depletion and reconstitution studies, it w a s further shown that monocytes were
responsible for this defect. Schrier et al (1986) also report decreased cytotoxic T
lymphocyte lytic (CTLL) activity. H C M V infection did not however alter the
performance of cells with respect to antibody-dependent cell-mediated cytotoxicity
(ADCC) (Rice et al 1984 & Schrier et al 1986).

1.1.5.3. Effect on T cell phenotvpe
Carney and Hirsch (1981) observed a reversal in the ratio of helper to
suppressor T cells in mononucleosis patients. This w a s confirmed by Kim Sing and
Garnett (1984) using in vitro studies.

1.1.5.4. Effect on monocyte function
It has been repeatedly demonstrated that monocytes challenged with H C M V
have the capacity to suppress lymphocyte and N K activity. The question arises as
to what aspects of monocyte function may be responsible for mediating the
suppressive effect, and in this regard the effect of H C M V on monocyte function has
been more extensively studied. Detailed information on these specific monocyte
functions is reviewed in section 1.2.

a) Selected functions:
Garnett (1981) has demonstrated that there is a change in the surface topography
of infected monocytes as viewed by electron microscopy, with infected monocytes
becoming rounded and losing microextensions such as microvilli. Dudding (1986)
examined the effect of H C M V on various monocyte functions. H C M V infection
significantly reduced both adherance and spreading of peripheral blood monocytes as
well as their ability to phagocytose yeast particles, suggesting a disruption of
cytoskeletal elements. Kapasi and Rice (1986) also found that C M V infection
reduced monocyte phagocytic ability as measured by phagocytosis of radiolabeled
erythrocytes and suppressed the attendant respiratory burst / oxygen radical
production as measured by a chemiluminescence assay.

b) Antigen presentation:
An evaluation of the effect of H C M V on the antigen presenting ability of monocytes
should distinguish between those investigations using cells from HCMV-seropositive
donors as opposed to seronegative donors. The lymphocyte D N A stimulation assay
with H C M V antigen in vitro is virus specific and thought to be major
histocompatibility ( M H C ) restricted (Wahren et al 1986); thus, seropositive
patients will have memory T cells specific for H C M V antigen which will respond to
H C M V antigen presented by monocytes in an in vitro assay. T cells from
seronegative donors on the other hand do not respond to H C M V antigen. H C M V
infection of monocytes does not appear to affect their ability to present H C M V
antigen to T cells from seropositive donors (Wahren et al 1986). However, because
this system involves specific stimulation of in vivo primed H C M V lymphocytes, it
differs from investigations involving the ability of monocytes to present other
antigens to T cells.

Buchmeier and Cooper (1989) examined the ability of HCMV infected monocytes to
present a range of other antigens (tetanus toxoid, Candida albicans , and m u m p s

virus antigens) to autologous lymphocytes from seronegative donors. Using a range
of laboratory adapted and patient derived H C M V strains, they found that monocyte
antigen presenting ability w a s impaired with virus infection and in addition there
was suppression of interferon y mediated upregulation of H L A D R and D Q M H C
molecules. The extent of virus influence was questioned however because
suppression w a s only partial and variability in the degree of suppression was
observed when different monocyte populations were infected with virus from the
s a m e source. Regarding donor variability, it was noted that while all donors were
seronegative, the immune status of donors may have differed for a number of
reasons unrelated to HCMV-serostatus and this m a y also have influenced the
outcome of in vitro HCMV-cell interactions. This variability m a y have significance
to the in vivo situation where a variety of co-factors m a y influence the degree of
immunosuppression seen in H C M V infected patients, as m a y the H L A phenotype of
the infected individual. Indeed, differences in mitogen hyporesponsiveness amoung
H C M V mononucleosis patients have been reported (Carney and Hirsch 1981 &
Rinaldo et al 1980). The authors concluded that although a measure of suppression
was observed with H C M V infection, the degree of immunosuppression that could
result from this outcome of direct infection of monocytes is alone not sufficient to
cause the immune hyporesponsiveness of H C M V infected patients.

c) Cytokine production:
W h e n discussing changes in cytokine production, it is important to distinguish
between changes in the production of a cytokine per se and changes in the biological
activity of that cytokine; the latter phenomenon

being susceptible to influence from

additional stimulatory or suppressive soluble factors that m a y be concurrently
produced and mask the true biological activity of the cytokine under study. It has
been widely suggested that the suppressive effect of H C M V infected monocytes is
due at least in part to a virus-induced alteration in one or more of the range of
cytokines normally produced by monocytes. The cytokine that has been the most

widely studied to date is interleukin 1 (IL 1). In 1985, Rodgers et al reported that
in vitro infection of both peripheral blood monocytes and a monocytic (U937) cell
line with A D 169 abrogated their constitutive production of IL 1 activity. The IL 1
activity in supernatants generated from monocytes over a three day infection
period w a s measured by a conventional murine thymocyte assay. Infectious virus
w a s required for this effect but it w a s observed in the absence of virus replication
or detectable virus protein expression. It w a s suggested that this w a s due to the
release of a protein inhibiting IL 1 activity and column fractionation of crude
monoctyte supernatants indicated that this inhibitory substance had an apparent
molecular weight ( M W ) of 95 kDa. The potential m o d e of action of this inhibitor was
investigated and it was found to inhibit thymocyte proliferation induced by con A, a
crude monocyte supernatant or purified IL 1. It did not however effect the
interleukin 2 (IL 2)-mediated proliferation of IL 2-dependent P H A blasts. This data
suggested that the inhibitor w a s acting directly against IL 1 although the authors did
not rule out the possibility of inhibition of con A/IL 1-induced production of
thymocyte IL 2. The above studies were conducted on monocytes that had not been
stimulated in vitro with lipopolysaccharide (LPS). Dudding and Garnett (1987)
compared the effects of H C M V challenge on the IL 1 activity of LPS-stimulated and
unstimulated monocytes. Infection of both stimulated and unstimulated monocytes
with A D 169 or a clinical isolate of H C M V resulted in a marked reduction in the IL 1
activity of three day monocyte supernatants. Similarly, stimulated and
unstimulated monocytes were suppressive for the autologous T cell response to
PHA. Both these phenomena were more marked in L P S stimulated monocytes. The
suppressive effect of L P S stimulated infected monocytes on T cell mitogen
responsiveness could be reversed by reconstituting cultures with IL 1, whereas the
suppressive effect of unstimulated monocytes could not be similarly overcome.
Thus, these results also suggested the production, at least by unstimulated
monocytes, of an inhibitor of IL 1 activity. Kapasi and Rice (1988) reported
decreased IL 1 activity in supernatants from infected P B M C cultures and monocyte

cultures alone. These supernatants were suppressive for lymphocyte proliferative
responses and suppression could not be overcome by addition of IL 1 or IL 2,
suggesting the presence of an inhibitor. The fact that supernatants did not affect
the IL 2 activity of a standard IL 2 preparation suggested that the inhibitor was
directed against IL 1 activity. In 1989, the group that originally suggested the
presence of a specific inhibitor of IL 1 activity (Rodgers et al 1985) attributed the
production of this inhibitor to mycoplasma contamination of virus stocks (Scott et al
1989). They proposed that M. hyorhinis, the contaminating mycoplasma strain,
m a y release a pyrimidine-specific nucleoside phosphorylase which causes
degradation of thymidine, thus giving reduced c p m in T cell proliferation assays.
Scott's group further reported that infection of monocytes with mycoplasma-free
virus strains gave negligible suppression. Similarly, Buchmeier and Cooper (1989)
found no significant change in the IL 1 activity of supernatants of H C M V infected
monocytes as compared to mock infected controls and also reported the enhanced
immunosuppressive effect of infection with mycoplasma-contaminated as opposed to
mycoplasma-free virus stocks. It has been suggested that mycoplasma
contamination of H C M V stocks m a y be more widespread than w a s previously
recognised, and it appears that all data collected to date should be evaluated in this
light.

Turtinen et al (1989) provide the first published report of cytokine upregulation as
a result of H C M V infection. Working with the myelomonocytic cell line THP-1, they
found that H C M V infected cultures released almost 2-fold more IL 1 B and 2.5-fold
more tumour necrosis factor a (TNF a ) than uninfected cells. T N F a and IL 1 B
were measured using specific ELISA, thus providing the first report of direct assay
of cytokine production as opposed to an inference of amounts as obtained from
biological activity. In addition, T N F a and IL 1 B m R N A levels were measured and
found to be significantly higher in infected cells. However, only 1 % of THP-1 cells
expressed H C M V IE proteins and these cells did not overexpress IL 1. This led the

authors to speculate that the influence of H C M V on IL 1 release is indirect and that
T N F a or other as yet undefined factors released in excess by H C M V infected
monocytes m a y cause a rise in IL 1 B in the whole monocyte population. They
further speculate that the decreased IL 1 activity described by others m a y actually
reflect alterations in IL 1 inhibitor levels as a result of H C M V infection.

1.2 MONOCYTES
1.2.1

Introduction
Peripheral blood monocytes and their tissue counterparts the macrophages

are integral components of the cellular network responsible for mediation of both
specific and non-specific immune response mechanisms. The ability to function as
both a secretory and a phagocytic cell has enabled the monocyte to perform this
central and varied role. Phagocytic functions include ingestion and killing of
intracellular parasites and extracellular pathogens, ingestion and elimination of
damaged or dying cells and the engulfment of foreign antigen into specialized
vesicles for processing and subsequent presentation to T cells. Secretory functions
include the secretion of lysosomal enzymes, cytolytic proteinases, toxic oxygen
metabolites such as superoxide anion and hydrogen peroxide, and specific cytokines
both for microbiocidal or tumouricidal action and for the mediation of inflammatory
and immune responses (Kaplan 1983; Musson et al 1980; Nakagawara 1981 &
Schnyder and Baggiolini 1978). Included in this functional repetoire therefore is the
capacity of the monocyte both to present antigen and deliver stimulatory cytokines
to immune effector cells and to secrete cytokines that function directly as effector
molecules, and thus to function as an efficient and indispensable immune accessory
cell.

1.2.2.

Origin and

development

Monocytes originate from the bone marrow which, as a source of
regenerating tissue and soluble regulatory elements comprising a finely balanced
microenvironment, is known as the haemopoetic system. The haemopoetic system
has three main levels of organization; there is a stem cell compartment which is
the source of developmental^ restricted progenitor cells with the capacity to
proliferate and develop into mature blood cells. In the case of monocyte
development, the bone marrow progenitor cell is a granulocyte-macrophage colony
forming unit (CFU-GM) which, under the influence of colony stimulating factors
(CSFs), differentiates into a monoblast and then a promonocyte. After a bone
marrow transit time of approximately six days, mature monocytes enter the blood
stream where they have a half life of about three days (Johnston 1988). The blood
monocytes have the capacity to undergo diapedesis across the endothelial wall of
blood vessels and so enter the tissue. In the absence of a localized inflammatory or
immune response, migration of monocytes into the tissue is a random process and
once in the tissue, monocytes do not re-enter the circulation (Van Furth et al 1979).
During an infection or in response to tissue injury, chemoattractants released by
neutrophils and lymphocytes at the site of inflammation induce monocytes to
migrate more vigorously and specifically to the localized trauma site. Once in the
tissue, monocytes undergo transformation to tissue macrophages. Because
macrophages in different tissue systems have distinct morphological and functional
features, it is probable that certain transformation stimuli are tissue specific.
Under conditions of infection or injury, resting tissue macrophages are induced by
various stimuli to an "activated" state; a process that involves morphological and
biochemical changes and an associated enhancement of the macrophage functional
repetoire (Carlson and Prydz 1988 & Nathan et al 1984).

1.2.3

Monocyte/macrophage

activation

The process of activation involves the transformation of quiesent or
resting monocytes/macrophages into larger, more metabolically active cells with
an enhanced functional capacity. Specifically, activated cells aquire an enhanced
phagocytic (Karnovsky and Lazdins 1978) and secretory (Nathan et al 1987)
ability, which includes an increased respiratory burst for the production of oxygen
metabolites, elevated expression of H L A class 2 molecules necessary for effective
antigen presentation (Unanue and Allen 1987), and enhanced cytokine production
(Dinarello 1985). As a consequence, activated monocytes and macrophages become
more efficient mediators of non-specific defense mechanisms and specific
immunological events.

In vitro activating agents have been shown to include bacterial endotoxin, phorbol
esters, zymosan, immune complexes and cytokines (either derived from mitogenstimulated T cells or recombinant products). In vivo stimuli include infectious
agents, tumours, contact with other immune cells or their cytokines, autoimmune
disease and over-exposure to irritants (Schnyder 1981). The c o m m o n feature of
all these stimuli is that they induce activating cytokines from lymphoid and myeloid
cells such as IFN y and granulocyte-macrophage colony stimulating factor (GM-CSF)
from T cells (Nathan et al 1984), and T N F a from monocytes (Beutler and Cerami
1987). The ability of T N F a to act as a macrophage activating factor m a y allow
monocytes or macrophages at the site of an infection to activate themselves, thus
facillitating a more rapid and extremely localized attainment of enhanced function
(Johnston 1988).

A more recent and as yet only partially characterized marker of activated
monocytes/ macrophages is the expression of a receptor thought traditionally to be
restricted to cells of the T cell lineage, the interleukin 2 receptor (IL 2R). IFN y has
been shown to induce IL 2R on human peripheral blood monocytes (Hermann et al

1985, Holter et al 1986 & Holter et al 1987), alveolar macrophages (Hancock et al
1987) and monocytic cell lines (Hermann 1985 & Hancock et al 1987). Holter et al
(1986) report that although freshly isolated monocytes are IL 2R negative, in vitro
culture is sufficient to induce RIL 2 synthesis and expression in approximately one
third of monocytes, with IFN y treatment doubling expression levels. Hancock et al
(1987) demonstrated that alveolar macrophages could also be induced to express IL
2R by IFN Y stimulation and to a lesser extent by IL 2 itself, and that alveolar
macrophages from patients with the inflammatory condition

pulmonary sarcoidosis

expressed similar levels of IL 2R without in vitro stimulation. In 1987, Holter et
al showed that L P S stimulation was alone a potent inducer of IL 2R on monocytes,
but that L P S and IFN y had an additive effect regarding both the number of receptorpositive cells and the number of IL 2R per cell. In the same report, they
demonstrated the presence of soluble IL 2R in the supernatants of activated
monocytes. The functional significance of these observations is not yet clear, but
Hermann et al (1985) have speculated that receptor-positive monocytes m a y
adsorb IL 2 at inflammatory sites, thus initiating a negative feedback loop. Holter
et al (1987) showed that monocytes exposed to recombinant IL 2 showed an
increased production of oxygen metabolites, suggesting that IL 2 m a y function as an
additional monocyte activating agent for enhanced microbiocidal/tumouricidal
function. A further possible functional mechanism has been suggested by Pleau and
Hancock (1989) w h o demonstated that incubation of IL 2R-positive monocytes with
IL 2 greatly enhanced IL 1 production. The existence of an associated negative
feedback loop has however also been postulated, whereby enhanced IL 1 levels may
stimulate G M - C S F and/or prostaglandin (PG) production, both of which have the
potential to downregulate monocyte IL 2R expression (Hancock et al 1987).

1.2.4

The monocyte as an immune accessory cell
1.2.4.1. Antigen processing and presentation
a) Introduction

While B cells express receptors that are surface m e m b r a n e versions of serum
immunoglobulins that can directly bind soluble antigen, the T cell receptor is a
heterodimer with different recognition requirements (Germain, 1986). Thus, while
antibodies tend to be produced in response to native proteins, in the T cell response
only specific determinants on the foreign antigen are recognized and these are
generally not accessible on the native antigen. T h e antigen must therefore first
undergo processing to expose the relevent determinants which are then preserved
and presented to the T cell in a recognizable form. Such a recognizable form is one
in which the specific antigenic determinants are presented in close association with
autologous molecules of the M H C gene complex. For proliferation in response to
recognized antigen, T cells require additional cell-associated and soluble activating
stimuli. These T cell recognition and response criteria require accessory cells
firstly to take up, process and present foreign antigen in the context of surface
M H C molecules, and secondly to supply the requisite secondary signals for T cell
proliferation and hence clonal expansion.

In addition to monocytes, certain other cells have the capacity to act as antigen
presenting cells (APC) under the appropriate conditions. These cells include B cells,
endothelial cells, dendritic cells, skin Langerhans cells and liver Kupffer cells
(Unanue 1984).

b) MHC restriction
Rosenthal and Shevach (1973) showed that antigen-specific T cells could only
recognize antigen presented by accessory cells bearing the s a m e M H C class II
molecules. T-B cell interactions are also class II restricted (Babbitt et al 1985). In
contrast, cytotoxic T cell (CTC) recognition and lysis of target cells w a s shown to

be M H C class I restricted (McMichael 1980). Both classes of M H C molecules are
encoded within the M H C gene complex region located on the short arm of
chromosome 6 in man. The class I restricting elements include the HLA-A, B and C
molecules and are coded for by genes at three linked loci (Reisfeld and Ferrone
1981). The class II restricting elements or immune associated (la) molecules
include the gene products of the DR, D Q (DS) and D P (SB) loci. D R and D Q in m a n are
equivalent to mouse l-E and l-A molecules respectively. Although class II M H C
genes are generally recognized as immune response (Ir) genes (Benacerraf 1988),
HLA-DR molecules at least are expressed not only on cells of the immune system
but also on a variety of tissue cells with no traditional immunological function. It is
not surprising therefore that additional characteristics are required for a cell type
to qualify as a functional A P C .

c) Antigen processing
Ziegler and Unanue (1981), using monocytes as A P C and the bacterial antigen
Listeria monocytogenes,

showed that formaldehyde-fixed A P C were able to present

antigen to T cells only if an obligatory processing period was allowed to occur prior
to fixation. They further showed that treatment of monocytes with lysosomotropic
agents such as chloroquine or a m m o n i u m sulphate inhibited antigen-presenting
ability. Lysosomotropic agents are weak bases that alkalinize intracellular acidic
vesicles, thus inhibiting function. This includes inhibition of lysosomal/endosomal
catabolism, endosome fusion and vesicle recycling. The identification of a lag phase
before effective antigen presentation combined with the ability of lysosomotropic
agents to disrupt presentation argued for a necessary period of antigen processing
within acidic intracellular compartments. Shimonkevitz et al (1983) presented
further evidence for an antigen processing event by demonstrating that the protein
albumin, after enzymatic degredation, could be presented to T cells by autologous
but metabolically inactive A P C .

A s well as M H C Class II restricted antigen presentation, Unanue (1984) has also
described two M H C unrestricted, chloroquine insensitive forms of exogenous
antigen handling; in the first instance the immunogenic molecule is surface bound to
the monocyte and can be internalized and recycled to the surface without entry into
chloroquine-sensitive compartments; while in the second instance the molecule is a
soluble protein or protein fragment in the immediate extracellular fluid and is
thought to represent a small amount of an internalized protein pool. In neither
instance is the protein fragment available for presentation to T cells, but instead
represents a source of easily accessible molecules that can be further processed by
the s a m e monocyte or other A P C for subsequent M H C restricted presentation. B
cells for instance, which m a y have difficulty internalizing large particulate matter,
m a y interact with the partially altered soluble particles released by monocytes.

Studies have shown that certain antigens, human fibrinogen for example (Allen
1987), can be presented without any apparant processing requirements, and it has
even been proposed that antigens do not have to be processed at all. To reconcile
the sometimes conflicting data on antigen processing requirements, Allen (1987)
has presented an operational definition of antigen processing whereby antigen
processing is seen as any "change in an antigen which affords it the conformational
freedom to form a secondary structure which will allow the agretope (or H L A class
II molecule contact site) and the epitope (or T cell receptor contact site) to form".
O n this basis, Allen has proposed that there are three basic levels of processing
depending on the status of the antigen :
i) A level where no processing is required because in the native state the antigen
has sufficient conformational freedom to form both an agretope and an epitope.
H u m a n fibrinogen is such an example.
ii) A level where processing involves only denaturation to unfold the peptide chains
and expose agretope and epitope. This has been shown to be sufficient for antigens
such as lysozyme, myoglobin and ribonuclease.

iii) A level where processing involves peptide denaturation and degradation through
proteolytic cleavage. This has been shown to occur with ovalbumin, insulin and
cytochrome C, and also with lysozyme, myoglobulin and ribonuclease.
In the light of the above, it is probably not necessary to restrict a protein to a
single processing requirement because the immunogenic determinants m a y differ
depending on the T cell recognition system, and different determinants m a y have
distinct processing requirements.

Distinctions have also been drawn between processing of endogenous and exogenous
antigens (Gerlier and Rabourdin-Combe 1989). Most endogenous proteins are
proteolytically degraded via neutral, non-lysosomal pathways. Exogenous proteins
on the other hand are engulfed into early endosomes which subsequently fuse with
Golgi-derived endosomes. Acidification of the fused endosomes is thought to
activate the processing proteases. It has also been proposed that the biosynthetic
pathway for M H C class II molecules m a y intersect the endosome pathway. Although
endogenous and exogenous antigens are preferentially presented by M H C class I and
class II molecules respectively, class II association has also been observed for
endogenous molecules, and class II restricted cytotoxic T cells m a y develop in
response for instance to certain viral infections.

d) Expression of MHC Class II molecules
The expression of class II H L A molecules on the monocyte surface is not
constitutive; it depends upon the location, age and activation state of the monocyte
and, within a certain phenotypic state, is subject to further modulation by up- and
down-regulating influences. The initial studies on regulation of class II molecules
were performed on the I region encoded molecules on mouse and rat macrophages:
the l-E and l-A molecules which were also originally called the la molecules. It was
found that each tissue had a characteristic ratio of la positive to la negative
macrophages that reflected the balance of stimulatory and inhibitory la expression

stimuli (Unanue 1984). Maintenance of the la positive state required initial
activation and then the continual presence of the stimulus. The primary in vivo
stimulus for la induction w a s found to be the T cell lymphokine IFN y (Steeg et al
1982 & Virelizier et al 1984) while inhibitors included corticosteroids,
prostaglandins (Snyder et al 1982), endotoxin (Steeg et al 1982). Studies with
h u m a n monocytes showed similar phenomena whereby class II H L A molecules
decayed rapidly in culture in the absence of stimuli and could be increased by IFN y
and inhibited by endotoxin (Sztein et al 1984 & Y e m and Parmely 1981).

It has been repeatedly shown that changes in expression of class II HLA molecules on
the surface of an A P C correlates with the antigen presenting capacity of the A P C
(Beller and H o 1982, Beller 1984, Bergholtz and Thorsby 1978, G o n w a et al
1983, Koide et al 1981 & Zlotnik et al 1983) and that a threshold level of class II
expression m a y have to be reached in order for a given T cell to be activated
(Lechleret al 1988). Beller (1984) for example demonstrated that culture-induced
loss of class II H L A resulted in decreased antigen presentation while IFN y-induced
expression caused a proportional restoration of accessory cell function. The
central role of IFN y in modulation of antigen presentation is important in that it
implies the existence of an amplification loop (Unanue, 1984) whereby Class II
positive cells present antigen which activates T cells to secrete IFN y, thereby
increasing the percentage of class II H L A positive cells in the immediate
environment.

e) Co-stimulatory signals
These involve M H C - n o n restricted mechanisms and include both cell-associated
molecules and soluble cytokines. Monocytes express surface molecules that are
involved in antigen independent contact with T cells, thus overcoming the natural
repulsion between cells and facillitating contact between presented antigen and the T
cell receptor. The best characterized of these molecules is the intercellular

adhesion rnolecule-1 (ICAM-1), the ligand for lymphocyte function associated
antigen-1 (LFA-1) which is expressed on the surface of the T cell (Makogoba et al,
1989). The interaction between these molecules m a y be particularly important
when the concentration of antigen on the A P C is limiting.

Monocytes also produce a selection of cytokines, either constitutively or after
appropriate stimulation. Those that play a key role in immunological and/or
inflammatory responses include IL 1, T N F a, interleukin 6 (IL 6), platelet activating
factor (PAF) and transforming growth factor B (TGFB); all of which are discussed
in detail in section 1.3. of this review.

1.2.4.2. Cytokine responsiveness
As well as producing cytokines, the ability of monocytes to respond to
cytokines is integral to their function. Those cytokines that have the most
influential effect on monocyte immune function include factors produced by
monocytes themselves and factors produced by other immunologically active cells
including IFN y, interferon a/B (IFN a/B), interleukin 4 (IL 4) and others.
Information pertaining to this aspect of monocyte function has also been included in
Section 1.3..

1.3 CYTOKINES
1.3.1

General

Introduction

Cytokines can be broadly defined as a heterogeneous group of molecules
that control the growth and differentiation and/or function of cells of the
haemopoetic and lymphoid lineages as well as many non-lymphoid cell types.
Despite the heterogeneity of this group of proteins, there are s o m e c o m m o n
characteristics:

i) Cytokines are generally low molecular weight (< 80 kDa) single chain
polypeptides which are often glycosylated and m a y group to form heterodimers.
ii) They are usually produced locally and for a regulated, transient period.
They act in an autocrine or paracrine way and m a y have both systemic and local
effects.
iii) Most of the cytokine-specific m R N A s are undetectable unless the
producer cells are appropriately stimulated. Induction of transcription does not
generally require de novo

protein synthesis, thus implying that an extracellular

induction stimulus results in the activation of transcriptional machinery through
the modification of pre-existing activators or repressors. While a cytokine m a y
be induced by a variety of stimuli, different control elements in the genes m a y be
responsive to the different induction mechanisms.
iv) T h e majority of cytokine genes are only transiently transcribed and the
m R N A species havs a relatively short half-life as compared to other m R N A s . For
example, B globin m R N A has a half-life of 17 hours while that of G M - C S F in P H A
stimulated T cells is less than 30 minutes (Miyajima et al 1988). Specific
message stabilizing mechanisms and degradation pathways exist and these play a
crucial role in controlling the level and duration of cytokine production. m R N A
processing mechanisms represent another level of post-transcriptional control.
v) Cytokines interact with specific high affinity receptors on the target cell
surface and are active at very low concentrations. Modulation of receptor
expression is another strategy for control of cytokine activity.
vi) Receptor binding leads to intracellular signal transduction resulting in
changes in cell R N A and protein synthesis and ultimately in altered cell behaviour.
vii) The magnitude of the response to a given cytokine is subject to
modulation from other stimuli to which the target cell m a y have been pre- or
concurrently exposed.

viii) Certain cytokines m a y synergize with others allowing for responses
that are greater than the additive response of the individual components or
allowing for activity at low concentrations that would be inactive alone.
ix) The ability of cytokines to enhance or suppress the production and/or
action of other cytokines has allowed for the development of a complex network of
feedback and cascade systems.

The bulk of the current knowledge on cytokines and their biological activities has
c o m e from in vitro studies frequently involving an ill-defined mixture of
cytokines, thus making definition of the activity spectrum of any one particular
cytokine difficult, as well as confounding cause and effect relationships.
Alternatively, with the advent of recombinant D N A technology, cytokines have
also been studied in isolation, thus negating the contributory influences of other
cytokines that m a y be required to demonstrate the true functional repetoire of the
particular cytokine under study. So, although cytokine activities that have been
demonstrated in vitro have a potential in vivo function, it is difficult to predict
the true role of a cytokine in the in vivo situation w h e n a cell would be exposed to
an array of different and perhaps contradictory messages. Differences in
responsiveness of different cell types to the individual components of a cytokine
mixture m a y allow for cell-specific differences in the pattern of responsiveness
within a tissue or localised body region. The information presented in the following
review on cytokines and their biological function should be evaluated with these
comments in mind.

1.3.2. Colony Stimulating Factors
During normal steady-state haemopoesis, the level of mature blood cells is
maintained primarily through amplification of the committed progenitor stem cell
compartment. If the level of mature cells drops, or if increased levels of cells are
required for the initiation and maintenance of an immune or inflammatory

response, then stem cells are also recruited into an active state. Ultimately, this
allows for restoration of normal levels, or for mature cells to be produced from
the bone marrow in increased amounts over steady state levels for delivery to
areas of inflammation (Cannistra and Griffin, 1988). In both cases, the
functionally mature cells are derived from a pool of committed haemopoetic
progenitor cells under the influence of a heterogeneous family of glycoproteins, the
colony stimulating factors (CSFs). There are four major C S F s : interleukin 3 (IL
3), granulocyte macrophage C S F (GM-CSF), granulocyte C S F (G-CSF) and
macrophage C S F (M-CSF) (Schrader 1988). IL 6 has also been shown to have a
degree of colony stimulating activity (Bendtzen 1988).

At the site of an infection, monocytes and T cells are activated by the invading
pathogen to produce C S F s or to produce secondary mediators that provide signals
for the induction of C S F production by cells in the local microenvironment and in
the bone marrow stroma (Metcalf 1989). This allows for increased proliferation
and differentiation of progenitor bone marrow cells as well as for the activation
and enhanced effector function of the mature myeloid cells collected at the area of
infection. The monocyte-derived cytokines interleukin 1 (IL 1) and tumour
necrosis factor a (TNF a) are the major humoral factors involved in stimulating
C S F secretion from the source cells. They m a y also synergise with the C S F s for
enhanced function and their production m a y in turn be upregulated by C S F s
(Cannistra and Griffin 1988). Thus, due to the action of the CSFs, large numbers
of myeloid cells are produced within the bone marrow microenvironment, migrate
to the site of inflammation and are activated for eradication of infection.

The sources and major activities of the CSFs are summarised in the following table
(adapted from Cannistra and Griffin 1988, Miyajima 1988, Lindemann et al 1988
& Metcalf, 1989).
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BIOLOGICAL CHARACTERISTICS OF THE CSFs.

FACTOR

Mr

MAJOR

BIOLOGICAL ACTIVITY

SOURCES
IL3

14-15 kDa;

Activated T

Multi-CSF : stimulation of neutrophil,

(species

up to30 kDa

cells

eosinophil, monocyte, megakaryocyte,

specific

with variable

erythroid and mast cell (mouse) colony

action)

glycosylation

formation.
Burst promoting activity.
Growth factor for haemopoetic cell lines.
Stimulation of eosinophil A D C C ,
phagocytosis and superoxide production. I
Histamine producing-cell stimulatory
activity and histamine release activity.

GM-CSF

22 kDa;

Activated T

Stimulation of neutrophil, eosinophil and

(species

14-30 k D a

cells

monocyte colony formation.

specific

with variable

Endothelial

Burst promoting activity.

action)

glycosylation

cells

Growth factor for haemopoetic cell lines.

Fibroblasts

Growth inhibitor for monocytic (U937)

Monocyte

cell line due to induction of autoinhibitory

cell lines

factors.

Stroma

Stimulation of neutrophil and eosinophil

cells

A D C C and phagocytosis.
Expression of neutrophil C D 11b.
Enhancement of monocyte tumouricidal
and cytotoxic activity.
Induction of T N F a, IL 1 and M - C S F from
monocytic cell lines.
Histamine release activity.

G-CSF

19.6 kDa

Endothelial

Stimulation of neutrophil colony

cells

formation.

Fibroblasts

Stimulation of neutrophil A D C C and

Monocytes

superoxide production.

macrophage
Stromal
cells
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M-CSF

47-94 kDa;

Endothelial

glycosylated

cells
Fibroblasts

homodimer

Monocyte/

Stimulation of monocyte colony
formation.
Stimulation of monocyte A D C C and
cytotoxicity.

macrophage
Stromal
cells

1.3.3 T Cell Derived Cytokines
The first step in T cell activation and clonal expansion involves triggering of
the T cell antigen receptor/CD 3 complex by specific antigen (or in vitro via
mitogen or anti-receptor antibodies) in the presence of soluble T cell-activating
factors such as IL 1, IL 6 and T N F a. This, and possibly triggering of other T cell
surface molecules, allows for signal transduction and the generation of
intracellular signals. Accessory cells such as monocytes process and present
antigen, express other necessary T cell-triggering surface molecules and are
immediate sources of the T cell activating factors. Intracellular signals include the
activation of protein kinase C and an increase in the intracellular C a
2+

concentration (Imboden 1988). The consequent biochemical changes in the cell

result in the production of a selection of T cell-derived cytokines including IL 2, IL
3, IL 4, IL 5, tumour necrosis factor B (TNF B), IFN y, IFN a and G M - C S F , that
regulate the development and function of lymphoid and haemopoetic cells (Miyajima
et al 1988). Clonal expansion of antigen-activated T cells is then brought about
through the action of IL 2 which promotes progression of T cells into the S phase
(Robb 1984). Signals induced by IL 2 are transmitted intracellularly via specific
binding of IL 2 to an IL 2 receptor (IL 2R) with a high affinity [Kd ± 10 pM] for IL 2
(Robb et al 1984; Depper et al 1985). The high affinity IL 2R is composed of the
combination of two distinct sub-units, an a chain and a B chain, each with a distinct
IL 2-binding site (Smith 1988). The a chain, (also called the Tac antigen, C D 25 or

the p55 component) has a molecular weight of 55 kDa and binds IL 2 with low
affinity [Kd ± 10 n M ] . It has an intracytoplasmic tail of only 13 amino acids
(Tsudo et al 1989) and thus does not appear to contain a functional domain for
signal transduction. The B chain (p70 component) has a molecular weight of 70-75
kda and binds IL 2 with intermediate affinity [Kd ± 100 pM]. The intracytoplasmic
tail is composed of 286 amino acids (Tsudo et al 1989) and appears to contain the
functional domain necessary for the transduction of intracellular signals.
Internalization of IL 2 is thought to be mediated by the high affinity IL 2 R or by the
B chain alone, but not by the a chain. A restricted region of the B chain that is
essential for signal transduction has been identified (Hatakeyama et al 1989).
Chains that are mutated in this region cannot transduce intracellular signals
although they retain the capacity to complex with the a chain for formation of high
affinity receptors and to internalize IL 2. It is interesting to note that the
functional region of the intracellular domain lacks the typical tyrosine kinase
sequence c o m m o n to growth factor receptors. Further characterization of the
molecular nature and mechanism of action of the B chain w a s facillitated by the
recent development of a mouse M A B specific for the B chain of the human IL 2R
(Takeshita et al 1989). This M A B (TU 27) completely blocked IL 2 binding to the
p70 chain and to the high affinity IL 2R, but not to the low affinity p55 chain.
Using this M A B , and a conventional anti-Tac M A B , the differential expression of
the individual IL 2 R sub-units on peripheral blood T cells could be evaluated (Ohashi
et al 1989). Although the expression of sub-units on resting T cells is generally
low, p55 could be marginally detected on a proportion C D 4-positive cells while C D
8-positive cells were significantly expressing p70. After PHA-induced activation,
the levels of p55 and p70 on C D 4 and C D 8 cells respectively is greatly enhanced;
in addition, C D 4 cells express p70 and C D 8 cells express p55.
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The major biological activities of the T cell cytokines are presented in the
following table (adapted from Trinchieri and Perussia 1985; Strober and James
1988 and Miyajima 1988)

BIOLOGICAL CHARACTERISTICS O F THE T CELL CYTOKINES

FACTOR

SYNONYMS

Mr

MAJOR

BIOLOGICAL ACTIVITY

SOURCES
IL2

T cell derived
growth factor
T cell replacing
factor
Killer helper
factor

15-17 kDa

Activated
T cells

Co-factor for growth
and differentiation of
T and B cells.
Stimulation of N K cell,
LAK cell and oligodendrocyte proliferation.
Increased T cell, N K
cell and monocyte
cytotoxicity.

IL3

As for table p.32
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IL4

B cell growth

(species

factor (BCGF)

15 kDa;
higher with

specific
action)

Bcell

glycosylation

T cells

Growth factor for T
and B cells.
Induction of monocyte

stimulating
factor-1
(BSF-1)

fusion and giant multinucleate cell
formation.
Stimulation of
erythroid, myeloid,
megakaryocyte and
mast cell (mouse)
colony formation.
Modulation of HLA
Class II expression.
Induction of IgE low
affinity receptor (CD
23) on B cells.
lgG1 and IgE
enhancement and
thymocyte growth
(mouse).

IL5

B C G F II
IgA enhancing
factor
Eosinophil C S F

50-60 kDa
multimer
(18 kDa
glycosylated
subunits)

Activated
T cells

B cell growth factor.
Stimulation of
eosinophil colony
formation.
Enhancement of IL 4
induced Ige production
and C D 23 expression.
IgA and IgM
enhancement.
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TNFB

Lymphotoxin

17 kDa

Activated

Anti-viral effect.

T cells

Cytostatic/cytotoxic
for various cells and
tumours.
Stimulation of N K
activity.
Inhibition of LAK
activity.
Enhancement of H L A
class I and II antigens.
B cell stimulation.

IFNy

Type 2IFN

T cells;

Enhanced T cell and N K

Immune IFN

(immune

cell cytotoxicity

stimuli)

Monocyte activating
factor :
B cell maturation and
Ig secretion.
Induction/
enhancement of H L A
class II antigens on a
variety of cell types.
Differentiation and
activation of myelomonocytic cells.

IFN a

Type 1 IFN

T cells;

Anti-viral effect.

Viral IFN

(virus

Monocyte activating

stimuli)

factor.

Other

Induction of H L A class

leucocytes

1 antigens.

'

Inhibition of
haemopoetic stem cell
proliferation.
GM-CSF

See table p.32

j
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1.3.4

Platelet-activating

factor

Platelet-activating factor (PAF) is a 523 D a phospholipid that has been
identified as being 1-0-alkyl-2-acetyl-s_o.-glyceryl-3-phosphorylcholine ( A c G E P C ;
Demopoulos et al 1979). It is produced by monocytes and macrophages, endothelial
cells, basophils, neutrophils, eosinophils, platelets, mast cells, large granular
lymphocytes, EBV-transformed lymphoblastoid cell lines and some leukaemic T and
B cell lines. Production stimuli include antigens, mitogens, phorbol esters, calcium
ionophores, bacterial products, chemotactic agents and cytokines. A s well as being
a potent stimulator of acute inflammatory responses, P A F is also an immune
response mediator, having influences on lymphocytes, monocytes, neutrophils and
platelets as well as on a variety of tissue systems within the body. These
activities are summarised in the following table (adapted from Braquet and RolaPleszczynski 1987).

BIOLOGICAL ACTIVITIES O F PAF O N SELECTED CELL LINEAGES.

NEUTROPHILS

EOSINOPHILS

MONOCYTE/

PLATELETS

LYMPHOCYTES

MACROPHAGE
Chemotaxis

Chemotaxis

Chemotaxis

Activation

a) T cells;

Aggregation

Degranulation

Aggregation

Aggregation

Enhanced NK

Adherance

Enhanced

Enhanced

Enhanced

activity

Lysosomal

cytotoxicity

cytotoxicity

secretion

Increased

Increased

Increased

suppressor cell

enzyme release ImmunoSuperoxide

suppressive

suppressor

thrombin

activity.

anion

proteins

activity

production

Increased

production

Superoxide

TxA2 synthesis response to IL

Leukotriene

anion

PI turnover

2.

synthesis

production

Calcium uptake

Decreased IL 2
production

Calcium uptake

Prostaglandin

Decreased

synthesis

proliferation

Increased T N F
a
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Increased IL 1
at low [PAF];

b) B cells;

decreased IL1
at high [PAF]

increased at
low [PAF] &

Proliferation-

decreased at
hiqh [PAF1

1.3.5

Transforming

Growth

Factor G

The transforming growth factors T G F a and B were so called due to their
initial characterisation as the products of virally transformed cells that were able
to induce the transformation of non-neoplastic cells. It is now known that they are
distinct peptides with separate receptor systems that are produced by normal as
well as neoplastic cells, and that they have activities extending beyond a
transforming function. T G F B is a 25 kDa homodimeric peptide produced by
inflammatory cells such as lymphocytes, monocytes and platelets. It is a potent
regulator of immune and inflammatory responses and an important mediator of
tissue repair systems (Wahl et al 1989).

TGFB secreted by platelets in the initial phases of an inflammatory response is a
potent chemoattractant for mononuclear cells. The recruited monocytes are
activated to secrete IL 1, T N F a, platelet derived growth factor (PDGF) and
fibroblast growth factor (FGF) through enhancement of gene expression (Wahl et al,
1989). These inflammatory mediators as well as T G F B itself stimulate fibroblasts
and endothelial cells for fibroblast matrix protein production and angiogenesis. An
autocrine pathway for monocyte T G F B also exists; monocytes constitutively
express the T G F B gene and upon activation (by for example T G F ) T G F B is produced
through the induction of post-transcriptional control mechanisms (Wahl et al,
1989). T G F B is secreted in an inactive form and must be activated via cleavage
prior to receptor binding. Processing of the latent precursor is presumably an

important regulatory mechanism and m a y occur through cell-derived proteases;
thus target cell susceptibility m a y depend on the ability of the target cell to process
the precursor.

Although TGF B stimulates monocytes to transcribe and produce cytokines with a
dual immunostimulatory and inflammatory function, it suppresses IL 1-induced T
cell proliferation via a pathway that appears to be IL 2 independent (Wahl et al
1988) and also has the capacity to suppress B cell proliferation. In addition, T G F B
has been reported to block the T cell IL 2 response through binding to membrane
receptors that are distinct from the IL 2R, as well as through a downregulation of IL
2R expression (Miyajima et al 1988). Thus, having both pro-inflammatory and
immunosuppressive activities, T G F B m a y function in vivo to inhibit immune
function in inflammatory lesions. This would ultimately protect the host from a
prolonged inflammatory burden and promote tissue repair.

1.3.6 Interleukin 1
1.3.6.1.

Introduction

IL 1 w a s originally described in the 1940s as a heat-labile protein found in acute
leukocytic exudate. W h e n this fluid was injected into animals or humans it produced
fever. The active material was identified as a small protein and was called
endogenous pyrogen (Atkins 1960). In 1972, Gery and W a k s m a n identified a
macrophage factor that augmented the T cell proliferative response to antigens and
mitogens. They n a m e d this factor lymphocyte activating factor (LAF) but it was
subsequently found to be identical to endogenous pyrogen and in fact to a range of
other factors discovered both before and after the initial identification of LAF.
These other factors, originally n a m e d for their distinguishing biological activity,
include leucocytic endogenous mediator, catabolin, osteoclast activating factor,
mononuclear cell factor and haemopoietin 1, and are n o w collectively known as
interleukin 1.
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Generally, IL 1 is an upregulator of cellular metabolism and it increases the
expression of genes encoding other biologically active molecules. It is one of the
key mediators of the body's reaction to pathogenic attack, inflammation and
immunological responses and is a vital part of both the beneficial and the
destructive arms of the host response to infection and injury. Thus, by the very
nature of its ability to orchestrate these responses, it can have severe detrimental
effects on the host unless its production and activity are appropriately modulated.

1.3.6.2 The Nature of the Molecule
The mature IL 1 molecule is a 17.5 kDa non-glycosylated polypeptide. T w o forms of
IL 1 were originally identified by isoelectric focusing: an acidic form (pi 5.0) and a
basic form (pi 7.0) named IL 1a and IL 1B respectively (Oppenheim et al 1986).
Both forms of IL 1 have since been cloned; IL 1B from human blood monocytes by
Auron and co-workers in 1984 and IL 1a from a mouse macrophage cell line by
Lomedico and co-workers in the same year. IL 1a and B are products of two
separate genes each located on chromosome 2 in humans. The two products are
structurally different (March 1985), sharing only 2 6 % homology, but they bind to
the same receptor and thus exhibit the s a m e range of biological functions. It is
proposed (Kilian 1986) that the receptor recognition site is contained within the
regions of homology. IL 1B is the predominant form of IL 1 both with respect to
amounts secreted from the cell and the levels of m R N A detectable within the cell at
any one time. A number of studies have shown that IL 1a remains primarily cellassociated.with IL1B being the primary secreted form (Conlon et al 1988 & Tron et
al 1988). m R N A levels show 10- to 50-fold greater amounts of IL 1B m R N A . It has
been proposed (Kurt-Jones 1985) that membrane-bound IL 1a is biologically active
although this has recently become a controversial issue (Minnich-Carruth et al
1989).

1.3.6.3 IL 1 Production
A wide variety of cell types have the capacity to produce IL 1. These include the
synovial fibroblasts, keratinocytes and Langerhans cells of the skin; cells of
lymphoid lineages such as monocyte/macrophages, B cells, N K cells and s o m e T cell
lines; the astrocytes and microglial cells of the brain; corneal, gingival and thymic
epithelial cells; kidney mesangial cells and cells of the endothelium. The monocyte
is one of the most important producers of IL 1 because of its strategic and variable
location throughout the body, its ability to synthesise large amounts of protein (eg:
100 fg IL 1B/cell/24 hours) and its ability to process precursor molecules more
effectively than most other cell types (Dinarello 1988).

There are a number of stimuli that induce IL 1 production depending on the type and
location of the source cell. These include : bacterial call wall components such as
lipopolysaccharide (LPS), phorbol esters, leukotrienes, immune complexes, U V
radiation, complement, clotting components, adherance to surfaces, cell-cell
contact and the influence of other cytokines ( Strober and James 1988, Dinarello
1989). IL 1B transcripts are detectable as early as 15 minutes after an
appropriate IL 1-induction stimulus ( Fenton et al 1987 & 1988). Transcription
peaks in 3-4 hours and then decreases. The first translation product of IL 1 m R N A
is a 31 kDa precursor molecule found primarily in the intracellular pool. A 22 kDa
form is found both intra- and extracellularly and m a y be located transiently in the
membrane. Most of the extracellular IL 1 is the 17.5 kDa species but a 22 kDa form
as well as biologically active smaller fragments (11, 6, 4 and 2 kDa) have also been
found. Processing of IL 1 is brought about by the action of serine proteases,
particularly elastase and plasmin (Matsushima 1987), and in the cell IL 1 is found in
association with lysosomes rather than the endoplasmic reticulum. Another unusual
feature of the IL 1 molecule is that it lacks the conventional signal peptide for
secreted proteins and appears that different cell types have differing abilities to
secrete this protein. Monocytes appear to be the cells with the greatest ability to

secrete IL 1. Other IL 1-producing cells can transcribe message and translate
protein but the majority remains intracellular as a 31 Kda precursor molecule
(Auron 1987 & Matsushima et al 1986). It m a y be that the cell type-specific
enzyme battery determines the fate of IL 1 in the cells.

Processing events are subject to modulation and this represents one mechanism
whereby the levels of available IL 1 m a y be controlled. Transcriptional repressors
may be freshly translated or activated by phosphorylation and these suppress
transcription and/or increase the rate of m R N A degradation. Production of m R N A
transcripts does not necessarily correlate with the amount of IL 1 protein
ultimately produced; s o m e stimuli m a y induce IL 1 m R N A transcription only, with
an additional signal being required for translation of the message. In monocytes for
example, L P S and IL 1 are examples of dual stimuli (Dinarello et al 1987 & Warner
et al 1987) while adherance to a glass or plastic surface only induces m R N A with a
second signal being required for message translation. The s a m e phenomenon is
applicable to negative regulators of IL 1 production. Prostaglandins and
prostacyclins for example (Knudsen et al 1986 & Kunkel et al 1985) reduce
translation of IL 1 m R N A but have no effect on initial transcription. Control of
translation can also be affected by other cytokines. IFN y for example suppresses IL
1-induced IL 1 translation but enhances endotoxin- or TNF-induced IL 1 translation.

1.3.6.4 The IL 1 Receptor
IL 1 has a wide range of target cells and activity is mediated through binding to a
specific IL 1 receptor expressed on all IL 1-sensitive cells. Binding is followed by
internalisation of the receptor-ligand complex and down-regulation of receptor
expression. Internalised IL 1 is not degraded and m a y be transported into the
nucleus with the potential to directly influence intranuclear events (Mizel et al
1987). Indeed, Grenfell et al (1989) have recently presented evidence that
following receptor-mediated endocytosis, IL 1a is transported to the nucleus in an

intact form via an endosomal pathway where it binds to a specific high affinity
nuclear receptor. The evidence suggests that IL 1B has an equal capacity to bind the
receptor and that binding kinetics are similar to those for plasma m e m b r a n e
receptor binding. Whether nuclear and cell surface receptors are identical is not
yet clear. Although there is incomplete and conflicting evidence regarding the exact
nature of post-binding intracellular events, it is generally agreed that signal
transduction results in an effect on the transcription of specific genes in a variety
of cell types.

The receptor molecule itself is an 80 kDa glycoprotein that binds both IL 1a and IL
1B, although specific receptor-ligand binding for the two forms m a y differ
(Dinarello 1989). The 30 kDa IL 1 a precursor molecule is also capable of binding to
the IL 1 receptor and is thus presumably biologically active (Dower and Urdal
1987). Reports of larger (>30 kDa) molecules with IL 1 -like biological activity m a y
reflect the release of unprocessed IL 1 from the cells. The amino acid sequence of
the molecule indicates that it is a m e m b e r of the immunoglobulin superfamily. As
reviewed by Dinarello 1989, the intracellular domain does not contain any
sequences indicative of tyrosine kinase activity but there is a sequence which m a y
represent a protein kinase C phosphorylation site. There are seven potential
glycosylation sites in the extracellular domain

and the extent of glycosylation m a y

explain s o m e of the different molecular weights reported for IL 1 binding proteins.
IL 1 binding proteins with a wide variation in molecular weight (26 kDa, 43 kDa,
110 kDa, 116 kda and 220 kDa) have been described and while s o m e of these m a y be
attributable to differential glycosylation or m a y represent aggregates or breakdown
products of the 80 kDa molecule, it has also been suggested (Dinarello et al 1989)
that the 80 kDa receptor m a y have a second component with the two-chain complex
resulting in a higher affinity receptor than either single chain alone. It has been
proposed that the 80 kDa chain is responsible for IL 1 binding with the second chain
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initiating the as yet unclarified signal transduction mechanisms. H o w this relates to
the nuclear receptor described by Grenfell et al (1989) remains to be elucidated.

Expression of the IL 1 receptor is subject to modulation. Receptor upregulation on
con A-stimulated human T cells and mononuclear cells treated with corticosteroids
has been reported (Kilian et al 1986). A number of groups have also reported
downregulation of IL 1 receptors (Matsushima et al 1986, Mizel et al 1987 &
Savage et al 1988) and this will be discussed in more detail in section 1.4.

1.3.6.5 Biological effects of IL 1
The major biological effects of IL 1 on target cells have been summarised in the
following table (adapted from Martin and Resch 1988 & Dinarello 1988a).

T H E BIOLOGICAL ACTIVITIES O F IL 1.

IL1 RESPONSIVE CELLS
A N D / O R TISSUES

BIOLOGICAL EFFECT

T cells

Influence on early T cell development
Enhancement of cytotoxic activity
Costimulator activity for proliferative response
Synergy with IL 6 and T N F a
Chemotaxis promotion
Cytokine synthesis : IL 2, IL 3, IFN y, C S F and BSFs
Increased IL 2 receptor expression/binding

B cells

Chemotaxis promotion
Costimulator activity for B cell growth

anddifferentiation
Synergy with IL 4 and IL 6
Growth factor for transformed B cells
Enhancement of antibody production
N K cells

Increased IL 2 receptor expression
Increased binding to tumour cells and enhancement of
cytotoxic activity
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Synergy with IL 2 and IFN y
Cytokine synthesis : IFN y
Monocytes/macrophages

Enhancement of cytotoxic activity
Chemotaxis promotion
Prostaglandin synthesis
Generation of oxygen radicals
Cytokine synthesis : T N F a, IL 1 and CSFs.
Synergy with T N F a

Neutrophils

Chemotaxis promotion
Thromboxane synthesis
Degranulation
Oxidative burst

Other leucocytes

Basophil histamine release
Eosinophil degranulation

Bone marrow cells

Increased synthesis of C S F s
Synergy with C S F s
Haemopoietin activity

Hepatocytes
fibrinogen,

Enhanced production of acute phase reactants :
haptoglobulin, C reactive protein, serum amyloid
Decreased hepatic albumin synthesis
Increased hepatic metallothionein transcription
Decreased synthesis of lipoprotein lipase

Endothelial cells

Enhanced leucocyte adherance (increased ICAM-1)
Procoagulant activity
Production of plasminogen activation inhibitor for
thrombin activation
Cytokine secretion : G M - C S F
Increased synthesis of vasodialators; P A F and P G s

Epithelial cells

Enhanced proliferation
Collagen synthesis

Fibroblasts

Enhanced proliferation
Prostaglandin synthesis
Expression of ICAM-1
Expression of receptors for fibroblast growth factors

eg:

epidermal growth factor
Cytokine secretion : G M - C S F

Synovial cells

Enhanced proliferation
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Prostaglandin synthesis
Secretion of collagenase
Secretion of plasminogen activator
Muscle cells

Proteolysis
Prostoglandin synthesis
Vascular smooth muscle cell proliferation

Bone cells

Osteoclasts: bone resorption
Osteoblasts: prostaglandin synthesis

Chondrocytes

Prostaglandin synthesis
Secretion of neutral protease, proteoglycanase and
collagenase
Cartilage proteoglycan resorption
Inhibition of proteoglycan and collaqen synthesis

Mesangial cells

Proliferation
Prostaglandin synthesis
Secretion of Type IV collagenase and neutral protease

Pancreas islet cells

Cytotoxicity

Pituitary gland
Astrocytes
Central nervous systems

A C T H release
Prostaglandin synthesis
Fever, somnolescence, anorexia
Enhanced secretion of neuropeptides and hormones

Tumour cells

Type specific; including cytostasis/cytotoxicity/
differentiation or proliferation

The effects of IL 1 have been broadly subdivided by Dinarello (1988a) into systemic
and local effects. Local effects are important because cells/tissues that produce IL
1 are often target cells or are adjacent to target cells. W h e n IL 1 gains access to
the circulation it has a hormone-like effect resulting in a number of changes in
neurological, metabolic, haematologic and endocrine systems. Through its ability to
induce and/or synergize with other cytokines.the biological effects of IL 1 m a y be
extended still further. IL 1 is thus a mediator of communication both within the
immune system and between the immune system and virtually all the other major
organ systems in the body.

1.3.6.6 The role of IL 1 in T cell activation
The use of recombinant IL 1 and anti-IL 1 antibodies have confirmed the presence of
IL 1 receptors on T cells and the status of IL 1 as a T cell activator. What is still an
open question however is whether IL 1 is an absolute requirement for a primary
immune response. There is evidence that IL 1 has a limited ability to activate T
cells in the absence of accessory cells : Koide et al (1987) have shown that IL 1
has no effect on murine T cell proliferation in the absence of accessory cells
although it does augment the response in the presence of low numbers of accessory
cells; and Mizel (1987) reports that anti-IL 1 antibodies have no effect on antigenor mitogen-induced proliferation of murine spleen and lymph node cells. O n the
basis of these observations he proposes that IL 1 plays an enhancing rather than an
obligatory role in T cell proliferation. Ellis et al (1988) also support the idea of an
augmenting role for IL 1 in optimal T cell proliferation. These observations may be
explained by the recent reports that IL 1 and IL 6 synergize to induce an optimal T
cell response (Holsti and Raulet 1989, Houssiau et al 1989 & Mizutani et al 1989)
and that the T cell requirement for monocyte factors can be replaced by IL 6 and IL
1 but not by IL 1 alone (Kawakami et al 1989).

1.3.7. Tumour Necrosis Factor a
1.3.7.1. Introduction
In 1975, Carswell and colleagues (Carswell et al 1985) identified a
macrophage-derived activity in the post-endotoxin serum of Bacillus CalmetteGeurin (BCG)-primed mice which caused haemorrhagic necrosis of tumours. In the
decade that followed, human T N F was purified, cloned and sequenced (Aggarwal et al
1985 & Pennica et al 1984). In independent studies, a macrophage factor called
cachectin - originally identified through its ability to suppress lipoprotein lipase
synthesis (Kawakami and Cerami 1981) - was purified and sequenced and found to
be identical to T N F (Beutler et al 1985). Because lymphotoxin (LT), a protein

product of activated T cells, is structurally and functionally similar to T N F (Gray et
al 1984), the nomenclature T N F a for macrophage-derived T N F and T N F B for the T
cell product has been adopted. Both species of T N F have a Mr of 17 kDa, but may
aggregate to higher molecular weight forms. Although T N F a and B have limited
homology, they bind to the s a m e receptor, are both located on chromosome 6 and
both m a p to the class III region of the M H C (Old 1987). It has been proposed that
genes in the HLA-DR region m a y control the production and/or secretion of T N F a
(Bendtzen, 1988).

1.3.7.2. TNF tt production
Relative to IL 1, T N F a is produced by a relatively narrow range of cells including
monocytes and macrophages, keratinocytes, certain tumour cells and T cells under
limited conditions. Cells of the monocyte lineage are however the major producers
of T N F a. Monocytes do not not constitutively produce T N F a and must be activated
by appropriate stimuli such as bacterial endotoxin or, in vitro, L P S or phorbol
esters. It has been reported (Beutler et al 1986) that when monocytes are exposed
to LPS, transcription of the T N F a gene increases approximately 3-fold with the
amount of message increasing from barely detectable levels to approximately 0.5%
of the total cellular m R N A . As with IL 1, T N F a message is not automatically
translated into protein and T N F a production is also susceptible to control at the
post-transcriptional level. IFN y is reported to enhance the production of T N F a
after appropriate initial stimulation (Nedwin et al 1985 & Hart et al 1989). The
T N F a precursor is a 233 amino acid single chain polypeptide. Like IL 1, it has no
signal sequence and is thought to be transported to the cell membrane in precursor
form with the mature T N F a molecule being generated at the cell surface by limited
proteolysis.

1.3.7.3. The T N F a receptor
The T N F a receptor is composed of 4 non-covalently linked proteins ( M W of 138,
90, 75 and 54 kDa) which m a y act independently or as multiple sub-units. The
primary binding sub-unit appears to be the 75 kDa component (Kull 1985) while the
138 kDa sub-unit m a y be selectively responsible for T N F a-mediated cytotoxicity.
Post-binding events include rapid internalisation and degredation of the molecule,
but the exact mechanisms of signal transduction have yet to be elucidated (Beutler
and Cerami 1986 & Strober and James 1988).

1.3.7.4. Biological activity
In addition to the activity for which T N F w a s already identified - haemorrhagic
necrosis and regression of experimental tumours - T N F a also has effects on normal
cell type including lymphoid cells, fibroblasts and endothelial cells. As a mediator
of immunological function, T N F a is influential in T cell activation and the
expression of IL 2 receptors on T cells; B cell stimulation ; neutrophil activation
leading to increased phagocytic ability and increased cytotoxicity towards
pathogens; expression of M H C class 1 molecules and adhesion molecules for
lymphocytes on endothelial cells; and the synthesis and release of immunologically
important cytokines such as IL 1 and IL 6 from monocytes, fibroblasts and
endothelial cells. T N F a also amplifies IFN y-mediated M H C class II gene expression,
but unlike the mechanism of class I induction, it has no direct effect on class II gene
expression (Arenzana-Seisdedos et al 1988). Scheurich et al (1987) caution about
evoking a primary role for T N F a as an inducer of IL 2R because they have
demonstrated that induction of T N F a receptors (and hence T N F responsiveness) on
T cells is concurrent with, and not prior to, IL 2R induction.

TNF a plays a significant contributory role in the immunopathological consequences
of the immune response mounted by a host against a foreign invasion. The
potentially harmful biological activities of T N F a are largely due to its role as a

mediator of endotoxin shock, its activity in wasting (cachexia) and its pyrogenic
activity - both in its o w n right and as an inducer of IL 1. The role of T N F a in
endotoxin shock and cachexia w a s reviewed by Cerami and Beutler in 1988 and can
be attributed primarily to the following:
i) activation of neutrophils leading to massive accumulations in the lungs;
ii) conversion of the endothelial cell surface from a normal coagulating to a
procoagulating surface;
iii) increased prostaglandin synthesis by lymphoid cells and cells of the
hypothalamus, thereby eliciting a febrile response;
iv) release of other potentially harmful secondary mediators such as leukotrienes,
IL 1, P A F and complement activating components
v) suppression of lipoprotein lipase, an enzyme crucial for normal fat storage, and
accelerated glycogenesis leading to glycogen depletion and increased lactate
production.

1.3.7.5. TNF a and IL 1
Whereas almost every non-immunological biological property of IL 1 has also been
attributed to T N F a, only s o m e of the lymphocyte-activating properties of IL 1 are
shared with T N F a and appear, at least in vitro, to need higher concentrations of
TNF. Ranges et al (1988) for example report that the molar T N F a concentration
required to stimulate immunocompetent cells is one or two orders of magnitude
greater than IL 1. There are also a number of distinct differences in the activity
spectra displayed by the two products (Dinarello 1989):

IL 1 is produced by a

much wider range of cells; IL 1 alone has haemopoetin-1 activity while in contrast,
T N F a can suppress bone marrow colony formation; T N F a is not as efficient a
signal for T cell activation; T N F a is more active in inducing tumour necrosis in
vivo, has more potent in vitro cytotoxicity against tumour cells than IL 1 (Old
1987) and is cytotoxic for a range of tumour cells against which IL 1 is inactive,
while IL 1 is cytotoxic for melanoma cells against which T N F a is inactive; T N F a

stimulates human neutrophil oxidative metabolism whereas IL 1 does not, while only
IL 1 induces basophil and eosinophil histamine release (Pincus et al 1986); IL 1 does
not upregulate M H C class I molecules on endothelial cells.

Synergy between IL 1 and TNF a has been observed in a number of independent
studies and considering that the two cytokines would often be present together in
the same body fluids, this m a y have in vivo importance.

1.3.8. Interleukin 6
1.3.8.1. Introduction
A soluble factor isolated from T cell lines or T cell hybridomas and termed B cell
differentiation factor (BCDF) or B cell stimulating factor-2 (BSF-2) due to its effect
on stimulating B cell growth and differentiation was cloned and sequenced by Hirano
et al (1986) and become known as IL 6. At about the same time it w a s shown that IL
6 w a s identical to a factor with anti-viral properties, interferon 32 (Sehgal and
May 1987) and a monocyte factor previously known as hepatocyfe stimulating
factor (Gauldie 1987). Cloning and sequencing studies indicated that IL 6 is a 26 kDa
polypeptide with sequence and structure homology to G M - C S F .

1.3.8.2. IL 6 production
The gene for IL 6 is located on chromosome 7 in humans (Sehgal et al 1986). It has
several initiation sites that m a y give rise to variant molecules with a degree of
tissue specificity. Cells producing IL 6 include monocytes and macrophages, T and B
cells, endothelial cells, epithelial and mesenchymal cells, keratinocytes, fibroblasts
and synovial cells and certain tumour cells including osteosarcoma, carcinoma and
multiple myeloma cells. IL 6 is constitutively produced by s o m e cell types but
production is increased following appropriate stimulation; stimuli include bacterial
endotoxin, mitogen or antigen exposure and the action of other cytokines such as IL
1 and to a lesser extent T N F a , P D G F and IFN 31. Production is subject to

regulation at the level of gene transcription or post-transcriptional events. In
contrast to T N F a and IL 1, the IL 6 precursor (a 212 amino acid single chain
polypeptide ) contains a hydrophobic signal sequence of 28 amino acids and is
secreted via the normal pathway for secretory proteins. Differential glycosylation
m a y occur in different cell types, acounting for variations in molecular weight of
the mature product ranging from 16-26 kDa. The degree of glycosylation m a y also
affect the activity of the molecule.

1.3.8.3. Biological activities
In accordance with its original names, IL 6 has weak anti-viral activity, induces B
cell differentiation and stimulation of immunoglobulin secretion and is an inducer of
acute phase reactants from hepatocytes. IL 6 thus shares with IL 1 and T N F a the
ability to induce acute phase responses and to act as an endogenous pyrogen. As
well as its influence on B cells, IL 6 also has a strong influence on other
immunocompetent cells. IL 6 has been reported to induce IL 2 production from con A
stimulated cytotoxic murine T cell lines and antigen/mitogen stimulated peripheral
blood T cells (Garman and Raulet 1987) and it is a co-stimulator for murine
thymocyte proliferation (Le et al 1988) and h u m a n T cells (Lotz et al 1988). Baroja
et al (1988) report that IL 6 induces expression of functional IL 2 receptors (IL 2R)
and an increase in the p55 component of the IL 2R has been reported in murine (Le et
al 1988) and h u m a n (Houssiau et al 1989) systems. There is however controversy
about the absolute role of IL 6 in these mechanisms; Lotz et al (1988) for example
report that IL 6, although co-mitogenic for PHA-stimulated T cells, does not induce
p55 expression, while Ceuppens et al (1988) report that p55 is only expressed in
the additional presence of accessory cells. It m a y be therefore that additional
factors are required for optimal IL 6 action in this regard. Similarly, both Ceuppens
et al (1988) and Tosato and Pike (1988) report that IL 6 alone does not induce IL 2
production in the human system. The potential role of IL 1 as a co-factor for IL 2

production and responsiveness is discussed in section 1.3.8.4. The effect of IL 6 on
expression of the p70 component of the IL 2R has not been directly addressed.

IL 6 is an important as a mediator of haemopoesis; supporting the proliferation of
granulocyte and macrophage progenitors and enhancing IL 3-dependent blast cell
colony formation in mouse and human systems (Wong and Clark 1988).
Despite its beneficial role in immunological systems, the inflammatory properties it
shares with IL 1 and T N F a m a k e it another potential contributor to the pathological
lesions that accompany a host response to infection or injury. Since IL 1 and T N F a
are potent inducers of IL 6 in many cell types however, it has been suggested that IL
6 is a second mediator of the acute phase response initially elicited by IL 1 and/or
T N F a. Serum levels of IL 6 have been correlated with the severity of fever in
burn patients and elevated IL 6 levels have also been reported in patients
undergoing renal rejection (Bendtzen 1988) and in the cerebrospinal fluid of patients
with infections in the central nervous system (Houssiau et al 1986). IL 6 has
hybridorna, plasmocytoma, and lymphoblastoid growth factor activity

and

upregulated production m a y thus also be important in the manifestation of various
"myelomas and T or B cell lymphomas.

1.3.8.4. IU and IL 6
Although IL 1 and IL 6 appear to share similar lymphocyte activating properties,
differences in the dose requirements have been reported. Dinarello (1989)
examined the dose-response effects of IL 1 and IL 6 in in vitro and in vivo
systems; in rabbits, 20-50 fold greater amounts of IL 6 were required to produce
a rise in body temperature comparable to that induced by IL 1, and 50-100 fold
more IL 6 than IL 1 was required to induce similar prostaglandin E2 (PGE2)
production from human monocytes, synovial cells and fibroblasts. While human
recombinant IL 1 could stimulate murine thymocyte proliferation at 1-10 pg/ml, 110 ng/ml of IL 6 was required to induce comparable proliferation. A strong

synergistic relationship for IL land IL 6 has however been repeatedly documented
(Ceuppens et al 1988, Houssiau et al 1989 & Le et al 1988) allowing IL 6 to be
effective in thymocyte and T cell proliferation at much lower doses. As the two
cytokines are generally co-existent in monocyte supernatants, this observation is
of physiological significance. Garman and Raulet (1987) reported that IL 6 was
effective as a T cell proliferative signal in the absence of accessory cells under
conditions where high concentrations of IL 1 were ineffective. This led them to
speculate that IL 6 rather than IL 1 provides the essential co-mitogenic signal for
stimulating T cell proliferation. This s a m e group later reported (Holsti and Raulet
1989) that both cytokines are required, but that T cells must be pre-exposed to IL 6
or exposed to IL 1 and IL 6 simultaneously for optimal proliferation. They concluded
that both factors were required for optimal IL 2 production and responsiveness.
Houssiau et al (1989) have proposed that IL 1 is important with respect to IL 2
production with IL 6 being required for optimal IL 2 responsiveness, particularly to
low levels of IL 2. Kawakami et al (1989) also report a dual role for IL 1 and IL 6.
Unlike IL 1 and T N F a, IL 6 does not activate endothelial cells in vitro (Dinarello
1989). As a further difference, IL 6 does not induce IL 1 or T N F a production by
monocytes and can in fact suppress endotoxin- or TNF-induced IL 1 production
(Dinarello 1988).

Generally, as compared to IL 1 or TNF a, IL 6 appears to be a weak inflammatory
peptide while having similar or greater positive effects on T and B cell function,
bone marrow cells and non-specific host defense mechanisms.

1.4.

INHIBITORS OF INTERLEUKIN 1 PRODUCTION AND ACTIVITY

1.4.1 Introduction
The potent and fundamental effects of IL 1 in immunological and other
physiological systems suggests that its availability in a bioactive form should be
strictly controlled. This m a y be achieved either by regulating the production of IL
1, its biological action once produced, or through modulation of the mechanisms that
it has the potential to induce. Antagonists of IL 1 can thus theoretically act at the
following levels:
i) affecting the production and release of a bioactive molecule,
ii) affecting the expression of the IL 1 receptor,
iii) affecting the integrity of the molecule and/or its receptor so as to inhibit
effective binding and/or signal transduction,
iv) affecting the activity of a mechanism secondarily induced by IL 1 so that
ultimately the effect of IL 1 is negated.

The majority of studies involving production of IL 1 and IL 1 inhibitors have been
performed using biological activity assays. It should be remembered that the net
proliferative activity of a culture supernatant is in fact a summation of inhibitory
and stimulatory influences coexistent in the supernatant. In addition, stimulatory
activity is not necessarily due only to IL 1 and thus inhibitory activity is not
necessarily due only to direct IL 1 antagonists. For example, in the standard murine
thymocyte or h u m a n T cell proliferation assay, the proliferative response to IL 1
depends on the successful production of IL 2 and the expression of functional RIL 2
and the ability of a target cell to respond to the IL 1 signal m a y be largely dependent
on the simultaneous presence of IL 6 in the test supernatant; thus the possibility
that inhibitors of IL 6 production and/or action or inhibitors of the IL 2 response
m a y also be present in the test supernatant should be considered. Inhibitors of IL 1
production or its biological action have been isolated from a number of sources

including body fluids, supernatants from cells isolated from the body and cultured in
vitro and supernatants from cell lines. The following summary has been subdivided
according to the origin of the inhibitory influence.

1.4.2. Inhibitors from urine
A 30-35 kDa protein isolated from the urine of febrile patients with the
ability to inhibit the co-mitogenic effect of IL 1 in the murine thymocyte assay has
been described by Liao et al (1984 & 1985) and by Brown and Rosenstreich (1987).
The inhibitor w a s not cytotoxic, did not block IL 1 receptor binding and w a s
effective against IL 1-primed thymocytes as late as 48 hours after initial IL 1
activation via a prostaglandin (PG)-independent pathway. Rosenstreich et al (1988)
undertook to further characterize this factor and reported that it w a s a 38 kDa
glycoprotein with DNA-degrading activity and that it shared close homology with
mammalian DNase enzymes.

Uromodulin is an 85 kDa protein originally isolated from the urine pregnant women
(Muchmore et al 1985 & Braun et al 1986) that inhibits the mitogenic effect of IL 1
for thymocytes, probably by binding IL 1 and thus preventing receptor binding
(Muchmore et al, 1986).

Seckinger et al (1987) report the purification of a 18-25 kDa protein from the urine
of patients with monocytic leukaemia that blocks IL 1-induced fibroblast
proliferation and chondrocyte collegenase production through specific competion for
IL 1 receptor binding. They propose that malignant monocytes are the original cell
source of this inhibitor.

A 30 kDa sialoglycoprotein has been recently isolated from the urine of febrile and
kidney transplant patients (Kabir and Wigzell 1989) that inhibits IL 1 activity in the
thymocyte co-mitogenesis assay but has no effect on the thymocyte response to

mitogen alone. The mechanism of action of the inhibitor has yet to be elucidated but
it does not bind IL 1 directly or prevent IL 1 receptor binding.

Inhibitors have also been found in the urine of normal donors; Svenson and Bendtzen
(1988) report the identification of an inhibitor that suppressed both IL 1 activity in
the thymocyte co-mitogenesis assay and the response of an IL 2-dependent cell line
to exogenous IL 2.

1.4.3. Inhibitors from monocytic cell lines
M 20 is a myelomonocytic cell line that in addition to producing IL 1, also
produces a 52 kDa inhibitor of IL 1 activity (Barak et al 1986). This factor
inhibited the co-mitogenic effect of IL 1 for thymocytes, antigen- or antigen plus IL
1-stimulated h u m a n T cell proliferation and, to a lesser extent, proliferation of T
cells optimally stimulated with the mitogen P H A . It had no effect on IL 2-dependent
T cell growth.

A number of inhibitory influences have been identified in the supernatants of the
U937 cell line, a h u m a n histiocytic lymphoma with the capacity to produce IL 1
when appropriately stimulated. In 1984, Wilkins and Warrington reported that
lectin-stimulated U 9 3 7 cells produce a 68 kDa inhibitor of mitogen-stimulated T cell
proliferation. In 1986, Fujiwara and Ellner identified an 85 kDa heat and acid labile
factor that w a s spontaneously produced by U 9 3 7 cells over a 5 day culture period.
This factor inhibited the direct and co-mitogenic activity of IL 1 and the comitogenic activity of IL 2 for murine thymocytes via a PG-independent mechanism.
The following year, the s a m e group (Fujiwara et al 1987) reported that as well
being suppressive for murine thymocyte proliferation, the factor also inhibited the
blastogenic response of antigen and mitogen-stimulated h u m a n peripheral blood
cells. The mechanism of action of this factor w a s further investigated and it w a s
found to inhibit the production of IL 2 and the expression of the low affinity p55

component of the IL 2R. The proposal that the IL 2 response was the prime locus of
inhibition w a s confirmed by the fact that addition of exogenous IL 1 could not
reverse the suppression of proliferation and that IL 2 production w a s reduced
whether its induction w a s IL 1 dependent or independent. Addition of exogonous IL 2
or a crude T cell supernatant however also failed to reverse suppression of p55
expression in T cells and the factor, at the concentration used, had no effect on the
proliferative response of a murine IL 2-dependent T cell line to exogenous IL 2. The
inhibitory influence co-purified in supernatant fractions with a M W ranging from
67-130 kDa suggesting that more than one specific factor m a y contribute to the
reported inhibitory activities.

In 1989, Sugimura et al attempted to purify another inhibitory factor from crude
U937 supernatants. The factor, termed lymphocyte blastogenesis inhibitory factor
(LBIF), is a 45-67 kDa factor that specifically inhibits IL 1-induced murine
thymocyte proliferation while having no effect on IL 2 production or the expression
of the p55 component of the IL 2 receptor. LBIF was found to inhibit T cell
proliferation through arresting PHA-stimulated T cells at the early G1 phase of the
cell cycle and so inhibit entry into the S phase. As LBIF is active against murine
and human lymphocytes, the authors propose a conservation of structure between
species.

The THP cell line has also been identified as a source of IL 1 inhibitors; Krauker
(1985) reports the presence of a 60-70 kDa factor in 2 or 3 day culture
supernatants that inhibited the mitogenic effect of P H A and con A on human
peripheral blood mononuclear cells ( P B M C ) . It also inhibited the thymocyte
response to P H A and IL 1, P H A and IL 2, and IL 2 alone, as well as the production of
IL 2 by mouse splenocytes and human peripheral blood T cells. In contrast to the
factor described by Fujiwara et al (1987), the factor from T H P cells w a s able to
suppress the response of an IL 2 dependent T cell line to exogenous IL 2 while having

no effect on IL 2-independent cells. It w a s confirmed that this factor w a s not IFN a
or B.

1.4.4. Inhibitors from normal monocytes
Arend et al (1985) reported that monocytes cultured on adherent immune
complexes or adherant IgG alone (Arend et al 1989b) for 24 hours produced a 22
kDa protein that inhibited IL 1-induced collegenase production by chondrocytes and
the direct or co-mitogenic effect of IL 1 for thymocytes. It did not inhibit IL 2induced thymocyte proliferation or IL 2-induced stimulation of IL 2-dependent cell
lines. The m o d e of action w a s through blocking of IL 1 receptor (IL 1R) binding,
although the factor w a s distinct from IL 1 and showed no cross-reactivity with IL 1
a or B. It w a s also distinct from T G F B although it showed s o m e functional
similarity, being able to induce P G E 2 production from fibroblasts and synovial cells.
Hannum et al (1990) confirmed that the factor (named IL 1 receptor antagonist; IL
1 ra) w a s a pure receptor antagonist with similar affinity for binding as IL 1 but
with no IL 1 activity. They reported the isolation of two glycosylated variants with
M W of 22kDa and a non-glycosylated 18 kDa form. It is likely that this is the same
factor as that isolated by Seckinger et el (1987) from the urine of monocytic
leukaemia patients. Carter et al (1990) report the purification and characterization
of an additional IL 1 receptor antagonist protein (IRAP) from PMA-treated U937
cells after stimulation with G M - C S F . IRAP w a s determined to be a 25 kDa
competitive of IL 1 binding to the T cell-fibroblast form of the IL 1R. It inhibited the
in vitro action of IL 1 on T cells and endothelial cells and induced corticosteroid
production in vivo . N o inhibition of IL 2-induced thymocyte proliferation w a s noted.
The possibility that IRAP m a y selectively bind to IL 1 receptors expressed on
certain cell lineages only was proposed, as w a s a role for the protein as a negative
feedback inhibitor whose role in vivo m a y be to regulate specific IL 1 functions.

In 1986, Berman et al reported the production of a 5-9 k D a factor from normal
monocytes after 24 hours of culture that suppressed IL 1 activity in the thymocyte
co-mitogenesis assay but had no effect on the proliferation of an IL 2-dependent cell
line. In the following year, the s a m e group (Berman et al 1987) confirmed the
presence of this factor as well as an additional inhibitory activity in the 50-100
kDa fractions of supernatants from unstimulated P B M C of normal adult donors.
They also confirmed that the 5-9 kDa factor had no effect on mitogen-induced T cell
proliferation or IL 2 synthesis and action. It w a s proposed that the inhibitor m a y
interfere with IL 1-dependent signals required by immature T cells only. Inhibitor
action w a s PG-dependent but the factor ifself did not contain prostaglandins.

Kashiwado et al (1989) identified a 130-150 kDa factor in 48 and 72 hour
supernatants of LPS-stimulated h u m a n peripheral blood monocytes. This factor
inhibited the co-mitogenic action of IL 1 on murine thymocytes, mitogen-stimulated
P B M C proliferation and IL 2 production by T cells. Further evidence for a locus of
action directed at the IL 2 response c a m e from the observations that the factor
inhibited the proliferative response of an IL 2-dependent cell line to exogenous IL 2,
while having no effect on IL 1-dependent fibroblast proliferation. This factor
showed functional similarities with the 60-70 kDa factor isolated by Krauker
(1985) from T H P cells and indeed it cross-reacted with antibodies raised against
the T H P factor, suggesting that despite the size difference, the two factors were
related. A further indication that production of this or related factors w a s not
restricted to peripheral blood monocytes w a s the observation that the 130-150 kDa
factor w a s also produced by LPS-stimulated h u m a n umbilical cord endothelial cells
(EC).

Goeken et al (1989) report that 6 day monocyte supernatants contain high levels of
a 60-70 kDa protein known as plasminogen activator inhibitor (PAI). Because
proteolytic cleavage of IL 1 may be required for precursor IL 1 molecules to become

active, these workers have speculated that PAI plays a role in reducing the levels
of bioactive IL 1. Endothelial cells m a y also play a role here because they also
produce PAI under the influence of T G F B.

1.4.5. Inhibitors from virus-infected monocytes
Roberts et al (1986) investigated the effect of influenza virus and
respiratory syncytial virus (RSV) on cytokine secretion by unstimulated
monocytes. Influenza virus induced enhanced secretion of an IL 1 -like activity as
compared to uninfected controls, while an influence inhibitory to murine thymocyte
proliferation w a s also detected in supernatant fractions corresponding to a Mr of
approximately 99 kDa; the net activity in unfractionated supernatants after 24
hours of monocyte culture w a s however stimulatory. R S V infection of monocytes
was also associated with the production of a 99 kDa protein inhibitory to murine
thymocyte proliferation, but in contrast to the situation with influenza virus, the
net activity in unfractionated 24 hour supernatants from VSV-infected monocyte
cultures w a s inhibitory to thymocyte proliferation. Consequently, although IL 1
secretion was similarly induced by V S V infection, it could only be detected in
supernatant fractions separated from the masking inhibitory influence. Neither
inhibitor affected the IL 2 response of an IL 2-dependent cell line. The s a m e group
(McCarthy et al 1989) later confirmed that R S V challenge of monocytes resulted in
the production of supernatants with a net IL 1-inhibitor activity, while influenza
virus-challenged monocytes produced supernatants with a net proliferative
activity. They further showed that the RSV-induced antiproliferative activity was
also effective against mitogen-stimulated human peripheral blood T cells.

The effect of human immunodeficiency virus (HIV), the aetiological agent of the
aquired immunological deficiency syndrome (AIDS), on monocyte cytokine has
recently been investigated by a number of groups. In 1987, Berman et al
demonstrated that the 6-9 kDa and 50-100 k D a inhibitors they identified in the

supernatants of normal monocytes were also produced, but in significantly
increased amounts, following in vitro infection with HIV. Fractionation of
supernatants from infected cultures indicated that IL 1 production w a s also
enhanced by HIV infection but the masking effect of the inhibitors w a s such as to
lower the IL 1 activity of crude supernatants relative to uninfected controls. An
acid and heat labile 9 k D a inhibitor of IL 1 activity w a s also detected by Locksley
et al (1988) in the supernatants of h u m a n monocyte-derived macrophages that had
been experimentally infected with HIV. This factor, called contra-IL 1, inhibited the
co-mitogenic effect of IL 1 in the thymocyte assay and the mitogen- or antigeninduced proliferation of P B M C . Inhibition could however be reversed by
supplementing test cultures with exogenous IL 1. That the inhibitor w a s directed
against IL 1 w a s further confirmed by the fact that it had no effect on the
proliferation of IL 2- and IL 4-dependent cell lines. Inhibition apparently occured at
a post-binding site since the inhibitor did not interfere with specific receptor
binding. Roy et al (1988) reported that the IL 1 activity secreted by monocytederived macrophages infected with HIV was reduced by up to 8 0 % as compared to
control systems similarly stimulated with L P S or latex beads. In contrast to the
aforementioned reports however, they failed to show production of an inhibitor that
could interfere with the measurement of IL 1 activity.

Rodgers et al (1985) have described the production of a 95 kDa inhibitor of IL 1
activity from monocytes infected with H C M V , although the s a m e group (Scott et al,
1989) later attributed this observation to mycoplasma contamination of virus
stocks. Dudding and Garnett (1987), Kapasi and Rice (1988) and Turtinen et al
(1989) have independently proposed that H C M V infection of peripheral blood
monocytes, P B M L or a monocytic cell line respectively w a s associated with the
production of inhibitors of IL 1 activity. The details of these reports are described
in the relevant section on H C M V and leucocyte function (1.1.5.4c).

1.4.6.

Inhibitors associated with other disease states
Lotz et al (1988) have implicated a monocyte-derived inhibitor in the

inability of T cells from patients with rheumatoid arthritis (RA) to suppress
Epstein-Barr virus (EBV)-infected B cells. The inhibitor reduced EBV-induced IL 1,
IL 2 and IFN y activities and was also able to inhibit the IL 1-dependent synthesis of
IL 2 and IFN yby normal P B M C .

1.4.7. Inhibitors from murine monocytes/macrophages
The production of inhibitors of IL 1 activity from murine monocyte cell
lines and macrophages has also been well documented. Cells of the murine
macrophage cell line P388D1 for example produce a peak of IL 1 activity 24 hours
post L P S stimulation and a peak of IL 1 inhibitory activity 72 hours post stimulation
(Nishihara et al 1988). The inhibitor had a M W of 160 kDa although the possibility
that this w a s due to aggregation of lower molecular weight inhibitors was
considered. The inhibitor suppressed both the co-mitogenic and the direct activity
of IL 1 in the murine thymocyte assay via a PG-independent mechanism, while
having no effect on the IL 2 response of an IL 2-dependent cell line. It w a s later
"reported (Isono and Kumagai 1989) that even in the absence of an added stimulus,
the P388D1 cell line produced an influence inhibitory for direct and co-mitogenic IL
1 activity. This influence w a s found to be due to at least two separate 40-60 kDa
molecules; a heat and acid sensitive molecule with a pi of 6 and a heat and acid
resistant molecule with a pi of 5.3. These factors had no suppressive effect on the
activities of IL 2, IL 3 or IL 4 and only influenced IL 1 activity when added during
the first 8 hours of IL 1-thymocyte interaction, although IL 1 receptor binding was
not affected. It was suggested that the factor(s) m a y interfere with PHA- or P H A
and IL 1-stimulated IL 2 production.

Malick et al (1989) reported that splenic and peritoneal macrophages from normal
and tumour-bearing host (TBH) mice produced supernatants that inhibited mitogen-

and alloantigen-induced T cell proliferation and IL 2 production. While inhibitory
activity in both systems w a s associated with factors larger than 67 kDa, only the
inhibitory activity in T B H supernatants w a s neuraminidase sensitive and w a s
present in isoelectric focusing (IEF) fractions corresponding to p H 4-6. The
neuraminidase-insensitive activity from normal supernatants w a s found in IEF
fractions with a p H of 6.5-7.6. This suggests that the tumour burden induces
variable glycosylation of a normal macrophage factor and/or production of an
additional factor. Malick et al have speculated that variable glycosylation m a y alter
recognition phenomena and/or increase the half-life of a produced factor, thus
causing a normal homeostatic control mechanism to be disrupted and become
immunosuppressive.

1.4.8. Inhibitors derived from other ceil sources
Influences inhibitory to the biological action of IL 1 have also been reported
from non-monocyte IL 1 producing cells and cell lines, both under natural conditions
and after virus infection. Walsh et al (1986) for example have reported that in
addition to producing IL 1, keratinocytes also produce a 97 kDa protein that inhibits
IL 1-and IL 2-induced thymocyte proliferation. Scala et al (1984) isolated a 95 kDa
inhibitor from an EBV-transformed lymphoblastoid cell line R O H A - 9 that originally
masked detection of IL 1 activity coexistent in a crude culture supernatant. The
factor suppressed the co-mitogenic effect of IL 1 for murine thymocytes, the
proliferative response of P B M C to antigen and sub-optimal doses of mitogen and the
response of purified T cells to alloantigen. It had however no effect on IL 2-induced
thymocyte proliferation or the response of an IL 2-dependent cell line.

1.4.9. Prostaglandins
Although prostaglandins (PG) play a well characterized role in the negative
control of IL 1 production and action, the inhibitory influences described above are
distinct from P G and the majority of them were found to function via PG-

independent pathways. P G , in particular P G E 2 > do however play an important role
as second messengers for the regulation of IL 1 activity (Kunkel et al 1986). A s
well as suppressing IL 1 production, P G m a y also influence the outcome of
production of an IL 1 pulse through their ability to influence IL 2 production and
responsiveness. In 1982, Tilden and Balch reported that P G E 2 suppressed human
P B M C proliferation via a direct effect on IL 2 production and IL 2 receptor
expression. They found no evidence for PGE2-mediated induction of suppressor
cells. In 1989, Santoli and Zurier demonstrated that P G E 2 precursor fatty acids
also have the potential to directly control IL 2 production. In contrast to these
results, Chohaib and Fradelizi (1982) reported that the P G E 2 effect on IL 2
production w a s mediated via PGE2-activated suppressor T cells. Alterations in IL 2
production seen with various infections have been attributed to enhanced P G
production in response to the infection. Makonkawkeyoon and Kasinrerk (1989)
report that Mycobacterium

leprae has an inhibitory effect on IL 2 production from

P B M L cultures through induction of monocyte P G production.

Because of their potential to regulate IL 1 production and/or biological action, PG
are also important components of the homeostasis mechanisms that exist in normal
cells for the regulation of cytokine function. For example, stimuli that upregulate IL
1 and T N F a, such as endotoxin or IL 1 itself, also induce P G E 2 thus creating a
localized negative feedback pathway. Systemic feedback pathways also exist for IL
1 regulation; Kunkel (1988) has described a hormonal counter-regulatory
mechanism whereby IL 1 induces adrenocorticotropic hormone (ATCH) from
pituitary cells which in turn induces the adrenal gland to produce corticosteroids
which suppress expression of IL 1 m R N A .

1.4.10. Inhibitors of TNF a activity
Seckinger et al (1988) report the first characterization of an inhibitor of
T N F a activity; a 40-60 kDa protein isolated from the urine of febril patients.

Preliminary data suggest that it is active through competition with T N F a, possibly
at the level of receptor binding. It w a s shown to be distinct from the urine-derived
IL 1 inhibitors isolated by this group and others that have been previously
described.

1.5. SCOPE OF THE STUDY
1.5.1

Study

aims

The reported immunosuppressive effects of H C M V have been detailed in this
review. This information suggests that HCMV-infected monocytes play an
important role in HCMV-induced immunosuppression. The aim of this study was to
test the hypothesis that in vitro challenge of monocytes with H C M V could alter key
components of monocyte accessory cell function. Specifically, the study attempted
to ascertain whether H C M V challenge influenced:

i) the expression of class II MHC determinants on the monocyte surface - required
for class II restricted presentation of foreign antigen to effector T cells.
ii) the presentation of foreign antigen by monocytes to effector T cells - necessary
for the initiation of a cell mediated immune response.
iii) the production of immunostimulatory monocyte cytokines - required for
initiation and effective upregulation of the induced response
iv) the production of immunosuppressive monocyte factors, which may
downregulate the immune response.

It is hoped that an evaluation of the effect of HCMV on monocytes in vitro may
contribute to an understanding of the interactions between monocytes and H C M V in
vivo .

1.5.2.

Importance of the study
In patients with defects in cell-mediated immunity (due to clinical

treatment or immunosuppressive disease syndromes such as AIDS), infection
with/reactivation of C M V and the concurrent development of symptomatic
secondary infections is c o m m o n . That this occurs despite apparently normal levels
of circulating antibody indicates that efficient cell-mediated immunity is crucial for
limiting the severity of CMV-associated disease and resolution of the infection.
This study hopes to increase the understanding of the of the nature of the
interaction between C M V and components of the cell-mediated immune system, such
an understanding being central to the development of potential mechanisms for
counteracting CMV-mediated suppression. Treatment of H C M V infections has
included interferons and nucleoside antivirals but this has also been largely
unsuccessful. Development of a safe treatment regime ideally requires background
knowledge of the degree of endogenous production of antiviral and other
immunologically important factors in the infected host, so as not to inadvertently
exacerbate immunopathological disease syndromes. This study thus also hopes to
contribute to this aspect of H C M V research.
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2.0.0. METHODS AND MATERIALS

2.1.

Reagents
Cytokines: Human recombinant IL 6 (rIL 6; 2 x 1 0 8 U/mg), human

recombinant IL 1 (rIL 1; 1 x 1 0 7 U/mg) and human T cell-derived IL 2 (200 U/ml)
were obtained from Boehringer-Mannheim (North Ryde, N S W ) . Human cell line derived IL 1 (200 U/ml) was obtained from Genzyme (Boston, MA). Human
recombinant T N F a (rTNF a ; 1 x 10 7 U/mg) was obtained from Amgen Biologicals
(Thousand Oaks, CA).
Kits: An ELISA for IL 1B was purchased from Cistron Biotechnology
(Pinebrook, NJ) and an a-naphthyl acetate esterase staining kit was obtained from
Sigma (St. Louis, M A ) .
Monoclonal antibodies (MAB): M A B used included an M A B against IL 1 (IgM),
an anti HLA-DR (lgG2a, Clone L243) M A B and an FITC-conjugated anti-CD 3 (Leu 4,
lgG1) M A B all from Becton-Dickinson (Mountain View, CA); a M A B against the C M V
68 kDa immediate early (IE) antigen (MAB 810, lgG1) from Chemicon International (El
Segundo, CA); an FITC-congugated M A B against a C M V 43 kDa early (E) antigen
(DAKO-CMV, lgG1, clone CCH2), a M A B against the p55 component (a chain, T A C
antigen) of the IL 2 receptor (IL 2R; DAKO-IL 2R, lgG1, clone ACT-1) and a purified
phycoerythrin (PE)-conjugated mouse lgG1 M A B (DAKO-G04, negative control for
flow cytometry) from Dakopatts (Glostrup, Denmark). A M A B against the p70
component (B chain) of the IL 2R (TU 27 M A B ) was a gift from Dr. Shinsuke Taki from
the Ajinomoto Co.,Inc. (Kawasaki, Japan). Second conjugates, a PE-conjugated sheep
anti-mouse (IgG, F(ab')2 fragment) and an FITC-conjugated goat anti-mouse (IgG,
whole molecule) were obtained from Sigma.
Miscellaneous: Purified phytohaemagglutinin (PHA-P) was obtained from
Wellcome Diagnostics (Dartford, England); a purified protein derivative of Tuberculin
(PPD) from Commonwealth Serum Laboratories (CSL, Melbourne, Victoria);
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lipopolysaccharide (LPS) from Difco (Detroit, Ml) and chloroquine and concanavalin A
(con A) from Sigma.

2.2. Cells and culture media
Human monocytes and T cells were freshly obtained from the peripheral blood
of healthy H C M V seronegative adult donors (isolated as described in section 2.4) and
cultured in RPMI 1640 (Appendix A) supplemented with 5 % human type A B serum or
autologous serum (Appendix B), 2 m M glutamine, and antibiotics (100 U/ml penicillin
and 100 u.g/ml streptomycin).
Murine thymocytes were freshly obtained from 6-8 week old BALB/c mice
(as described in section 2.10.1) and cultured in RPMI 1640 supplemented with 1 0 %
foetal calf serum (FCS),2 m M glutamine, and antibiotics (100 U/ml penicillin and 100
u.g/ml streptomycin).
The following cell lines were used:
a) Human foreskin fibroblasts (HFF); cultured in C M R L 1969 (Appendix A)
supplemented with 10 % FCS, 2 m M glutamine and antibiotics (100 U/ml penicillin and
100 (ig/ml streptomycin).
b) Murine L929 fibroblasts; supplied by Professor Len Harrison (Walter and Eliza
Hall Institute of Medical Research, Melbourne, Victoria) and cultured in C M R L 1969
supplemented with 1 0 % F C S , 2 m M glutamine, 2 mercaptoethanol (2 M E ; 5x10' 5 M)
and antibiotics (100 U/ml penicillin and 100 jig/ml streptomycin).
c) The IL-6-dependant murine B cell hybridoma 7TD1; supplied by Dr Jacques van
Snick, (Ludwig Institute for Cancer Research, Brussels, Belgium) and cultured in RPMI
1640 supplemented with 1 0 % FCS, 1 0 % concanavalin A activated spleen cell
supernatant (con A sup; Appendix C), 2 m M glutamine, 2 M E and antibiotics (100 U/ml
penicillin and 100 u.g/ml streptomycin).
d) The murine IL 2-dependent cytotoxic T cell line, CTLL; provided by Dr Anne Kelso,
(Walter and Elisa Hall Institute of Medical Research, Melbourne, Victoria) and cultured
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in RPMI 1640 supplemented with 1 0 % F C S , 2 m M glutamine, 2 M E , interleukin 2
(20U/ml) and antibiotics (100 U/ml penicillin and 100 u.g/ml streptomycin).

Unless specified, all cell cultures were performed in the relevant medium,
supplemented as described above, in a humidified 37°C atmosphere. For RPMI
cultures, a 5 % C O 2 atmosphere w a s used. RPMI, F C S and glutamine were obtained
from Flow Laboratories (North Ryde, N e w South Wales) while C M R L and antibiotics
were obtained from Commonwealth Serum Laboratories.

2.3 Preparation of virus stocks
T w o strains of H C M V were used; the laboratory-adapted strain A D 169 was
obtained from the American Type Culture Collection (Rockville, M D ) and the clinical
isolate (p72) w a s obtained from the State Health Laboratory Service (Perth, Western
Australia). Both strains were propagated in mycoplasma-free (determined by regular
DAPI staining; Boehringer- Mannheim; Appendix D) human foreskin fibroblasts
cultured at 37°C in C M R L without antibiotics and 2 % F C S only. Cells and supernatants
were harvested when the cytopathic effect was well advanced. Intracellular and/or
cell-associated virus w a s released by freeze-thawing harvested cells three times,
followed by low speed centrifugation to remove cell debris. Extracellular virus was
pelleted by centrifugation at 20 OOOg for 2h and virus pellets resuspended in equal
volumes of C M R L and 7 0 % sorbitol to yield an infectious dose for each strain of 1 0 8
plaque-forming units/ml (pfu/ml; Appendix K).

For virus titrations, H C M V -

inoculated fibroblast monolayers were centrifuged at 500g for 20 minutes prior to the
standard 90 min passive adsorption period. Hudson (1988) has recommended low
speed centrifugation in order to enhance C M V detection and to optimize infectivity
assays. Centrifugal infection resulted in a 10-fold increase in the sensitivity of
fibroblasts to infection by the clinical isolate, while the response to A D 169 was as
for a standard infection. Viral stocks were stored in liquid nitrogen and regularly
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tested for mycoplasma using a commercial screening system

(Mycotrim® TC, Hana

Biologies, Alameda, CA; Appendix D).

2.4. Preparation of mononuclear cells
Human peripheral blood mononuclear cells (PBMC) obtained from the
heparinized (10 U/ml) venous blood of H C M V seronegative adult donors was separated
according to the principle of B 0 y u m (1984) on a hypaque-ficoll density
gradient(Mono-poly resolving medium; Flow). Undiluted blood was layered onto the
resolving medium and centrifuged at 500g for 45 min. Mononuclear cells were
aspirated from the plasma-medium interface, washed three times in calcium- and
magnesium-free Hank's balanced salt solution (HBSS; Appendix A) and resuspended at
a concentration of 1 x 1 0 7 cells/ml in RPMI. For washing steps, cells were pelleted
by centrifugation for 4 min at 400 g.

2.4.1 Isolation of monocytes
To isolate adherent cells, 5 x 1 0 7 P B M C in 10 ml RPMI were incubated in 90
m m tissue culture treated petri-dishes (Nunc, Roskilde, Denmark) for 90 min. The
medium containing non-adherent cells was aspirated and retained for the isolation of T
cells. The adherent monolayer was well rinsed with H B S S and adherent cells
recovered by incubation with 10 m M E D T A in P B S at 4°C for 30 min and subsequent
vigorous pipetting. Recovered cells were routinely > 9 0 % viable as assessed by
trypan blue exclusion and 95-98% non-specific esterase positive and are hereafter
refered to as monocytes. For antigen presentation assays, monocytes were
introduced into 96 well trays (Nunc) for re-adherence and treatment as described in
section 2.7. W h e n monocytes were to be used for supernatant generation or M A B
staining (as outlined in sections 2.6.1 and 2.12 respectively), the adherence step was
performed directly in Linbro 24 well trays (Flow). In selected experiments,
monocytes cultured for supernatant generation (section 2.6.1) were isolated by
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adherence in petri-dishes as described and then cultured in suspension in 1ml volumes
of RPMI culture medium (section 2.2) in siliconized 1.5 ml Eppendorf tubes at a
concentration of 5 x 1 0 5 cells/ml. Adherent monocytes were cultured in 24 well
trays at a density of 5 x 1 0 5 cells/well in a total culture well volume of 1ml, or in
96 well trays at a concentration of 2 x 1 0 4 cells/well in a total culture well volume
of 250 u.l.

2.4.2. Isolation of T cells
T cells were isolated from the non-adherent cell fraction by passage through
a nylon wool column using a modification of a previously described method (Litvin and
Rosenstreich, 1984). A nylon wool column prepared under sterile conditions
(Appendix E) was rinsed sequentially with 15 ml serum free RPMI and supplemented
RPMI followed by incubation at 37°C for 30 min. The non-adherent cell suspension
was adjusted to 5 x 1 0 7 cells/ml in 4 ml R P M I and applied to the column. After 30
min incubation at 37°C the nylon wool non-adherent fraction w a s recovered by elution
with 20 ml of RPMI at a rate of about one drop/second. The recovered cell population
was > 9 0 % viable as assessed by trypan blue exclusion and > 9 5 % of the population
reacted with an FITC-conjugated anti-Leu 4 (CD3) monoclonal antibody (BectonDickinson). T cells were used either for the production of T cell factors as described
or for co-culture with autologous monocytes at a 1:1 ratio.

2.5 Virus challenge of monocytes
Monocyte monolayers in 96- or 24-well trays were inoculated with virus
suspension diluted in 100 u.l or 200 u.l of serum free R P M I respectively to give the
appropriate multiplicity of infection (moi). Monolayers were centrifuged at 500g for
20 min followed by a 90 min passive adsorbtion period at 37°C. The virus inoculum
was removed and monolayers rinsed three times in serum-free RPMI before use in
subsequent treatments. A similar mock-infection procedure using serum-free RPMI
alone was followed for control cultures. Monocytes were challenged as soon after
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isolation as possible, ie: directly after completion of the adherence step in 24- or
96-well trays or, where appropriate, only after additional manipulations were
performed. For example, when an L P S pre-stimulation regime w a s used (section 2.8),
monocytes were challenged only following this procedure and in selected antigen
presentation assays (as specified in section 2.7) monocytes were pulsed with P P D for
three hours prior to virus challenge. Monocytes cultured in suspension in Eppendorf
tubes were challenged by inoculating suspension cultures with virus. Suspension
cultures were centrifuged at 500g for 20 min followed by a 90 min passive adsorbtion
period at 37°C as described for challenge of adherent monocyte monolayers.

2.6. Supernatant generation
2.6.1

Generation of monocyte supernatants .
Monocyte supernatants were generated by incubating HCMV-challenged or

control monocytes (5 x 1 0 5 cells/well of a 24 well tray) in R P M I (1 ml/well) in the
presence or absence of an optimum concentration (20 u.g/ml) of L P S (Difco, Detroit,
Ml) for various times. In selected experiments, monocytes were cultured in the
presence of 1 0 % autologous T cells (1:1 ratio), T cell supernatants ( 2 0 % v/v) or rIL
13 (2000pg/ml and 5000pg/ml). For supernatant collection, two different protocols
were followed: supernatants were harvested at discrete intervals within the total
culture period and replaced by fresh appropriately supplemented medium for
subsequent supernatant generation from the same monolayer; or alternatively
supernatants were harvested at the termination of a particular culture period only.
After harvesting, monocyte supernatants were clarified by low speed centrifugation
(500g for 5 min) followed by high speed centrifugation (16 OOOg for 1 h at 4°C) to
sediment any residual virus. In selected experiments, clarified supernatants were
extensively dialysed (12 kDa molecular weight cut-off) against a balanced salt buffer
(10 m M H E P E S , 0.15 M NaCI; pH 7.4) for 48 h at 4 ° C to remove low molecular weight
contaminants. All supernatants were filtered through 0.22 u.m filters (Millipore,
Bedford, M A ) , aliquoted into small volumes and stored at -70°C until use.
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To collect intracellular products, monocyte monolayers (5 x 1 0 5 cells in 1
ml RPMI) were detached into the culture medium using a rubber policeman and cell
lysates generated through three freeze-thaw cycles. Cell debris was removed by low
speed centrifugation (500g for 5 min) and supernatants treated as described above.

2.6.2 T cell supernatants
T cell supernatants were generated from mitogen-activated T cells for use both as a
crude preparation of stimulatory factors for cell proliferation assays and as a source
of HLA-DR-inducing material for monocytes. T cells ( 2 x 1 0 6 cells/ml ) were
incubated in R P M I supplemented with P H A (2u.g/ml) for 72 h. The resultant
supernatants were filtered, aliquoted and stored at -70°C.

Preliminary experiments indicated that monocytes incubated for 48 h in the
presence of such supernatants at a concentration of 1 0 % v/v expressed significantly
increased amounts of HLA-DR as compared to controls. The described protocol was
thus considered suitable for use in the generation of T cell supernatants with HLA-DRinducing potential. T cell supernatants prepared in this way contained between 20 and
25 U/ml IL 2 as determined using the IL 2-dependent C T L L cell line as a source of
indicator cells (section 2.11.3) and were able to induce considerable thymocyte
proliferation. These supernatants were thus also used ( 2 0 % v/v) in selected
experiments as a crude mixture of T cell cytokines to augment P H A (1 u.g/ml and 2
(ig/ml)-stimulated thymocyte and T cell proliferation.

2.7. Antigen pulsing of monocytes
The antigen chosen for use in antigen presentation assays was a purified
protein derivative of Tuberculin (PPD, C S L Laboratories, Melbourne, Vic). Responder
lymphocytes were obtained from previously immunized donors and initially tested for
their capacity to exhibit a high PPD-specific proliferative response in the presence of
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autologous antigen presenting cells (APC). Monocytes were usually pulsed with
antigen after challenge/mock-challenge in 96-well trays, but in selected experiments
monocytes were PPD-pulsed prior to, or during, virus challenge. Adherent monocytes
(2 x 1 0 4 cells/well) were incubated in serum-free R P M I (100u.l/well) supplemented
with P P D (100u.g/ml RPMI) in a total well volume of 250 u.l for 3 h. Cells were then
thoroughly washed to remove free P P D prior to use as A P C . Control cultures were
incubated in PPD-free medium and similarly washed.

In some experiments, lysosomal function was disturbed by treatment with
the lysosomotropic agent chloroquine (Sigma, St Louis, Mo.). Chloroquine was
dissolved in serum-free RPMI to yield a final concentration per well of 0.1 m M or 0.5
m M . Monocytes were exposed to chloroquine 30 min prior to addition of P P D and for
the duration of the pulse, or chloroquine was added only 30 min or 120 min after
initiation of pulsing.

2.8. Lymphocyte proliferation assays
Monocyte accessory cell function was assessed by measuring the
proliferative response to T cells co-cultured with the test monocytes. Cultures were
performed in flat-bottom 96-well trays with a lymphocyte : monocyte ratio of 10:1.
As described in Results (section 3.1.1), initial T cell proliferation assays using
different concentrations of monocytes showed this to be an optimum ratio. Monocytes
(2 x 1 0 4 cells/well in 100u.l RPMI) were added to appropriate wells and allowed to
adhere. The adherent cells were subjected to some or all of the following treatments
: LPS stimulation, virus challenge and P P D pulsing. For L P S stimulation, selected
monocyte monolayers were pre-stimulated with LPS-supplemented (20u.g/ml) RPMI
for 6 h before H C M V challenge, P P D pulsing and use in subsequent antigen
presentation studies. L P S pre-stimulation was performed on adherent monocytes in
petri-dishes prior to lifting with E D T A (10mM) and transfer to 96-well trays.
Unstimulated cultures were incubated in parallel with unsupplemented RPMI.

HCMV
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challenge and P P D pulsing are separately described. Between all monocyte treatment
protocols and washing steps described, cells were spun down at low speed (400g for 5
min) to prevent inadvertant cell loss during supernatant aspiration. Following these
treatments, T cells (2 x 1 0 5 cells/well in 100 u.l RPMI) were added either directly,
24 h or 48 h later. Lymphocyte proliferation was assessed by measuring the
incorporation of exogenous tritiated thymidine ([3H] thymidine; 1u.Ci/well; Sp. Act.
3.777 GBq/ml) into T cell D N A

over the last 18 h of a 5 day culture (Bradley 1980).

Cells were harvested onto glass fibre filter paper discs (Skatron, Suffolk, England)
using a Titertek multi-well harvester (Flow Laboratories). Filter discs were dried,
each disc added to 5 ml of a premixed scintillation cocktail and disc solubilizer
(Scintisol; Isolab, Ohio, U S A ) and cellular [3Hj thymidine incorporation measured
using an LKB liquid scintillation counter (Linbrook International, N.S.W., Australia).
Monocytes alone incorporated minimal amounts of thymidine. All cultures were
performed in triplicate and results expressed as mean cpm ± 1 S D values or as a
percentage increase over the cpm obtained for lymphocytes exposed to unpulsed
normal monocytes or pulsed mock-challenged monocytes. Standard errors for the
means of triplicate cultures were calculated and the significance of differences
between supernatant samples was determined using the Students t -Test where a
value of p < 0.05 was considered to be significant.

2.9. ELISA
Immunoreactive IL 1B w a s detected using a commercially available ELISA for
IL 13 (Cistron Biotechnology, Pine Brook, NJ; Appendix F). Monocyte supernatant
samples were tested at two dilutions and each dilution was tested in duplicate
according to the manufacturers instructions. The average A490 readings for each
sample were converted to pg IL 1B/ml of supernatant tested using a prepared
standard curve. Differences in the amount of IL 1 B between treatments were
assessed using the Students f-Test where a value of p < 0.05 was considered to be
significant.
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2.10.

Biological assays for m o n o c y t e

2.10.1

IL 1 assay.

cytokine activities

The IL 1 activity of test supernatants was assessed by using a standard
thymocyte co-mitogenic assay (Mizel, 1981). Thymocytes were obtained from 6 to 8
week old BALB/c mice sacrificed by cervical dislocation following the method of
Kleiman et al (1984): a thymus was teased apart with sterile forceps into H B S S .
Tissue pieces were sedimented by gravity and cell aggregates removed by passage of
the cell suspension through a stainless steel mesh. The resulting single cell suspension
was pelleted by centrifugation (400g for 4 min), rinsed two times in H B S S and
resuspended in RPMI supplemented as described in Section 2.2. Thymocytes isolated
in this manner were incubated (1 x 1 0 6 cells/ well) in round bottom 96 well trays in
RPMI additionally supplemented with 1 u,g/ml PHA. With the exception of experiments
involving dialysis steps (as detailed in section 2.6.1), monocyte supernatants were
used at 1 0 % v/v in a final well volume of 250 u.l. Thymocyte proliferation was
assessed by measuring the uptake of [3H] thymidine (0.5u.Ci/well) over the last 18
hours of a three day culture as described in detail in section 2.8. IL 1 activity was
expressed as mean cpm ± 1 S D values for triplicate samples. Standard errors for the
means of triplicate cultures were calculated and the significance of differences
between supernatant samples was determined using the Students t -Test where a
value of p < 0.05 was considered to be significant. In order to compare data using
supernatants from different donors under different experimental conditions, biological
activity was expressed as a percentage relative to that of control thymocyte cultures
represented as 100 %. W h e n supernatants from monocytes cultured in the presence
of LPS, T cell factors or IL 1 were tested, the appropriately supplemented controls
were included. W h e n supernatant fractions from gel fractionation procedures were
used, the equivalent fractions of supplemented R P M I alone were also included.
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2.10.2

Assay for T N F a

The T N F a content of monocyte culture supernatants w a s measured using actinomycin
D-treated L929 cells in a standard cytotoxicity assay (Flick and Gifford, 1984).
Briefly, L929 cells cultured in C M R L 1969 medium supplemented as described in
section 2.2 were seeded into 96 well flat-bottomed plates (Nunc, Roskilde, Denmark)
and grown for 5 hours to establish a confluent monolayer. Monolayers were exposed
to monocyte test supernatants (50 u,l/well) in the presence of actinomycin D (1
u.g/ml) in a final well volume of 200 u.l. After 24 hours, monolayers were rinsed
with P B S and stained with 0.5% crystal violet (200 uJ/well; Appendix G ) for 15
minutes. Dye w a s eluted in 3 3 % acetic acid (200 u.l/well; Appendix G) and A 4 9 0
determined with an M R 600 microplate reader (Dynatech Laboratories, Alexandria,
VA). The T N F a activity (U/ml) in a sample w a s calculated by comparison to a
standard curve prepared using a recombinant human T N F a (1 x 1 0 7 U/mg) at various
dilutions as the test supernatant. Each supernatant w a s tested in triplicate. Standard
errors for the means of triplicate cultures were calculated and the significance of
differences between supernatant samples was determined using a students t -Test
where a value of p < 0.05 was considered to be significant.

2.10.3 Assay for IL 6
The IL 6 activity in culture supernatants w a s measured using 7TD1 cells as
described (Van Snick et al, 1986). Briefly, 2x10 3 7TD1 cells in con A sup-free RPMI
(ie: RPMI supplemented as described in section 2.2 but without con A sup.) were
incubated with 2-fold dilutions of test supernatant in 200u.l volumes in 96 well flatbottomed plates (Nunc). Proliferation was assesed by a [3H] thymidine pulse (0.5
uCi/well) over the final 18 h of a 3 day culture as described in detail in section 2.8.
For each assay performed, IL 6 activity in test samples was expressed in U/ml
relative to the activity of a crude IL 6 supernatant (supplied by Dr Anne Kelso, Walter
and Elisa Hall Institute of Medical Research, Melbourne, Victoria) where 1 unit was
defined as the reciprocal of the dilution causing half-maximal proliferation of 7TD1
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cells. All samples were tested in triplicate. In s o m e experiments, monocyte
supernatants were size-fractionated by gel filtration as described in section 2.14.
Fractions eluting in the size range encompassing the IL 6 polypeptide (20-40 kDa)
were tested for IL 6 activity as described. Standard errors for the m e a n s of
triplicate cultures were calculated and the significance of differences between
supernatant samples was determined using the Students t -Test where a value of p <
0.05 was considered to be significant.

2.10.4 Assay for il 2
The IL 2 activity in T cell supernatants was measured using C T L L cells in a
standard IL 2 assay as described (Gillis et al 1978). Briefly, C T L L cells (4 x 1 0 3
cells/well cultured in R P M I supplemented as described in section 2.2 but without
additional IL 2 ) were incubated with 2-fold dilutions of test supernatant in 200 u.1
volumes in 96-well round-bottom trays (Nunc). C T L L proliferation w a s assessed
using a [3H] thymidine pulse (0.5 u.Ci/well) over the final 18 h of a 3 day culture as
described in detail in section 2.8. IL 2 activity w a s calculated by comparison to a
standard curve prepared using a 2-fold dilution series of a purified IL 2 standard (200
U/ml).

2.11. Inhibitor assays
2.11.1

Using thymocytes
Thymocytes obtained from 6 to 8 week old BALB/c mice (as described in

section 2.10.1) were incubated (1 x 1 0 6 cells/well) in round bottom 96 well trays in
RPMI supplemented as described in section 2.2. The proliferation stimuli used were
P H A (1 jig/ml) alone, or P H A and one of the following: rIL 1, rIL 2, rIL 6, crude IL 6
(prepared from monocyte supernatants size fractionated by gel filtration as described
in section 2.14) or crude monocyte or T cell supernatants (prepared as described in
section 2.6) at the concentrations indicated in results. Dilutions of test supernatant
or control medium were added at 1 0 % v/v or as indicated in results to a final volume
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of 200 u.l. Thymocyte proliferation w a s assessed by measuring the uptake of [ 3 H]
thymidine as described in section 2.8. In order to compare data using supernatants
from different donors under different experimental conditions, proliferation of
thymocytes cultured in the presence of stimuli and suppressive supernatants was
usually expressed as a percentage relative to that of thymocytes cultured in the
presence of stimuli alone or stimuli and supernatants from mock-challenged
monocytes that contained no suppressive influence.

2.11.2 Using peripheral blood human T cells
The principle of the assay was as described (section 2.11.1) for thymocytes,
but human T cells isolated from peripheral blood (as described in section 2.4) and
cultured in medium supplemented as described in section 2.2 were used as the
indicator cells. T cells were cultured at 2 x 1 0 5 cells/well and stimulated with P P D pulsed monocytes (at a monocyte:T cell ratio of 1:10) or 2 % normal monocytes and
either P H A (2 |ig/ml) alone or P H A and rIL 2 or rIL 6 at the concentrations indicated
in results.

2.11.3 Using CTLL cells
CTLL cells cultured as described in section 2.2 were incubated in roundbottom 96-well trays at two cell densities (2 x 1 0 3 cells/well or 2 x 1 0 4 cells/well)
in the presence of IL 2 (10 U/ml or 50 U/ml) and the test supernatant ( 1 0 % v/v).
Proliferation of C T L L cells under these conditions w a s assessed by a [3H] thymidine
pulse (0.5 uCi/well) over the final 18 h of a 3 day culture (as described in section
2.8).
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2.12.

Immunofluorescence

2.12.1

For the detection of H C M V antigens
Monocytes were cultured in RPMI and 5 % A B serum, additionally

supplemented as described in section 2.2. Monocytes were stained with M A B 810
reactive against a 68 kDa IE non-structural nuclear antigen, and D A K O - C M V , an FITCconjugated M A B reactive against a 43 kDa nuclear antigen, expressed in productively
infected fibroblasts both at the early and late stages of infection. Monocytes were
cultured on glass coverslips in the wells of 24 well trays (1 x 1 0 5 cells/well) and
challenged with H C M V as described above. Staining was performed at various times
post challenge. Monocytes were fixed in P B S containing 2 % paraformaldehyde
(Appendix I) for 20 min at room temperature and Fc receptors (FcR) blocked with
1 0 % type A B serum (Appendix B) in P B S for 20 min at 37°C. For indirect staining,
cells were incubated with M A B 810 (1:100 dilution) followed by a sheep anti-mouse
FITC conjugate (1:100 dilution). Both incubations were performed for 45 min at
37°C. For direct staining, monocytes were permeabilized after fixation by treatment
with 0.1% Triton X 100 in P B S for 5 min at 4 ° C and stained with D A K O - C M V (1:5
dilution) for 45 min at 37°C. Between all staining steps, coverslips were well rinsed
with staining buffer (Appendix H). Control coverslips with mock-infected monocytes
(and for indirect staining samples incubated with the second conjugate only) were
routinely included. Coverslips were mounted in Fluorornount™ (BDH Chemicals,
Kilsyth, Victoria) and analysed using a Leitz Dialux fluorescent microscope. Between
200-300 cells were counted over a number of randomly selected fields.

2.12.2 For detection of HLA DR molecules
Glass coverslip-adherant monocytes were cultured and challenged with H C M V
as described above. In some experiments, R P M I was supplemented with LPS (20
M-g/ml) or an experimentally generated (section 2.6.2) T cell supernatant ( 1 0 % v/v).
Staining was performed at various times post challenge. Immediately prior to
staining, coverslips were rinsed with staining buffer (Appendix H) and FcR were
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blocked with 1 0 % type A B serum (Appendix B) in P B S for 20 min at 37°C.
Monolayers were incubated with an anti-HLA-DR M A B (L234) at the manufacturers
recommended concentration (20u,l/106 cells) and rinsed three times before incubation
with a goat anti-mouse FITC conjugate (1:100 dilution). Control samples were
incubated with the second conjugate only. Both incubations were performed at 4 ° C for
45 min. Coverslips were rinsed prior to fixation in P B S with 2 % paraformaldehyde
(Appendix I) for 5 min at room temperature. After a final rinse, coverslips were
mounted in Fluoromount™ and analysed using a Leitz Dialux fluorescent microscope.
Between 200-300 cells were counted over a number of randomly selected fields.
Differences in expression of HLA-DR between treatments were assessed using the
Students t - test where a value of p < 0.05 was considered significant.

2.13 Cytofluorometric analysis
Expression of the p55 (a chain or T A C antigen) and p70 (B chain) components
of the IL 2R was analyzed by indirect immunofluorescence and analyzed by flow
cytometry on an EPICS V (Coulter Electronics, Brookvale, N S W ) . Nylon wool-purified
T cells were cultured at 2 x 1 0 5 cells/well in 200 u.l volumes of RPMI (supplemented
as described in section 2.2) and P H A (1 u,g/ml or 5u.g/ml) in round bottom 96-well
trays for 3 days. This protocol was initially shown to induce expression of p55 and
p70. T cells were incubated in the presence or absence of supernatant fractions
(added at 1 0 % v/v) from mock- and HCMV-challenged monocytes. The test fractions
were obtained by gel filtration of monocyte supernatants as described in section 2.14
and corresponded to the M.W. range 130-180 kDa (called Fraction 2) and 75-100 kDa
(called Fraction 4). After 3 days incubation.T cells were harvested into Eppendorf
tubes , washed with unsupplemented RPMI and incubated for 1 h at 37°C in RPMI,
additionally supplemented with 25 m M H E P E S , to remove residual P H A and endogenous
IL 2. Cells were washed again and incubated for 10 min at 37°C in P B S containing 0.3
M N-acetyl D-galactosamine to disaggregate PHA-induced cell clumps. T cells were
incubated in blocking buffer (Appendix H) for 20 min at 4°C to block FcR and
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resuspended in staining buffer (Appendix H) at a concentration of 2 x 1 0 5
cells/Eppendorf tube in 50 u,l volumes. Cells were stained with anti IL-2R (1:50
dilution) and T U 2 7 (1:50 dilution) M A B s which recognize the p55 and p70 components
of the IL 2R respectively. A PE-conjugated goat-anti mouse IgG (1:25 dilution) was
used as the second conjugate. Negative controls included a purified PE-conjugated
mouse lgG1 M A B (1:50 dilution) or the second conjugate alone. All samples were
additionally stained with an FITC-conjugated anti-CD 3 (Leu 4, lgG1) M A B (1:50
dilution). All staining steps were performed on ice for 30 min, with two washes
between each incubation. Staining buffer (Appendix H) was used for all staining,
washing and diluting procedures. For the washing steps, cells were pelleted in an
Eppendorf 5415 centrifuge for 3 min at 300 g. Samples were analyzed at 488 n m
with electronic gates set on C D 3-positive cells only.

2.14. Gel chromatography
Monocyte supernatants were generated from mock- and HCMV-challenged
monocytes as described in section 2.6.1 and harvested at 48 hr intervals to yield 048, 48-96 and 96-144 h supernatants, where time 0 h w a s equivalent to the time of
culture initiation and the time of virus challenge. Harvested supernatants were
concentrated 5-fold using Centriprep-10 concentrators (Amicon, Danvers, M A ) and 1
ml concentrates were loaded onto a Sephacryl S-200 H R (Pharmacia LKB, Uppsala,
Sweden) column (90 x 1.5 cm) equilibrated in Tris-NaCI buffer (0.1M-0.5M; pH 8) and
maintained at 4°C. Eight ml fractions were collected by elution with Tris-NaCI at one
of two flow rates. Initially a flow rate of 12 ml/h w a s used, but this w a s
subsequently reduced to 8 ml/h to allow more extensive separation of monocyte
supernatant components. The A209 of the column eluant was monitored with a Uvicord
Sll recorder (LKB, Bromma, Sweden). Fractions were reconcentrated to 1 ml
volumes using Centriprep-10 concentrators, sterilized by passage through 0.22 u.m
M-star filter units (Costar, Cambridge, M A ) and 25 u,l aliquots tested for their
influence on PHA-induced thymocyte proliferation as described in section 2.10.1. Due
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to the concentration steps used, components present in supernatant fractions were 5
times more concentrated than the corresponding components present in unfractionated
supernatants. Control samples were prepared by concentrating and fractionating
supplemented R P M I exactly as for test supernatants. Molecular weight standards
(Pharmacia) included blue dextran 2000 (void), bovine serum albumin (67 kDa)
ovalbumin (43 kDa), chymotrypsinogen A (25 kDa) and ribonuclease A (13.7 kDa).

The A280 of fractions eluting between void (V0) and total volume (Vt) was
measured using an LKB Ultrospec II (LKB, Bromma, Sweden). The A209 and A280
profiles of test samples eluting directly from the column were no different to those of
control medium only samples (RPMI 1640 supplemented with 5 % autologous human
serum, 2 m M glutamine, 100 U/ml penicillin and 100 [ig/ml streptomycin), indicating
that the absorbance peaks observed were due to medium serum constituents. Thus,
although the absorbance profiles did not reflect the different biological activities in
the monocyte supernatant fractions, they allowed monitoring of individual supernatant
fractionation procedures to ensure that consistent elution conditions were maintained.
To illustrate this point, the A280 elution profiles obtained for supernatants generated
from LPS-stimulated, mock-and H C M V (p72; moi 10:1)-challenged monocytes (0-48,
48-96 and 96-144 h after initiation of culture) are illustrated in Appendix L. Also
shown is the A280 profile of the corresponding medium only control.

2.15 Preparation of supernatants from HCMV-challenged fibroblasts
and endothelial cells
Supernatants generated from fibroblasts and endothelial cells were supplied
by Dr G. Sullivan-Tailyour and Dr S. Woodroffe (University of Wollongong,
Wollongong, N S W ) respectively. These supernatants were tested for an effect on
thymocyte stimulation using the method described in 2.10.1 for monocyte
supernatants. The methods used to generate the test supernatants are briefly
outlined:
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2.15.1

Fibroblasts
H u m a n foreskin fibroblasts infected with A D 169 at an moi of 3:1 were

cultured in 75 c m 2 tissue culture flasks in the presence of 10 ml C M R L 1969 medium
(additionally supplemented as described in section 2.2). Supernatants were harvested
after 3 days. Control supernatants were 3 day supernatants generated from similarly
passaged but uninfected fibroblasts.

2.15.2 Endothelial cells
Endothelial cells (EC) were derived from human umbilical cord vein (Appendix
J) and culture was established in E C growth medium. Established E C were cultured in
24 well trays in 1 ml volumes of growth medium and mock-challenged or H C M V challenged with A D 169 at an moi of 3:1. Supernatants were harvested at 24 h
intervals over a 4 day culture period (ie: at 24, 48,72 and 96 h after virus challenge)
with fresh, appropriately supplemented medium being replaced after each harvest.

3.0

RESULTS

3.1

M o n o c y t e s and antigen presenting function

3.1.1

Establishment of optimal monocvte-T cell culture conditions.
To determine satisfactory conditions for the co-culture of monocytes and T

cells in the 5 day antigen presentation assay, freshly isolated adherent monocytes in
flat-bottomed 96 well trays (10 4 cells/well) were pulsed with P P D (100 u.g/ml) as
described in section 2.7 and cultured with freshly isolated, nylon wool purified,
autologous T cells (2 x 1 0 5 cells/well) to give a monocyte :T cell ratio of 1:20 ( 5 %
monocytes) in a total well volume of 250 u,l. The PPD-pulsed monocytes and T cells
were cultured with an increasing percentage of additional unpulsed autologous
monocytes that had been LPS-prestimulated (20 u,g/ml) for 6 h as described in section
2.8, or that were unstimulated (Table 1). A maximal T cell proliferative response
was obtained when monocytes were used at a total concentration of 10 - 1 5 % relative
to autologous T cells. O n the basis of these observations, a monocyte: T cell ratio of
1:10 (10% monocytes) w a s selected for use in future antigen presentation assays.
P P D pulsed monocytes and T cells were always co-cultured at 2 x 1 0 4 cells/well and
2 x 1 0 5 cells/well respectively, in a final well volume of 250 jil, to yield a
monocyte:T cell ratio of 1:10.

3.1.2. Monocyte dependence of the optimal T cell response to PPD.
To ascertain if monocytes were required for an optimal response to P P D , or
if P P D had a mitogenic effect, freshly isolated, nylon wool purified, T cells were cocultured with PPD-pulsed monocytes immediately after the pulse regime, or with P P D
alone. Three different P P D concentrations were tested (Table 2). Monocytes that
were pulsed with a P P D concentration of 100u,g/ml supported optimum T cell
proliferation and hence this concentration w a s chosen for use in subsequent antigen
presentation assays. At the optimal concentrations used for monocyte pulsing, the
mitogenic effect of P P D was found to be minimal. Post-pulse washing steps prior to
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TABLE 1: T CELL PROLIFERATION IN RESPONSE TO INCREASING MONOCYTE
nONCENTRATlONS

% OF MONOCYTES ADDED

|T CELL PROLIFERATION
(cpm)c

PPD-PULSED MONOCYTES

ADDITIONAL MONOCYTES

a

(+/- LPS) b

5
5

0
1

(+ LPS)

5
5
5
5

1
5
5
10

(- LPS)
(+ LPS)
(- LPS)
(+ LPS)

5
5

10 (- LPS)
20 (+ LPS)

9203
8208
8560
1762

5
5

20 (- LPS)
50 (+ LPS)

3581 ±315
663 ± 266

5

50 (- LPS)

620 ± 331

7381 ±1212
8843 ± 160
8141 ± 1762
8227 ± 2408
±
±
±
±

2616
2013
565
74

Note: T cells were cultured at 2 x 10 5 cells/culture well; the concentration of monocytes used
is given as a percentage relative to this
a

Monocytes were pulsed with P P D and used in an antigen presentation assay at a fixed

concentration (1x10 4 cells/ culture well or 5 % )
D

Additional unpulsed monocytes were precultured for 6 hours with 20 jig/ml L P S (+ LPS) or

without L P S (- LPS) and used in the antigen presentation assay in increasing concentrations (2 x
10 3 -1 x 1 0 5 cells/culture well or 1-50%).
c

Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures. T h e

experiment shown is representative of two similar experiments.
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TABLE 2: THE T CELL PROLIFERATIVE RESPONSE TO PPD - MONOCYTE REQUIREMENT
AND THE EFFECT OF PPD CONCENTRATION.

PPD CONCENTRATION
(u.g/ml)

T CELL PROLIFERATION (cpm)b W H E N T CELLS

a

INCUBATED WITH
PPD-PULSED MONOCYTES

25

6676 ± 1036

FREE PPD
1057 ± 177

100

14719 ± 967

3702 ± 751

200

11617 ± 1368

9753 ± 883

Note: cpm for T cells stimulated with P H A (2 (i.g/ml) and co-cultured with unpulsed monocytes
was
25162 ±1417
a

P P D was used to pulse monocytes or incubated with T cells as free P P D at one of three

concentrations.
b

Thymidine incorporation is expressed as mean c p m ± 1 S D for triplicate cultures. The

experiment shown is representative of two similar experiments.

monocyte-T cell co-culture would also minimise the availability of free P P D with
mitogenic potential. These data demonstrate that in this system, monocytes are
required to present P P D to T cells in a form that induces optimal T cell proliferation.

3.1.3 The requirement for a period of intracellular antigen handling.
Lysosomotropic agents such as chloroquine disrupt intracellular p H gradients
and prevent endocytosis and/or processing in intracellular compartments (Harding and
Unanue 1989). To determine whether the monocyte dependence demonstrated in this
system w a s due to a requirement for intracellular processing, or whether monocytes
were passively presenting P P D after cell surface interactions only, monocytes were
exposed to chloroquine before the start of the 3 h P P D pulse, or 30 min or 2 h after
the start of the 3 h pulse. The data in Table 3 indicate that treatment with chloroquine
at concentrations of 0.1 m M and 0.5 m M affected the ability of monocytes to present
P P D to responder T cells. The response appeared to be dose dependent and the earlier
the treatment, the greater w a s the interference with antigen handling. The possibility
that chloroquine might be suppressing the T cell proliferative response due to a
generalised cellular toxicity w a s ruled out by adding chloroquine, at the two
concentrations used, to cultures containing monocytes and PHA-stimulated T cells.
Chloroquine at 0.1 m M w a s not at all toxic, while cultures incubated with 0.5mM
showed a marginally decreased proliferative response.

On the basis of these results, it was concluded that a degree of antigen
processing, involving s o m e intracellular metabolic steps, is required of the monocyte
prior to antigen presentation to T cells for an optimal antigenic response. P P D was
thus considered suitable for use as a model antigen to measure the ability of
monocytes to function as A P C , with the magnitude of the T cell proliferative response
being taken as representative of the relative success of the presentation event.
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TARLE 3: REQUIREMENT FOR AN INTRACR IIIIAR ANTIGEN PROCESSING STEP - THE
FFFECT OF CHLOROQUINE TREATMENT ON MONOCYTE PPD-PRESENTING ABII ITY

CHLOROQUINE

TIME CHLOROQUINE ADDED

T CELL PROLIFERATIVE

CONCENTRATION (mM)

(w.r.t. PPD PULSE ) a

RESPONSE (cpm)b

0.1

30 min before

1150 ± 122

30 min after

3976 ± 751

120 min after

0.5

7194 ± 1368

30 min before

1095 ± 54

30 min after

1681 ± 246

120 min after

5101 ± 142

Note: c p m for T cells stimulated with P H A (2\iglm\) and co-cultured with normal monocytes
that had been pre-exposed to chloroquine for 120 min was 24673 ± 1223 (chloroquine at 0.1
m M ) and 22546 ± 777 (chloroquine at 0.5 m M ) .
a

PPD-pulsing w a s performed for 180 min (3 h). Chloroquine w a s added 30 min prior to pulse

initiation and was present for the duration of the pulse, or w a s present for the last 150 or 60
min of the pulse period (where added 30 or 120 min after pulse initiation respectively).
b

Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures. T h e

experiment shown is representative of two similar experiments.

3.1.4

The effect of HCMV-challenae on monocyte antiaen presenting ability.
LPS-pre-stimulated or unstimulated monocytes were mock-challenged or

challenged with H C M V prior to P P D pulsing and co-culture with T cells in the antigen
presentation assay as described in section 2.8. Monocyte-T cell co-culture w a s
initiated either immediately following H C M V challenge (0 h; Table 4a) or only 48 h
after the pulse/challenge regime (Table 4b). Four separate donors were used and
HCMV-challenged monocytes consistently showed a reduced ability to support antigenspecific T cell proliferation. This decrease in accessory cell activity w a s not always
significant when monocytes and T cells were co-cultured immediately after infection,
but became very marked when the infection w a s allowed to proceed for 48 hours prior
to the initiation of monocyte-T cell co-culture. The magnitude of the suppressive
effect was also dependent on the m.o.i. used. These trends are graphically presented
in Figure 1. It w a s also noted that the absolute levels of T cell proliferation attained
with LPS-stimulated monocytes as accessory cells were always lower than those
attained with unstimulated monocytes. This phenomenon w a s directly addressed in
subsequent experiments (described in section 3.1.6).

A reduction in antigen-presenting ability was observed if monocytes were
virus-challenged during the period of antigen pulsing or after completion of the P P D
pulse (Table 5), This suggested that HCMV-challenge w a s not interfering with initial
P P D uptake into the monocyte, but with subsequent event(s) associated with P P D
handling and presentation on the monocyte surface. In addition, initial observations
that HCMV-challenge did not induce any obvious cytopathic effect, and that the
viability of mock and challenged monocyte cultures w a s the s a m e for up to 1 week,
suggested that the decreased accessory cell activity was not due to a reduction in cell
viability or to virus-mediated C P E , but w a s due to s o m e functional defect asssociated
with infection that became more marked with time.

TABLE 4a: THE EFFECT OF HCMV CHALLENGE ON THE ABILITY OF MONOCYTES TO
PRESENT PPD TO T CELLS WHEN CO-CULTURE IS INITIATED FOLLOWING THE
CHALLENGE/PULSE REGIME.
DONOR3

A

MONOCYTE
STIMULUS

MONOCYTE
CHALLENGE

(+/- LPS) b

STATUS0

+ LPS

Mock
AD 169 1:1

2334 ± 426

100% ± 18

1152 ± 154

49% ± 7

10:1
1:1

1124 ± 229

48% ±10

Mock

1125 ± 250
1308 ± 176
2497 ±216

48% ± 11
56% ± 8
100% ± 9

AD 169 1:1
10:1

1698 ± 302 *
1604 ± 386 *

68% ± 12
64% ± 15

p72

1294 ± 258
1578 ± 33

52% ± 10
63% ± 1

10603 ± 436

100% ± 4

p72

10:1
- LPS

1:1
10:1

B

+ LPS d

Mock
AD 169 1:1
p72

- LPS

9628 ± 489 *

91% ± 5

AD 169 1:1

16596 ± 936
5211 ± 1497

57% ± 3
18% ± 5

Mock

30073 ±3134

100% ± 10

AD 169 1:1

24323 ± 1788 *
23004 ± 1338

81% ± 6
76% ± 4

19117 ± 2874

63% ± 10

Mock

16410 ± 1987

100% ± 12

AD 169 1:1

10487 ± 1002

64% ± 6

10:1

8978 ±1416

55% ± 9

Mock

10:1
- LPS

78% ± 14
67% ± 8
78% ± 7
100% ± 12

5:1

D

8218 ± 1472 *
7062 ± 871
8227 ± 739
29160 ± 3521

10:1
C

TO MONOCYTES; PRESENTED AS:
cpm
% of Mock

10:1

!
- LPS

10:1
1:1

T CELL PROLIFERATION IN RESPONSE

TARLE 4b: THE EFFECT OF HCMV CHALLENGE ON THE ABILITY OF MONOCYTES TO
PRESENT PPD TO T CELLS WHEN CO-CULTURE IS INITIATED AT 48 HOI IRS POST
CHALLENGE.
DONOR3

MONOCYTE
STIMULUS
(+/- LPS)

A

+ LPS

b

MONOCYTE

T CELL PROUFERATION IN RESPONSE

CHALLENGE

TO MONOCYTES; PRESENTED AS
cpm
% of Mock

0

STATUS
Mock

3717 ± 15

100% ± 0.4

AD 169 1:1

1807
1752
1816
1574

49%
47%
49%
42%

p72

10:1
1:1
10:1

- LPS

Mock
AD 169 1:1
p72

10:1
1:1
10:1

B

+ LPS d

Mock
AD 169 1:1
p72

10:1
1:1
10:1

- LPS

AD 169 1:1

C

D

10:1
- LPS

- LPS

673
456
689
163

± 18
± 12
± 19
±4

8193 ± 1885
3383 ± 572

100% ± 23
41% ± 7

1895 ± 253
4486 ± 229
3157 ± 185

23% ± 3
55% ± 3
39% ± 2

8420 ± 941

100% ± 11

3181
1522
3474
1716

38% ± 6
18% ± 3
41% ± 12
20% ± 2

±
±
±
±

536
240
978
164

10433 ± 3556

Mock

i

±
±
±
±

5461 ± 166
2788 ± 1237

100% ± 34
52% ± 2
27% ± 1 2

Mock

39985 ± 3889

100% ± 10

AD 169 1:1
5:1

21856 ± 1209
19416 ± 928

55% ± 3
49% ± 2

10:1

19880 ± 6770

50% ± 16

2455 ± 274

100% ± 11

Mock
AD 169 1:1
10:1

836 ± 198

34% ± 8

734 ± 50

30% ± 2

Tahle 4 a and b ( c o n U :

Note: Data is presented as absolute c p m ± 1 S D values for triplicate cultures, or as a
percentage of T cell proliferation obtained by culture with mock-challenged monocytes alone
(adjusted to 1 0 0 % ) .

Symbol '*' indicates where suppression relative to proliferation in mock

cultures w a s not significant.
a Results from 4 independent experiments using different donors are shown.
b Monocytes were pre-stimulated (+) with L P S (20 ^ig/ml) or unstimulated (-).
c Monocytes were mock- or virus challenged as indicated and pulsed with P P D ; co-culture
with T cells w a s initiated immediately following (Table 4a), or 48 h after (Table 4b), the
challenge/pulse regime.
d

This data set is graphically represented (Figure 1).

F I G U R E 1: The effect of H C M V challenge on the ability of PPD-pulsed moncytes to
support antigen-specific T cell proliferation. Monocytes and T cells were co-cultured
either immediately after virus challenge (AD 169 or p72; 1:1 and 10:1) and P P D
pulsing (0) or 48 h after the challenge/pulse regime (48). Thymidine incorporation
(mean c p m ± 1 S D for triplicate cultures) by T cells co-cultured with virus-challenged
monocytes is expressed as a relative percentage of that obtained for T cells with mock
challenged monocytes at each time period (adjusted to 100%). This figure is
representative of data presented in Table 4a (Oh) and 4b (48h) for LPS-stimulated
monocytes from Donor B. Detailed culture conditions are as described for these tables.
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Figure 1 : T cell proliferation supported by PPD-pulsed
mock and HCMV-challenged monocytes.
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M p72 10:1

48
Time of monocyte-T cell co-culture (h post challenge).
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TABLE 5: THE EFFECT OF CHALLENGING MONOCYTES WITH HCMV DURING OR AFTER THE
PPD PULSE REGIME.

MONOCYTE T CELL PROLIFERATION (cpm):

T CELL PROLIFERATION (cpm):

CHALLENG

Monocytes pulsed and challenged

Monocytes pulsed and then challenged

E

simultaneously b. T cell co-culture

c

STATUS 3

initiated at :

Mock

. T cell co-culture initiated at :

0 hours d

48 hours e

0 hours

48 hours

50801 ± 1302

112824 ±

54335 ± 3219

118613 ± 9842

10100

HCMV 5:1

HCMV

(100% ± 3)

(100% ± 9)

(100% ± 6)

(100% ± 8)

31356 ± 6543

72865 ± 1064

34232 ± 7028

58967 ± 6495

(62% ± 13)

(65% ± 1)

(63% ± 13)

(50% ± 5.5)

33087 ± 4805

62406 ± 1560

28476 ± 2638

58173 ± 9032

(65% ± 10)

(55% ± 1)

(52% ± 5)

(49% ± 8)

10:1

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures. Figures
in parentheses are c p m adjusted to a percentage of the c p m when T cells were cultured with
mock-infected monocytes (100%). T w o independent experiments are shown where each is a
representative experiment of two.
a

Monocytes were pre-stimulated with L P S (20 ng/ml for 6 h) and were mock- or H C M V (AD

169; moi 5:1 & 10:1)-challenged.
1:5

Virus challenge was performed concurrently with the last 90 minutes of the 3 hour P P D

pulse.
c

°

Monocytes were virus-challenged after the P P D pulse.
T cell-monocyte co-culture w a s initiated immediately following challenge/pulse regimes -

refered to as Time 0 hours.
e

T cell-monocyte co-culture was initiated 48 hours after the challenge/pulse regimes -

refered to as Time 48 hours.

3.1.5

Expression of monocyte HLA-DR molecules.
3.1.5.1. Expression of HLA-DR on normal monocytes.
Surface expression of HLA-DR molecules was examined using

immunofluorescent staining and fluorescence microscopy. HLA-DR expression on
normal monocytes was found to change with time in culture and upon exposure to
various stimuli (Table 6). Generally, 7 0 % of a freshly isolated monocyte population
was HLA-DR positive, but this dropped naturally with time in culture. Addition of a
supernatant produced from activated T cells (as described in section 2.6.2) to
monocytes that had been in culture for 24 h reduced the magnitude of the HLA-DR loss
measured at at 48 h and induced a significantly (p < 0.05) increased expression at 72
h. W h e n monocytes were cultured in the presence of L P S however, the level of HLAD R dropped rapidly to only 1 0 % .

3.1.5.2. Expression of HLA-DR on mock- and HCMV-challenaed monocytes
The effect of H C M V challenge on the maintenance of the HLA-DR-positive
state as well as the effect on IFN y-mediated DR-induction were investigated. Mockand HCMV-challenged (AD 169; 1:1 and 10:1) monocytes were cultured for up to 5
days in the presence or absence of a supernatant from activated T cells with an HLADR-inducing potential (Figure 2). In the absence of T cell factors, expression of HLADR fell naturally to about 5 0 % over a 5 day culture period. The loss of HLA-DR was
accentuated with H C M V infection in a dose- and time-related manner, falling as low as
2 0 % 5 days after virus challenge. W h e n mock-challenged monocytes were cultured in
the continuous presence of activated T cell supernatants (section 2.6.2), the
percentage of DR-positive cells rose to almost 1 0 0 % . HCMV-challenged cells
responded initially to this upregulation, but this ability w a s lost as with time postchallenge and after 5 days the percentage of HLA-DR-positive monocytes was
equivalent to that in the unsupplemented cultures.
Thus, because HCMV-challenged monocytes lacked the capacity to respond to HLA-DR
upregulation, the suppressive effect of H C M V on HLA-DR expression was significantly

TABLE 6: THE EXPRESSION OF HLA-DR ON MONOCYTES AFTER EXPOSURE TO VARIOUS
STIMULI WITH TIME IN CULTURE.
CULTURE CONDITIONS3

TIME IN CULTURE (h) b

HLA-DR POSITIVE
MONOCYTES (%)c

No added supplements

+ T cell supernatant
|

(at 24 h)

+ LPS

0
24
48
72

70% ± 6
45% ± 5
41% ± 3
24% ± 4

48
72

58% ± 7

48

9.4% ± 3

64% ± 8

Note: Results are presented as the percentage (%) of cells expressing detectable fluorescence
relative to the total number of cells.
a

Monocytes were cultured in medium alone, medium supplemented after 24 h with a

supernatant from activated T cells ( 1 0 % v/v) or medium supplemented with L P S (20 jig/ml).
b

Time in culture represents the time after isolation; (eg: at 0 h, monocytes were tested

immediately after the 90 min adherence step).
c The results shown are the means ± 1 S D of 200-300 cells counted over 10-15 randomly
selected fields for each treatment at each time. Shown is a representative experiment of
three.

F I G U R E 2: The expression of HLA-DR on mock-and HCMV-challenged monocytes with
time in culture. Monocytes were cultured in medium alone (unsupplemented cultures)
or medium supplemented (10% v/v) with a supernatant from activated T cells and
stained for HLA-DR (section 2.12.2). Time post culture initiation represents the time
after adherence, where at 0 h monocytes were tested immediately following the 90 min
adherence step. The % H L A D R positive cells represents the percentage of cells
expressing detectable fluorescence relative to the total number of cells. Shown are the
means ± 1SD of two separate experiments where 200-300 cells were counted over 1015 randomly selected fields for each treatment (ie: supplemented /unsupplemented at
each time.
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Figure 2 : Expression of HLA-DR by mock- and HCMVchallenged monocytes.
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1
(p < 0.05) enhanced in the presence of a supernatant derived from activated T cells.
It should be noted that culture in the presence of a T cell supernatant simulates more
closely the co-culture systems used in this study for antigen presentation assays, and
indeed is likely to be more representative of the in vivo situation.

3.1.6 The effect of LPS stimulation on monocytes antiaen-presentina ability.
Considering the effect of L P S stimulation on H L A - D R expression (Table 1) and
the observation (section 3.1.4) that LPS-stimulated monocytes were less effective as
accessory cells regardless of their HCMV-challenge status, the effect of L P S
stimulation on the ability of PPD-pulsed monocytes to support T cell proliferation was
directly studied (Table 7). Monocytes pre-stimulated with L P S (20 u.g/ml) for 6 h
prior to antigen pulsing and T cell co-culture were consistently less efficient in
supporting antigen-specific T cell proliferation than monocytes that had not been
exposed to LPS. This w a s seen despite the fact that L P S stimulation is known (LepeZuniga and Gery 1984) and w a s subsequently shown (section 3.2) to enhance monocyte
IL 1 production. The decreased antigen-presenting ability of LPS-stimulated
monocytes relative to unstimulated monocytes was observed with a range of donors
and with mock- and virus-challenged monocytes, where monocytes were challenged
after L P S stimulation but prior to P P D pulsing. Figure 3 illustrates these decreases in
accessory cell function where the degree of T cell proliferation supported by LPSstimulated monocytes is expressed as a relative percentage of that supported by the
corresponding unstimulated monocyte cultures (shown as 100%). The decrease in the
ability of L P S stimulated monocytes to support antigen-specific T cell proliferation
may be associated with LPS-induced suppression of H L A - D R expression.

3.1.7 The ability of exogenous IL 1 and T cell factors to restore monocyte antigen
presenting ability.
To further examine the possibility that HCMV-challenged monocytes were
resistant to upregulatory stimuli supplied by T cell supernatants (section 2.6.2) with
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TABLE 7: T H E E F F E C T O F LPS STIMULATION O N T H E ABILITY O F M O N O C Y T E S T O
P R E S E N T ANTIGEN T O T CELLS

EXPERIMENT

MONOCYTE

a

CHALLENGE STATUS RESPONSE TO PPD-PULSED MONOCYTES,

T CELL PROLIFERATION (cpm) IN
EITHER c:

b

LPS STIMULATED

UNSTIMULATED

1

Mock

12797 ± 725

16410 ±1987

2

Mock

3

Mock

10603 ±436
19234 ± 1753

14832 ± 140
30073 ± 3134

4

Mock
HCMV 1:1

14800 ±413
9486 ±1164

39985 ± 3889
21856 ± 1209

9789 ±47
9819 ± 548

19416 ± 928
19880 ± 6770

35333 ± 2751
19798 ±1188

54335 ± 3219
34232 ± 7028

5:1
10:1
5

Mock
HCMV 5:1

Note: This data is additionally illustrated in Figure 3, where cpm for T cells cultured with LPS
stimulated monocytes is expressed as a relative percentage of that supported by the
corresponding unstimulated monocyte cultures (shown as 100%).
a

Experiments using 4 separate donors are shown; experiments 4 and 5 include results from

HCMV-challenged monocytes. Thymidine incorporation is expressed as mean cpm ± 1SD for
triplicate cultures.

b

In experiments 4 and 5, monocytes were challenged with A D 169 or

mock-challenged prior P P D pulsing.
0

Monocytes were pre-stimulated for 6 hours with or without LPS (20jig/ml) prior to P P D

pulsing and co-culture with T cells.

F I G U R E 3: The effect of LPS-stimuIation on the ability of PPD-pulsed monocytes to
support antigen-specific T cell proliferation. Thymidine incorporation (mean ± 1 S D
for triplicate cultures) by T cells co-cultured with L P S (20 pg/ml for 6 h prior to
P P D pulsing)-stimulated monocytes (LPS) is expressed as a relative percentage of that
obtained for T cells with unstimulated monocytes (No LPS) adjusted to 1 0 0 % . Bars
numbered 1 to 9 are representative of the data presented in Table 7. Detailed culture
conditions are as described for this table.
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Figure 3 : T cell proliferation supported by PPD-pulsed,
LPS stimulated and unstimulated moncytes

M

No LPS

E3 LPS

100
% proliferation with '+ LPS' relative to 'no LPS' (100%).

HLA-DR inducing potential, antigen presentation assays were performed as before
(section 3.1.4), but cultures were additionally supplemented ( 1 0 % v/v) with the DRinducing T cell supernatant. The possibility that HCMV-challenged monocytes m a y be
defective in the production of endogenous stimulatory factors w a s also considered.
Antigen presentation culture systems were thus also supplemented with exogenous IL
1. Monocytes were co-cultured with T cells plus supplements (IL 1 or T cell
supernatant) either immediately after virus challenge and P P D pulsing (Table 8a) or
only 48 h later (Table 8b).

3.1.7.1. Addition of IL 1
In order to determine if IL 1 w a s limiting in antigen presentation assays,
exogenous IL 1 was added to the culture system at 4U/ml. Although this dose level
significantly augmented the proliferation of P H A (2 p.g/ml) stimulated T cells cocultured with monocytes, it had no significant (p < 0.05) effect on the antigen
presenting ability of normal monocytes. This implied that whatever the optimal IL 1
requirements of the antigen presentation system are, these are fulfilled in the normal
system, making the addition of exogenous IL 1 superfluous. This m a y also explain why
LPS-stimulated monocytes, although having the capacity to produce elevated levels of
IL 1, are not as effective in presenting antigen as unstimulated monocytes. Adding
exogenous IL 1 to HCMV-challenged monocytes enhanced the amount of T cell
proliferation they supported, but suppression relative to mock-challenged controls
remained significant in all cases except where monocyte-T cell co-culture w a s
initiated 48 h after virus challenge with A D 169 or p72 at an moi of 1:1 (Table 8b).
Figure 4 illustrates the inability of exogenous IL 1 to restore the antigen-presenting
capacity of HCMV-challenged monocytes.

3.1.7.2. Addition of T cell factors
Antigen presentation assay systems were supplemented with a T cell
supernatant with HLA-DR-inducing potential and the percentage T cell proliferation
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TABLE 8a: THE ABILITY OF IL 1 OR T CELL FACTORS TO OVERCOME THE SUPPRESSIVE
FFFECT OF HCMV ON MONOCYTE ANTIGEN PRESENTING ABILITY WHEN PRESENTATION IS
INITIATED IMMEDIATELY AFTER VIRUS CHALLENGE.

EXCG

MONOCYTE

T CELL PROLIFERATION WHEN T CELLS INCUBATED WITH PPD
PULSED MONOCYTESa AND EITHER:

FACTOR CHALLENGE

NO ADDITIONAL FACTORS

EXOGENOUS FACTOR ADDED

ADDED13 STATUS

cpm

% of Mock

cpm

IL 1 @

14832 ± 140

100 ± 0.9

AD 169 1:1
10:1

9016 ± 496
8175 ±1155

61 ± 3.3
55 ± 8

15332 ± 1431 103 ± 10
10610 ± 107 72 ± 0.7
12117 ± 166

82 ± 1

p72

2671 ± 662
1783 ± 535

36 ± 9
24 ± 7

4763 ± 437
2962 ± 588

64 ± 6
40 ± 8

TCELL Mock

12797 ± 725

100 ± 5.7

SPNT.@ AD 169 1:1

8785 ± 1133

69 ± 1

14451 ± 1026 113 ± 8
12451 ±
97 ± 8

4U/ml

Mock

1:1
10:1

% of Mock

1056*
10%
v/v

10:1

10046 ± 737

78 ± 6

11409 ±
1 176*

89 ± 9

Note: Thymidine incorporation is expressed as absolute c p m ± 1 S D or as a percentage of T cell
proliferation obtained by culture with mock-challenged monocytes alone (adjusted to 100%).
Symbol '*' indicates where suppression relative to proliferation in mock cultures w a s not
significant. Results from two independent experiments are shown where each is representative
of two similar experiments.
a Monocytes were mock- or virus challenged as indicated and pulsed with P P D ; co-culture
with T cells w a s initiated immediately after the virus challenge followed by P P D pulse regime.
b IL 1 at 4U/ml augmented the T cell response to mitogen (PHA at 2|xg/ml) and mockchallenged monocytes by 1 4 6 % in parallel cultures.
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TABLE 8b: THE ABILITY OF IL 1 OR T CELL FACTORS TO OVERCOME THE SUPPRESSIVE
FFFECT OF HCMV ON MONOCYTE ANTIGEN PRESENTING ABILITY WHEN PRESENTATION IS
INITIATED 48 h AFTER VIRUS CHALLENGE.

EXDG
MONOCYTE
FACTOR CHALLENGE
ADDED0 STATUS

T CELL PROLIFERATION WHEN T CELLS INCUBATED WITH PPD
PULSED MONOCYTES a A N D EITHER:
N O ADDITIONAL FACTORS
EXOGENOUS FACTOR ADDED
cpm
% of Control cpm
% of Control

IL 1 @ Mock
(4U/ml) AD 169 1:1
10:1
1:1
p72
10:1

7426
2671
1783
1977
2216

TCELL MOCK
SPNT.@ AD 169 1:1
10%
10:1
v/v

1804 ± 1 5 0
880 ± 5 2
617 ± 85

±1224
± 662
± 535
± 633
± 932

100 ± 16
36 ± 9
24 ± 7
27 ± 9
30 ± 13

7952
4763
2962
4595
3374

100 ± 8
49 ± 3
34 ± 5

1922 ± 3 4 7
719 ± 133
623 ± 7 8

±
±
±
±
±

1141
437*
588
1056*
314

107 ± 15
64 ± 6
40 ± 8
62 ± 14
45 ± 4
107 ± 19
40 ± 7
35 ± 4

Note: Thymidine incorporation is expressed as absolute cpm or as a percentage of T cell
proliferation obtained by culture with mock-challenged monocytes alone (adjusted to 100%).
Symbol '*' indicates where suppression relative to proliferation in mock cultures was not
significant. Results from two independent experiments are shown where each is representative
of two similar experiments.
a Monocytes were mock- or virus challenged as indicated and pulsed with PPD; co-culture
with T cells was initiated 48 h after the virus challenge followed by PPD pulse regime.
b IL 1 at 4U/ml augmented the T cell response to mitogen (PHA at 2 (j.g/ml) and mockchallenged monocytes by 309% in parallel cultures.

F I G U R E 4: The ability of exogenous IL 1 to reconstitute the T cell proliferative response
supported by HCMV-challenged, PPD-pulsed monocytes. Monocytes and T cells were cocultured either immediately after virus challenge (AD 169 or p72; 1:1 and 10:1) and
P P D pulsing (0) or 48 h after the challenge/pulse regime (48). Exogenous IL 1
(4U/ml) w a s added at the time of co-culture. Thymidine incorporation (mean cpm ±
1 S D for triplicate cultures) by T cells co-cultured with virus-challenged monocytes in
the presence of exogenous IL 1 is expressed as a relative percentage of that obtained for
T cells co-cultured with mock challenged monocytes only (adjusted to 100%). The
experiment shown is representative of 2 similar experiments. The symbol '-»'
indicates where differences between T cell proliferation in the presence of mock- and
virus-challenged monocytes was not significant.

Figure 4 : The effect of exogenous IL 1 on the antigen presenting
ability of HCMV-challenged monocytes
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assessed relative to that supported by mock-challenged, PPD-pulsed monocytes in the
absence of T cell supernatant supplementation. The slight enhancement of accessory
cell activity seen with supplemented mock-infected cultures w a s not significant
relative to the control, suggesting that the level of D R expression in the normal coculture system is at a regulated optimum naturally, probably as a result of
endogenous production of IFN yfrom T cells, and does not require further augmentation
from exogenous stimuli. In support of this proposal, Sztein et al (1984) report that
under normal conditions, lymphocytes are capable of producing sufficient IFN y in vitro
to allow for maintenance of monocyte HLA-DR. Addition of T cell supernatants to coculture systems initiated immediately following virus challenge and P P D pulsing w a s
able to completely reconstitute the accessory cell activity of challenged monocytes.
W h e n co-culture w a s initiated only at 48 h post challenge however, T cell factor
supplementation had no reconstituting effect and the decrease in the level of T cell
proliferation supported by virus-challenged monocytes remained significant (p <
0.05). These trends are graphically depicted in Figure 5. This supported the previous
observations (Table 7) that virus challenge perturbs the level of H L A - D R expression
and that cells initially responsive to DR-induction lose their resposiveness with time
after H C M V challenge, and further supports the proposal that the virus-induced defect
in monocte accessory cell function is related to expression of class II M H C molecules
rather than a defect in IL 1 production.

3.2 Monocytes and interleukin 1 production
Production of IL 1 by peripheral blood monocytes w a s assessed in two
different ways:
i) Biological IL 1 activity in monocyte supernatants w a s determined by measuring the
ability of the supernatants to augment the proliferative response of murine
thymocytes to sub-optimal levels of PHA.
ii) The amount of immunoreactive IL 13 in monocyte supernatants w a s measured
using an ELISA.

F I G U R E 5: The ability of a supernatant from activated T cells to reconstitute the T cell
proliferative response supported by HCMV-challenged, PPD-pulsed monocytes.
Monocytes and T cells were co-cultured either immediately after virus challenge (AD
169 or p72; 1:1 and 10:1) and P P D pulsing (0) or 48 h after the challenge/pulse
regime (48). A supernatant prepared from activated T cells (section 2.6.2) was added
( 1 0 % v/v) at the time of co-culture. Thymidine incorporation (mean c p m ± 1 S D for
triplicate cultures) by T cells co-cultured with virus-challenged monocytes in the
presence of exogenous T cell supernatant is expressed as a relative percentage of that
obtained for T cells co-cultured with mock challenged monocytes only (adjusted to
100%). The experiment shown is representative of 2 similar experiments. The
symbol '-»' indicates where differences between T cell proliferation in the presence of
mock- and virus-challenged monocytes w a s not significant.

Figure 5 : The effect of exogenous T cell factors on the antigen
presenting ability of HCMV-challenged monocytes.

•

Mock

0 AD169 1:1
• AD169 10:1

48
Time of monocyte-T cell co-culture (h post challenge)
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3.2.1

IL 1 activity produced bv normal monocytes

The pattern of IL 1 activity production by normal monocytes over the first three days
following isolation w a s examined (Table 9). IL 1 activity w a s highest over the first
24 h post isolation, with production rate decreasing during the following 24 h and
dropping steeply to low levels of activity by the third day in culture. Within the
period of peak production (ie: the first 24 h), IL 1 activity w a s readily detectable as
early as 6 h after initiation of culture, with maximal levels reached by 16 h and
maintained over the 16-24 h period. Intracellular IL 1 activity w a s also examined by
preparing cell lysates of monocyte cultures at the time intervals indicated.
Intracellular II 1 activity followed a

similar pattern with time, with the rise and

subsequent fall in activity preceding that seen in the extracellular medium. Figure 6
illustrates the relative proportions of intracellular and extracellular IL 1 activity
produced over a 72 h period.

3.2.2 The effect of HCMV challenge on the production of IL 1 activity.
Table 10 demonstrates the change in IL 1 activity with time when
supernatants generated from mock- and HCMV-challenged monocytes were harvested
at 48 hour intervals for a period of 8 days. The IL 1 activity produced by viruschallenged monocytes over the first two 48 hour incubation periods w a s significantly
less than that produced by control cells. Activity in both m o c k and challenged cell
supernatants decreased with increasing time in culture however, and for the
remainder of the culture period (ie: after monocytes had been in culture for longer
than 96 h), activity w a s low in both treatments. This w a s observed with monocytes
from different donors and w h e n monocytes were cultured either with LPSsupplemented medium or medium supplemented with a supernatant from activated T
cells. This pattern is graphically illustrated in Figure 7.

The data presented in section 3.2.1. suggested that maximal IL 1 activity was
elaborated over the first 48 h in culture, while studies with normal monocytes (Table
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TARI E 9: PRODUCTION OF INTRACELLULAR AND EXTRACELLULAR IL 1 ACTIVITY RY
NORMAL MONOCYTES

THYMOCYTE PROLIFERATION IN RESPONSE TO MONOCYTE IL 1 ACTIVITY, EITHER:a
EXTRACELLULAR

INTRACELLULAR

TIME (h) b

% of Control

TIMElh)c

% of Control

0-6

710 ± 146
1300 ± 81

0-6
0-1 6

1325 ± 110
1121 ± 162

0-24

1167 ± 258
1351 ± 16
1417 ± 162

6-16
16-24
24-48
48-72

210 ± 83

0-48
0-72

752 ±219
169 ± 12

Note: Thymidine incorporation (mean c p m ± 1 S D for triplicate cultures) is presented as a
percentage increase over proliferation (expressed as 1 0 0 % ) obtained w h e n control thymocytes
in the presence of P H A (1 ng/ml) only were cultured. Results shown are representative of
three similar experiments. These trends are graphically depicted in Figure 6.
a

'Extracellular' refers to the IL 1 activity contained in LPS-stimulated (20 ^ig/ml) monocyte

supernatants , while 'Intracellular' refers to the IL 1 activity in prepared cell lysates.
Supernatants and lysates were tested at 1 0 % v/v.
b

Supernatants were in contact with monocyte monolayers for the time intervals indicated.

Time 0 refers to the time of culture initiation
c

Monocyte monolayers were incubated for the time intervals indicated before recovery for

extraction of cell lysates as described.

!

1

TARI F 10: PRODUCTION OF IL1 ACTIVITY FROM MOCK AND HCMV-CHALLENGED
MONOCYTES AT 48 h INTERVALS OVER AN 8 DAY CULTURE PERIOD.

SUPER-

THYMOCYTE PROLIFERATION IN RESPONSE TO

NATANT

SUPERNATANTS FROM MONOCYTES EITHERa

TIME

MOCK-

HCMV-CHALLENGED WITH

DONOR STIMULUS'3 (h) c

CHALLENGED

AD 169 1:1

AD 169 10:1

Bd

22409 ± 1468
(1852 ± 121)
9456 ±1168
(540 ± 68)

11638 ± 2447
(962 ± 202)
7067 ± 825
(404 ± 47)

13449 ± 1519
(1112 ± 126)
2743 ± 542
(157 ± 31)

2403 ± 602
(137 ± 34)
940 ± 106
(75 ± 9)

2015 ± 285
(115 ± 16)
986 ± 234
(79 ± 19)

8943
(739
5051
(289

9266
(766
3397
(194

MONOCYTE

LPS

0-48
48-96

3562
(204
144-192 1280
(102

96-144

C

LPS

0-48
48-96

±218
± 13)
± 222
± 18)

17082 ± 497
(1412 ± 41)
7859 ± 821
(449 ± 47)

3559 ± 751
(203 ±43)
144-192 1566 ± 171
(125 ±14)

96-144

T Cell

± 1330
± 110)
± 338
±19)

±
±
±
±

1357
112)
14
1)

1957 ± 384
(112 ± 22)
1562 ± 194

1863 ± 379
(106 ± 22)
1132 ± 83

(124 ± 15)

(91 ± 6)

20770 ± 295

13284 ± 1085 8641 ± 404

(1716 ± 24)

(1089 ± 90)

(714 ± 33)

7796 ± 989

3949 ± 194

2899 ± 66

(445 ± 57)

(226 ±11)

(166 ± 4)

4689 ± 695

1841 ± 200

2392 ± 290

(268 ± 40)
144-192 2042 ± 85
(163 ± 7)

(105 ± 11)
1801 ±217

(137 ± 17)
1605 ± 204

(144 ± 17)

(128 ± 16)

0-48

Supernatant
48-96
96-144
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Note: Thymidine incorporation is presented as m e a n cpm ± 1 S D for triplicate cultures. Figures
in parentheses are cpm adjusted to a percentage of the c p m obtained (expressed as 100%) for
control thymocytes cultured with P H A (1 |ig/ml) alone. For assays with 0-48 h spnts = 1210
± 181 (100% ± 15); for 48-96 & 96-144 h spnts = 1750 ± 139 ( 1 0 0 % ± 8); for 144-192 h
spnts = 1252 ± 1 1 2 ( 1 0 0 % ± 9). Results from three independent experiments using two
different donors are shown.
a

Monocytes from 2 different donors were mock-challenged or challenged with A D 169 at an

moi of 1:1 or 10:1.
b

Monocyte culture medium w a s supplemented with L P S (20 ng/ml) or a supernatant generated

from T cells ( 2 0 % v/v).
c

Supernatants were harvested at 48 h intervals (48, 96, 144 & 192 h) after initiation of

culture with fresh, appropriately supplemented medium being replaced after each harvest.
Time of supernatant harvest w a s equivalent to time after virus challenge. Supernatants were
tested at 1 0 % v/v.
d

This data set is graphically represented (Figure 7).

F I G U R E 6: The production of IL 1 activity by monocytes as a function of time in culture.
Freshly isolated, adherant monocytes were cultured for a three day (0-72 h) period in
the presence of L P S (20 u.g/ml). For the determination of extracellular activity
(Figure 6a), monocyte supernatants were generated from the s a m e monolayers over the
time intervals indicated. For the determination of intracellular IL 1 activity (Figure
6b), monocyte monolayers were detached at the time intervals indicated (ie: after 6,
16, 24, 48 & 72 h) and processed for preparation of cell lysates as described (section
2.6.1). IL 1 activity in supernatants and lysates (tested at 1 0 % v/v) w a s determined
using a murine thymocyte assay (section 2.10.1). Thymidine incorporation (mean cpm
± 1 S D for triplicate cultures) by thymocytes at each time period is expressed as a
relative proportion of the total amount of IL 1 activity produced over the three day
culture period.
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Figure 6 : Relative levels of IL 1 activity produced by monocytes
at intervals over a three day culture period.

a) Extracellular activity

•
M

0-6
6-16

E3 16-24
•

24-48

•

48-72

b) Intracellular activity

•

0-6

m
m

0-16

•
•

0-24
0-48
0-72

F I G U R E 7: IL 1 activity in 48 h supernatants from mock- and HCMV-challenged
monocytes. Supernatants from LPS-stimulated (20 p.g/ml) mock- and H C M V (AD 169;
moi 1:1 & 10:1)-challenged monocytes were harvested at 48 h intervals (ie: 48, 96,
144 & 192 h) after initiation of culture. This w a s equivalent to time after virus
challenge. The IL 1 activity in these supernatants (tested at 1 0 % v/v) was determined
using a murine thymocyte assay (section 2.10.1). Thymidine incorporation (mean cpm
± 1 S D for triplicate cultures) is expressed as a percentage of that for control
thymocytes cultured with P H A (1 u.g/ml) alone (adjusted to 100%). The experiment
shown is representative of two similar experiments.
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Figure 7 : IL 1 activity in 48 h supernatants from
mock- and HCMV-challenged monocytes.
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9) indicated that the peak of IL 1 activity production actually occurred within the first
24 h of culture. It w a s therefore considered important to investigate the effect of
H C M V challenge on the IL 1 activity produced at time intervals within the first 48 h
after virus challenge. Monocytes isolated from four different donors were tested and
with one exception the IL 1 activity produced by virus challenged monocytes over the
first 24 hours of culture w a s significantly higher than that produced by mockchallenged monocytes (Table 11). However, w h e n IL 1 activity produced by these
same monocytes over the second half of the 48 hour culture period (ie: 24-48 h after
challenge) w a s tested, no reproduceable pattern w a s observed. Differences between
activity produced by mock- and challenged monocytes were either not significant, or
if significant, no consistent trend could be established; activity w a s greater in
supernatants from challenged monocytes that were additionally LPS-stimulated and
less when the monocytes were not LPS-stimulated. Culturing monocytes in suspension
as opposed to adherence had no effect on the trends in IL 1 activity described.

In addition to measuring IL 1 activity in supernatants that had been harvested
at discrete intervals throughout the total culture period, the IL 1 activity in
supernatants that had remained in contact with the monolayer for the duration of a
longer culture period (6 or 8 days) w a s measured (Table 12). Six day supernatants
from HCMV-challenged monocytes showed a significant decrease in IL 1 activity
relative to supernatants from mock-challenged monocytes. This effect w a s marked at
the higher m.o.i. and w a s apparent whether monocytes were stimulated with LPS, a T
cell supernatant or T cell co-culture. IL 1 activity w a s generally lower after an
additional 2 days in culture (8 day supernatants), and the decreased activity in
supernatants from virus challenged LPS-stimulated monocytes w a s only significant at
the higher m.o.i. tested.
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TARI F 11: IL 1 ACTIVITY SECRETED BY MOCK- AND HCMV-CHALLENGED MONOCYTFS
WITHIN THE FIRST 48 HOURS IN CULTURE.

DONOR;
EXPERI-

MONOCYTESb

SUPERNAT ANT

THYMOCYTE PROLIFERATION IN RESPONSE TO
SUPERNATANTS FROM MONOCYTES EITHER

MENT#a

+/- LPS

TIMEC

MOCK-

HCMV-CHALLENGED WITH

(h)

CHALLENGED

AD 169 @ 10:1 p72 @ 10:1

+ LPS

0 - 24

5500 ± 2087
(423 ±161)

9213 ± 380 *
(709 ± 29)

- LPS

0 - 24

2720 ± 497
(209 ± 38)

13113 ± 1868
(1009 ± 144)

+ LPS

0-6

8755 ± 646

12878±1714

11593 ± 1638

(462 ± 34)

(679 ± 90)

(611 ± 86)

24 - 48

2178 ± 195
(115 ± 10)

4512 ± 185
(230 ± 10)

3305 ± 1553*
(174 ± 82)

0 - 24

5684 ± 1030

13744 ± 1700

(300 ± 54)

(725 ± 90)

A; #1

B; #1

#2

#3

,C; #1

+ LPS

- LPS

0 - 24

4958 ± 198
(262 ± 10)

10400 ± 896
(549 ± 46)

+LPS

0 - 24

14734 ± 2558
(1133 ± 197)
6879 ± 1437

21136 ± 2353
(1626 ± 181)
4971 ± 49 *

(529 ±110)

(382 ± 4)

10613 ± 2478

15681 ± 177

(816 ± 90)
4667 ± 889

(1206 ± 14)
1323 ± 444

(359 ± 68)

(102 ± 34)

24 - 48
- LPS

0 - 24
24 - 48

7529 ± 104
(397 ± 55)

#2

+ LPS

0 - 24

24 - 48

D; #1

+ LPS

0-6

6 - 24

#2 d

+ LPS

0 - 24

24 - 48

- LPS

0-24

24 -48

7374 ± 314

11223 ± 1020

(688 ± 29)

(1061 ± 96)

6132 ± 531

8659 ± 1593*

(580 ± 50)

(818 ± 151)

2760 ± 81

4551 ± 402

3798 ± 423

(1082 ± 32)

(1785 ± 158)

(1489 ± 166)

1435 ± 15

4175 ± 6 1 8

2653 ± 645

(563 ± 6)

(1637 ± 242)

(1040 ± 253)

17037 ± 877

31175 ± 4209

19902 ± 1 3 1 4

(1311 ± 67)

(2389 ± 324)

(1531 ± 1 0 1 )

3613 ± 62

6376 ± 76

3537 ± 721 *

(278 ± 5)

(490 ± 76)

(272 ± 55)

9082 ± 1062

13057 ± 2723

19562 ± 2250

(699 ± 82)

(1004 ± 209)

(1505 ± 1 7 3 ) j

5031 ± 18

2482 ± 169

5898 ± 928 *

(387 ± 18)

(191 ± 13)

(454 ± 71)

Note: Thymidine incorporation is presented as mean cpm ± 1SD for triplicate cultures. Figures
in parentheses are cpm adjusted to a percentage of the cpm obtained in a particular experiment
for control thymocyte cultures stimulated with PHA (1 n.g/ml) but with no added supernatant
(100%). Symbol '*' indicates where differences between thymocytes treated with mock- and
HCMV-challenged supernatants were not significant.
a

Eight separate experiments using different supernatant generation protocols and/or different

donors are shown.
Monocyte culture medium was unsupplemented (-) or LPS supplemented (+) at 20 |ig/ml.
c

Supernatants were 6 h (0-6) and 24 h (0-24 or 24-48) supernatants. Time of supernatant

harvest (6, 24 or 48 h) is equivalent to time after HCMV challenge.
For this experiment monocytes were challenged and cultured in suspension (as outlined in
section 2.4.1).
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TABLE 12: PRODUCTION OF IL 1 ACTIVITY FROM MOCK AND HCMV-CHALLENGED
MONOCYTES OVER EXTENDED PERIODS OF CULTURE.

THYMOCYTE PROLIFERATION IN RESPONSE TO
SPNT

MONOCYTE

SUPERNATANTS FROM MONOCYTES *- EITHER:

TIME

CULTURE

MOCK-

DONOR (days)
D

6

b

STIMULUS0 CHALLENGED

HCMV-CHALLENGED WITH
AD 169 1:1

AD 169 10:1

LPS

8925 ± 271

3969 ± 1587

1875 ± 68

T cell

(1318 ± 40)
10622 ± 646

(586 ± 234)
7397 ± 701

(277 ± 10)
3965 ± 87

supernatant (1569 ± 95) (1093 ± 104) (586 ± 129
T cell co- 14022 ± 1422 8955 ±1176
4684 ± 433

C

8

culture

(2071 ± 210) (1323 ± 174) (692 ± 64)

LPS

9115 ± 1227

7201 ± 735*

5568 ± 1472

(728 ± 98)
(575 ± 59)
T cell
12246 ±1108 7321 ±1313
(585 ± 105)
supernatant (978 ± 88)
T cell co- 14588 ± 1308 11319 ± 183
culture
(1165 ± 104) (904 ± 105)

(445 ±118)
5724 ± 546
(457 ± 44)
9669 ± 735
(772 ±118)

Note: Thymidine incorporation is presented as m e a n c p m ± 1 S D for triplicate cultures. Figures
in parentheses are c p m adjusted to a percentage of the c p m obtained (expressed as 100%) for
control thymocyte cultures with no added supernatant. T h e symbol '*' indicates where
differences between thymocytes treated with mock- and HCMV-challenged supernatants were
not significant.
a

Shown are six separate experiments using two different donors where monocytes were

mock-challenged or challenged with A D 169 at an moi of 1:1 or 10:1.
b

Supernatants were harvested after being in contact with the monocyte monolayer for 6 or 8

days and tested at 1 0 % v/v. Harvest time w a s equivalent to time after virus challenge.
c

Monocyte culture medium w a s supplemented with L P S (20 |Kj/ml), a supernatant generated

from activated T cells ( 2 0 % v/v) or 1 0 % autologous T cells.

1
3.2.3

The effect of H C M V challenge on IL 1 production measured bv ELISA.
W h e n the amount of immunoreactive IL 13 in normal monocyte supernatants

was measured by ELISA (Table 13; Figure 8), the changes in the magnitude of the IL 1
response as a function of time in culture followed the s a m e pattern as that seen with
biological activity: the amount of IL 13 secreted w a s high over the first 24 h in
culture, followed by a rapid drop and then a gradual decrease to minimal levels with
extended time in culture. Although this pattern w a s observed in supernatants from
both mock- and HCMV-challenged monocytes, the amount of IL 13 secreted after virus
challenge w a s always significantly greater than that secreted by mock-challenged
monocytes over the first 4 days in culture. With extended culture, levels of IL 18
were generally low. These patterns were observed whether the IL 1 produced was
enhanced by L P S stimulation or by co-culture with T cell supernatants.

When long term supernatants were tested by ELISA, the amount of IL 1 3 in
the 6 day supernatants from challenged cells was significantly greater than that in
mock infected controls,even though IL 1 activity studies (Table 12) suggested the
opposite. Despite the significant decrease in the IL 1 activity of 8 day supernatants
from challenged cells relative to controls, there w a s no significant difference in the
amount of IL 1 3 measurable in these supernatants. Figure 9 illustrates these
phenomena.

These results illustrate that the IL 1 activity of test supernatants does not
accurately reflect the amount of IL 1 actually present in those supernatants. Although
both assays measured a natural decrease in IL 1 secreted with time, the biological
assay further suggested a defect in the IL 1 response as a result of virus challenge,
whereas an ELISA revealed that the amount of IL 1 secreted by the virus challenged
cells was in fact greater, particularly over the first 48 h in culture.

121

TARI F 13: IL 1 SECRETED WITH TIME IN CULTURE AS MEASURED BY ELISA

MONOCYTE
SPNT. TIME

CULTURE

IL 1 PRODUCTION (pg/ml) BY MONOCYTES, a
EITHER:

DCNOR

(h/days) b

STIMULUS0

MOCK-CHALLENGED

HCMV-CHALLENGED

Cd

0-24h
24-48h

LPS
LPS

3500 ± 400

7530 ± 650

48-72h

LPS

1736 ± 70
1540 ± 40

2640 ± 56
2500 ± 50

72-96h

LPS

360 ± 56

1708 ± 42

0-48h
48-96h

T cell spnt
T cell spnt

B

9 6-1 44h

1800 ± 350
550 ± 35
T cell spnt 200 ± 4

4600 ± 300
1250 ± 25
150 ± 2

D

6 days

LPS

800 ± 140

1360 ± 140

C

8 days

LPS

1800 ±240

2140 ± 60

Note: Shown are results from 4 independent experiments. The amount of IL 1 B is expressed as
mean picograms per milliliter (pg/ml) of test supernatant ± S D for duplicate samples at two
dilutions as determined from a prepared standard curve.
a

Monocytes from 3 different donors were mock-challenged or challenged with A D 169 at an

moi of 1:1 or 10:1.
b

Supernatants were either harvested at 2 4 or 48 h intervals after initiation of culture (donor

C and B respectively), with fresh, appropriately supplemented medium being replaced after
each harvest, or harvested only after being in contact with the monocyte monolayer for a total
of 6 or 8 days (donor D and C respectively). Time of supernatant harvest w a s equivalent to
time after virus challenge.
c

Monocyte culture medium w a s supplemented with L P S (20 ^g/ml) or a supernatant generated

from activated T cells ( 2 0 % v/v).
d

This data set is graphically represented (Figure 8).

F I G U R E 8: The amount of IL 13 secreted by mock- and HCMV-challenged monocytes with
time in culture. Supernatants from LPS-stimulated (20 u.g/ml) mock- and H C M V (AD
169; moi 10:1)-challenged monocytes were harvested at 24 h intervals (ie: 24, 48,
72 and 96 h) after initiation of culture. This was equivalent to time after virus
challenge. The amount of IL 1 3 in these supernatants was determined using a specific
ELISA (section 2.9). This figure is representative of data presented in Table 13 for
Donor C. Detailed assay conditions are as described for this table.
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Figure 8 : IL 13 in 24 h supernatants from mockand HCMV-challenged monocytes

Mock

8000ii

AUl 69 10:1
-L\

6000-

CJ)
Q.

CO

4000-

2000-

T

k
\

... i

24

48

1

1

72

96

Time of supernatant harvest (h)

F I G U R E 9: Relative levels of IL 1 activity or IL 13 in supernatants from mock- and
HCMV-challenged monocytes. Shown is a comparison of the relative proportions of IL 1
activity in LPS-stimulated (20 u.g/ml) mock- and H C M V (AD 169; moi 10:1)challenged monocyte supernatants (tested at 1 0 % v/v) from 6 and 8 day monocyte
cultures (measured using a thymocyte proliferation assay and expressed as a percentage
of control thymocyte proliferation in response to 1 uxj/ml P H A alone); and the relative
proportions of IL 13 (measured using a specific ELISA and expressed in pg/ml)
contained in these same supernatants.
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Figure 9 : Relative levels of IL 1 activity or IL 13 in supernatants
from mock- and HCMV-challenged monocytes
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1
3.2.4

Production of dialvsable suppressor factors bv monocytes earlv in culture.
Following the observation that measurements of IL 1 activity did not

correlate with the levels of IL 13 actually present in test supernatants, the possibility
that monocytes m a y be producing low molecular weight factors with the potential to
interfere with the thymocyte response to available IL 1 w a s examined (Table 14).
Mock- and HCMV-challenged monocyte supernatants from the first 48 hours in culture
contained low molecular weight (< 12 kDa) factor(s) that decreased the potential IL 1
activity supported by these supernatants. Production of these dialysable factors w a s
however restricted to the first 48 hours in culture. A s an alternative to dialysis,
this influence could be effectively removed by diluting the test supernatants to 1 0 %
of the total thymocyte culture volume (25 u.l test supernatant in a total well volume
of 250 u,l).

3.2.5. The production of IL 1 activity bv normal monocytes exposed to exogenous IL

When normal monocytes were cultured in the presence of high concentrations
of exogenous IL 1 (5000 pg/ml) the endogenous IL 1 activity produced by these
monocytes over the first 48 h in culture w a s significantly lower than that produced
by normal monocytes that had not been exposed to extra IL 1 (Table 15). This
suggested that IL 1 naturally has the potential to be autoregulatory, and that when
monocytes are exposed to threshold concentrations of IL 1, natural regulatory
pathways are activated. A s highlighted in Figure 10, significant differences in
endogenous IL 1 activity were only observed over the first 48 h in culture, despite
the fact that fresh exogenous IL 1 w a s replaced along with fresh medium after each
supernatant harvest (ie: at culture initiation and again 48 h and 96 h later). This
suggested that it is only here that the levels of IL 1 (ie the sum of that endogenously
produced and that exogenously added) are high enough to reach the threshold for
activation of autoregulation. W h e n the level of exogenous IL 1 added was reduced to
2000 pg/ml, this phenomenon w a s only seen where monocytes had been additionally
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TARI E14 : THE PRODUCTION OF LOW MOLECULAR WEIGHT SUPPRESSOR FACTORS BY
MONOCYTES EARLY IN CULTURE

TIME OF

SUPER-

THYMOCYTE PROLIFERATION (cpm) IN RESPONSE TO

SUPER-

NATANT

SUPERNATANTS FROM MONOCYTES EITHER:b

NATANT

(%

v/v)

HARVEST

MOCK-CHALLENGED

HCMV-CHALLENGED

(h) a

DIALYSISc

DIALYSIS

NO DIALYSIS

48

96

144

NO DIALYSIS

50

13381 ± 729 5868 ± 234

9405 ± 152

2633 ± 684

40

9583 ± 781

5760 ± 401

5451 ± 217

2319 ± 398

20

4919 ± 383

5293 ± 881

2919 ± 848

2300 ± 334

1 0

2623 ± 374

2454 ± 500

50

7585 ± 680

6994 ± 1237 1756 ± 146

1548 ± 148

40

1717 ± 409

1728 ± 243

1070 ± 134

780 ± 90

20

680 ± 25

579 ± 50

536 ± 65

398 ± 66

1 0

765 ± 114

665 ± 225

50

1211 ± 287

1182 ± 69

430 ± 52

373 ± 50

40

823 ± 94

755 ± 72

403 ± 53

325 ± 74

20

604 ± 116

563 ± 53

360 ± 3 3

318 ± 33

1 0

671 ± 62

552 ± 30

j

Note: Thymidine incorporation is expressed as mean cpm ± 1SD for triplicate cultures. The
results from two separate experiments are shown.
a

Monocyte supernatants were harvested 48,96 and 144 hours after initiation of culture with

fresh medium being added after each harvest. Time of supernatant harvest is equivalent to
time after virus challenge.
b Monocytes were mock-challenged or challenged with A D 169 at an moi of 10:1.
c

Supernatants were dialysed for 48 h at 4 ° C against a balanced salt buffer using dialysis bags

with a molecular weight cut-off of 12 kDa and tested at the dilution (%v/v) indicated.
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TARLE 15: PRODUCTION OF IL 1 ACTIVITY FROM NORMAL MONOCYTES CULTURED IN THE
PRESENCE OF EXOGENOUS IL 1

LPS STIMULUS GENERATION.

THYMOCYTE PROLIFERATION IN RESPONSE TO
SUPERNATANTS FROM MONOCYTES CULTURED IN
THE PRESENCE OF EXOGENOUS IL 1:

(+/-) a

TIME (h) b

0 pg/ml

2000 pg/ml

5000 pg/ml

0-48
48-96
96-144

1211 ± 102
208 ± 19

803 ± 12
114 ± 4

810 ± 60
183 ± 4 *

99.5 ±26

71 ± 31 *

93 ± 13.8 *

0-48
48-96
96-144

1071 ± 3 5
267 ± 42
96 ± 10

883 ± 128 *
232 ± 35 *
130 ± 14 *

717 ± 86
278 ± 90 *
172 ± 46 *

0-144
0-144

618 ± 5
522 ± 26

656 ± 103 *
465 ± 40 *

718 ± 6
433 ± 63 *

SUPERNATANT

+c

+

Note: Data is expressed as a % increase over proliferation (mean c p m ± 1 S D for triplicate
cultures adjusted to 1 0 0 % ) when thymocytes were cultured with P H A alone, minus the %
proliferation attributable to residual exogenous IL 1 ( - 2 6 3 % for 2000pg/ml IL 1 and - 4 4 3 %
for 5000pg/ml IL 1) to give the proliferation attributable to endogenous IL 1 activity alone.
The symbol '*' indicates where differences between endogenous IL 1 activity produced by
monocytes cultured with or without extra IL 1 were not significant.
a

Monocyte culture medium w a s supplemented (+) with L P S (20 jig/ml) or unsupplemented (-).

b

Monocyte supernatants were harvested at 48 h intervals (48, 96 & 144 h) after initiation of

culture, with fresh appropriately supplemented (+/- IL 1 and LPS) medium being replaced after
each harvest, or only after the medium had been in contact with monocyte monolayers for the
entire 144 h period.
c

This data set is graphically represented (Figure 10).

F I G U R E 10: IL 1 activity produced by normal monocytes exposed to high concentrations
of exogenous IL 1. LPS-stimulated (20 ng/ml) monocytes were cultured in the absence
(0 pg/ml) or presence (2000 & 5000 pg/ml) of exogenously added h u m a n recombinant
IL 1 for 6 days. 48 h supernatants were harvested at 48, 96 and 144 h after initiation
of culture (with fresh IL 1- and LPS-supplemented medium being replaced after each
harvest) and tested ( 1 0 % v/v) for endogenous IL 1 activity using a thymocyte
proliferation assay.(section 2.10.1). Thymidine incorporation (mean cpm ± 1 S D for
triplicate cultures) is expressed as a percentage of that for control thymocytes cultured
with P H A (1 p.g/ml) alone (adjusted to 100%). This figure is representative of data
presented in Table 15. Detailed culture conditions are as described for this table.

re 10 : IL 1 activity produced by normal monocytes
in the presence of exogenous IL 1

0 pg/ml
2000pg/ml
5000 pg/ml

250"

48

96

144

Time of supernatant harvest (h)

stimulated by LPS, and when 6 day supernatants were collected, it was only noted in
monocyte cultures supplemented with the higher concentration of exogenous IL 1.
Both observations support the proposal that monocytes must be exposed to a certain
level of IL 1 (whether endogenously produced or exogenously added) for production of
endogenous IL 1 activity to be downregulated. The other possibility that should be
considered is that when exposed to threshold levels of IL 1, monocytes m a y produce
factors that suppress the ability of thymocytes to proliferate to any IL 1 available in
the same test supernatant. The two possibilities need not be mutually exclusive;
factors involved in downregulation of IL 1 production m a y also have the capacity to
interfere with the thymocyte response to IL 1, as has been reported in the literature
for certain metabolites such as prostaglandins (Kunkel et al 1986 & Knudsen et al
1986).

3.3 Production of TNF a activity
Using a biological assay with TNF-sensitive indicator cells (L929
fibroblasts), the levels of T N F a activity in monocyte supernatants over time in
culture and the effect of H C M V challenge on these levels w a s studied. Initially, the
pattern of T N F a activity produced by LPS-stimulated monocytes over the first three
days following isolation from peripheral blood w a s examined. Figure 11 illustrates
the relative proportions of T N F a activity produced at intervals over the 72 h culture
period. T N F a could be detected in the supernatants of LPS-stimulated monocytes as
early as 4 h after initiation of culture, with levels remaining high throughout the first
24 hours (Table 16a). Production of T N F a subsequently decreased with increasing
time in culture and w a s low or negligible in supernatants harvested after monocytes
had been in culture for longer than 48h. W h e n LPS-stimulated monocytes were
challenged with H C M V , T N F a levels were consistently significantly enhanced (Tables
16a-c). Virus- mediated enhancement w a s particularly marked over the period of
maximal T N F a production (ie: 0-24 h post culture initiation) and increased with
increasing virus dose (Table 16b). Increased T N F a production in response to virus

F I G U R E 11: The production of T N F a activity by monocytes as a function of time in
culture. Freshly isolated, adherant monocytes were cultured for a three day (0-72 h)
period in the presence of L P S (20 pg/ml) and supernatants generated over the time
intervals indicated. T N F a activity determined using a cytotoxicity assay (as described
in section 2.10.2) is expressed as U/ml of monocyte supernatant and is the m e a n of
triplicate assay cultures. T N F a at each time period is expressed as a relative
proportion of the total T N F a activity produced over the three day culture period.
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Figure 11 : Relative levels of T N F activity secreted by monocytes
at intervals over a three day culture period

1
TABLE 16a: TNF a ACTIVITY IN MONOCYTE SUPERNATANTS OVER TIME

DONOR
C

SUPERNATANT

TNF a ACTIVITY (U/ml) IN SUPERNATANTS FROM

GENERATION

HCMV-CHALLENGED MONOCYTES,3 EITHER:

TIME (h) b

MOCK

AD 169

p72

0-4
4-24

78
80.4
17

220.8
225
35.4

196
228
37.6

26

64

94

18-24

65
54

91
88

104
88

24-48
48-72

7
trace

8.9*
trace

5*
trace

24-48
D

0-4
4-1 8

TABLE 16b: TNF rx ACTIVITY IN 24 h MONOCYTE SUPERNATANTS

TNF a ACTIVITY (U/ml) IN SUPERNATANTS FROM
HCMV-CHALLENGED MONOCYTESa, EITHER:

SPNT.

LPS

DONOR

TIME
(h) b

MOCK
STIM.
(+/.) c

B

0-24

+

24-48

+

38
9

0-24

+

24

198

257

6.5
8.8
tracee
2

8 *
30
trace
17.2

trace

C

24-48
48-72
D

+
+

AD 169
1:1

10:1

p72
1:1

10:1

232

132

15

1 8

8.9 *
76
trace
62

226
14
19.2

285
16
78

trace
n/d

trace
1*

trace

trace

trace

trace

0-24

+

41

166

208

24-48
48-72

+
+

7.2

16.8

18.9

5.2

12

14
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TARI E 1fie:TNF rx ACTIVITY IN 48 h MONOCYTE SUPERNATANTS

TNF a ACTIVITY (U/ml) IN
SUPERNATANT

SUPERNATANTS FROM HCMV-

GENERATION

LPS STIMULUS

TIME (h) b

(+/-)

CHALLENGED MONOCYTESa EITHER:

c

MOCK

+

31.6

162

trace

1 6

0-48

AD 169 - 10:1

48-96

+

5
trace

16.9
15.7

96-144

+

trace
trace

10.2
trace

TABLE 16d: PRODUCTION OF TNF g ACTIVITY BY PPD-PULSED MONOCYTES

SUPERNATANT
GENERATION
DONOR

TIME (h)
B

C

b

TNF a ACTIVITY (U/ml) IN SUPERNATANTS FROM
HCMV-CHALLENGED MONOCYTESa, EITHER:
MOCK

AD 169 1:1

AD 169 10:1

0-48
48-96
96-144
0-144

19.1
10.4

172
61.6

136
97

12.3*
11.4

18*
201

17.2*
205

0-48
48-96

14
9.8

132
35

148
77

96-144

10*
13

18.4*
164

17*
176.4

0-144

1

TARI F. 16e: PRODI JCTION OF TNF a ACTIVITY BY MONOCYTES CO-CULTURED WITH
T CELLS.

SUPERNATANT
DONOR
C

D

GENERATION

TNF a ACTIVITY (U/ml) IN SUPERNATANTS FROM
HCMV-CHALLENGED MONOCYTESa EITHER:

TIME (h) b

MOCK

AD 169 1:1

AD 169 10:1

0-48

19.8

121

135.2

48-96

9

67

129

96-144
0-144

12.4*
12.3

11.8*
169.4

15.6*
212

0-48
48-96
96-144
0-144

20.2

101

104

11
9.6*

70.4
12.2*

121.6
14.4

16.6

146

159.6

Note: T N F a activity expressed as U/ml of monocyte supernatant (determined using a standard
cytotoxicity assay as described in section 2.10.2) is the m e a n of triplicate assay cultures.
Differences between activity produced by mock- and HCMV-challenged monocytes for each time
period were significant (p < 0.05) except where indicated by '*'.'Trace' values were not
significantly greater than background.
a Monocytes from three separate donors were mock- or HCMV-challenged with A D 169 or p72
at moi of 1:1 or 10:1. For table D, monocytes were pulsed with P P D (100ng/ml) for 3 h prior
to supernatant generation; for table E, monocytes were co-cultured with 1 0 % T cells.
b..Supernatants were in contact with the monolayer for the time intervals noted, with fresh
medium added after each harvest time. Time of supernatant harvest w a s equivalent to time
after initiation of culture and time after virus challenge. Supernatants were added at 2 5 %
v/v.
c.Monocyte cultures were supplemented (+) with L P S (20 ng/ml) or unsupplemented (-). For
Tables A, D & E, all cultures were LPS-supplemented;
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challenge w a s maintained during the 24-48 h culture period but this increase w a s not
always significant. Although the levels of T N F a activity in supernatants harvested
after 48 h in culture were generally low, they remained higher in challenged than in
unchallenged monocytes. These trends are graphically presented in Figure 12.

Monocytes that were not LPS stimulated produced only low levels of TNF a.
In mock-challenged monocytes, measureable levels were produced only over the first
24 h in culture. Under these conditions, although remaining low, T N F a activity was
both enhanced and prolonged after H C M V challenge, and in 48 h supernatants (Table
16c) or 24 h supernatants after challenge with p72 (Table 16b) the degree of
enhancement w a s significant.

The production of TNF a by LPS-stimulated monocytes that were additionally
PPD-pulsed (Table 16d) or cultured with 1 0 % T cells (Table 16e) was also examined.
Supernatants were harvested at 48 h intervals over a period of 6 days or only after
termination of culture. As noted previously, maximal T N F a production occured over
the first 48 h in culture, but under these experimental conditions activity w a s still
detectable in supernatants generated 96-144 h after initiation of culture. T N F a
activity in supernatants from HCMV-challenged monocytes was elevated relative to
that in mock-challenged monocytes at all times tested. These differences were not
significant over the 96-144 h culture period where levels were generally low, but
were very marked in supernatants harvested over the first 4 days in culture and in
the total time (0-144 h) supernatants.

Figure 13 is representative of the appearance of the TNF-sensitive L929
indicator cells used in the T N F a assay after exposure to supernatants from mock- and
HCMV-challenged monocytes.

F I G U R E 12: Production of T N F a activity by mock- and HCMV-challenged monocytes.
24 h supernatants were harvested from freshly isolated LPS-stimulated (20 u.g/ml)
mock- and H C M V (AD 169; moi 1:1 & 10:1)-challenged monocytes at 24, 48 and 72h
after initiation of culture. This was equivalent to time post virus challenge. T N F a
activity determined using a cytotoxicity assay (as described in section 2.10.2) is
expressed as U/ml of monocyte supernatant and is the mean of triplicate assay cultures.
The experiment shown is representative of three similar.experiments.
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Figure 12 : T N F alpha activity produced by m o c k and
HCMV-challenged monocytes.

200-

Mock
AD169 1:1
AD169 10:1

150-

100-

50-

n-

24

48

Time of supernatant harvest (h)

72

F I G U R E 1 3 : Relative cytotoxicity of monocyte supernatants towards T N F a-sensitive
L929 murine fibroblasts. This figure directly illustrates the appearance of the
indicator cells used in the T N F a assay (described in section 2.10.2) after staining with
crystal violet. Monocyte supernatants (tested at 25 % v/v) were in contact with LPSstimulated (+LPS; 20 pg/ml) or unstimulated (-LPS) mock- and H C M V (AD 169; moi
1:1 & 10 : 1 )-challenged monocytes for the time intervals indicated. This was
equivalent to time of culture initiation and time post virus challenge. Control cells were
exposed to aliquots ( 2 5 % v/v) of monocyte culture medium (+/- LPS) alone.
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3.4.

Production of IL 6 activity

Using an IL 6 dependent cell line (7TD1 cells), production of IL 6 activity by
monocytes with time in culture and in response to L P S was examined (Table 17a). As
noted for production of T N F a activity, production w a s maximal over the first 24 h in
culture, with a sharp drop over the next 24 h followed by a gradual decrease with
prolonged culture. W h e n production kinetics over the first 24 h were examined,
production within the first 4 h w a s not high relative to the total 24 h yield, suggesting
a slower induction of production than w a s seen with T N F a where production was high
as early as 4 h after initiation of culture. Although L P S stimulation enhanced
production of IL 6 activity over the first 48 h in culture, unstimulated monocytes still
produced high levels of IL 6 activity. The decrease in activity produced by
unstimulated monocytes as a function of time in culture was not as marked as that
seen with L P S stimulation; thus, IL 6 activity levels in unstimulated monocyte
supernatants were relatively higher in supernatants harvested later than 48 h after
initiation of culture. In both these experiments and when supernatants were harvested
at 48 h intervals (Table 17b), challenge of monocytes with either A D 169 or the
clinical isolate of H C M V had no significant effect on the levels of IL 6 activity
produced.

Because biological proliferation assays may reflect a balance of inhibitory and
stimulatory influences as opposed to the absolute amounts of a particular cytokine, the
possibility that antagonistic influences in the HCMV-challenged monocyte supernatants
may interfere with the proliferative response of 7TD1 cells to available IL-6 w a s
considered. T o reduce this possibility, certain supernatants were size fractionated by
gel chromatography (section 2.14) and only the fractions eluting in the size range
corresponding to the IL-6 polypeptide (20-40 kda) were tested. Again no difference
was observed in the IL-6 activity of mock and challenged monocyte supernatants, but
the amounts of activity produced with time were maintained at much higher levels than
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TARLE 17a: IL 6 PRODUCTION BY MONOCYTES WITH TIME

DONOR -

SUPERNATANT

CHALLENGE

GENERATION

IL 6 ACTIVITY (U/ml) * |N SUPERNATANTS
FROM MONOCYTES, EITHER:

STATUS5

TIMEC

LPS STIMULATEDd

UNSTIMULATED

D - Mock

0-24
24-48
48-72

2120.2

948.8

106.9
69.1

237.2
114.6

72-96

21.1

55.3

0-4
4-24

86.2
661.7
97

14.9
477.7
11.7

724.1
54.9
548.8

512
9.2
544.9

B - Mock
AD 169
p72

0-4
4-24
0-4
4-24

Note: The results from five separate experiments using three different donors are shown.
a

IL 6 expressed as U/ml of monocyte supernatant (determined as described in section 2.10.3)

is the mean of triplicate assay cultures.
b

Monocytes from different donors were mock- or HCMV-challenged with A D 169 and p72 at

moi of 10:1.
c

Supernatants were in contact with the monolayer for the time intervals noted, with fresh

medium added after each harvest time. Time of supernatant harvest w a s equivalent to time
after initiation of culture and time after virus challenge.
d

..Monocyte cultures were supplemented (+) with L P S (20 ^g/ml) or unsupplemented (-).

e

Monocyte supernatants were size fractionated as described in Materials and Methods before

assay.
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TARI.E 17h: PRODUCTION O F IL6 BY MOCK- A N D HCMV-CHALLENGED M O N O C Y T E S
WITH TIME IN CULTURE.
IL 6 ACTIVITY (U/ml) a IN

DONOR
D

C

Ce

SUPERNATANT LPS

SUPERNATANTS F R O M HCMV-

GENERATION

CHALLENGED M O N O C Y T E S b, EITHER:

TIME (h)c

STIMULUS
(+/-) d

0-48

+

48-96
96-144

+
+

0-48

+

48-96

+

96-144

+

0-48
48-96
96-144

+
+
+

MOCK

HCMV-CHALLENGED

3444.3
256
32

3565.8
222.9
29.9

7418.9
5348.8
150.9
1201.8
15.5

7669.9
5642.1
154
1139.4
17.1

295.5

253.2

9332.2
3923.7

9171.9
3158.5

331.9

337.8

Note: The results from five separate experiments using three different donors are shown.
IL 6 expressed as U/ml of monocyte supernatant (determined as described in section 2.10.3)

a

is the mean of triplicate assay cultures.
b
Monocytes from different donors were mock- or HCMV-challenged with AD 169 and p72 at
moi of 10:1.
c

Supernatants were in contact with the monolayer for the time intervals noted, with fresh

medium added after each harvest time. Time of supernatant harvest was equivalent to time
after initiation of culture and time after virus challenge.
d

. Monocyte cultures were supplemented (+) with LPS (20 ^ig/ml) or unsupplemented (-).
Monocyte supernatants were size fractionated as described in Materials and Methods before
assay.
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1
in whole supernatants, suggesting that influences inhibitory to IL-6 activity as
recorded using 7TD1 indicator cells m a y be produced naturally by normal monocytes
with time in culture and that these influences can be removed by size fractionation of
supernatants.

3.5. Production of monocyte-derived suppressor factors
The observation that supernatants harvested from HCMV-challenged
monocytes at times later than 24 h post challenge supported less thymocyte
proliferation in the standard IL 1 activity assay than supernatants from mockchallenged monocytes, despite containing higher levels of IL 13, suggested that H C M V challenged monocytes may be producing suppressor factors that were affecting the
ability of thymocytes to proliferate in response to P H A and endogenous IL 1 and/or
other monocyte factors. In the standard thymocyte assay, IL 1 is stimulatory through
its contribution to induction of IL 2 production and responsiveness. The possibility
was therefore also considered that an influence suppressive for thymocyte
proliferation could be effective against components of the IL 2 response. This was
investigated in more detail by inducing thymocyte proliferation with various stimuli
and examining the effect that addition of supernatants from mock- and/or H C M V challenged monocytes had on the magnitude of the thymocyte proliferative response.
The stimuli used included P H A (1 pg/ml) alone or P H A and one of the following: pure
(human recombinant) IL 1 (1 or 2 U/ml), pure (human T cell-derived) IL 2 (2 or 20
U/ml), pure (human recombinant) IL 6 ( 500-2000 pg/ml), crude IL 6 ( 5 % v/v;
section 2.14) and crude monocyte or T cell cytokines (2-20% v/v; section 2.6).

3-5.1. The effect of monocyte supernatants on the thymocyte response to pure IL 1
and IL?,
The effect of supernatants generated over a 6 day culture period from mockand HCMV-challenged monocytes on the thymocyte response augmented by pure
preparations of IL 1 and IL 2 (at concentrations of 1 & 2 U/ml and 2 & 20 U/ml
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respectively) w a s tested. Table 18 shows the effect of supernatants from H C M V challenged monocytes on the thymocyte response to different doses of IL 1 and IL 2
relative to the effect of supernatants from mock challenged monocytes. Addition of
virus-challenged monocyte supernatants suppressed the thymocyte response between
50-80%, depending on the stimulus used, and w a s also suppressive for PHA-induced
stimulation alone. Figure 14 is a representative illustration of these trends.

3.5.2 The potential of exogenous factors to reverse suppressed thymocyte
proliferation.
The possibility that addition of exogenous IL 1 or IL 2 to thymocytes cultured
with P H A (1 pg/ml) and suppressive monocyte supernatants could restore the level of
thymocyte proliferation to that reached with P H A stimulation alone w a s examined
(Table 19). In confirmation of what w a s previously shown (Table 18), supernatants
from HCMV-challenged monocytes were suppressive for the PHA-stimulated
thymocyte response as compared to mock-challenged monocyte supernatants.
Addition of exogenous IL 1 failed to reverse this suppression , but IL 2 w a s able to
restore the response to normal levels at a dose of 2 U/ml and augment it at a dose of
20 U/ml. This degree of augmentation w a s not however as marked as that seen in
thymocyte cultures incubated with mock-challenged monocyte supernatants,
suggesting again that an influence w a s present in supernatants from HCMV-challenged
monocyte supernatants with the ability to interfere with the thymocyte response to IL
2.

3-5.3. Identification of the susceptible stage in the thymocyte proliferation cvcle.
The fact that IL 2 but not IL 1 could reverse suppression of the thymocyte
response to P H A induced by HCMV-challenged monocyte supernatants suggested that
the locus of action of the inhibitory influence w a s on a stage in the thymocyte
proliferative cycle that w a s IL 2-mediated.

To further test this hypothesis,

supernatants from mock- and HCMV-challenged monocytes were added to PHA, P H A

1

TABLE 18: SUPERNATANTS FROM HCMV-CHALLENGED MONOCYTES SUPPRESS THE
THYMOCYTE RESPONSE TO IL 1 AND IL 2

IL 1/IL 2

THYMOCYTE PROLIFERATION IN RESFONSETO EXOGENOUS IL1 OR IL2
AND SUPERNATANTS FROM MONOCY"rES a EITHER:

ADDED

MOCK-CHALLENGED

(U/ml)

CPM

HCMV-CHALLENGED

as 100 %

b

CPM

as a relative %

22997 ± 758

100 ±3.3

13891 ± 1136

60 ±4.9

IL1 @ 1 U 23402 ± 742

100 ±3.2

11751 ± 903

50 ±3.8

100 ±5.3

14244 ± 643

51 ±2.3

100 ± 6.5
100 ±2.1

22872 ± 1688

56 ±4.1

92392 ± 1900

77 ± 1.6

-

2U 27960 ± 1477
IL2@2U 40978 ± 2672
20 119861 ± 2532

c

U

Note: Data is presented as absolute c p m (mean ± 1 S D for triplicate cultures) or adjusted to
relative percentages. T w o separate experiments are shown where each is representative of
three similar experiments.
a

Supernatants were generated from unstimulated mock- or virus-challenged (AD 169; 10:1)

monocytes over a 6 day culture period and tested at 1 0 % v/v.
°
c

c p m for mock spnt-treated thymocytes.adjusted to 1 0 0 % for each treatment.
cpm for H C M V spnt.-treated thymocytes adjusted to a percentage of the corresponding mock

treatment.

F I G U R E 14: The influence of supernatants from mock- and HCMV-challenged monocytes
on the thymocyte response to PHA, P H A and IL 1 or P H A and IL 2. Test supernatants
were generated from unstimulated mock- or virus (AD 169; moi 10:1)-challenged
monocytes over a six day period and tested at 1 0 % v/v. Shown is the thymocyte
response to virus-challenged monocyte supernatants expressed as a relative percentage
(mean ± 1 S D for triplicate cultures)of the thymocyte response to mock-challenged
monocyte supernatants (mean ± 1 S D for triplicate cultures, adjusted to 100%).
Thymocytes were stimulated with P H A (1 mg/ml) alone or P H A plus IL 1 or IL 2 at
2U/ml. The trends illustrated are representative of three similar experiments.
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Figure 14 : Thymocyte proliferation in the presence of mockand HCMV-challenged monocyte supernatants.
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TABLE 19: THE SI JPPRESSIVE EFFECT OF HCMV-SUPERNATANTS ON THYMOOYTF
PROLIFERATION CAN BE REVERSED BY ADDING ADDITIONAL II. 2 BUT NOT IL 1.

INFECTION STATUS a THYMOCYTE PROLIFERATION (CPM) IN RESPONSE TO MONOCYTE
OFSUPERNATANT

SUPERNATANTS IN THE PRESENCE OF A POTENTIAL

SOURCE

RECONSTITUTING STIMULUS: IL 1 ADDED AT:
0 U/ml

1 U/ml

2 U/ml

Mock-challenged

25657 ± 1280

33750 ± 1247

30651 ± 1460

monocytes

(100 ± 5)

(132 ± 4.9)

(120 ± 5.7)

HCMV-challenged

14979 ± 1246

16561 ± 1138

16961 ± 1456

monocytes

(58 ± 4.9)

(65 ± 4.4)

(66 ± 5.7)

IL 2 ADDED AT:
0 U/ml

2.U/ml

20 U/ml

Mock-challenged

25657 ± 1280

35275 ± 3317

119583 ± 1828

monocytes

(100 ± 5)

(138 ± 13)

(466 ± 7)

HCMV-challenged

14979 ± 1246

29222 ± 611

100038 ± 2965

monocytes

(58 ± 4.9)

(114 ± 2.4)

(390 ± 12)

Note: Thymidine incorporation is expressed as mean c p m ± 1 S D for triplicate cultures.
Figures in parentheses are c p m adjusted to a percentage of the c p m obtained for thymocytes
cultured with the supernatant from mock-challenged monocytes and without additional IL 1/IL 2
(100% ± 4.9). T w o separate experiments are shown where each is representative of three
similar experiments.
a

Supernatants were generated from LPS-stimulated mock- or HCMV-challenged (AD 169;

10:1) monocytes over a 6 day culture period and tested at 1 0 % v/v.

144
and IL 1 or P H A and IL 2 stimulated thymocytes at the start of culture or only 24 h
after initiation of the proliferation cycle; ie: only after initiation of IL 1-mediated
events. Table 20 demonstrates that the response of thymocytes exposed to
supernatants from HCMV-challenged monocytes w a s suppressed relative to that of
thymocytes exposed to mock-challenged supernatants whether they were added at 0
or 24 h, suggesting that the suppressive influence w a s capable of acting on
thymocytes that had undergone an initial period of activation. To confirm the
effectiveness of the inhibitory influence on initially activated cells, thymocytes were
primed by culture in the presence of IL 1 alone for 24 h before being used in the
inhibitor assay (Table 21). Supernatants generated from LPS-stimulated and
unstimulated HCMV-challenged monocytes remained supressive to IL 1-primed
thymocytes.

Table 22 shows the results of pre-incubating thymocytes with supernatants
from mock- and HCMV-challenged monocytes for 8 h prior to exposure to proliferation
stimuli (PHA, or P H A and IL 1, or P H A and IL 2). Thymocytes were well washed
before addition of stimuli. N o suppression of the response as a result of pre-exposure
to virus-challenged monocyte supernatants w a s detected, indicating that the
suppressive influence has no effect on thymocyes before they are activated by
specific stimuli.

3.5.4 The effect of heat-treatment on monocyte suppressor factors.
The heat-sensitivity of the suppressive influence present in HCMV-challenged
monocyte supernatants w a s examined by incubating test supernatants at 5 6 ° C for 30
min and then testing them in inhibitor assays as before. Table 23 demonstrates that
heat treatment w a s effective in reducing the suppressive influence contained in the
test supernatants to a level where it w a s no longer significant (p < 0.05) and
suggested that the suppressor factor(s) was likely to be a heat-labile compound such

145
TABLE 20: THE SUPPRESSIVE INFLUENCE IN HCMV SUPERNATANTS IS EFFECTIVE WHEN
ADDED AFTER INITIAL THYMOCYTE ACTIVATION

THYMOCYTE PROUFERATION IN RESPONSE TO ADDED
STIMUU AND AT TIME INTERVALS SUPERNATANTS FROM
MONOCYTES 3 , EITHER:

TIME
INTERVAL

ADDED

MOCK-CHALLENGED

(h)b

STIMULUS

cpm

HCMV-CHALLENGED

as 100% c cpm
%

0 (start)

None

29452 ± 3 1 6 7 100 ± 11

as relative

d

20029 ± 899

68 ± 3

IL 1 (1U/ml) 30511 ± 2525 100 ± 8.2 17026 ± 596

56 ± 2

IL 2 (2U/ml) 94285 ± 3625 100 ± 3.8 50930 ±1137 54 ± 1.2
24

None

13078 ± 670

100 ± 5.1 10138 ± 552

78 ± 4.2

IL 1 (1U/ml) 20514 ± 1790 100 ± 8.7 12058 ±1455

59 ± 7

IL 2 (2U/ml) 38438 ± 925

75 ± 1

100 ± 2.4 28703 ± 4 1 6

Note: Data is presented as m e a n c p m ± 1 S D for triplicate cultures, or is adjusted to relative
percentages. The experiment shown is a representative experiment of three.
a Supernatants were generated from mock- or virus-challenged monocytes (AD 169: 10:1)
over a 6 day culture period.
b Supernatants ( 1 0 % v/v) were added to thymocytes at the start of the 72 h proliferation
assay (time 0 h) or after 24. Stimuli (IL 1/IL 2) were always added at time 0 h.
c cpm for mock spnt.-treated thymocytes adjusted to 1 0 0 % for each treatment.
d cpm for HCMV-spnt.-treated thymocytes adjusted to a percentage of the corresponding mock
treatment.
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TABLE 21: THE SUPPRESSIVE INFLUENCE IN HCMV-SUPERNATANTS REMAINS
FFFFCTIVE TOWARDS IL 1 -PRIMED THYMOCYTES.

PROLIFERATION OF IL 1-PRIMEDa THYMOCYTES IN
RESPONSE TO ADDED STIMULI AND SUPERNATANTS FROM
MONOCYTES, EITHER:

SUPERNATANT

ADDED

MOCK-CHALLENGED

# b

STIMULUS c

cpm

as 100% d

HCMV-CHALLENGED
cpm
%

# 1

None

81528 ± 7599

IL 1 (1U/ml) 102173 ± 3971

# 2

j

as relative

e

100 ± 9.3 50899 ± 1504

62 ± 1.8

100 ± 3.8 47433 ± 1 1 1 4

58 ± 1.4

IL 2 (2U/ml) 120346 ± 8517 100 ± 7

81968 ± 1966

68 ± 1.6

None

35926 ± 2196

57 ± 3.5

100 ± 3.6 44730 ± 2541

66 ± 3.8

100 ± 6.8 77190 ± 3504

76 ± 3.5

62913 ± 6699

IL 1(1 U/ml) 67379 ± 2438
IL 2(2U/ml)

101049 ± 6891

100 ± 11

Note: Data is presented as m e a n c p m ± 1 S D for triplicate cultures or adjusted to relative
percentages. Results from two independent experiments are shown.
a

Prior to use in the thymocyte proliferation assay, thymocytes were primed by incubation

with IL 1 (5U/ml) for 2 4 h in the presence of P H A (1 ng/ml). (This protocol w a s effective to
the extent that the P H A response of control primed thymocytes w a s 2 7 7 % greater than that of
unprimed controls).
b Supernatants were generated from mock- or HCMV-challenged (AD 169: 10:1) monocytes
over a six day culture period. Monocytes were unstimulated or LPS-stimulated for #1 and #2
respectively. Supernatants were tested at 1 0 % v/v.
c After priming, thymocytes were re-incubated in the presence of test supernatants and
freshly added stimuli: P H A (1^g/ml) alone or P H A and IL 1 or IL 2.
^ cpm for mock spnt-treated thymocytes adjusted to 1 0 0 % for each treatment.
e

cpm for HCMV-spnt.-treated thymocytes adjusted to a percentage of the corresponding mock

treatment.
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TABLE 22: THYMOCYTES ARE NOT AFFECTED BY HCMV-St JPERNATANTS DURING AN
FXPOSURE PERIOD PRIOR TO STIMULATION.

THYMOCYTE PROLIFERATION (cpm) IN
RESPONSE TO ADDED STIMUU AFTER
PRE-EXPOSURE * TO SUPERNATANTS
PRE-EXPOSURE

ADDED

FROM MONOCYTES, E THER

SUPERNATANT # b

STIMULUS

MOCK-CHALLENGED HCMV-CHALLENGED

None
IL 1 (1U/ml)
IL 2 (2U/ml)

4076 ± 1087

3102 ± 188

5700 ± 652

5218 ± 992

11951 ± 740

11117 ± 336

None

7811 ± 637

6271 ±1185

IL 1 (1U/ml)

8582 ± 744

6812 ± 1252

IL 2 (2U/ml)

14427 ± 2999

13751 ± 961

# 1

# 2

I

Note: Thymidine incorporation is expressed as mean c p m ± 1 S D for triplicate cultures.
Results from two independent experiments are shown.
a

Thymocytes in the absence of P H A were pre-exposed to monocyte test supernatants for 8 h

(-10% v/v), washed and used in a thymocyte proliferation assay in the absence of the
supernatants.
" Supernatants were generated from mock- or HCMV-challenged (AD 169: 10:1) monocytes
over a six day culture period and tested at 1 0 % v/v. Monocytes were unstimulated or LPSstimulated for #1 and # 2 respectively.
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TARI E 23: THE SI IPPRESSIVE INFLUENCE IN HCMV-SUPERNATANTS IS SENSITIVE TO
HFAT TREATMENT

THYMOCYTE PROLIFERATION IN RESPONSE TO ADDED
SUPERNATANT ADDED
#a

STIMULUS
# 1

STIMULI AND HCMV SUPERNATANTS EITHER
UNTREATEDb
HEAT TREATED

None
IL 1 (1U/ml)
IL 2 (2U/ml)

# 2

None
IL 1 (1U/ml)
IL 2 (2U/ml)

60% ± 4.9

86% ± 3.2 *c

50% ± 3.8
56% ± 4.1

93% ± 3.1 *
86% ± 2.9 *

58% ± 4.9
49% ± 3.4

89% ± 8.2 *
82% ± 1 1 *

83% ± 1.7

87% ± 4.8 *

Note: Thymocyte proliferation is expressed as a relative percentage of the m e a n c p m ± 1 S D
values for triplicate cultures (adjusted to 100%) obtained for thymocytes cultured with P H A
(1 ^g/ml) and the corresponding supernatant (untreated or heat treated) from mock-challenged
monocytes.The results from two independent experiments are shown, where each is
representative of two such experiments.
a

Supernatants were generated from mock- or HCMV-challenged (AD 169: 10:1) monocytes

over a six day culture period. Monocytes were unstimulated or LPS-stimulated for #1 and #2
respectively.
b

'Heat treated' supernatants were incubated at 5 6 ° C for 30 min.

c

The symbol '*' indicates where differences between thymocyte proliferation in the presence

of mock- and HCMV-challenged monocyte supernatants were not significant.

1
as a protein or to contain a protein component that w a s required to exert the
suppressive effect.

3.5.5 Suppressive effect of monocyte supernatants collected at intervals with time
in culture.
The monocyte supernatants used to investigate the presence of potential
suppressor factors were generated from monocytes cultured for a total of 6 days. In
addition to containing suppressor factors therefore, the supernatants were also likely
to contain factors that were directly stimulatory to thymocyte proliferation or that
may have influenced thymocyte responsiveness to added stimuli. Because earlier
studies had indicated that the peak production of certain monocyte cytokines occurs
for a defined and transient time only, a different supernatant generation protocol w a s
followed in an attempt to acheive a degree of temporal separation of monocyte factors
and hence to reduce the number of potentially confounding influences present in test
supernatants. For this protocol, supernatants were harveated from unstimulated
monocyte monolayers at 48 h intervals, with fresh medium being replaced after each
harvest for generation of subsequent 48 h supernatant from the s a m e monolayer.
Table 24a shows the effect of supernatants collected over such a time course on PHAstimulated thymocyte proliferation and indicates that 0-48 h supernatants from both
mock- and A D 169-challenged monocytes were rich in factors that augmented
thymocyte proliferation. Only supernatants generated from virus-challenged
monocytes b e c a m e actively suppressive for thymocyte proliferation with increasing
time in culture: 48-96 h supernatants from A D 169-challenged monocytes
suppressed thymocyte proliferation by 3 5 % , while in 96-144 h supernatants,
suppression increased to almost 6 0 % . The minimal suppression seen with
supernatants from mock-challenged monocytes over these times w a s not significant

A supernatant generated from HCMV-challenged monocytes over the last 2
days of a 6 day culture (96-144 h post culture initiation/challenge) w a s tested for its
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TABLE 24a: THE SI IPPRESSIVE INFLUENCE IN HCMV SUPERNATANTS DEVELOPS WITH
TIME AFTER VIRUS CHALLENGE

THYMOCYTE PROUFERATION IN RESPONSE TO SUPERNATANTS FROM
MONOCYTES, EITHER:a
SUPERNATANT

MOCK-CHALLENGED

HCMV-CHALLENGED

CPM

% of Control

CPM

% of Control R

0-48

2786 ± 366

135 ± 18

2743 ±346

133 ± 17

48-96

2047 ± 122

99 ± 6

1339 ± 122

65 ±6

[35]

96-144

1864 ± 192

90 ± 5

853 ±182

41 ±9

[59]

TIME (h)

b

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures.
Controls are thymocytes cultured with P H A only = 2068 ± 78 ( 1 0 0 % ± 4). The experiment
shown is representative of three similar experiments.
a Monocytes were mock- or HCMV-challenged with A D 169; 10:1.
b Monocyte supernatants were harvested at 48 h intervals after initiation of culture (48, 96
& 144 h) with fresh medium replaced after each harvest. Time of supernatant harvest w a s
equivalent to time after virus challenge. Supernatants were tested at 1 0 % v/v.
c Figures in brackets indicate the percentage suppression of the control thymocyte response
where a significant result (p < 0.05) w a s obtained.
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TABLE 24b: H C M V SUPERNATANTS F R O M 4 DAYS AFTER VIRUS CHALLENGE S U P P R E S S
THF T H Y M O C Y T E R E S P O N S E T O IL 1

A M O U N T O F HCMV-SUPERNATANT A D D E D
(% v/v)

a

THYMOCYTE PROLIFERATION IN RESPONSE
T O IL 1 b A N D A N HCMV-SUPERNATANT

0

2708 ± 532

(100 ± 20)

0.4

1488 ± 373

(56 ± 14)

2
4

1421 ± 310

(53 ± 11)

1348 ± 367

(50 ± 14)

1 0

1004 ± 325

(37 ± 12)

20

1082 ± 5

(40 ± 0.2)

Note: Thymidine incorporation is presented as mean cpm ± 1SD for triplicate cultures. Figures
in parentheses are cpm adjusted to a percentage of the cpm obtained for control thymocyte
cultures treated with PHA (1 mj/ml) plus IL 1 but no HCMV-supernatant (100%).
a

The 'HCMV-supernatant' was a supernatant generated from monocytes over the period 96-

144 h after virus challenge (AD 169; moi 10:1).
b

IL 1 was a purified preparation used at 4U/ml.
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effect on the thymocyte response to P H A and IL 1 (Table 24b) and found to be
suppressive even at the lowest concentration tested.

A supernatant generated from HCMV-challenged monocytes over the last day
of a 6 day culture (120-144 h post culture initiation/challenge) w a s tested for its
effect on the thymocyte response to P H A and IL 2 when added at the start of the
thymocyte proliferation cycle (time 0) or at time intervals (17^ 42 and 50 h) after
induction of thymocyte proliferation (Figure 15). The test supernatant suppressed
thymocyte proliferation by as much as 5 0 % when added at the start of proliferation
and was still significantly suppressive when added as late as 42 h after induction of
proliferation. W h e n supernatants were added after 50 h, (at the s a m e time that [ 3 H]
thymidine w a s added), suppression w a s no longer significant. This demonstrated that
the reduction in proliferation measured w a s not merely due to inhibition of thymidine
uptake by the thymocytes exposed to supernatants from virus-challenged monocytes.
The results of this time course addition suggested that events occuring as late as 42 h
in a 72 h proliferation cycle were susceptible to inhibition. The earlier the
suppressive supernatant w a s added however, the more marked was the level of
inhibition attained. Thus, supernatants generated from monocytes over the final 24 or
48 h after initiation of culture (ie: 4 or 5 days after virus challenge) are suppressive
for thymocyte proliferation whether stimulated by P H A alone (Table 24a) or
additionally augmented by IL 1 (Table 24b) and IL 2 (Figure 15), and are effective
against events occuring after initial thymocyte activation.

3.5.6. Effect of monocyte supernatants on the thymocyte response to conditioned
medium from activated monocytes and T cells.
The exogenous stimuli used to augment thymocyte proliferation were
commercial preparations of human IL 1 and IL 2. In vivo however, monocyte and T
cells would elaborate a variety of other cytokines that m a y influence the magnitude
and nature of the thymocyte proliferative response. In the thymocyte cultures set up

F I G U R E 15: The influence of supernatants from mock-and H C M V - challenged monocytes
on the thymocyte response to P H A and IL 2 when added at times after initiation of the
proliferation cycle. Test supernatants were generated from mock- or H C M V (AD 169;
moi 10:1)-challenged monocytes over a six day period and added ( 1 0 % v/v) to
thymocytes at the start of the 72 h proliferation assay (time 0 h) or at times (17, 42
& 50 h) after initiation of the assay. Stimuli, P H A (1 pg/ml) and IL 2 (2 U/ml), were
always added at time 0 h. Data is presented as m e a n values ± 1 S D for triplicate cultures
relative to proliferation obtained with P H A and IL 2 in the absence of the test
supernatant (adjusted to 100%), or as % suppression of the control response.
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Figure 15 : Thymocyte proliferation in response to PHA+IL2
in the presence of an HCMV-supernatant added
with time after initiation of culture
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-O- % suppression

40-

20-
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for inhibitor assays, thymocytes are exposed to a selection of monocyte factors coexistent in the potentially suppressive test supernatants and would be producing their
own array of T cell cytokines. Thus, despite the addition of only a limited range of
exogenous cytokines, the nature of the biological system used approximates the in
vivo situation more closely than the experimental protocol would suggest.
Experiments were however also designed to directly test the ability of potentially
suppressive supernatants to affect the thymocyte response to a complex mixture of
cytokines. To this end, conditioned media from activated monocytes or T cells
(prepared as described in sections 2.6.1 and 2.6.2 respectively) were used to
stimulate thymocyte proliferation as opposed to pure preparations of IL 1 or IL 2.
This data is presented in Table 25 and Figures 16 and 17.

The thymocyte response to PHA was augmented by monocyte conditioned
medium (a 24 h supernatant prepared from normal LPS-stimulated monocytes) and the
effect of a test supernatant generated from HCMV-challenged monocytes over the last
2 days of a 6 day culture (96-144 h post culture initiation/virus challenge) on this
response was investigated (Table 25). W h e n monocyte conditioned medium was added
at 1 0 % v/v, suppression w a s significant at concentrations of test supernatant as low
as 2 % v/v, but when the amount of conditioned medium was doubled, addition of a
correspondingly higher concentration of supernatant ( 4 % v/v) w a s required to
achieve a significant degree of suppression. W h e n the thymocyte response to P H A
was augmented by addition (at 2 0 % v/v) of a conditioned medium from activated T
cells, supernatants from HCMV-challenged monocytes were again suppressive for the
thymocyte response (Figure 16). These test supernatants were generated from
unstimulated or LPS-stimulated mock- and HCMV-challenged (AD 169; 1:1 and 10:1)
monocytes over a 5 day period.

The effect of time course addition of a suppressive supernatant produced
from A D 169-challenged monocytes over a 6 day period on the P H A stimulated

1

TABLE 25: A SUPERNATANT FROM HCMV-CHALLENGED MONOCYTES SUPPRESSES THE
THYMOCYTE RESPONSE TO A MIXTURE OF MONOCYTE CYTOKINES.

AMOUNT OF HCMV3

THYMOCYTE PROLIFERATION (cpm) IN RESPONSE TO AN HCMV-

SUPERNATANT

SUPERNATANT AND MONOCYTE CONDITIONED MEDIUM b

ADDED (% v/v)

C R U D E ( 2 0 % v/v)

C R U D E ( 1 0 % v/v)

7551 ± 373

8290 ± 1 1 8 8

(100 ± 5)

(100 ± 14)

7388 ± 11 *

6691 ± 237 *

(98 ± 0.2)

(81 ± 3)

6701 ± 176

5018 ± 186

(89 ± 2)

(61 ± 2)

5946 ± 352

5691 ± 538

(79 ± 5)

(69 ± 7)

6421 ± 1 1 7

5653 ± 537

(85 ± 2)

(68 ± 7)

5505 ± 491

5201 ± 4 1 8

(73 ± 7)

(63 ± 5)

0
0.4
2
4
1 0
20

Note: Thymidine incorporation is expressed as mean cpm ± 1SD for triplicate cultures.
Figures in parentheses are cpm adjusted to a percentage of the cpm obtained for control
thymocyte cultures treated with P H A (l^g/ml) and the relevant concentration of conditioned
medium (10% or 2 0 % v/v) but no HCMV-supernatant (100%). The symbol '*' indicates where
the difference between thymocyte cultures with and without added HCMV-supernatant is not
significant.
a

The 'HCMV-supernatant' was a supernatant generated from monocytes over the period 96-

144 h after virus challenge (AD 169; moi 10:1).
b The 'conditioned medium' was the source of monocyte cytokines and was a 24 h supernatant
from normal LPS-stimulated monocytes (prepared as described in section 2.6.1).

FIGURE 16: The influence of supernatants from mock- and HCMV-challenged monocytes
on the thymocyte response to P H A and a crude T cell cytokine mixture. Test
supernatants were generated from LPS-stimulated (+ LPS; 20 pg/ml) and
unstimulated (-LPS) mock- or virus (AD 169; moi 10:1)-challenged monocytes over a
six day period and tested at 1 0 % v/v. Data is presented as mean cpm ± 1SD for
thymocytes cultured with P H A (1 pg/ml) and a crude mixture of T cell cytokines (20%
v/v; prepared as described in section 2.6.2) only (Control), or with P H A and T cell
cytokines in the presence of test (Mock/AD 169) supernatants.

ure 16 : The effect of mock- and HCMV-challenged monocyte supernatants
on the thymocyte response to a T cell cytokine mixture
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F I G U R E 17: The influence of supernatants from mock-and H C M V - challenged monocytes
on the thymocyte response to P H A and a crude monocyte cytokine mixture when added at
times after initiation of the proliferation cycle. Test supernatants were generated from
mock- or H C M V (AD 169; moi 10:1)-challenged monocytes over a six day period and
added ( 1 0 % v/v) to thymocytes at the start of the 72 h proliferation assay (time 0 h)
or at times (17, 42 & 50 h) after initiation of the assay. Stimuli, P H A (1 pg/ml) and
a crude mixture of monocyte cytokines (20% v/v; prepared as described in section
2.6.1), were always added at time 0 h. Data (mean values ± 1 S D for triplicate
cultures) is presented as a percentage of the proliferative response obtained for
thymocytes cultured with P H A and the monocyte cytokine mixture in the absence of the
test supernatant (adjusted to 100%), or as % suppression of the control response.
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Figure 17 : Thymocyte response to monocyte cytokines in the
presence of an HCMV-supernatant added
with time after initiation of culture

100 -

|

% of control

'/o suppression

0

17

42

Time HCMV-supernatant added (h)

50

1
thymocyte proliferation cycle augmented by monocyte conditioned medium (section
2.6.1) was also tested (Figure 17). In agreement with results obtained using pure IL 1
or IL 2 (Tables 20 and Figure 15), events in the proliferation cycle augmented by a
mixture of monocyte factors remained susceptible to suppression even after a period
of initial activation. It is worth noting that when IL 2 w a s used as the augmenting
stimulus (Figure 15), suppression remained significant as late as 42 h after initiation
of thymocyte proliferation, but using the s a m e experimental protocol, suppression
with monocyte conditioned medium w a s only significant when supernatants were added
by 17 h.

3.5.7 The effect of monocyte supernatants on the thymocyte response to IL 6.
One of the major thymocyte stimulatory factors present in monocyte
supernatants apart from IL 1 is IL 6. The effect of monocyte supernatants on the
thymocyte response to exogenous
IL 6 was therefore tested (Table 26 and Figure 18). Test supernatants were
generated from unstimulated mock- and HCMV-challenged monocytes over time (as
described in section 3.5.3) and the IL 6 used w a s a crude preparation derived from
monocyte conditioned medium and partially purified on the basis of size by gel
filtration (section 2.14). This crude IL 6 preparation (at 5 % v/v) augmented the
response of thymocytes to P H A (1 pg/ml) almost three-fold. W h e n thymocytes were
additionally incubated with supernatants from mock-challenged monocytes this was
augmented still further, although the degree of augmentation supported by these
monocyte supernatants decreased as the time of monocyte culture increased. W h e n
supernatants from HCMV-challenged monocytes were used, those generated over the
first four days in culture (0-48 and 48-96 h post culture initiation/ challenge) were
similarly stimulatory for IL 6-augmented thymocyte proliferation , while
supernatants generated over the last two days in culture (96-144 h post culture
initiation/challenge) were suppressive.
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TARI F 26: THE EFFFOT OF UNFRACTIONATED MONOCYTE SUPERNATANTS ON THE
THYMOCYTE PROLIFERATIVE RESPONSE TO CRUDE IL 6.

SUPERNATANT
GENERATION

THYMOCYTE PROLIFERATION IN RESPONSE TO CRUDE IL 6a AND
SUPERNATANTS FROM MONOCYTESb, EITHER:

TIME (h) o

MOCK-CHALLENGED
CPM

0 -48
48-96
96-144

% of Control d

HCMV-CHALLENGED
CPM

% of control

49614 ± 3231 349 ± 23

49090 ± 4685 345 ± 33

38910 ± 1995 273 ± 14

32197 ± 2074 226 ± 15

23514 ± 3222 165 ± 23

9448 ± 506

67 ± 3.5

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures.
Controls are thymocytes cultured with P H A (1 n-g/ml)+ crude IL 6 only = 14234 ± 2094
(100% ± 15). (Thymocytes and P H A alone = 5248 ± 850). The experiment shown is
representative of two similar experiments.
a

Crude IL 6 w a s prepared from normal monocyte supernatants by gel filtration as described

(section 2.14) and used to augment thymocyte proliferation @ 5%v/v.
b Monocytes were mock-challenged or challenged with A D 169 at an moi of 10:1.
c

Supernatants were harvested at 4 8 h intervals after initiation of culture (48, 96 and 144 h)

with fresh medium being replaced after each harvest. Time of supernatant harvest w a s
equivalent to time after virus challenge. Supernatants were tested at 1 0 % v/v.
d This data is graphically presented in Figure 18.

F I G U R E 18: The influence of supernatants from mock- and HCMV-challenged monocytes
on the thymocyte response to P H A and monocyte-derived IL 6. Test supernatants were
generated from mock- and H C M V (AD 169; 10:1)-challenged monocytes over the time
intervals indicated (where time 0 h is equivalent to time of culture initiation and time
post virus challenge) and tested for their effect (at 1 0 % v/v) on the thymocyte
response to P H A (1 pg/ml) and a crude preparation of IL 6 ( 5 % v/v; prepared from
monocyte supernatants size-fractionated as described in section 2.14). Data (mean
values ± 1 S D for triplicate cultures) is presented as a percentage of the proliferative
response obtained for thymocytes cultured with P H A and IL 6 alone (14234 ± 2094;
adjusted to 1 0 0 % ± 15). This figure is representative of data presented in Table 26.
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18 : The effect of mock- and HCMV-challenged monocyte
supernatants on the thymocyte response to IL 6
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Thus, factors produced by HCMV-challenged monocytes were able to suppress
the thymocyte proliferative response to P H A alone, P H A and IL 1, P H A and IL 2, P H A
and IL 6 and P H A and conditioned media from activated monocytes and T cells.

3.5.8 Identification of suppressive fractions from monocyte supernatants
fractionated bv oel filtration.
To increase the degree of separation of potentially suppressive factors from
other influences co-existent in test supernatants, monocyte supernatants were
collected over time intervals and these supernatants were further fractionated on the
basis of size using gel filtration on sephacryl S-200HR gel beads (as described in
detail in section 2.14). Supernatants were initially separated at a flow rate of 12
ml/h into fractions in 80 to 100 kDa increments and these fractions tested for their
effect on thymocyte proliferation (Table 27). W h e n supernatants generated over the
first 48 h of culture from mock- and HCMV-challenged monocytes were so
fractionated, none of the fractions contained influences inhibitory to thymocyte
proliferation. However, w h e n supernatants generated from mock-as well as H C M V challenged monocytes over the times 48-96 and 96-144 h post culture
initiation/challenge were similarly fractionated, the fraction encompassing the 80180 kDa M.W. range contained an influence that was strongly suppressive to
thymocyte proliferation whether thymocytes were stimulated by P H A (1 pg/ml) alone
or proliferation was additionally augmented by IL 1 or IL 2 (at 1 or 2 U/ml
respectively). Figure 19 illustrates the percentage suppression of the relevant
control proliferative response where the level of suppression achieved w a s
significant. Suppression of thymocyte proliferation w a s seen in the presence of
supernatants from both mock- and HCMV-challenged monocytes, but the degree of
suppression induced by the virus-challenged monocyte supernatants w a s greater than
that induced by the mock-challenged monocyte supernatants.
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TABLE 27: THE EFFECT OF MONOCYTE FACTORS IN M.W. RANGE 80-180 kDa ON
THYMOCYTE PROLIFERATION

THYMOCYTE PROLIFERATION IN RESPONSE TO ADDED
STIMUU AND SUPERNATANT FRACTIONS a FROM
MONOCYTES, EITHER:

SPNT.
TIME

ADDED

MOCK-CHALLENGED

(h) b

STIMULUS

cpm

% of

control
0-48

4 8-96

HCMV-CHALLENGED
cpm

% of

control

3338 ± 670
None
IL 1 (lU/ml) 4780 ± 622
IL 2 (2U/ml) 11291 ± 1146

131 ±26 5364 ± 788
101 ± 13 7376 ±442
22561 ± 2926
90 ± 9

1419 ± 3 7
None
IL 1 (1U/ml) 2901 ± 628
IL 2 (2U/ml) 6229 ±113

56 ± 2

874 ± 7 0

34 ± 3

61 ± 13
50 ± 1

1403 ± 623
4358 ±311

30 ± 13
35 ± 2

43 ± 6
39 ± 3

587 ± 8 4
1493 ± 5 8
3326 ± 338

23 ± 3
31 ± 1
27 ± 3

1105 ± 157
96-144 None
IL 1 (1U/ml) 1849 ± 149
IL 2 (2U/ml) 5301 ± 685

42 ± 5

210 ± 31
155 ± 9
180 ± 23

i

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures. Data
shown is representative of two similar experiments. Controls are thymocytes cultured with
PHA (1 jig/ml) and the appropriate added stimulus only : thymocytes + P H A alone = 2553 ±
332 (100% ± 13); thymocytes + P H A + IL 1 = 4743 ± 948 ( 1 0 0 % + 20); thymocytes + P H A
+ IL 2 = 12548 ± 1323 ( 1 0 0 % ± 1 1 ) . This data, additionally represented as % suppression of
control thymocyte proliferation, is presented in Figure 19.
a The test fractions were obtained by gel filtration of supernatants generated from mock- or
virus-challenged monocytes (AD 169; 10:1) T h e fraction 80-180 k D a w a s tested ( 1 0 % v/v).
b Supernatants were harvested at 48 h intervals after initiation of culture (48, 96 and 144 h),
with fresh medium being replaced after each harvest. Time of supernatant harvest w a s
equivalent to time after virus challenge.

F I G U R E 19: The percentage suppression of thymocyte proliferation induced by an 80180 kDa fraction derived from mock- and HCMV-challenged monocyte supernatants.
This figure is representative of the data presented in Table 27, but adjusted to %
suppression of control thymocyte proliferation. Controls are thymocytes cultured with
P H A (1 pg/ml) or P H A and the relevent cytokine stimulus (IL 1/IL 2) where the
proliferative response is given as 100%. Detailed culture conditions are as described
in Table 27.

1
Monocyte supernatants were also separated into fractions encompassing
more limited molecular weight ranges by eluting supernatant components from the gel
at a reduced flow rate (8 ml/h). This allowed for sub-division of the previous 80180 kda fraction into three separate fractions. Although suppressive influences were
detected over the s a m e broad molecular weight range as seen previously, two
separate fractions were identified as suppressive; the 130-180 kDa fraction and the
75-100 kDa fraction, while the fraction inbetween (100-130 kDa) contained no such
suppressive influence. In addition to fractionation of test supernatants, control
culture medium alone w a s fractionated by gel filtration as for the monocyte
supernatants. Culture medium fractions eluting in the 75-100 kDa and 130-180 kDa
M.W. range were tested on thymocytes as controls to ensure that observed
suppression was due to monocyte factors and not merely due to concentration of
culture medium or serum components to levels that became inhibitory towards
thymocyte proliferation. For ease of reference, the 130-180 kDa fraction was named
fraction 2 and the 75-100 kDa n a m e d fraction 4; this terminology was based purely
on the order in which these fractions were eluted from the sephacryl gel.

Suppressive influences in fraction 2 were detected from both mock- and
HCMV-challenged monocytes (Table 28a and Figure 20a) while the inhibitory influence
in fraction 4 was exclusive to virus-challenged monocyte supernatants (Table 28b and
Figure 20b). Figures 20a and b illustrate the percentage suppression of the relevant
control proliferative response where a significant (p < 0.05) level of suppression was
achieved. W h e n fraction 2 from mock-challenged monocyte supernatants w a s tested
for an effect on the thymocyte response to PHA, suppression was only significant (p <
0.05) where the original supernatant w a s generated from monocytes after they had
been in culture for longer than 96 h (96-144 h post culture initiation). Suppression of
the IL 1- or IL 2-augmented thymocyte response was however significant ( p <
0.05)at all times. W h e n the corresponding fractions from HCMV-challenged
monocytes were tested, suppression was significant in all cases except one (the
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TABLE 28a: THE EFFECT OF FRACTION 2 ON THYMOCYTE PROLIFERATION

THYMOCYTE PROLIFERATION IN RESPONSE TO ADDED
STIMULI AND SUPERNATANT FRACTIONS a FROM
MONOCYTES, EITHER

SPNT.
TIME
(h,

b

ADDED

MOCK-CHALLENGED

STIMULUS

CPM

HCMV-CHALLENGED

% of control CPM

% of control

647 ±21
None
IL 1 (1U/ml) 806 ± 230
IL 2 (2U/ml) 32728 +1640

91 ± 3
24 ± 7
23+1

464 ±81
485 ±38

66 ± 11
15+1

16238 + 366

12 + 0.3

None
581 + 5 8
IL 1 (1U/ml) 491 ±51
IL 2 (2U/ml) 24978 ± 1452

82 ± 8

219 ± 44

30 ± 6

15 ± 1.5
18 ± 1

456 ± 37

14 ± 1

15170 ±648

11 ± 0.5

96-144 None
221 ±51
IL 1 (1U/ml) 403 ± 65
IL 2 (2U/ml) 18754 ± 1881

31 ± 7
12 ± 2
13 ± 1

181 ± 38
305 ± 66
8993 ±426

26 ± 5
9±2
6 ± 0.3

0-48

4 8-96

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures. Data
shown is representative of two similar experiments. Controls are thymocytes cultured with
PHA (1 |i.g/ml), a control medium fraction and the appropriate added stimulus only :
thymocytes + P H A + control fraction alone = 708 ± 89 ( 1 0 0 % ± 13); thymocytes + P H A +
control fraction + IL 1 = 3364 ± 165 ( 1 0 0 % + 5); thymocytes + P H A + control fraction + IL 2
= 140254 ± 9850 ( 1 0 0 % ± 1 1 ) . This data, additionally represented as % suppression of
control thymocyte proliferation, is presented in Figure 20a.
a The test fractions were obtained by gel filtration of supernatants generated from mock- or
virus-challenged monocytes (AD 169; 10:1).

Fraction 2 w a s tested ( 1 0 % v/v).

b Supernatants were harvested at 4 8 h intervals after initiation of culture (48, 96 and 144 h),
with fresh medium being replaced after each harvest. Time of supernatant harvest w a s
equivalent to time after virus challenge.
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TARLE 28b: THE EFFECT OF FRACTION 4 O N THYMOCYTE PROLIFERATION.

THYMOCYTE PROLIFERATION IN RESPONSE TO ADDED
STIMUU A N D SUPERNATANT FRACTIONS a FROM
MONOCYTES, EITHER

SPNT.
TIME

ADDED

MOCK-CHALLENGED

(h) b

STIMULUS

CPM

0-48

None

20825 ± 2129

HCMV-CHALLENGED

% of control C P M

% of control

589 ± 63

24465 ± 1 1 6 7

692 ± 33

IL 1 (1U/ml) 20616 ± 8 4 9

185 ± 8

22804 ± 2513

204 ± 23

IL 2 (2U/ml) 244448 ± 5 7 1 8

133 ± 3

254243 ±11552

138 +

6

4 8-96

None

4805 ± 904

IL 1 (1U/ml) 16506 ± 1 1 8

136 ± 26

2444 ± 3 6 4

69 ± 10

148 ± 1

2119 ± 234

19 ± 2

IL 2 (2U/ml) 175180 ± 2427 95 ± 1.3

109217 ± 5063 59 ± 2.7

82 ± 12

885 ± 226

25 ± 6

IL 1 (1U/ml) 8759 ± 901

79 ± 2

1501 ± 306

14 ± 3

IL 2 (2U/ml) 156827 ± 2001

85 ± 1

98221 ± 8465

53 ± 4.6

96-144 None

2880 ± 410

Note: Thymidine incorporation is expressed as mean cpm ± 1SD for triplicate cultures. Data
shown is representative of two similar experiments. Controls are thymocytes cultured with
PHA (1 ng/ml), a control medium fraction and the appropriate added stimulus only :
thymocytes + PHA + control fraction alone = 3533 ± 963 (100% ± 27); thymocytes + PHA +
control fraction + IL 1 = 11155 ± 805 (100% + 7); thymocytes + PHA + control fraction + IL
2 = 184079 ± 6317 (100% ± 4). This data, additionally represented as % suppression of
control thymocyte proliferation, is presented in Figure 20b where the level of suppression
acheived was significant (p < 0.05).
a The test fractions were obtained by gel filtration of supernatants generated from mock- or
virus-challenged monocytes (AD 169; 10:1) Fraction 4 was tested (10% v/v).
b Supernatants were harvested at 48 h intervals after initiation of culture (48, 96 and 144 h),
with fresh medium being replaced after each harvest. Time of supernatant harvest was
equivalent to time after virus challenge.

F I G U R E 20a: The percentage suppression of thymocyte proliferation induced by fraction
2 derived from mock- and HCMV-challenged monocyte supernatants. This figure is
representative of the data presented in Table 28a, but adjusted to % suppression of
control thymocyte proliferation. Controls are thymocytes cultured with P H A (1 pg/ml)
or P H A and the relevent cytokine stimulus (IL 1/IL 2) where the proliferative response
is given as 1 0 0 % . Detailed culture conditions are as described in Table 28a.
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Figure 20a : % Suppression of thymocyte proliferation
induced by fraction 2
100
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F I G U R E 20b: The percentage suppression of thymocyte proliferation induced by fraction
4 derived from mock- and HCMV-challenged monocyte supernatants. This figure is
representative of the data presented in Table 28b, but adjusted to % suppression of
control thymocyte proliferation where the level of suppression achieved was significant
(p < 0.05). Controls are thymocytes cultured with P H A (1 pg/ml) or P H A and the
relevent cytokine stimulus (IL 1/IL 2) where the proliferative response is given as
100%. Detailed culture conditions are as described in Table 28b.
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Figure 20b : % Suppression of thymocyte proliferation
induced by fraction 4
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effect on the thymocyte P H A response of fraction 2 from 0-48 h post culture
initiation/challenge). As a general rule, suppression w a s greater with fraction 2
derived from HCMV-challenged as opposed to mock-challenged monocytes, and
increased with increasing time of monocyte culture.

The same protocol was used to test fraction 4. Suppressive influences were
restricted to HCMV-challenged monocyte supernatants and were present only where
the original supernatant w a s generated from monocytes after they had been in culture
for longer than 48 h (48-96 and 96-144 h post culture initiation/challenge). It was
also noted that fraction 4 derived from supernatants produced over the first 48 h
culture period by both mock- and HCMV-challenged monocytes contained an influence
that augmented the thymocyte response to PHA, the degree of augmentation being
similar to that seen when thymocytes were cultured with P H A and IL 1. This influence
was however only detectable in supernatants generated over the first 48 h of
monocyte culture.

The gel filtration experiments described above were separate experiments
performed using two different blood donors, but in both cases monocytes were
unstimulated and challenged with A D 169. Experiments were also performed using
LPS-stimulated monocytes and the clinical strain p72 for virus challenge. Again,
suppressive influences were only detected in fractions 2 and 4. The effect of these
factors on the thymocyte response to P H A w a s tested (Table 29). With the mockchallenge regime, the only difference between this and experiments using A D 169 was
the addition of an L P S stimulus. As before, suppressive influences in mock-challenged
supernatants were restricted to fraction 2, but suppression was more marked and
significant at all three time intervals. The stimulatory influence in fraction 4 derived
from supernatants generated over the first 48 h of monocyte culture was also more
marked than that seen with unstimulated monocytes. W h e n fractions derived from
clinical virus-challenged monocyte supernatants were tested, the s a m e trend as seen
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TABLE 29: THE EFFECT OF FRACTION 2 AND FRACTION 4 ON THYMOCYTE
PROLIFERATION.

THYMOCYTE PROUFERATION IN RESPONSE TO SUPERNATANT
SPNT

SPNT

FRACTIONSa FROM MONOCYTES, EITHER

FRACTION

TIME

MOCK-CHALLENGED

(h) b

CPM

0-48

537 ± 5 7

44 ± 5

460 ±25

289 ±25

[56]
24 ± 2

38 ± 2
[62]

210 ±40

[76]
15 ± 0.8

105 ± 21

17 ± 3
[83]
8.6 ± 1.7
[91.4]

FRACTION 2

48-96

96-144 186 ± 1 0

HCMV-CHALLENGED

% of control CPM

% of control

[85]
FRACTION 4

0-4 8

18715 ± 1037

48-96

4222 ±417

96-144 2174 ± 196

11500 ± 1025
1251 ±
69
282 ± 28 929 ±106
145 ± 13 793 ± 62

796 ± 69
62 ± 7
[38]
53 ±4
[47]

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures.
Controls are thymocytes cultured with P H A (1 jig/ml) and the relevent control medium fraction
only : thymocytes + P H A + control fraction 2 = 1220 ± 14 ( 1 0 0 % ± 1.2); thymocytes + P H A
+ control fraction 4 = 1496 ± 1 1 4 ( 1 0 0 % + 8)
a The test fractions ( 1 0 % v/v) were obtained by gel filtration of supernatants generated from
LPS-stimulated (20 ^ig/ml) mock- or virus-challenged monocytes (p72; 10:1)
b Supernatants were harvested at 4 8 h intervals after initiation of culture (48, 96 and 144 h),
with fresh medium being replaced after each harvest. Time of supernatant harvest w a s
equivalent to time after virus challenge.
c Figures in brackets indicate the percentage suppression of the relevent control proliferative
response.

with A D 169 challenge were observed, but suppression induced with fraction 2 w a s
also more marked than that seen with A D 169 and unstimulated monocytes.

The effect of the suppressive fractions on the thymocyte response to IL 6
was tested. Samples of fraction 2 derived from mock-challenged monocytes that had
previously been shown to suppress the thymocyte response to PHA, P H A and IL 1 or
PHA and IL 2 were not suppressive for thymocyte proliferation that was augmented
by a crude preparation of IL 6 (Table 30). The corresponding fractions from H C M V challenged monocyte supernatants however remained suppressive, as did fraction 4
derived from HCMV-challenged monocyte supernatants generated over the time
periods 48-96 and 96-144 h post culture initiation/challenge.

The potential ability of IL 6 to counteract the suppressive influence in
fraction 2 was examined in more detail using recombinant IL 6 at different
concentrations (Table 31). IL 6 at a concentration of 500 U/ml was ineffective at
relieving suppression induced by any of the test samples. W h e n IL 6 w a s used at
higher concentrations (1000 and 2000 U/ml) the samples derived from mockchallenged supernatants over 0-48 and 48-96 h were no longer suppressive but for
supernatants harvested 96-144 h post culture initiation, suppression remained
significant in thymocyte cultures stimulated with IL 6 at 1000 U/ml. In thymocyte
cultures similarly treated but with factors derived from HCMV-challenged monocytes,
suppression of proliferation could only be relieved w h e n thymocytes were stimulated
with IL 6 at 2000 U/ml and this only when the test samples were derived from
monocyte supernatants generated over the first 4 days of culture (0-48 and 48-96 h
post culture initiation/challenge). Thus it appeared that the use of IL 6 as a
thymocyte stimulus could counter the effect of the suppressive influences present in
fraction 2, but that a dose-response effect was operating in that higher
concentrations of IL 6 were needed to be effective against test samples that had a
greater suppressive potential ie: those produced with increasing time in culture or
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TARLE 30: THE EFFECT OF FRACTION 2 AND FRACTION 4 ON THE THYMOCYTE
PROl IFERATIVE RESPONSE TO CRUDE IL 6..

SPNT

SPNT

THYMOCYTE PROLIFERATION IN RESPONSE TO CRUDE IL 6 a
AND SUPERNATANT FRACTIONS b FROM MONOCYTES, EITHER

FRACTION

TIME

MOCK-CHALLENGED

(h)c

CPM

0-48

2306 ± 392

FRACTION 2

48-96

2374 ± 7 4

96-144 1783 ± 158

HCMV-CHALLENGED

% of control CPM
110 ± 19

1130 ± 6 0

112 ± 3.5 889 ± 9 7
85 ± 7

554 ± 10

% of control
54 ± 3
[46]d
43 ± 5
[57]
27 ± 0.5
[73]

FRACTION 4

0-48
4 8-96

56664 ± 6988
31840 ± 1112

96-144 30631 ± 2327

274 ± 34 38866 ± 4351
154 ± 5.4 14867 ±1114
148 ± 11

13119 ± 506

188 ± 21
72 ± 5
[18]
63 ± 2.4

r37l
Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures. Data
shown is representative of two similar experiments. Controls are thymocytes cultured with
PHA (1 (ig/ml) + crude IL 6 and the relevant control medium fraction only: thymocytes + P H A
+ IL 6 + control fraction 2 = 2093 ± 105 ( 1 0 0 % ± 5); thymocytes + P H A + IL 6 + control
fraction 4 = 20721 ± 1363 ( 1 0 0 % ± 6.6).
a

Crude IL 6 w a s prepared from normal monocyte supernatants by gel filtration as described

(section 2.14) and used to augment thymocyte proliferation @ 5 % v/v.
b

The test fractions were obtained by gel filtration of supernatants generated from mock- or

virus-challenged monocytes (AD 169; 10:1).
c

Supernatants were harvested at 4 8 h intervals after initiation of culture (48, 96 and 144 h),

with fresh medium being replaced after each harvest. Time of supernatant harvest w a s
equivalent to time after virus challenge, supernatants were tested at 1 0 % v/v.
d

Figures in brackets indicate the percentage suppression of the relevent control proliferative

response where the level of suppression achieved w a s significant (p < 0.05)

1

TABLE 31: THE EFFECT OF FRACTION 2 ON THE THYMOCYTE PROLIFERATIVE RESPONSE
TO RECOMBINANT IL 6 (rIL 6)

SPNT

[IL 6]

THYMOCYTE PROLIFERATION IN RESPONSE TO rIL 6 AND
SUPERNATANT FRACTIONSa FROM MONOCYTES, EITHER

TIME

ADDED

MOCK-CHALLENGED

(h)

b

(U/ml)

CPM

HCMV-CHALLENGED

% of control CPM

% of control

c

0-48

48-96

1000

11414 ± 922

9.3 ± 2
[90.7] d
78 ± 6

2000

22214 ± 536

84 ± 2

19147 ± 2263

500

445 ± 99

7.6 ± 1.7
[92.4]

331 ± 37

5.6 ± 0.6
[94.4]

1000

11347 ± 591

77 ± 4

401 ± 42

2.7 ± 0.3
[97.3]
75 ± 4.4

500

546 ± 120

360 ± 2 2
485 ± 13

6 ± 0.4
[94]
3.3 ± 0.1
[96.7]
73 ± 8.6

20792 ±1229

79 ± 5

19789 ±1156

429 ± 85

7.3 ± 1.4
[92.7]

350 ± 52

5.9 ± 0.9
[94.1]

1000

3763 ± 296

26 ± 2
[74]

416 ± 76

2000

21466 ± 1217

82 ± 5

12570 ± 504

2.8 ± 0.5
[97.2]
48 ± 1.9
[52]

2000
96-144 500

1

Note: Thymidine incorporation is expressed as m e a n c p m ± 1 S D for triplicate cultures.
Controls are thymocytes cultured with P H A (1 |xg/ml) + the appropriate dose of rIL 6 only:
Control with IL 6 @ 500 U/ml = 5859 ± 429 ( 1 0 0 % ± 7); control with IL 6 @ 1000 U/ml =
14680 ± 1685 ( 1 0 0 % ± 12); control with IL 6 @ 2000 U/ml = 26350 ± 2126 (100 ± 8).
(Thymocytes and P H A alone + 5454 ± 283).
a

Test fractions were obtained by gel filtration of supernatants generated from LPS-

stimulated, mock- or virus-challenged monocytes (p72; moi 10:1). Fraction 2 w a s tested at a
concentration of 1 0 % v/v.
b

Supernatants were harvested at 48 h intervals after initiation of culture (48, 96 and 144 h)

with fresh medium being replaced after each harvest. Time of supernatant harvest was
equivalent to time after virus challenge.
c

This data is graphically represented in Figure 21.

d Figures in brackets indicate the percentage suppression of the relevant control thymocyte
proliferative response where the level of suppression achieved w a s significant result (p <
0.05).

1
produced by HCMV-challenged monocytes. This is represented graphically in Figure
21.

3.5.9 The suppressive effect of monocyte supernatants on peripheral blood T cells
The studies carried out to detect the presence of inhibitory influences in
human monocyte supernatants were performed using murine thymocytes as indicator
cells. To ensure that the observed phenomena would have relevence in the human
system, it was necessary to test the effectiveness of thymocyte-inhibitory
supernatants on human peripheral blood T cells.

Supernatants derived from AD 169- and p72-challenged monocytes over a 6
day period were tested at different concentrations for their effect on T cell
proliferation induced by antigen (PPD)-pulsed monocytes (Table 32). Addition of
HCMV-supematants significantly suppressed T cell proliferation with the degree of
suppression increasing as the amount of test supernatant added increased.

Monocyte supernatant fractions previously shown to be suppressive for
thymocyte proliferation ie: those encompassing the 130-180 kDa (fraction 2) and the
75-100 kDa (fraction 4) M . W . ranges were tested for their effect on the T cell
response to P H A (1pg/ml) alone or P H A and IL 2 or IL 6. T cells were cultured with a
feeder layer of 2 % normal monocytes. At the concentrations used, IL 2 augmented
PHA induced proliferation of control T cells by 156%, while IL 6 augmented
proliferation by 2 7 6 % . The data is presented in Table 33a and b for testing of
fractions 2 and 4 respectively. Where significant, the percentage suppression of the
relevant control proliferative response is graphically illustrated (Figures 22a and b).
Fraction 2 generated from mock- and HCMV-challenged monocytes suppressed T cell
proliferation by between 30 and 7 0 % (Table 33a). The only T cell cultures that were
not affected by the test sample were those that were stimulated by P H A and IL 6 and
exposed to samples derived from mock-challenged monocytes after 2 days in culture

F I G U R E 21: The influence of fraction 2 from mock- and HCMV-challenged monocytes on
the thymocyte response to P H A and increasing doses of human recombinant IL 6. This
figure is representative of the data presented in Table 31 and detailed culture conditions
are as described for this table. Proliferation of thymocytes (mean values ± 1 S D for
triplicate cultures) in the presence of supernatants ( 1 0 % v/v) generated from mockand virus (p72; moi 10:1)-challenged supernatants is shown relative to that of control
thymocytes cultured with P H A (1 pg/ml) and the relevent concentration of IL 6 (500,
1000 or 2000 U/ml) adjusted to 1 0 0 % .

Figure 21 : The effect of monocyte factors (130-180 kDa)
on the thymocyte response to IL 6
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TABLE 32: SUPERNATANTS FROM HCMV CHALLENGED MONOCYTES SI JPPRESS THE
T CELL PROLIFERATIVE RESPONSE TO ANTIGEN PRESENTED BY NORMAL MONOCYTES

AMOUNT OF HCMVSUPERNATANT
ADDED (% v/v)

T CELL PROLIFERATION (cpm) IN RESPONSE TO ANTIGENPULSED MONOCYTESa AND SUPERNATANTS,b FROM MONOCYTES
CHALLENGED WITH:
p72 @ 10:1

AD 169 @ 1:1

AD 169 @ 10:1

0

8500 ±311
(100 ± 4)

7011 ± 500
(100 ± 7)

7011 ± 500
(100 ± 7)

4

3128 ± 705
(37 ± 8)

2002 ± 595
(29 ± 9)

2496 ± 76
(36 ± 1)

10

1582 ± 560
(19 ± 7)
206 ± 105
(2.4 ± 1 )

1397 ± 13
(20 ± 0.2)
637 ± 176
(9 ± 2.5)

2148 ± 702
(31 ± 10)
441 ± 218
(6 ± 3)

20

Note: Thymidine incorporation is presented as m e a n c p m ± 1 S D for triplicate cultures. Figures
in parentheses are c p m adjusted to a percentage of the c p m for control T cells cultured with
antigen pulsed monocytes but no HCMV-supernatant (100%).
a Monocytes were pulsed with P P D before co-culture with autologous T cells as previously
described (section 2.8) for antigen presentation assays.
b The 'HCMV-supernatants' were supernatants generated from virus-challenged monocytes
over a 6 day culture period with time of culture initiation equivalent to time of virus challenge.

F I G U R E 22a: The percentage suppression of T cell proliferation induced by fraction 2
derived from mock- and HCMV-challenged monocyte supernatants. This figure is
representative of the data presented in Table 33a, but adjusted to % suppression of
control T cell proliferation. Controls are T cells cultured with P H A (2 pg/ml) or P H A
and the relevent cytokine stimulus (IL 2/IL 6) where the proliferative response is
given as 1 0 0 % . Detailed culture conditions are as described in Table 33a.
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Figure 22a : % Suppression of T cell proliferation induced
by fraction 2
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F I G U R E 22b: The percentage suppression of thymocyte proliferation induced by fraction
4 derived from mock- and HCMV-challenged monocyte supernatants. This figure is
representative of the data presented in Table 33b, but adjusted to % suppression of
control T cell proliferation where the level of suppression achieved w a s significant (p <
0.05). Controls are T cells cultured with P H A (2 pg/ml) or P H A and the relevent
cytokine stimulus (IL 2/IL 6) where the proliferative response is given as 1 0 0 % .
Detailed culture conditions are as described in Table 33b.
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Figure 22b
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TABLE 33a: THE EFFECT FRACTION 2 ON T CELL PROLIFERATION.

T CELL PROLIFERATION IN RESPONSE TO ADDED STIMULI
AND SUPERNATANT FRACTIONSa FROM MONOCYTES, EITHER
SPNT.
TIME

ADDED

MOCK-CHALLENGED

(h) b

STIMULUS

cpm
control

0-48

4989 ± 220
None
IL 2 (2 U/ml) 6522 ± 530
22530 ± 1914
IL 6 (100
U/ml)

60 ± 3
50 ± 4
98 ± 8

3972 ± 241

48 ± 3

7673 ± 1531
11470 ± 785

59 ± 12
50 ± 3

3616 ± 354
None
IL 2 (2 U/ml) 5538 ±212
IL 6 (100
13163 ± 1886
U/ml)

44 ± 4

2805 ± 513
8712 ± 751
11087 ± 923

34 ± 6
67 ± 6
48 ± 4

2332 ±197

28 ± 2

3721 ± 638
7188 ± 663

29 ± 5
31 ± 3

4 8-96

3875 ± 237
96-144 None
IL 2 (2 U/ml) 5156 ± 320
IL 6 (100
11168 ± 1238
U/ml)

% of

43 ± 2
57 ± 8

47 ± 3
40 ± 2.5
49 ± 5

HCMV-CHALLENGED
cpm
control

% of

Note: Data is presented as c p m and c p m adjusted to a percentage of control cultures, where
controls are T cells cultured with P H A (2(j.g/ml) and the appropriate added stimulus only : T
cells + P H A alone = 8320 ± 1358 (100% ± 1 6 ) ; T cells + P H A + IL 2 (2 U/ml) = 12986 ±
2318 (100% + 1 8 ) ; T cells + P H A + IL 6 (100 U/ml) = 22984 ± 1782 ( 1 0 0 % ± 8).
a

The test fractions ( 1 0 % v/v) were obtained by gel filtration of supernatants generated from

mock- or virus-challenged monocytes (AD 169; 10:1). Fractions 2 and 4 were used for results
reported in tables 22a and 22b respectively. This data, additionally represented as %
suppression of control T cell proliferation, is presented in Figure 26a for fraction 2 and Figure
26b for fraction 4 where the level of suppression achieved was significant (p < 0.05).
b

Monocyte supernatants were harvested at 48 h intervals after initiation of culture (48, 96

and 144 h), with fresh medium being replaced after each harvest. Time of supernatant harvest
was equivalent to time after virus challenge.
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TABLE 33b: THE EFFECT OF FRACTION 4 ON T CELL PROLIFERATION.

T CELL PROLIFERATION IN RESPONSE TO ADDED STIMULI
AND SUPERNATANT FRACTIONS a FROM MONOCYTES, EITHER
SPNT.
HCMV-CHALLENGED

TIME

ADDED

MOCK-CHALLENGED

(h) b

STIMULUS

cpm
control

0-48

13261 ± 2092
None
IL 2 (2 U/ml) 26180 ± 2269
IL 6 (100
25053 ± 591
U/ml)

159 ± 25 7499 ± 434
202 ± 18 9616 ± 639
109 ± 3
7832 ±1205

7986 ± 295
None
IL 2 (2 U/ml) 12260 ± 2672

96 ± 4
94 ± 21

25154 ± 1139

110 ± 5

4 8-96

IL 6 (100
U/ml)

7561 ± 914
IL 2 (2 U/ml) 14375 ± 1362
23981 ± 3087
IL 6 (100
U/ml)

96-144 None

% of

cpm
control

4959 ± 649
7759 ±1076
3706 ±517

2001 ±111
91 ± 11
111 ± 10 6333 ± 252
104 ± 13 3786 ± 292

% of
90 ± 5
74 ± 5
34 ± 5

60 ± 7
60 ± 8
16 ± 2

24 ± 1
49 ± 2
17 ± 1

Note: Data is presented as c p m and c p m adjusted to a percentage of control cultures, where
controls are T cells cultured with P H A (2|xg/ml) and the appropriate added stimulus only : T
cells + P H A alone = 8320 ± 1358 (100% ± 16); T cells + P H A + IL 2 (2 U/ml) = 12986 ±
2318 (100% + 18); T cells + P H A + IL 6 (100 U/ml) = 22984 ± 1782 ( 1 0 0 % ± 8).
a

The test fractions ( 1 0 % v/v) were obtained by gel filtration of supernatants generated from

mock- or virus-challenged monocytes (AD 169; 10:1). Fractions 2 and 4 were used for results
reported in tables 22a and 22b respectively. This data, additionally represented as %
suppression of control T cell proliferation, is presented in Figure 26a for fraction 2 and Figure
26b for fraction 4 where the level of suppression achieved was significant (p < 0.05).
b

Monocyte supernatants were harvested at 48 h intervals after initiation of culture (48, 96

and 144 h), with fresh medium being replaced after each harvest. Time of supernatant harvest
was equivalent to time after virus challenge.

1
only (0-48 h post culture initiation). In previous experiments (Tables 30 and 31) IL 6
stimulated thymocytes cultured in the presence of test samples of this category were
similarly resistant to suppression. Under none of the other conditions tested
however, could suppression of T cell proliferation be reversed.

As was seen with experiments using thymocytes(Table 28b and 29), fraction
4 generated from mock-challenged monocytes contained no suppressive influence
(Table 33b). In fact samples derived over the first 2 days in culture (0-48 h post
culture initiation) augmented PHA- or P H A and IL 2-induced T cell proliferation.
Fraction 4 generated from HCMV-challenged monocytes were significantly
suppressive for P H A and IL 2- or IL 6-induced T cell proliferation at each time
interval tested. Samples derived from supernatants generated over the last 4 days in
culture (48-96 and 96-144 h post culture initiation/challenge) were suppressive for
T cell proliferation induced by P H A alone.

3.5.10 The effect of monocyte suppressor factors on the IL 2 responsiveness of an IL
2 dependent cell line
To investigate the proposal that a potential locus of action of monocytederived suppressor factors w a s on components of the IL 2 response, the effect of
fractions 2 and 4 on the response of a murine IL 2-dependent cell line (CTLL cells) to
IL 2 was examined (as described in section 2.11.3). Three different culture regimes
were used: C T L L cells were cultured at a basic concentration and IL 2 dose (Table
34a) and then again using an increased cell number (Table 34b) or an increased
concentration of IL 2 (Table 34c). In control cultures, increasing the level of IL 2
resulted in a proliferation increase of between 215 and 2 2 0 % .

When CTLL cells were cultured under the basic regime with the test samples,
those samples designated 'suppressive' by virtue of their effects on h u m a n T cells and
thymocytes (ie: fraction 2 from mock- and HCMV-challenged monocytes and fraction

1

TABLE 34a: THE EFFECT OF FRACTION 2 AND FRACTION 4 ON THE CTLL RESPONSE TO IL2
PROLIFERATION OF CTLL CELLS (2x103 cells/well)IN
RESPONSE TO IL 2 (10U/ml) AND SUPERNATANT
SPNT

SPNT

FRACTIONSa FROM MONOCYTES, EITHER

FRACTION

TIME

MOCK-CHALLENGED

HCMV-CHALLENGED

(h) b

cpm

cpm

% of

control
FRACTION 2

0-48
48-96

control

5610 ± 342

20 ± 0.1

4473 ± 440

96-144 2893 ±238

2870 ± 200

10± 0.7

[80] c
16 ± 1.6
[84]

2884 ± 138

[90]
10 ± 0.6

11 ± 0.9

1600 ± 208

[90]
5.8 ± 0.8
[94.2]

5555 ±190

20 ± 0.7

[89]
FRACTION 4

0-48
48-96

29614 ±1129
28306 ±567

96-144 29632 ± 449

% of

108 ± 4
103 ± 2

3064 ±122

108 ± 1.6 2871 102

[80]
11 ± 0.5
[89]
10.5 ±0.4
[90.5]

Note: Thymidine incorporation by C T L L cells is expressed as m e a n c p m ± 1 S D for triplicate
cultures. Controls are C T L L cells cultured @ 2000 cells/well + IL 2 (10U/ml) and the relevent
control medium fraction only : C T L L + IL 2 + control fraction 2 = 27613 ± 227 ( 1 0 0 % ± 0.8);
CTLL + IL 2 + control fraction 4 = 27413 ± 3819 ( 1 0 0 % ± 14). (CTLL and IL 2 alone = 23729
±573; C T L L only = 1477 ± 131).
a The test fractions ( 1 0 % v/v)were obtained by gel filtration of supernatants generated from
mock- or virus-challenged monocytes (p72; 10:1)
b Monocyte supernatants were harvested at 4 8 h intervals after initiation of culture (48, 96
and 144 h), with fresh medium being replaced after each harvest. Time of supernatant harvest
was equivalent to time after virus challenge.
c Figures in brackets indicate the percentage suppression of the relevant control proliferative
response where a significant result (p < 0.05) w a s obtained. This data for is additionally
presented in Figure 23a and 23b for fraction 2 and fraction 4 respectively.
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TARLE 34b: THE EFFECT OF FRACTION 2 AND FRACTION 4 ON THE CTLL RESPONSE TO IL
2 WHEN THE CTLL NUMBER IS INCREASED.
PROLIFERATION OF CTLL CELLS (2x104 cells/well)IN
RESPONSE TO IL 2 (1 OU/ml) AND SUPERNATANT
SPNT

SPNT

FRACTIONS a FROM MONOCYTES, EITHER:

FRACTION

TIME

MOCK-CHALLENGED

(h)b

cpm

% of

cpm
control

% of

90 ± 0.3

19391 ± 1446

71 ± 5.3
[29]

14676 ± 206

54 ± 0.8
[46]
36 ± 2.3
[64]

control
FRACTION 2

0-48
48-96

24409 ±71
23756 ± 1020

96-144 22427 ± 960

FRACTION 4

0-48
48-96

25077 ±162
24052 ±698

96-144 26807 ± 1092

HCMV-CHALLENGED

[10]
88 ± 3.7
[12]
83 ± 3.5
[17]

9764 ± 628

107 ± 0.7 2761 ±227
102 ± 3
114 ± 4

1512 ± 152
1540 ± 88

11.7 ± 1
[88.3]
6.4 ± 0.6
[93.6]
6.5 ± 0.4
[93.5]

Note: Thymidine incorporation by C T L L cells is expressed as m e a n c p m ± 1 S D for triplicate
cultures. Controls are C T L L cells cultured @ 20000 cells/well + IL 2 (1 OU/ml) and the
relevent control medium fraction only : C T L L + IL 2 + control fraction 2 = 27138 ± 261
(100% ± 0.9); C T L L + IL 2 + control fraction 4 = 23528 ± 2302 ( 1 0 0 % ± 10). (CTLL and IL 2
alone = 24272 ± 1669; C T L L only = 1653 ± 199).
a The test fractions ( 1 0 % v/v) were obtained by gel filtration of supernatants generated from
mock- or virus-challenged monocytes (p72; 10:1)
b Monocyte supernatants were harvested at 48 h intervals after initiation of culture (48, 96
and 144 h), with fresh medium being replaced after each harvest. Time of supernatant harvest
was equivalent to time after virus challenge.
c Figures in brackets indicate the percentage suppression of the relevant control proliferative
response where a significant result (p < 0.05) w a s obtained.This data for fraction 2 is
additionally presented in Figure 23a.
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TABLE 34c: THE EFFECT OF FRACTION 2 AND FRACTION 4 ON THE CTLL RESPONSE TO IL
9 WHEN THE IL 2 STIMULUS IS INCREASED

PROLIFERATION OF CTLL CEELLS (2x103 cells/well) IN
RESPONSE TO IL 2 (50U/ml) AND SUPERNATANT
SPNT

SPNT

FRACTIONS a FROM MONOCYT ES, EITHER:

FRACTION

TIME

MOCK-CHALLENGED

HCMV-CHALLENGED

(h) b

cpm

cpm

% of

control
FRACTION 2

0-48

7222 ± 3 4 1

control
12 ± 0.6

2926 ± 67

[88]
48-96

5744 ± 353

9.5 ± 0.6

4.8 ± 0.2

2862 ± 86

0-48

58194 ± 1131

99 ± 1.9

4.7 ± 0.1
[95.3]

1484 ± 135

[95.2]

FRACTION 4

4.8 ± 0.1
[95.2]

[90.5]
96-144 2934 ± 134

% of

2.4 ± 0.2
[97.6]

28784 ± 7 1 8

49 ± 1.2
[51]

48-96

54306 ± 2584

93 ± 4.4

26306 ± 590

45 ± 1
[55]

96-144 57897 ± 2228

98 ± 3.8

23441 ± 994

40 ± 2
[60]

|

Note: Thymidine incorporation by C T L L cells is expressed as m e a n c p m ± 1 S D for triplicate
cultures. Controls are C T L L cells cultured @ 2000 cells/well + IL 2 (50U/ml) and the relevent
control medium fraction only : C T L L + IL 2 + control fraction 2 = 60742 ± 369 ( 1 0 0 % ± 0.6);
CTLL + IL 2 + control fraction 4 = 58715 ± 1 1 1 9 ( 1 0 0 % ± 1.9). (CTLL and IL 2 alone = 61522
± 2358; C T L L only = 1594 ± 54).
a The test fractions ( 1 0 % v/v) were obtained by gel filtration of supernatants generated from
mock- or virus-challenged monocytes (p72; 10:1)
b Monocyte supernatants were harvested at 48 h intervals after initiation of culture (48, 96
and 144 h), with fresh medium being replaced after each harvest. Time of supernatant harvest
was equivalent to time after virus challenge.
c Figures in brackets indicate the percentage suppression of the relevant control proliferative
response where a significant result (p < 0.05) w a s obtained. This data for fraction 4 is
additioally presented in Figure 23b
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4 from HCMV-challenged monocytes only) were found to have a profound effect on the
response of C T L L cells to 10 U/ml exogenous IL 2 (Table 34a). Samples that were not
previously identified as suppressive (fraction 4 from mock-challenged monocytes) had
no effect on IL 2 responsiveness. It w a s also noted that the influence present in
fraction 4 derived from 0-48 h monocyte supernatants that w a s able to augment
thymocyte and T cell proliferation had no such effect on the IL 2 responsiveness of
CTLL cells.

When fraction 2 test samples were incubated with CTLL cultures containing a
10-fold increase in the number of C T L L cells (Table 34b), the suppression of the
response of the cells to IL 2 remained significant relative to control cultures in the
absence of the test supernatant, but the degree of suppression was significantly
reduced relative to cultures containing the basic concentration of C T L L cells.
Reduction in suppression w a s particularly marked in cultures where test samples
were derived from mock-challenged monocytes and in cultures where the test samples
were derived from monocytes early in culture (0-48 h as opposed to 96-144 h).
These trends seen with increasing C T L L cell concentration are also illustrated in
Figure 23a. Thus it appeared that increasing cell numbers could counter the effects of
the suppressive influence on the response to a constant level of IL 2. The data further
indicated a dose-response effect, where the IL 2 reponsiveness of C T L L cells cultured
with test samples with a lower suppressive potential (ie: those derived from mockchallenged monocytes or from monocytes early in culture) had a greater potential to
be restored than when test samples derived from HCMV-challenged monocyte
supernatants or supernatants produced later in culture were used. W h e n a similar
experiment was performed using the basic number of C T L L cells but a 5-fold increase
in the IL 2 concentration (Table 34c), the suppressive effect w a s maintained in all
instances. This suggested that the mechanism of action of fraction 2 was independent
of the level of IL 2 available.

F I G U R E 23a : The effect of fraction 2 on the IL 2-responsiveness of C T L L cells at two
different cell densities. This figure illustrates the % suppression data presented in
Table 34a and 34b where the concentration of C T L L cells used w a s 2 x 1 0 3 (2000)
cells/culture well or 2 x 1 0 4 (20000) cells/culture well respectively. The control
proliferative response is that of the relevent C T L L cell density (2 x 1 0 3 or 2 x 10 4
cells/well) to IL 2 (1 OU/ml) in the absence of the test fraction 2. Detailed culture
conditions are as for table 34a and 34b.
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ure 23a

: The effect of fraction 2 on the IL 2-responsiveness
of CTLL cells cultured at two
different concentrations

•

2000 cells

(mock)

E2 20000 cells
2000 cells
E3 20000 cells

40-

20-

0-48

48-96

96-144

Time of supernatant harvest (h)

(HCMV)

F I G U R E 23b : The effect of fraction 4 on the responsiveness of C T L L cells to increasing
concentrations of IL 2. This figure illustrates the % suppression data presented in
Table 34a (IL 2 at 10 U/ml)and 34c (IL 2 at 50 U/ml) for C T L L cells cultured in the
presence of fraction 4 derived from HCMV-challenged monocyte supernatants only. The
control proliferative response is that C T L L cells (2 x 1 0 3 cells/well) cultured with the
relevent IL 2 concentration (10 U/ml or 50 U/ml) in the absence of the test fraction 4.
Detailed culture conditions are as for table 34a and 34c
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Figure 23b : The effect of fraction 4 on the response
of CTLL cells to two concentrations of IL 2
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This experimental protocol w a s repeated using fraction 4 test samples
derived from HCMV-challenged monocyte supernatants. W h e n these test samples
were added to C T L L cultures containing a 10-fold increase in the number of C T L L cells
(Table 34b), the magnitude of the suppressive effect remained unchanged. W h e n the IL
2 concentration w a s increased (Table 34c), suppression of proliferation, although
remaining significant relative to control cultures, w a s significantly less than in C T L L
cultures exposed to the lower dose of IL 2. These trends seen with increasing IL 2
concentration are also illustrated in Figure 23b. Thus, in contrast to the situation
observed with fraction 2, it appeared that the suppressive effect of fraction 4
towards the IL 2-responsiveness of C T L L cells could be reduced, if not overcome, by
increasing the concentration of IL 2.

3.5.11 Effect of monocyte suppressor factors on expression of the a and 3 chains of
the IL 2 receptor.
Expression of the p55 (a chain; TAC)and p70 (3 chain) components of the IL 2
receptor (IL 2R) was examined by F A C S analysis of nylon wool purified T cells stained
with DAKO-IL2R, an M A B (lgG-|) against the p55 component, or T U 27, a M A B (IgGi)
against the p70 component, and a PE-conjugated second antibody. Negative controls
included staining with C D 3 and a purified PE-conjugatad mouse M A B (lgG-|) or with C D
3 and the second conjugate alone. All cells were also stained with an FITC-conjugated
anti-CD3 M A B (IgG-i)and electronic gates set on C D 3-positive T cells to ensure that
expression of the IL 2R on C D 3-positive T cells only was assessed.

Preliminary experiments showed that while expression of both the a and 3
chains of the IL 2R were undetectable in unstimulated T cells, stimulation with P H A at
1 pg/ml induced expression of a measurable level of either chain after 72 h in culture,
while stimulation under identical conditions with P H A at 5 pg/ml induced high levels of
expression (Figure 24). Stimulation of T cells with 5 pg/ml P H A for three days was
thus chosen as an acceptable experimental regime for induction of IL 2R expression. T

F I G U R E 24: The effect of P H A concentration on expression of the p55 and p70
components of the IL 2R on T cells. Freshly isolated, nylon wool purified T cells (2 x
1 0 5 cells/culture well) were cultured for 72 h in the presence of P H A at 1 pg/ml and 5
pg/ml. Expression of p55 and p70 was determined by M A B staining and F A C S analysis
as described in section 2.13. Electronic gates were set on C D 3+ cells.

Figure 24 : The effect of P H A concentration
on p55 and p 70 expression
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cells treated in this way were additionally cultured in the presence of fraction 2 and
fraction 4 derived from fractionation of LPS-stimulated, mock- and p72-challenged
monocyte supernatants. The test fractions ( 1 0 % v/v) were added to T cells at the
start of the three day culture period or 24h after initiation of culture. T cells
cultured in the presence of fraction 2 showed no evidence of an alteration in
expression of either the p55 (Figure 25) or the p70 (Figure 26) component of the IL
2R relative to controls. Culture of T cells with fraction 4 derived from mockchallenged cells similarly had no effect on either component (Figures 27 and 28). T
cells cultured in the presence of fraction 4 derived from HCMV-challenged monocytes
showed no change in the expression of the p 70 component of the IL 2 receptor (Figure
28), but a marked reduction in the levels of expression of p 55 was noted (Figure 27).
This reduction occured whether T cells were incubated with the test samples for the
entire 72 h culture period or only for the last 48 h (data not shown). N o change in
either C D 3 expression or cell size was observed in any of theT cell cultures.

From these results it was not possible to conclude whether expression of the
p55 component per se was affected, or whether binding of the M A B to the IL 2R was
being blocked. Prior to staining however, all cells were treated to an acid wash
treatment to remove any endogenous IL 2 bound to the IL 2R that may have blocked
M A B binding. This w a s effective as shown by control staining and it is expected that
this treatment should also have been effective in removing any other potential IL 2Rbinding molecules.

3.6 Expression of virus-specific antigens by HCMV-challenged
monocytes.
Monocytes were challenged with H C M V using the same protocol as used for
previous experiments, ie: the laboratory adapted strain A D 169 and the clinical
strain p72 were used at moi of 1:1 and 10:1 with centrifugal enhancement. W h e n
monocytes were stained with M A B 810 for expression of a 68 kDa immediate early

F I G U R E 25: The effect of fraction 2 derived from mock- and HCMV-challenged monocyte
supernatants on expression of the p55 component of the IL 2R on T cells. Freshly
isolated, nylon wool purified T cells (2 x 1 0 5 cells/culture well) were cultured for 72
h in the presence of 5 pg/ml P H A and fraction 2 (10% v/v, originally generated from
mock- and H C M V (p72; moi 10:1)-challenged monocytes over the time 0-48, 48-96
and 96-144 h post culture initiation and virus challenge (represented on figures as
Mock/HCMV-48,96 & 144 h respectively). Expression of p55 was determined by M A B
staining and F A C S analysis as described in section 2.13. Electronic gates were set on C D
3+ cells.
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Figure 25 : The effect of fraction 2 on p55 expression
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F I G U R E 26: The effect of fraction 2 derived from mock- and HCMV-challenged monocyte
supernatants on expression of the p70 component of the IL 2R on T cells. Freshly
isolated, nylon wool purified T cells (2 x 1 0 5 cells/culture well) were cultured for 72
h in the presence of 5 pg/ml P H A and fraction 2 ( 1 0 % v/v, originally generated from
mock- and H C M V (p72; moi 10:1)-challenged monocytes over the time 0-48, 48-96
and 96-144 h post culture initiation and virus challenge (represented on figures as
Mock/HCMV-48,96 & 144 h respectively). Expression of p70 was determined by M A B
staining and F A C S analysis as described in section 2.13. Electronic gates were set on C D
3+ cells.

Figure 26 : The effect of fraction 2 on p70 expression
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F I G U R E 27: The effect of fraction 4 derived from mock- and HCMV-challenged monocyte
supernatants on expression of the p55 component of the IL 2R on T cells. Freshly
isolated, nylon wool purified T cells (2 x 1 0 5 cells/culture well) were cultured for 72
h in the presence of 5 pg/ml P H A and fraction 4 ( 1 0 % v/v, originally generated from
mock- and H C M V (p72; moi 10:1)-challenged monocytes over the time 0-48, 48-96
and 96-144 h post culture initiation and virus challenge (represented on figures as
Mock/HCMV-48,96 & 144 h respectively). Expression of p55 was determined by M A B
staining and F A C S analysis as described in section 2.13. Electronic gates were set on C D
3+ cells.

Figure 27 : The effect of fraction 4 on p55 expression.
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F I G U R E 28: The effect of fraction 4 derived from mock- and HCMV-challenged monocyte
supernatants on expression of the p70 component of the IL 2R on T cells. Freshly
isolated, nylon wool purified T cells (2 x 1 0 5 cells/culture well) were cultured for 72
h in the presence of 5 pg/ml P H A and fraction 4 (10% v/v, originally generated from
mock- and H C M V (p72; moi 10:1)-challenged monocytes over the time 0-48, 48-96
and 96-144 h post culture initiation and virus challenge (represented on figures as
Mock/HCMV-48,96 & 144 h respectively). Expression of p70 was determined by M A B
staining and F A C S analysis as described in section 2.13. Electronic gates were set on C D
3+ cells.
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Figure 28 : The effect of fraction 4 on p70 expression
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(IE) nuclear antigen, although an increase in IE-positive cells w a s seen with both
increasing virus dose and time post virus challenge, no more than 1 0 % of a challenged
cell population appeared to be expressing this IE antigen (Table 35). Parallel staining
procedures on mock-challenged monocytes (negative control) and HCMV-challenged
fibroblasts (positive control) confirmed the reliability of the staining protocol used.
Selected monocyte cultures were also stained with a M A B raised against a 43 kDa
nuclear antigen that can reportedly be detected in fibroblasts as early as 24 h after
infection. Only 1 2 % of a population of A D 169-challenged monocytes stained positive
for this antigen as late as 72 h post challenge.

3.7 Production of soluble factors from HCMV-challenged fibroblasts
and endothelial cells.
Supernatants were generated from HCMV-challenged fibroblasts and
endothelial cells and tested for their effect on the thymocyte response to P H A
(1pg/ml).

3.7.1. The effect of fibroblast supernatants on thymocyte proliferation.
Twenty four h supernatants generated from control and HCMV-challenged
fibroblasts over the period 120-144 h post challenge were tested for their influence
on thymocyte proliferation (Table 36). Supernatants from control fibroblasts had no
effect on the thymocyte response to PHA, while incubation with supernatants from
HCMV-challenged fibroblasts increased thymocyte proliferation in a dose-dependent
manner.

3.7.2. The effect of endothelial rell supernatants on thymocyte proliferation.
24 h supernatants were generated from control and HCMV-challenged
endothelial cells at intervals over a 4 day period and tested for their influence on
thymocyte proliferation (Figure 29). Supernatants from both control and challenged
cells contained a stimulatory influence that peaked 48-72 h after culture initiation. In

TABLE 35: EXPRESSION OF VIRUS-SPECIFIC ANTIGENS IN HCMV-CHALLENGED
MONOCYTE POPULATIONS.

PERCENTAGE (%) OF CELLS STAINING POSITIVE
FOR VIRUS SPECIFIC ANTIGEN AFTER CHALLENGE
TIME
MAB
USED

CELL
3

TYPE

MAB 810

DAKO-

WITH

(h post
b

Monocyte

challenge)
24

AD 169
1:1
<1

P72
10:1

1:1

10:1

2

1

2

48

1

3

1

5

144

3

10

4

10

Fibroblast 2 4

53

75

61

85

Monocyte

NTC

12

NT

NT

72

CMV

Note: The percentage of cells expressing HCMV-specific antigens was determined by
immunofluorescent staining as described under Methods and Materials.
a

Two different M A B were used; M A B 810 specific for a 68 kDa IE antigen and D A K O - C M V

specific for a 43 kDa nuclear antigen.
b

Monocytes were the cell type under study; fibroblasts were included as a positive control.

0

Not tested.

TARI F 3fi: PRODI JCTION OF THYMOCYTE STIMULATING ACTIVITY FROM CONTROL AND
HCMV-CHALLENGED FIBROBLASTS.

THYMOCYTE PROLIFERATION IN RESPONSE TO
SUPERNATANTS FROM FIBROBLASTS, EITHER a
SUPERNATANT DILUTION b

CONTROL

HCMV CHALLENGED

4 % v/v

98 ± 6

136 ± 11

15% v/v

92 ± 7

166 ± 9

Note: Data is presented as a percentage increase over cpm (mean ± 1 S D for triplicate cultures
adjusted to 100%) obtained when control thymocytes without fibroblast supernatants were
cultured. Control c p m = 1372 ± 230 (100 ± 17).
a

Supernatants were harvested from control or HCMV-challenged (AD 169; 3:1) fibroblasts

over the period 120-144 h post challenge.
b

Supernatants were tested in the thymocyte assay at two dilutions.

F I G U R E 29: The effect of supernatants from mock-and HCMV-challenged endothelial
cells on PHA-stimulated thymocyte proliferation. 24 h supernatants were harvested
from control and HCMV-challenged (AD 169; 5:1) endothelial cells at 24, 48,72 and
96 h after virus challenge and tested ( 1 0 % v/v) for their effect on thymocyte
proliferation. Data is presented as m e a n ± 1 S D for triplicate cultures adjusted to a
relative percentage of the proliferative response to P H A (1 pg/ml) alone.
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Figure 29 : Thymocyte stimulating activity in 24 h supernatants
from mock- and HCMV-challenged endothelial cells
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control supernatants, this influence caused an almost 3-fold increase in the thymocyte
response to P H A . In supernatants from virus-challenged endothelial cells, the
stimulatory effect w a s dramatically enhanced, causing a 10-fold increase in
thymocyte proliferation after 48 h and still being very marked over the period 72-96
h post challenge.
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4.0.0. DISCUSSION

The successful induction of a cell-mediated immune response is dependent
upon the effectiveness of the initial contribution provided by accessory cells. In the T
cell proliferative response to foreign antigen for instance, antigen presentation by
accessory cells represents the crucial induction event. Accessory cells perform two
distinct functions in this regard: firstly, they assist in the initiation of the response
by presenting processed antigen to T cells in an M H C - restricted fashion and in the
presence of soluble stimuli; secondly, they influence the magnitude and duration of
the clonal expansion of activated T cells through producing appropriate regulatory
signals and participating in feedback circuits (Koide et al 1981 & Rhodes et al 1986).
Because of the ability to transduce communication signals both via direct cell-cell
contact and through the production of soluble factors, antigenic specificity is initially
established and maintained, while the accessory cell retains the potential to influence
the clonally expanding cell population. Cell types with accessory function include
monocytes, dendritic cells, endothelial cells, B cells, myeloid precursor cells, liver
Kupffer cells and skin Langerhans cells (Unanue 1984).

The accessory cell upon which this study focused was the human peripheral
blood monocyte. Monocytes express M H C molecules (Unanue and Allen 1987) and
produce a range of soluble factors (Dinarello 1985). A defect in either the antigen
presenting or the regulatory function of monocytes could manifest as an impairment in
the T cell response to foreign antigens and thus contribute to immunosuppression.
Infection with H C M V is associated with immunosuppression, the inability of the host to
mount an effective cell-mediated immune response against secondary infections being
a c o m m o n feature (Griffith and Grundy 1988). It w a s proposed that altered monocyte
accessory cell function is central to this host defect, and the present study w a s
undertaken to examine the effect of in vitro H C M V challenge on the aspects of
accessory cell function described.
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Because an in vitro culture system was exclusively used, it was necessary
to carefully define monocyte responses under conditions of mock-virus challenge or
'normal' in vitro culture, before the extent of a virus-specific effect could be
established. Monocyte antigen presenting ability was assessed by measuring the
proliferative response of T cells to a soluble protein antigen presented by pre-pulsed
autologous monocytes. While establishing an operational antigen presentation system
under normal conditions, it was noted that when the total monocyte concentration
used exceeded 1 5 % relative to T cell number, the magnitude of the T cell response
dropped accordingly (Table 1). Unsgaard et al (1977) have shown that the T cell
response to PPD-pulsed monocytes increases with increasing monocyte concentration
up to a level between 7-19%, after which it declines. In a more recent report of an
antigen presentation system using P P D , Zembala et al (1988) report that normal Fc
receptor-positive monocytes have the capacity to induce suppressor T cells; thus a
reduced P P D response is recorded, albeit in the absence of an intrinsic monocyte
defect. In the present study, whether the monocytes were themselves suppressive,
or were inducing suppressor T cells, was not determined. Importantly though, the
monocyte : T cell ratio chosen for use was one that allowed an optimal T cell response
under normal conditions.

Because only low levels of T cell proliferation were observed when T cells
were cultured in the presence of P P D alone (Table 2), it was proposed that the T cell
response to P P D was monocyte dependent. These results are in agreement with
reports (Bergholtz and Thorsby 1978, Koide et al 1981 & Koide and Yoshido 1984)
that the optimal proliferative response of T cells from immune donors to low doses of
P P D in vitro is dependent on the presence of autologous monocytes, with antigen
being presented by the monocyte in the context of gene products encoded by the
HLA/DR region of the M H C . Studies with the lysosomotropic agent chloroquine (Table
3), demonstated that impaired lysosomal function was associated with decreased
antigen presentation and suggested that a period of metabolic processing was required
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prior to the presentation event. The earlier the chloroquine treatment, the greater
was the interference with antigen handling. These observations correspond to those
made by Scala and Oppenheim (1983) and Ziegler and Unanue (1981) who report that a
pulse period of at least 20 minutes is required for detectable uptake and
internalization of antigen by monocytes, while a minimum of two hours is necessary
to induce optimal lymphoproliferative responses.

HCMV-challenged monocyte populations showed a dose- and time-dependent
decrease in the ability to support antigen-specific T cell proliferation (Table 4a & 4b;
Figure 1). Differences in absolute responses were seen with different C M V seronegative donors, but relative trends were the same. A similar suppressive
effect w a s seen regardless of whether the laboratory adapted strain or a clinical
isolate of H C M V w a s used.

Having identified a defect in antigen presenting ability associated with virus
challenge, it w a s then necessary to determine which aspect of presentation was being
affected. Regarding the antigen presentation system as a whole, a number of
susceptible targets can be defined: initial antigen uptake, antigen processing events,
expression of sufficient levels of class II H L A molecules, complexing of processed
peptides with H L A molecules in a form that is recognizible for the T cell receptor,
appropriate production of co-stimulatory cell-associated molecules and/or soluble
cytokines and responsiveness to feedback signals from the contacted T cells are all
mechanisms that m a y be defective. Because these events can be dissociated and
independently regulated, a c o m m o n result (ie: a decrease in T cell proliferation) could
be due to one or more of a number of these potential defects. Independent regulation
of these mechanisms has been frequently demonstrated ; for example Palay et al
(1986) demonstrated that a cyclosporin-induced defect in antigen presentation was
due specifically to interference with the correct complexing of processed antigenic
determinants and H L A molecules, while Rhodes and Tite (1988) report that low dose
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aldehyde treatment of monocytes can abolish H L A - D R expression, while preserving
the ability to take up and process antigen and secrete soluble mediators.

Ferro et al (1987) report instances in both murine and human systems where
defective antigen presentation by macrophages is explained by a decreased ability of
the macrophages to take up and process antigen. The possibility that defective antigen
uptake m a y account for the deficient antigen presenting ability of HCMV-challenged
monocytes seen the present study w a s therefore examined. Monocytes challenged
with H C M V at the s a m e time as antigen pulsing, or challenged after they had been
allowed to take up antigen and initiate processing in the absence of virus, were as
suppressive for antigen-specific T cell proliferation (Table 5) as monocytes that were
challenged prior to antigen pulsing (Table 4a & 4b; Figure 1). These observations did
not therefore suggest that a defect in initial antigen uptake and processing accounted
for the deficient antigen presentation by HCMV-challenged monocytes. The next
mechanism considered as a potential target for interference by H C M V w a s the
expression of class II H L A molecules.

It has been well established that there is a direct relationship between the
antigen-presenting capacity of a monocyte population and the proportion of cells
expressing H L A class II molecules (Beller 1984, Nouri-Aria et al 1988, Unanue 1984
& Zlotnik et al 1983). Further, the expression of class II molecules is not a stable
characteristic; it is a readily inducible but transient event that is extremely
susceptible to local immunologic stimuli.

The major defined stimulus for the upregulation of HLA molecules on
monocytes is the T cell product IFN y. (Beller & H o 1982, Portillo 1989, Sztein et al
1984, Virelizier et al 1984, Zlotnik et al 1983). IFN y-induced upregulation is at the
level of gene transcription (Fertsch-Ruggio et al 1988). Other upregulating stimuli
include G M - C S F (Portillo et al 1989),TNF a (Arenzana-Seisdodos et al 1988) and IL 4
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(Littman et al 1989). These factors do not however have a direct effect on H L A gene
expression, but enhance IFN y-mediated effects. Factors that downregulate H L A
include prostaglandins, glucocorticoids, serotonin, a fetoprotein, immune complexes,
type 1 interferons (IFN a/3), T G F 3 and bacterial endotoxin (Fertsch-Ruggio et al
1988, Hamilton et al 1987, Hanaumi et al 1984, Portillo et al 1989, Steeg et al 1982
& Y e m and Parmely 1981). Factors such as these have the potential to influence
monocyte accessory cell function via their capacity to regulate M H C class II synthesis
and/or expression. It is possible that one effect of H C M V challenge on monocyte
antigen presenting ability m a y be due to the capacity of the virus to influence class II
molecule expression. The effect of H C M V challenge on the surface expression of HLAD R was therefore specifically examined.

Sztein et al (1984) report that about 75% of freshly isolated peripheral
blood monocytes express H L A - D R molecules. This expression decreases with time in
culture but the loss can be delayed or restored by incubation with a T cell
supernatant, of which IFN y is the primary active ingredient. IFN y-induced
upregulation is associated with both an increase in the absolute number of HLA-DRpositive cells and in the density of molecules per cell. In the normal system initially
tested in this study, results for expression of H L A - D R as assessed by fluorescence
microscopy were in agreement with what has been reported in the literature; ie: H L A
expression was found to decrease with time in culture, to be responsive to
upregulation by T cell factors and to be downregulated by L P S (Table 6). The fact that
LPS-stimulated monocytes were less efficient in presenting antigen than their
unstimulated counterparts (Table 7; Figure 3) further supported the proposed
relationship between antigen presenting ability (in this case P P D ) and expression of
class II molecules (in this case HLA-DR) in the system used in the present study.
Seitz et al (1988) report that the presentation of P P D to T cells by normal monocytes
can be blocked by a M A B to HLA-DR, while Y e m and Parmely (1981) have shown that
LPS pre-treatment of monocytes reduces their ability to present P P D to T cells and
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suggested that this m a y be related to an LPS-mediated decrease in H L A expression.
Thus, it appeared that a decreased level of H L A - D R could be reflected in the level of
PPD-specific T cell proliferation measured.

When the expression of HLA-DR in HCMV-challenged monocytes was studied,
it was found that virus challenge could significantly reduce the proportion of H L A - D R
positive cells and that this influence w a s resistant to lymphokine-mediated
upregulation (Figure 2). The possibility that monocytes co-cultured with T cells in an
antigen presentation system m a y be similarly resistant to lymphokine-mediated
upregulation w a s investigated in the present study by co-culturing HCMV-challenged,
PPD-pulsed monocytes and T cells in the presence of an exogenously added DRinduction stimulus (a supernatant from activated T cells). W h e n monocyte -T cell coculture was initiated immediately after virus challenge, the T cell supernatant was
able to reconstitute T cell proliferation to levels similar to those induced by PPDpulsed, mock-challenged monocytes. However, when T cells were co-cultured with
antigen-pulsed monocytes 48 h after virus challenge, the addition of exogenous T cell
supernatant w a s not able to reconstitute the T cell response. Examination of data
obtained from detection of H L A - D R expression and from functional antigen
presentation assays suggested firstly that the initial monocyte-T cell interaction m a y
be impaired in an antigen presentation event due to a virus-induced decrease in
expression of surface D R molecules; and secondly, that virus-challenged monocytes
show a reduced capacity to respond to H L A - D R induction signals from T cells over the
course of the cellular interaction. The importance of T cell feedback responses for
effective upregulation of the monocyte-T cell interaction has been widely documented.
(Antonelli et al 1988, Fischer et al 1988, Huet et al 1988 & Zuckermann et al 1988).
The suppression by H C M V of monocyte responsiveness to feedback signals from a
contacted T cell m a y thus have a greater effect on the eventual outcome of the
presentation event than the effect of the virus on the initial expression of H L A -DR.
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The expression of H L A - D R in association with certain pathologies has been
studied. Indeed, Buchmeier and Cooper (1989) recently have examined the effects of
H C M V on monocyte A P C function. They reported that challenged monocytes showed an
impaired presentation of tetanus toxoid and a decrease in HLA-DR and D Q in response
to IFN y. They concluded however that the magnitude of this effect is not enough to
cause the degree of immunosuppression seen in C M V patients. Monocytes are
susceptible to infection with HIV (Ho et al 1986) and, in a situation analogous to
infection with H C M V , the infection is not directly lethal but m a y have profound effects
on the functional properties of the cell. Decreased HLA-DR expression has been
reported on A P C from HIV- infected individuals ( Heagy et al 1984 & Belsito et al
1984). Petit et al (1987) demonstated that in vitro infection of monocytes results in
downregulation of surface H L A - D R , and suggested further that impaired A P C function
may result. Contrary to what was found with H C M V in the present study though, HIVinfected cells were responsive to IFN y (Petit et al 1987 & Heagy et al 1984). Seitz
et al (1983 & 1988) examined the expression of HLA-DR on monocytes from patients
with rheumatoid arthritis (RA). In 1983 they reported that R A monocytes showed a
reduced ability to present antigen to T cells, while T cells retained their mitogen
responsiveness and later (1988) correlated this with decreased levels of surface
HLA-DR.

An HCMV-induced decrease in monocyte expression of HLA-DR is apparent;
several possible mechanisms could contribute to this decrease. As previously
mentioned, one of the agents known to downregulate H L A is IFN a/3, with the level of
action being at gene transcription (Fertsch-Ruggio et al 1988). Inaba et al (1986)
have related a defect in monocyte antigen presenting ability to an IFN a/3-mediated
block in IFN y induced HLA. In the murine system, Blank et al (1985) report that
macrophages exposed to IFN a/3 retain the ability to take up antigen, but their ability
to present it effectively to T cells is compromised. Kitaura et al (1988) report that
the downregulatory effect of IFN 3 and possibly IFN a on expression of H L A is not
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direct but mediated by newly synthesized proteins. Johnson et al (1989) working
with rat synovial fibroblasts report that if IL 1 is added to the system before or
during the first 24 h of an IFN y-mediated HLA-induction regime, H L A class II
expression is inhibited. Thus, although the murine and rat systems described m a y not
be directly applicable to the h u m a n monocyte system, they do illustrate that IFN yinduced H L A expression is subject to inhibition from soluble mediators. Grundy et al
(1988) have confirmed that H C M V infection of fibroblasts induces IFN 3 and it is
recognized that a variety of viruses can induce release of IFN 3 from monocytes
(Goldfeld and Maniatis 1988). It is possible that HCMV-challenge of peripheral blood
monocytes m a y induce overproduction of IFN 3 which has the capacity to
downregulate levels of class II M H C m R N A and further render the monocyte resistant
to the enhancing effects of IFN y. A future area of study should involve investigation
of the production of IFN 3 by monocytes in response to H C M V challenge. With respect
to the in vivo situation, secondary bacterial infections in H C M V patients m a y
increase monocyte exposure to endotoxin, thus contributing further to the decreased
levels of H L A - D R and the associated implications.

Although only HLA-DR expression was directly quantitated in this study, it
should also be kept in mind that the other class II molecules, namely H L A - D Q and DP,
may be important in antigen presentation and that their expression m a y be influenced
by virus challenge. It has been reported for example (Gonwa et al 1983 & Nunez et al
1987) that expression of D Q determinants correlates both with monocyte antigenpresenting ability and with an increased density of D R (Nunez et al 1987). The
expression of D P and D Q is also controlled by IFN y and thus, although expression of
D P and D S w a s not directly measured, the functional reconstitution studies performed
would suggest that neither of these two determinants w a s expressed at levels
sufficient to allow antigen presentation to continue as normal in the face of the
measured decrease in HLA-DR. Geppert et al (1987) have stated that although HLArestricted antigen presentation is essential for monocyte-T cell contact and T cell
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activation, to function as an effective A P C a cell must also engage in M H C - n o n
restricted interactions. Thus, other molecules induceable by IFN y m a y be important
candidates for an effective monocyte -T cell interaction. O n e such interaction that is
thought to play a central role is that between the T cell antigen LFA-1 and its ligand
ICAM-1 which is basally expressed on monocytes and is very susceptible to IFN ymediated upregulation (Kawakami et al 1989). Future studies should involve a direct
examination of the effect of H C M V challenge on monocyte expression of H L A - D Q and
DP, as well as on molecules such as ICAM-1 that are involved in M H C unrestricted
interactions.

Two possible mechanisms responsible for the inability of HCMV-challenged
monoctes to support antigen-specific T cell proliferation have been examined in the
preceding section: a defective ability to take up and present antigen and a decreased
expression of class II M H C determinants. The third potential defect considered was
the reduced secretion of soluble stimulatory factors such as IL 1. It was considered
possible that levels of IL 1 m a y be a limiting factor in the accessory cell ability of
virus-challenged monocytes. Thus, HCMV-challenged, PPD-pulsed monocytes were
co-cultured with T cells, and exogenous IL 1 was added to this antigen presentation
system to see if it could reconstitute the T cell proliferative response. Exogenous IL
1 had a limited reconstituting potential (Tables 8a & 8b; Figure 4), suggesting that IL
1 was not a limiting factor in the antigen presenting system. Kern et al (1988b) used
IL 1 reconstitution assays to investigate the reasons for the decreased antigen
presenting ability of low density alveolar macrophages (AM) as compared to high
density A M and blood monocytes. They reported an inability of exogenous IL 1 to
completely restore the proliferative response to antigen presented by low density A M
and concluded that although decreased IL 1 secretion m a y have been partly
responsible, other processes were contributing to the decreased accesory cell
function.
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It it is possible that exogenous IL 1 m a y have a limited potential to
reconstitute antigen presentation systems such as the one described here (Tables 8a
& 8b; Figure 4) and by others (Kern et al 1988 & Bauer et al 1989) because, as has
been suggested by Mayernik et al (1984), it is not a vital component of the antigen
presentation system. With this in mind, the role of IL 1 in antigen-presenting systems
was more closely evaluated. Although IL 1 is readily secreted in response to
bacterial endotoxin and a variety of other stimuli, soluble protein antigens do not
directly stimulate IL 1 production (Weaver and Unanue 1986) and additional signals
are required from the T cell after initial monocyte-T cell contact. According to
Bhardwaj et al (1989), in antigen presentation events, IL 1 is primarily a product of
the efferent rather than the afferent limb of the immune response and is produced in
appreciable amounts only after monocyte T cell contact. This group, and Kawakami et
al (1989) both emphasize the importance of M H C - n o n restricted as well as restricted
contact events, and Kawakami et al (1989) further propose that after initial M H C restricted contact has occured, unrestricted events are important for release of
soluble factors. It has also been widely suggested, in both murine (Kurt Jones et al
1985) and human (Hurma and Seppala 1988) antigen presenting systems, that the
important IL 1 species is a membrane associated IL 1 a molecule. Other researchers
(Minnich-Carruth et al 1989 & Mizel 1987) have disputed the existance of a
membrane-associated form of IL 1. They state that on the basis of its structure and
route of secretion, IL 1 a is unlikely to be a membrane protein, and propose that
previous claims of detection were likely due to artifacts of fixation. Whatever the
exact nature of the IL 1 species implicated in antigen presentation events, it is
generally agreed that there is an absolute requirement for T cell signals for IL 1
induction. Weaver and Unanue (1986) have proposed that these involve both direct
cell-cell contact and soluble factor release. Weaver et al (1989) later identified T N F
6 (lymphotoxin) as the T cell product responsible. It is also agreed that the IL 1
produced is restricted to the immediate site of the immune response, thereby
minimizing the potential for the often deleterious systemic effects of IL 1 (Wasik et al
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1988). Bendtzen (1988) proposes a model whereby IL 1 produced in response to T
cell contact remains closely associated with the interacting cells. This is facillitated
by either species of IL 1 binding to the specific IL 1 receptor which remains physically
or functionally associated with the C D 4 molecule; C D 4 is in turn intimately
associated with the T cell receptor complex. Thus, because of this close physical
association, it is easy to envisage that only IL 1 produced as part of a local circuit for
monocyte-T cell antigen-specific contact would be able to participate effectively in
subsequent T cell activation events.

In the light of what has been reviewed above, the results of the IL 1
reconstitution experiments performed here (Tables 8a & 8b; Figure 4) could be
interpreted to m e a n that IL 1 could still be a limiting factor but that, because the IL 1
added w a s exogenous and not induced by monocyte T cell contact, it could not form the
correct association with the IL 1 receptor and associated cell-cell contact molecules
and was thus ineffective as a restoring stimulus. Bauer et al (1989) used exogenous
IL 1 a and 8 at doses of up to 100 U/ml in an unsuccessful attempt to reconstitute a
defective antigen presentation system. In the present study, although L P S stimulation
enhanced monocyte IL 1 production (Table 11), it did not enhance monocyte antigen
presenting capacity (Table 3). This could be explained by the fact that because
monocytes were L P S stimulated prior to T cell co-culture, the IL 1 induced by L P S
stimulation w a s ineffective in the context of antigen presentation.

A number of workers have questioned the nature of the role of IL 1 in antigen
presentation systems (Beller 1984, Ferro et al 1987, Koide et al 1987, Mizel 1987
& McKean et al 1985), the most c o m m o n conclusion being that it does play an
important contibutory role but that other cytokines m a y be equally or more important
than IL 1 as co-factors for antigen presentation and T cell proliferative responses.
These include tumour necrosis factor (TNF a), through its ability to synergise with
IFN yfor upregulation of H L A - D R molecules (Pfizenmaier et al 1987 & Arenzana-
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Seisdedos 1988); IL 6, which is a potent co-stimulant for T cells (Baroja et al 1988;
Houssiau et al 1989, Tosato(& Pike 1988); and other as yet undefined factors
(Antonelli et al 1988) which are able to activate T cells for enhanced IFN y production.
W h e n Buchmeier and Cooper (1989) examined the production of IL 1 in an antigen
presentation system with HCMV-challenged monocytes, they did not detect any
significant changes in IL 1 activity in supernatants from HCMV-infected monocytes
collected 3 or 6 days post infection, as measured using the murine thymocyte assay.
These workers tested monocyte supernatants at a 1 in 4 dilution (ie: 2 0 % v/v), while
in the present study, supernatants were tested at 1 0 % v/v.

In the present study, it is proposed that possible defects associated with IL 1
should not be ruled out as contributing to decreased antigen presentation by H C M V challenged monocytes. It is suggested however that if IL 1 is to be limiting in the
antigen presentation system, then it is due to a defect in the expression of IL 1 that is
active only in the immediate monocyte T cell environment and which is induced only
after initial monocyte-T cell contact. Thus, an observed defect m a y be due to a
direct effect of H C M V on IL 1 produced in response to T cell signals, or it may be
secondarily manifested due to a compromised monocyte-T cell contact event.

In addition to evaluating the importance of HCMV and IL 1 in antigen
presentation systems, it w a s necessary to understand what effect H C M V had on
monocyte IL 1 and IL 1-related effects independent of the issue of antigen
presentation.

Although there are reports of constitutive IL 1 production by monocytes in
the literature, they are likely to be due to low levels of bacterial endotoxin present in
culture media, non-specific activation during isolation procedures or as a response to
a prior in vivo stimulus (Oppenheim et al 1986). L P S can be stimulatory at levels of
10 pg/ml (Arend et al 1985), thus inadvertant stimulation due to low level
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contamination is a probability. In addition, a number of reports clearly indicate that
isolation and culture of peripheral blood monocytes induces IL 1 even in the absence of
an experimentally added stimulus such as L P S (Lepe-Zuniga et al 1984, Treves et al
1983 & Tanaka et al 1987). In the present study too, measureable IL 1 activity was
secreted by monocytes that had not been experimentally stimulated by L P S (Table
11). Monocytes referred to as 'unstimulated' are thus only unstimulated relative to
monocytes exposed to a specific LPS-stimulation regime.

The kinetics of IL 1 production by peripheral blood monocytes have been
extensively examined. W h e n monocytes are freshly isolated and introduced into
culture, both extracellular and intracellular IL 1 levels peak during the first 24 hours
and subsequently decline with time (Elias et al 1985, Lepe-Zuniga et al 1984,
Mayernik et al 1984 & Newton 1986). These kinetic studies were performed using
biological and immunoassays and are paralleled by levels of IL 1 m R N A . There is a
rapid accumulation of IL 1 m R N A as early as 2 h after stimulation, a peak at 6 h and a
progressive decline thereafter (Bernaudin et al 1989, Kern 1988 & Scales 1989). In
the present study, the biological activity of IL 1 as a function of time in culture
correlated well with these previous reports (Table 9; Figure 6), suggesting that in the
culture system used here, the IL 1 response of normal monocytes w a s satisfactory.
On this basis, the IL 1 activity produced by mock infected and H C M V challenged
monocytes at specific time intervals w a s examined.

When supernatants were harvested from mock- and HCMV-challenged
monocytes at 48 h intervals over a period of 8 days, the IL 1 activity in challenged
cell supernatants w a s always lower than that in control supernatants (Figure 7). This
was observed with different donors and different virus strains and doses (Table 10).
In contrast, when supernatants were harvested at or before 24 h (in other words,
over the time when IL 1 production is increasing or at its peak), the activity produced
by virus challenged cells w a s always significantly greater than that of control cells

214
(Table 11). It became evident however that this increase in IL 1 activity w a s a
transient phenomenon, restricted to the time when IL 1 production is increasing in
normal monocytes. It is proposed that the lack of consistency observed over the
subsequent 24-48h period of culture w a s due to the fact that during this period IL 1
activity w a s dropping rapidly in both mock and HCMV-challenged monocytes, with the
rate of decrease being extremely variable both within and between treatments. After
48 hours in culture consistency w a s again established, but with IL 1 activity always
being comparatively greater in m o c k infected cultures. Previous studies investigating
the effect of H C M V on IL 1 production in monocytes have only used biological response
assays for the measurment of IL 1 activity. Three of these studies report a decrease
in IL 1 activity (Dudding and Garnett 1987, Kapasi and Rice 1984 Rodgers et al
1985) while one reports no change (Buchmeier and Cooper 1989). In all of these
studies, supernatants were harvested for assay only after the infection had been
allowed to proceed for at least three days. In the present study, data obtained for 6
and 24 h supernatants (Table 11) appeared to contradict these published reports;
however when supernatants were harvested at time periods comparable to those
already quoted in the literature, those generated from HCMV-challenged moncytes
were also found to have reduced IL 1 activity relative to mock-challenged monocyte
supernatants (Tables 10 & 12; Figure 7).

Measurements of the IL 1 response obtained from biological thymocyte
assays have been specifically referred to as levels of IL 1 activity as opposed to IL 1
production per se . This is because biological response assays can be modulated by
factors other than the parameter being measured and hence m a y be non-specifically
influenced by other monocyte factors co-existent in test supernatants. These could
be either costimulatory factors that give rise to falsely elevated measurements, or
factors inhibitory for thymocyte proliferation that m a s k the potential stimulatory
action of available IL 1.

The issue of co-stimulatory factors w a s addressed. The present study
indicated that the period of peak IL 1 production (0-24 h post culture initiation)
coincided with the time interval for peak production of two other immunoregulatory
monocyte cytokines, T N F a (Table 16a) and IL 6 (Table 17a). H u m a n T N F a is not a
stimulus for murine thymocytes (Le and Vilcek 1988, Molvig et all 988 & Ranges et al
1988). Thus, although T N F a activity w a s shown to be elevated in virus challenged
monocyte supernatants (Tables 16a-e), T N F a was not considered to be a potential
confounding factor for accurate measurements of IL 1 levels in the present biological
system. O n the other hand, murine thymocytes responded very well to human IL 6,
whether recombinant (Table 31) or cell derived (Table 26). The role of IL 6 as an
intermediate in thymocyte proliferation has been described in the literature, but the
dose response of thymocytes to IL 6 differs from the response to IL 1 (Helle et al
1989 & W o n g and Clark 1988). Although relatively high levels of IL 6 are required to
stimulate thymocytes, the response to IL 6 is enhanced in the presence of IL 1 (Holsfi
and Raulet 1989). Thus it should be kept in mind that the IL 6 in monocyte test
supernatants m a y synergize with IL 1 to stimulate thymocyte proliferation, with the
synergistic stimulus being greater in supernatants from HCMV-challenged monocytes
due to the higher levels of IL 1 they contain.

Factors produced by normal monocytes that inhibit the murine thymocyte
response to interleukins have been reported. These include protein molecules that
may have physiological significance as immune response regulators (Arend et al
1985, Berman et al 1986 & Fujiwara and Ellner 1986) and low molecular weight
metabolites such as prostaglandins and leukotrienes (Kunkel et al 1986 & Hart et al
1989). Otterness et al (1988) agree that an apparent decrease in IL 1 as measured
using the thymocyte assay m a y be due to the effect of prostaglandins present in the
same supernatant and recommend neutralizing this effect by dialysing or diluting
supernatants prior to testing. Molvig et al (1988) also state that the influence of
prostaglandins in the murine thymocyte assay can be effectively diluted out. The
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dilution and dialysis experiments performed in this study (Table 14) suggested that
dialysable substances inhibitory to thymocyte proliferation were indeed co-existent
in monocyte supernatants over the period of peak IL 1 production, but were no longer
present after 48 h in culture, a time at which IL 1 levels in dialysed supernatants
were also low. Because the inhibitory influence of the low molecular weight factors
in 48 h supernatants were removed by supernatant dilution, and because supernatants
from HCMV-challenged as well as control monocytes responded similarly to dilution
and dialysis treatments over time, low molecular weight inhibitory factors were not
considered to be responsible for masking true levels of IL 1 under the conditions used.
The potential masking effect of non-dialysable proteins on true levels of IL 1 could not
however be ruled out and thus it w a s concluded that despite precautions taken, the
thymocyte assay for IL 1 activity m a y not accurately reflect the amount of IL 1
present in monocyte supernatants.

Because of the possible lack of correlation between IL 1 activity and absolute
amounts of IL 1, test supernatants were also assayed using an ELISA specific for IL
13. Although IL 1a w a s not specifically measured, it has been reported that
approximately 9 0 % of the IL 1 secreted by h u m a n monocytes is IL 13 and it is likely
that it contributes the majority of the IL 1 activity elaborated by h u m a n monocytes
(Auron et al 1987, Bernaudin et al 1988 & Kern et al 1988). These relative levels of
IL 1 protein are paralleled by levels of a and 3 m R N A ( Oppenheim et al 1986). In the
present study, the use of ELISA demonstrated that virus-challenged cells were
consistently producing higher amounts of IL 13 and that they retained this capacity at
each time interval tested (ie: over 4, 6 & 8 day periods; Table 13; Figure 8). The
failure of the biological assay to reflect this relative increase over this time period
(Figure 9) supports the notion that HCMV-challenged cells are induced to produce an
influence that masks the thymocyte response to available IL 1 by 4 days post
challenge. In addition, the fact that IL 1 activity w a s initially found to be higher in
HCMV-challenged cell supernatants (Table 11) suggests that peak production of an
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inhibitor of IL 1 activity is at a stage subsequent to peak IL 1 production. At or before
24 hours therefore, IL 1 activity would be more representative of the actual amount
of IL 1 present in the supernatant. Supernatants harvested at later time periods
would however also contain IL 1 inhibitory activity, thus effectively reducing
biological activity even in the presence of elevated amounts of IL 1.

Prostaglandins elaborated by monocytes are of physiological significance in IL
1 downregulation. Stimuli such as LPS, that induce IL 1 production, also induce
production of prostaglandins which in turn feed back and downregulate IL 1 (Kunkel et
al 1986). This mechanism m a y operate by impairing translation of IL 1 m R N A or
interfering with post-translational processing (Knudsen et al 1986). Kunkel et al
(1986) and Dinarello et al (1987) also implicate prostaglandins directly in IL 1
autoregulation; high levels of IL 1 induce prostaglandin release, creating a negative
feedback system whereby IL 1 production is downregulated. This m a y be an important
mechanism responsible for the transient nature of the monocyte response following a
specific stimulus; ie: IL 1 is rapidly induced and, upon reaching a threshold level, it
activates autoregulatory circuits of which the prostaglandins are important
components. In this study therefore, the decrease in IL 1 activity recorded in
dialysed samples with time (Table 14) could reflect a true drop in IL 1 levels, these
being regulated by prostaglandins produced by monocytes over the first 48 h in
culture. Prostaglandins m a y not be the only mechanisms by which IL 1 is naturally
self regulating however. Arend et al (1989a) propose that the decrease in IL 1 levels
after only 24 h in culture is due to proteins that repress IL 1 gene transcription or
interfere with the protein processing that is so essential for IL 1 release. In this
study, culture of monocytes in the presence of high concentrations of exogenous IL 1
appeared to reduce the production of endogenous IL 1, suggesting induction of
autoregulatory pathways (Table 15; Figure 10). Given the ease and rapidity at which
IL 1 can be induced, it would appear essential for the monocyte to have the inherent
capacity to control the levels of such a potent inflammatory mediator. It is important
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to stress however that these mechanisms of IL 1 downregulation are operational in
normal monocytes. Thus it is proposed that although autoregulatory mechanisms are
likely to be operating in both mock and HCMV-challenged monocytes under the
conditions used in the present study, these mechanisms are unrelated to virus
challenge. Further, there is little evidence from the data that H C M V interferes with
the production of these normal regulatory factors.

Previous reports of decreased IL 1 activity following HCMV challenge have
suggested both a direct decrease in the amount of IL 1 present relative to uninfected
cells (Kapasi and Rice 1988) and the production of a virus-specific inhibitor (Dudding
and Garnett 1987). An inhibitor of IL 1 activity associated with H C M V infection has
also been described by Rodgers et al (1985) but was later reported to be due to
mycoplasma contamination of virus preparations (Scott et al 1989). In the present
study, virus stocks were routinely screened and found to be mycoplasma free and it
is not therefore anticipated that a mycoplasma-induced effect has been recorded here.
The decreased IL 1 activity reported by Dudding and Garnett (1987) was observed in
supernatants generated from monocytes over a three day period (0-72h). In the light
of the present study, it is likely that influences inhibitory for the thymocyte response
to IL 1 m a y have been co-existent in their test supernatants. The studies of Kapasi
and Rice (1988) and Rodgers et al (1985) were also based on IL 1 activity
measurements, not absolute amounts of IL 1, and at no time in their studies were
supernatants harvested from monocytes over the period restricted to peak IL 1
production (ie: 0-24 h). The importance of harvest time, if IL 1 activity is to reflect
true levels of IL 1, w a s clearly shown in this study. It is therefore proposed that
previous reports of decreased IL 1 activity are in fact complimentary to the report of
elevated IL 1 levels documented here, with an enhanced production of IL 1 being
undetected because of the co-existence of factors suppressive for the thymocyte
response to IL 1. Such a mechanism has been recognized for R S V (Roberts et al 1986)
and HIV (Berman et al 1987) infection of h u m a n peripheral blood monocytes. Merril et
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al (1989) and Roux-Lombard et al (1989), using 6 and 18 h supernatants
respectively, were able to document elevated levels of IL 1 from HIV-infected
monocytes. These observations are similar to those m a d e in this system where an
HCMV-induced increase in IL 1, as suggested by the biological activity assay, was
only recorded in 6 and 24 h supernatants.

When Turtinen et al (1989) used a commercial IL 16 ELISA similar to that
used in the present study, they reported elevated levels of IL 16 following H C M V
infection and found additionally that this elevation reflected increased m R N A levels.
The system used w a s however notably different from the one used here in that a
myelomonocytic cell line (THP-1) w a s used as the study cell. THP-1 does secrete
authentic monocyte IL 1 in response to L P S stimulation, but in the study by Turtinen
et al, extracellular IL 1 reached peak levels only 72 h after L P S induction. These
authors also reported changes in the production of T N F a by THP-1 cells after H C M V
challenge. The production of T N F a by peripheral blood monocytes after H C M V
challenge w a s investigated in the present study, as w a s the production of another
immunologically important monocyte cytokine, IL 6. Biological activity was
measured, using cell lines which are considered to have a specific response to the
cytokine (TNF a or IL 6) measured.

Normal LPS-stimulated monocytes released the bulk of TNF a activity in the
first 48 h of culture (Table 16a; Figure 11), a rapid accumulation occuring after only
4 h in culture, with peak production occuring by 24 h. These production kinetics are
in agreement with previous data: Scales et al (1989) report that accumulation of T N F
a m R N A peaks at 3 h, while Economou et al (1989) report a peak at 4 h post-induction
and a decline by 16 h. There is a corresponding pattern of protein production where
proteins are readily detected at 8 h, peak at 12 h and decline by 24 h. As has been
shown for IL 1, prostaglandins m a y play a role in this natural decrease seen with

time; Spengler et al (1989) and Heidenreich et al (1989) report that P G E 2 can
downregulate T N F a through blocking m R N A translation.

After challenge with either AD 169 or the clinical isolate p72, TNF a levels
were significantly enhanced (Figure 12). The s a m e relative trends were observed
with cells from different H C M V seronegative donors and under a variety of
experimental conditions ie: whether monocytes were L P S stimulated (Tables 16a-c)
or additionally P P D pulsed (Table 16d) or co-cultured with T cells (Table 16e). The
enhancement of T N F a activity by virus challenge w a s particularly marked over the
peak time period of T N F a production but, unlike measurements of IL 1 activity, the
biological assay for T N F a production from virus challenged monocytes suggested a
sustained elevation throughout the time of the experiments.

It is interesting to note that the production kinetics of TNF a by THP cells
described by Turtinen et al (1989), as measured by m R N A levels and specific ELISA,
(a rapid accumulation of T N F a as early as 3 h post-induction with a marked drop of
T N F a by 72 h) matched those described here more accurately than was seen for the
kinetics of T H P IL 1 production. O n the basis of the differential production kinetics
observed with myelomonocytic cells, Turtinen et al (1989) speculated that T N F a
induction m a y be a direct result of H C M V infection, with the subsequent increase in IL
1 being TNF-induced, or that novel IL 1 inducers m a y be rapidly induced upon exposure
to virus and subsequently enhance IL 1 production. In the current study, the peak of
TNF a production only marginally preceded the elevation in IL 1 levels, but a cascade
effect of T N F a production inducing IL 1 could still exist. Scales et al (1989) report
that while T N F a m R N A peaks at 3 h post induction in LPS-stimulated human
monocytes, IL 1 m R N A peaks later at 6h. A further proposition by Turtinen et al
(1989) is that C M V immediate early proteins have a frans-stimulatory effect on
cellular cytokine genes. They use this hypothesis to explain how infection of only 1 %
of cells can have a general effect on IL 1 and T N F a production.

Augmented T N F a has been reported in sera or in culture supernatants of
monocytes from AIDS patients (Lau and Livesey 1989; Navarro et al 1989 & Molina
et al 1989) and from monocytes (Merrill et al 1989) or monocyte cell lines (Navarro
et al 1989) infected in vitro . According to Goldfeld and Maniatis (1989), Sendai
virus is also an induction stimulus for T N F a

As observed for IL 1 and TNF a, IL 6 activity was rapidly induced in culture,
with peak production occuring in the first day followed by a time related decrease
(Table 17a). Bauer et al (1988) report that IL 6 m R N A can be detectedl h after
stimulation with a peak 3 h post induction. This is followed by a sharp decrease after
1 day and a decrease to negligible levels with increasing time in culture. As w a s
noted in the present study, Andersson and Matsuda (1989) suggest that the production
of IL 6 starts later than that of T N F a. Studying cytokine production at the single
monocyte level they they recorded a T N F a peak at 2 h and an IL 6 peak at 3 h after
LPS stimulation. In the present study, although differences in IL 6 production were
readily observed with time in culture, H C M V challenge per se had no effect on the
levels of IL-6 produced by monocyte cultures (Table 17b). There are reports of other
viruses influencing IL 6 production. Infection of rat astrocytes with N D V (Lieberman
et al 1989), or murine astrocytes and microglial cells with lymphocytic
choriomeningitis virus (LCMV) or vesicular stomatitis virus (VSV;

Frei et al 1989),

induced IL 6 production. Nakajima et al (1989) report that HIV induces monocyte IL 6
production and propose that it m a y have pathogenic potential by inducing polyclonal B
cell activation. Elevated levels of IL 6 have been reported in the sera of burn patients
and patients with acute bacterial infections (Jablons et al 1989), as well as in the
cerebrospinal fluid of patients with acute viral meningitis or encephalitis (Frei et al
1989). There are also reports of decreased IL 6 levels associated with disease
states. Stryckmans et al (1988) report that mononuclear cells from patients with
chronic lymphocytic leukaemia produce reduced levels of IL 6 after L P S stimulation
relative to healthy controls.
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Although in the current study mock- and HCMV-challenged monocytes
required a specific stimulus (in this case LPS) for T N F a induction, adherance to a
plastic surface w a s a sufficient stimulus for release of IL 6. IL 6 activity was
however enhanced by L P S stimulation. Navarro et al (1989) report the induction of IL
6 production by adherance and Roux-Lombard et al (1989) have shown that activation
of monocytes by adherance alone can induce IL 6 m R N A in less than 2 hours. O n the
other hand, the requirement for T N F a induction stimuli such as L P S has been widely
reported (Debets et al 1988, Economou et al 1989 & Merrill et al 1989). Lau et al
(1989) report that monocytes from AIDS patients spontaneously produce increased
levels of T N F a and are hypersensitive to LPS stimulation relative to controls. In this
study, L P S stimulation w a s required in addition to H C M V challenge for appreciable T N F
a induction. This observation may have relevance to mechanisms of H C M V
pathogenesis in vivo. Because a variety of secondary infections often occur during
H C M V infection, exposure to stimuli such as bacterial endotoxin would be a reasonably
common occurence in vivo and could enhance an HCMV-induced upregulation.

HCMV-induced upregulation of IL-1 and TNF a has been demonstrated both in
this study and by Turtinen et al (1989). Similar patterns of HIV-induced upregulation
have been documented. Roux-Lombard et al (1988) report that 18 h supernatants
from HIV-infected monocytes contain elevated levels of both IL 1 and T N F a. They
propose that HIV m a y directly induce elevation of both cytokines, or that IL 1 may be
secondarily induced in response to T N F a upregulation. Turtinen et al (1989) have
suggested that a similar sequence of events occurs in HCMV-infected THP-I cells.
Molina et al (1989) infected THP-1 cells with HIV and found that acutely infected cells
produced increased amounts of T N F a and IL 1 relative to chronically- or mockinfected cells. Levels of m R N A paralleled amounts of secreted protein. Merrill et al
(1989) found that upon exposure to HIV, normal monocytes produced a burst of IL 1
activity 4-6 h after exposure and a T N F a burst peaking at 6-12 h, but with increased

levels seen as late as 48 h. These results for HIV infection of monocytes do not
appear to support the proposal that T N F a is induced first, with IL 1 being secondarily
induced as a normal consequence of elevated T N F a levels. Irrespective of the
relative kinetics of accumulation, there is a strong synergistic relationship between
T N F a and IL 1 (Dinarello 1989) and thus concurrent upregulation of IL 1 and T N F in
vivo could greatly enhance the deleterious effects of increased monokine production.

Co-infection of a monocytic cell line with CMV and the human
immunodeficiency virus type 1 (HIV 1) has been shown to result in enhanced HIV
replication (Skolnik et al 1988). McKeating et al (1990) have also studied the
interactions between HIV and C M V . They propose that HIV-antibody complexes can
co-infect CMV-infected cells via entry through CMV-induced Fc receptors.
Synergistic interactions could then potentially occur, with C M V trans-activating
factors enhancing HIV replication and HIV co-infection stimulating development of a
productive C M V infection. The stimulatory effect of T N F a in inducing HIV replication
has been well documented (Clouse et al 1989, Israel et al 1989, Matsuyama et al
1989 & Merrill et al 1989). Of particular interest is the suggestion by Merrill et al
(1989) that HIV induction of T N F a, followed by T N F a-enhanced replication of HIV,
creates a positive feedback loop for replication, amplification or reactivation of a
latent infection. It is reasonable to speculate that the ability of H C M V to induce HIV
replication m a y be due at least in part to enhanced production of monokines such as
TNF a.

The observtions made in this study relating to the effect of virus challenge on
IL 6 production suggest that HCMV-induction factor(s) do not cause a general and nonspecific upregulation of monokine production. Differential cytokine production has
been reported for infection of rat astrocytes with N D V (Lieberman et al 1989); while
N D V is an induction stimulus for IL 6 and TNF, it does not induce IL 1 suggesting that
different cytokine genes m a y or m a y not have elements responsive for a particular
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virus in their regulatory regions. Clouse et al (1989) reported that only certain viral
antigen preparations could induce cytokines from a promonocytic cell line. These
cytokines were not identified, but they were shown in turn to be capable of enhancing
HIV expression in this s a m e cell line. C M V and E B V antigen preparations were capable
of stimulating monokine release while HSV-1, HSV-2 and a selection of non-herpes
viruses were not.

Goldfeld and Maniatis (1989) recently reported that IFN 3 and TNF a are coinduced in U937 cells after Sendai virus infection. L P S or phorbol ester (PMA)
induction of T N F a does not however induce IFN 3. The authors propose that viral
induction of T N F a and IFN 3 m R N A involves a c o m m o n and physiologically significant
pathway, while the LPS- and PMA-mediated induction pathways for T N F a are
distinct. Grundy et al (1988) have reported enhanced levels of fibroblast IFN 3 from
HCMV-infected fibroblasts. It is possible that HCMV-induction of T N F a may induce
monocyte IFN 8 via elements of their overlapping induction pathways. The possible
role of IFN 3 in blocking the IFN y upregulation of HLA-DR expression was raised
earlier in this discussion. This could provide a means whereby HCMV-challenged
monocytes, through enhanced production of IFN 3, could produce an influence with the
potential to downregulate monocyte HLA-DR expression and hence antigen presenting
function. Because LPS-mediated T N F a induction is via a distinct mechanism, this
model also allows for separation of LPS-mediated and HCMV-mediated mechanisms of
depressing monocyte accessory cell function. This suggestion m a y appear
conradictory to other reports that T N F a has the capacity to upregulate HLA-DR
(Arenzana-Seisdedos et al 1988). However, it has been shown that T N F a does not
directly induce the H L A - D R gene; it merely amplifies ongoing gene expression
whether constitutive or IFN y-induced. Thus, the key to the proposed role for T N F a in
decreasing H L A - D R remains the antagonistic effect of IFN y and virally induced IFN 3.
A direct role for IFN a/3 as antagonists of IFN y-mediated M H C class II induction has

been demonstrated (Fertsch-Ruggio et al 1988, Inaba et al 1986 & Kitaura et al
1988).

IFN 3 is induced in fibroblasts by HCMV infection (Grundy et al 1988) and it
was thus d e e m e d of interest to ascertain if there w a s evidence of upregulation of
cytokines in the fibroblast system and in endothelial cells. The thymocyte assay w a s
chosen as the indicator system. Fibroblasts are fully permissive for H C M V
replication in vitro , and h u m a n umbilical vein endothelial cells appear to support a
productive cycle in a restricted number of cells (Waldman et al 1989). Both these
cell types produce IL 1 upon appropriate stimulation (Oppenheim et al 1986). Studies
with supernatants generated from fibroblasts (Table 36) and endothelial cells (Figure
29) demonstrated that HCMV-induction of thymocyte-stimulatory activity is not
restricted to the virus-monocyte interaction. The exact nature of the thymocytestimulating activity produced by fibroblasts and endothelial cells w a s not determined
from these initial studies. As both cell types produce IL 1 and IL 6 (Elias et al 1989;
Howells et al 1988 & Ray et al 1988) it could be due to either or both of these
factors, or indeed to production of an undefined activity. Further, it is likely that the
kinetics of production, observed with endothelial cells, reflects a cell type-specific
pattern of cytokine production. The greatly elevated response observed between 4872 h post virus challenge (Figure 29) is suggestive of a synergistic mechanism, and it
may be that a particular endothelial cell cytokine peaks naturally after three days in
culture but that this peak is greatly enhanced due to a virus-induced upregulation of an
additional cytokine that alone is not as stimulatory. In fibroblasts for example it has
been demonstrated (Elias et al 1989) that upon appropriate stimulation (in this
instance rIL 1), fibroblasts produced a thymocyte stimulating activity that is largely
due to a synergistic effect of fibroblast-derived IL 1 and IL 6; unstimulated
fibroblasts did not constitutively produce any thymocyte-stimulating activity. In the
present study, supernatants from control fibroblasts similarly did not contain any
such activity, while H C M V infection appeared to be a suitable induction stimulus.

Future studies should involve identification of the nature of the thymocyte-stimulating
activities induced/enhanced after H C M V challenge of fibroblasts and endothelial cells.

In the current study, the thymocyte assay system could only detect
increases in the IL 1 activity of virus-challenged monocyte supernatants over the
first 24 h of culture. Although IL 1 production declined as a natural consequence of
time in culture in both m o c k and challenged monocytes, with increasing time post
challenge, challenged monocyte supernatants contained an influence that prevented the
thymocyte biological activity assay from reflecting the true amount of IL 1 present.
Because studies had suggested that dialysable suppressor factors were produced by
monocytes irrespective of challenge status and because suppressive influences were
seen in supernatants appropriately diluted to negate their effects, it w a s proposed
that the factor(s) responsible for decreased thymocyte responsiveness to IL 1 coexistent in culture supernatants were higher molecular weight monocyte-derived
suppressor factors secreted as a result of H C M V challenge

Studies designed to further investigate this hypothesis suggested that the
factor(s) present in H C M V challenged supernatants were suppressive for the murine
thymocyte response to P H A alone, or for the thymocyte response additionally
augmented by IL 1 (Table 18), IL 2 (Table 18) and IL 6 (Figure 18) as well as crude
cytokine preparations derived from activated monocytes (Table 25a; Figure 17) and T
cells (Figure 16). Suppression of the thymocyte response in the presence of viruschallenged monocyte supernatants w a s significant relative to the thymocyte response
to added stimuli alone and to the response of stimulated thymocytes cultured in the
presense of supernatants generated from corresponding mock-challenged monocyte
cultures. Inclusion of crude cytokine preparations w a s considered to be important
because it allowed for the evaluation of potentially suppressive factors in the
presence of a spectrum of cytokines that they would be likely to be exposed to in vivo
. Such a situation would be almost impossible to simulate by addition of individual
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purified components.

Heat treatment destroyed the inhibitory potential of test

supernatants (Table 19), suggesting that the suppressive influence was associated
with heat labile molecule(s).

Influences that are suppressive for thymocyte proliferation may either
directly affect the stimulatory potential of monocyte factors such as IL 1 or
secondarily interfere with the responses that they induce. Examples of the first
mechanism could include suppression of IL 1 production or interference with molecule
integrity so as to affect receptor binding; inhibition of IL 1 receptor (IL 1R)
expression; and inhibition of effective binding via receptor blocking. An example of
an inhibitor of IL 1 action that functions via direct binding to the molecule is the 85
kDa protein uromodulin (Muchmore et al 1986) initially isolated from the urine of
pregnant w o m e n (Brown et al 1986). Suppressor factors that function via blocking of
the IL 1R include an 18-22 k D a protein (IL 1ra) initially isolated from the urine of
monocytic leukaemia patients (Seckinger et al 1987) but later found to be produced by
normal monocytes (Hannum et al 1990) and a 25 kDa protein (IRAP) isolated from
U937 cells that were stimulated with P M A in the presence of G M - C S F (Carter et al
1990). Locksley et al (1988) describe production of a 9 kDa protein from HIVinfected h u m a n macrophages (contra-IL 1), that does not interfere with IL 1-receptor
binding, but has a locus of action that is IL 1-specific. A factor that affects the
production of bioactive IL 1 is plasminogen activator inhibitor (PAI) which is produced
by normal monocytes and which m a y interfere with proteolytic cleavage of IL 1
precursors (Goeken et al 1989).

Secondary responses induced by the successful initial contact of monocyte
factors with thymocytes or mature T cells include production of IL 2, and expression
of IL 2R and subsequent to this, IL 2-induced upregulation of IL 2R and hence enhanced
IL 2 responsiveness. Inhibitory influences could thus suppress IL 2 production and/or
responsiveness. Krauker (1985) and Kashiwado et al (1989) have identified 60-70
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kDa and 130-150 kDa suppressor factors (produced by a monocytic cell line and
normal monocytes respectively) that suppress IL 2 production. These factors and
others (Fujiwara and Ellner 1989, Sugimura et al 1989 & Svenson and Bendtzen
1988) are also reported to affect IL 2 responsiveness. Because the magnitude of the
proliferative response in the thymocyte assay depends ultimately on an appropriate
thymocyte response to available IL 2, the net outcome is the s a m e whether monocyte
factors fail to initially contact the cell, whether the mechanisms they have the
potential to induce are not initiated, or whether there is a defect in the subsequent IL
2-mediated T cell response. Indeed a number of factors have been described purely
for their suppressive effect on IL 1 activity, with the exact locus of action not
elucidated (Barak et al 1986, Kabir and Wigzell 1989 & Wilkins and Warrington
1984). The suppressor factors reviewed herein were isolated from a range of
different sources including urine, peripheral blood monocytes and monocytic cell
lines; from cells that were normal or stimulated with LPS, mitogens, growth factors
or virus-infection; and over a range of times after initial stimulus.

Possible reasons for the suppressive potential of HCMV-challenged monocyte
supernatants collected several days after virus challenge were examined. The fact
that the monocyte-derived influence w a s suppressive for the thymocyte response to
exogenously added T cell factors (IL 2 or a crude mixture; Table 18 & Figure 16) as
well as monocyte factors (IL 1, IL 6 or a crude mixture; Tables 18, 26 & 25a)
suggested that the susceptible stage in the thymocyte proliferation cycle was one that
occured after initial thymocyte activation. The observation that addition of
exogenous IL 2 could restore the P H A response of thymocytes exposed to suppressive
supernatants under conditions where exogenous IL 1 w a s ineffective (Table 19),
similarly suggested that IL 2-related events were the susceptible targets. In
confirmation of this proposal, it w a s shown that thymocytes primed by IL 1 for 24 h
prior to addition of suppressive supernatants were still susceptible to suppression
(Table 21) and that supernatants were still significantly suppressive for thymocyte
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proliferation when added 24 h after initiation of a 72 h proliferation cycle (Table 20;
Figures 15 & 17). Pre-incubation studies showed that the suppressor factors had no
effect on unstimulated thymocytes (Table 22), confirming that it w a s events
associated with thymocyte activation that were susceptible to suppression.

When potentially suppressive supernatants were collected from monocytes at
discrete intervals as opposed to over an entire culture period, (ie: with increasing
time post virus challenge as the variable), the magnitude of the suppressive effect
increased with time (Tables 24a & 24b). This was interpreted to m e a n that
production of the virus-induced suppressive influence increased as the monocytevirus interaction developed with time. It could however also reflect a decrease in
monocyte factors produced early in culture with the potential to counter the
suppressive effect. Size fractionation of supernatants by gel filtration indicated that
both mechanisms suggested above m a y be in operation.

Size fractionation of monocyte supernatants from virus-challenged cells on
Sephacryl S200 gel revealed that not one but two separate suppressor factors were
detectable: a 130-180 kDa factor (fraction 2; Table 28a & Figure 20a) and a 75100 kDa factor (fraction 4; Table 28b & Figure 20b). They have been termed
fraction 2 and fraction 4 purely on the basis of the eluted test fraction in which they
were detected. W h e n supernatant fractions, as opposed to whole supernatants, from
mock-challenged monocytes were tested for their effect on thymocyte proliferation,
it became evident that fraction 2 w a s also produced by mock-challenged monocytes
(Table 28a; Figure 20a). Detection of fraction 2 and fraction 4 was repeatable with
blood initially drawn from two separate H C M V seronegative donors , when monocytes
were LPS-stimulated or unstimulated, and when either a laboratory-adapted (AD 169)
or a clinical (p72) strain of H C M V w a s used (Tables 28a, 28b & 29).
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The fact that the effect of the inhibitor in fraction 2, produced by mockchallenged monocytes, w a s only detectable after size fractionation implied that its
influence in complete supernatants must have been effectively negated by some
monocyte cytokine. That fraction 2 did not significantly diminish the thymocyte
response to IL 6 suggested that IL 6 m a y be the candidate cytokine (Table 30). The
question then arose as to why fraction 2 from virus-challenged monocytes w a s still
effective in the face of IL 6 coexistent in monocyte supernatants; earlier studies
(Table 17b) had clearly demonstrated that supernatants from H C M V and mockchallenged monocytes contained identical levels of IL 6 for each particular time period
tested, even though there w a s a time-dependent decrease. An examination of the
thymocyte response to different levels of rIL 6 in the presence of fraction 2
generated from monocytes over time helped to answer this question (Table 31; Figure
21). Experimental results suggested that a dose-response mechanism w a s in
operation, whereby the relative effectiveness of fraction 2 suppression depended on
the dose of IL 6 that thymocytes were co-exposed to. With this model, it was
proposed that in whole supernatants from mock-challenged monocytes, because of IL 6
and possibly other undefined cytokines co-existent in the supernatant, the level of
fraction 2 produced w a s never high enough to allow it to exert its effect on
thymocyte poliferation. Size fractionation of monocyte supernatants however
removed these cytokines, allowing the effect of fraction 2 alone to be felt. The fact
that the suppressive influence was enhanced with time suggested that levels of
fraction 2 m a y increase as a function of time in culture.

Production of fraction 2 from HCMV-challenged monocytes was evaluated.
The magnitude of the suppressive effect of fraction 2 alone from virus-challenged
monocytes w a s greater at each time than that of fraction 2 derived from mockchallenged monocytes (Tables 28a & 29; Figure 20a). This implied that the level of
fraction 2 production was enhanced as a result of virus challenge. This was borne out
when the influence of different concentrations of IL 6 on fraction 2-mediated

suppression w a s tested (Table 31; Figure 21). For each particular time, thymocytes
exposed to fraction 2 derived from HCMV-challenged monocyte supernatants required
a higher dose of IL 6 than thymocytes exposed to fraction 2 derived from mockchallenged monocytes to achieve a similar relief of suppression. Virus-induced
induction of elevated levels of the inhibitor in fraction 2 relative to levels in the mock
fraction 2 would also explain why, in the face of a constant amount of IL 6, whole
supernatants from virus monocytes could still contain a fraction 2-induced net
suppressive influence.

With this model, the potential exists that in the face of a time dependent
increase in fraction 2 and a concomittant decrease in IL 6 with culture, a suppressive
influence m a y be detected even from normal monocytes. Indeed it is proposed that a
mechanism such as this is part of a normal regulatory pathway in monocytes whereby
T cell proliferation can be downregulated. It m a y also explain the slight but nonsignificant suppressive effect produced by mock cultures with extended time in
culture, as well as reports by other researchers that with time in culture monocytes
become suppressive. This phenomenon, along with decreased IL 6, m a y be related to
conversion to a more mature phenotype.

The suppressive influence in unfractionated monocyte supernatants which is
induced by H C M V challenge (as detected in the thymocyte assay) could thus be a dual
effect of the influences of fraction 2 and fraction 4. Fraction 4 generated from virus
challenged monocytes later than 48 h post challenge suppressed the thymocyte
response to PHA, IL 1, IL 2 and IL 6 (Tables 28b, 29 & 30). The fact that suppression
was undetectable in identical fractions derived from virus-challenged monocyte
supernatants generated over the first two days in culture could be interpreted to
mean either that the production of fraction 4 by monocytes reached functional levels
only 48 h after virus challenge, or that the inhibitory influence in fraction 4 w a s
present but w a s masked by a thymocyte stimulatory factor co-existent in the 0-48 h
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monocyte supernatant fraction. Evidence for such a stimulatory factor arises from
observations of stimulation of thymocyte proliferation by the identical fraction
derived from mock-challenged monocytes over 0-48 h (Tables 28b & 29).

That human monocyte factors suppressive for thymocyte proliferation can be
induced in adherent monocyte cultures in response to virus challenge is an interesting
observation. The aim of the present study however was to examine the effect of
H C M V on human monocyte function and interaction with with other immune response
cells in vitro, and to relate this to mechanisms of immunosuppression associated with
H C M V infection in vivo. Thus, to be relevant to a study of HCMV-induced
immunosuppression, the monocyte factors identified must be active against human T
cells. Hence, the effect of suppressive influences present in monocyte factors on
human peripheral blood cells was investigated. Supernatants harvested from
monocytes 6 days after challenge with either a laboratory adapted (AD 169) or a
clinical (p72) virus strain suppressed antigen-specific proliferation of human
peripheral blood T cells in a dose-dependent way (Table 32). Fraction 2, derived from
the supernatants of mock- or HCMV-challenged monocytes, was suppressive for the T
cell response to P H A alone and for the response augmented by IL 2 or IL 6 (Table 33a
& Figure 22a). Fraction 4 derived from virus-challenged monocyte supernatants was
suppressive for these responses (Table 33b & Figure 22b), but the same fraction
from supernatants of mock-challenged cells was not. Thus, the patterns of
suppression seen with human T cells exposed to monocyte test supernatants appeared
to be the s a m e as those observed with murine thymocytes exposed to the test
supernatants.

To summarize, it is proposed that monocytes naturally produce a 130-180
kDa factor (fraction 2), which, although potentially suppressive for murine
thymocyte and h u m a n T cell proliferation, has little effect when complete
supernatants from normal monocytes are used in these assays. This factor may
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however play a role in downregulation of lymphocyte proliferation in vivo . As H C M V
challenge appears to elevate its production, this could alter the balance of
induction/suppression in a localized area of virus infection in vivo , resulting in
immunosuppression.

Further, virus-challenged monocytes produce an additional 75-

100 kDa suppressive factor (fraction 4). The suppressive potential of these fractions
appears to increase as a result of time post virus challenge and/or as a natural
function of time alone.
The apparent molecular weights determined for the inhibitory fractions 2
(130-180 kDa)and 4 (75-100 kDa) derived from mock- and/or challenged monocytes
in the present study were compared to those reported in the literature for other
inhibitors detected in supernatants from h u m a n peripheral blood monocytes or
monocytic cell lines.

A 130-150 kDa factor in 48 and 72 h supernatants of normal LPS-stimulated
monocytes has been described by Kashiwado et al (1989). This factor was shown to
inhibit the thymocyte response to IL 1 as well as the proliferation of mitogenstimulated h u m a n T cells. It w a s also shown to cross react with a M A B raised against
a 60-70 kDa factor present in 2 and 3 day supernatants from a monocytic cell line
(THP-1 cells). This factor w a s shown (Krauker 1985) to inhibit the thymocyte
response to P H A and IL 1, P H A and IL 2 and IL 2 alone, as well as the proliferation of
mitogen-stimulated h u m a n T cells. O n the basis of functional and size similarities, it
is possible that fraction 2 m a y be related to the 130-150 kDa factor described by
Kashiwado et al. It should be noted that the 130-150 kDa factor and the 60-70 kDa
factor described by Krauker et al were also reported to inhibit the production of IL 2
by T cells. In the present study, the effect of fraction 2 on the production of IL 2
from T cells w a s not evaluated because of the complicating influence of fraction 2
carried over in the test supernatant on the IL 2 indicator cells.
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There are examples in the literature of h o w in certain disease states,
upregulation or alteration of normally produced regulatory factors occurs to the
extent that they b e c o m e associated with the pathology of that disease state. For
example, Berman et al (1987) report that monocyte factors suppressive for IL 1
activity, that are produced by normal monocytes (Berman et al 1985), are produced
in significantly greater amounts upon in vitro infection with HIV. In a murine system
involving normal and tumour-bearing mice, Malick et al (1989) have proposed a model
whereby differential glycosylation of regulatory proteins can allow a normal
homeostatic mechanism to b e c o m e suppressive.

While there are other reports of production of suppressor factors from
virus-challenged monocytes, none of the existing literature details an inhibitor
similar in both function and size to the 75-100 kDa fraction 4 described in this study.
A 50-100 kDa factor produced by HIV-infected monocytes (Berman et al 1987) w a s
not virus-specific in that it w a s also produced by normal monocytes, albeit in lower
amounts. Factors of 99 kDa produced by influenza virus- and RSV-infected monocytes
(Roberts 1986) were determined to have a locus of action distinct from that of
fraction 4. The 95 kDa inhibitor of IL 1 activity produced by HCMV-infected
monocytes described by Rodgers et al (1985) w a s later attributed to a mycoplasma
influence (Scott et al 1988). In addition to the fact that mycoplasma-free conditions
were maintained in the present study, the locus of action of the inhibitor described by
Rodgers and co-workers w a s also distinct from that of fraction 4, the factor
described by these workers acting directly against IL 1.

Although fractions 2 and 4 have been compared to other suppressor factors
partially on the basis of size, it is prudent to remember that the apparent molecular
weight.of a suppressive fraction m a y not reflect the size of the active molecule.
Nishihara et al (1988) for example report the isolation of an 160 kDa inhibitor of IL 1
activity torn a murine macrophage cell line but point out that it m a y represent an
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aggregation of lower molecular weight inhibitors. Clark et al (1988) have
demonstrated that suppressor factors can associate with protein or glycoprotein
carrier molecules, thus forming a complex larger than the active moiety. The
possibility that one of these mechanisms m a y be in operation in the present system
should be kept in mind.

Having established a definite effect of monocyte-derived suppressor factors
on human T cells, it was of relevence to more carefully define the exact mechanism of
action of the observed suppressive influence. Initial studies with thymocytes had
implicated an effect on IL 2 responsiveness. Depressed IL 2 responsiveness could
presumably result from a decreased expression of functional IL 2 R or, despite the
presence of IL 2R, a defect in IL 2 binding, internalization of the IL 2-IL 2R complex,
or subsequent signal transduction . The initial thymocyte assays were performed
with whole monocyte supernatants, while subsequent supernatant fractionation
studies suggested the presence of separate fractions with different mechanisms of
suppression. The potential influence of fraction 2 and fraction 4 on IL 2
responsivenessness w a s therefore tested. The specificity of the suppressive effect
against IL 2-mediated events was confirmed by testing the ability of the fractions to
affect the IL 2 response of a murine IL 2-dependent cytotoxic T cell line (CTLL cells).
Kashiwado et al (1989), Krauker (1985) and Svenson and Bendtzen (1988) all report
the use of C T L L cells to verify that an inhibitor interferes with the m o d e of action of
IL 2, this being a system in which IL 1 plays no role. Expression of IL 2R on human
peripheral blood T cells after exposure to factor 2 and factor 4 w a s directly studied,
with both components of the IL 2 R (p55/Tac and p70) being separately assayed by
F A C S analysis.

The ability of fraction 2 to abrogate the CTLL response to IL 2 (Table 34a)
confirmed that the locus of action was indeed on s o m e IL 2 dependent process. The
observation that the suppressive effect could be partially overcome by increasing the

number of C T L L cells exposed to fraction 2 (Table 34b; Figure 23a) suggested that the
mechanism of suppression w a s not due to a defect in actual IL 2 R expression. Fraction
2 had no effect on the expression of either component of the IL 2 R, as directly shown
by F A C S analysis of receptor expression on peripheral blood T cells (Figure 25& 26).
The fact that suppression w a s independent of IL 2 concentration (Table 34c) implied
that IL 2 w a s not limiting and that the suppressive mechanism w a s related to the
capacity of the cells to respond appropriately to the available IL 2 . Taking the above
points into consideration, it is proposed that fraction 2 binds directly to the T cell and
inhibits IL 2-receptor binding or the post-binding processes of internalization and/or
signal transduction. This could be either due to a direct interaction of fraction 2 with
the IL 2 R which effectively blocks IL 2 binding, or due to an interaction of fraction 2
at a site distinct from the IL 2R, but one that nonetheless interferes with acquisition
of T cell competence and/or entry into S phase. The 130-150 kDa inhibitor described
by Kashiwado et al (1989) also appears to inhibit the C T L L response to added IL 2 by
binding directly to the T cell; the inhibitory effect disappeared when the concentration
of the C T L L cells w a s increased while it decreased only partially on increasing the
concentration of exogenous IL 2.

In the present study, the partially reconstituting effect of increasing cell
number can be related to the earlier observation that IL 6 w a s also effective in
partially overcoming the suppressive effect of fraction 2 (Table 31). A role for IL 6
in enhancing expression of the IL 2 receptor has been demonstrated (Baroja et al 1988
Ceuppens 1989 & Houssiau 1989). It m a y be therefore that the presence of a
constant number of cells with additional receptors per cell, or additional cells with a
constant receptor number (as could be envisaged by treating with IL 6 or increasing
cell number respectively), would allow for binding of factor 2 and its removal from
circulation while still allowing sufficient unaffected receptors to remain for
complexing with available IL 2 and initiation of signal transduction. Kashiwado et al

(1989) have demonstrated that pre-absorbtion of a 130-150 kDa inhibitory fraction
with C T L L cells could remove the inhibitory activity.

In addition to enhancing p55 expression, Houssiau et al (1989) report that the
elevated IL 2 responsiveness of T cells treated with IL 6 is associated with a marked
increase in cell size and protein synthesis. IL 6 m a y thus be an important competence
factor for acquisition of IL 2 responsiveness via additional mechanisms of T cell
activation. Inhibitors of T cell IL 2 responsiveness that act at a site distant from the
IL 2 receptor have been described: Sugimura et al (1989) report that a 45-67 kDa
lymphocyte blastogenesis factor inhibits T cell proliferation by arresting PHAstimulated T cells at the early Gi phase of the cell cycle, while inhibition of IL 2
responses by T G F 3 is thought to result from binding to membrane receptors that are
distinct from IL 2 R (Clark 1988).

It should be noted that because an MAB for the p70 component of the IL 2R
has only recently b e c o m e available (Takeshita et al 1989), the effect of IL 6 on p70
has not as yet been detailed in the literature. If a direct influence on p70 was
observed, this m a y also help to explain the ability of IL 6 to reverse the suppressive
effects of fraction 2. Whatever the mechanisms of IL 6 action and fraction 2 action, a
feasible model is one in which the cytokine IL 6 has the ability to reverse the
suppressive effect of fraction 2 on the acquisition of T cell competence.

The virus-specific nature of fraction 4 was confirmed by the fact that the
75-100 kDa supernatant fractions derived from mock-challenged monocytes had no
effect on the proliferative response of C T L L cells to IL 2, or on the expression of
either component of the IL 2 R on h u m a n T cells. The effect of fraction 4 derived from
HCMV-challenged monocytes on C T L L IL 2 responsiveness (Table 34a) confirms the
proposal that, like fraction 2, fraction 4 is active against an IL 2-dependent process.
The mechanism of action appeared however to be distinct in that, unlike the results
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obtained with fraction 2, increasing the number of C T L L cells had no diminishing effect
on the suppressive potential of fraction 4 (Table 34b). W h e n the IL 2 concentration
was increased 5-fold, while maintaining a constant number of C T L L cells, the
magnitude of the fraction 4-induced suppressive effect was halved (Table 34c; Figure
23b). The ability of these cells to respond to IL 2, albeit at a higher concentration,
indicated that IL 2 R could be expressed or were partly functional.

FACS analysis of PHA-stimulated peripheral blood T cells that had been
exposed to fraction 4 for 72 h showed that expression of p55 (Figure 27) w a s greatly
reduced while the levels of p70 (Figure 28) were unaffected. It is therefore proposed
that the mechanism of action of factor 4 is on expression of the p55 component of the
IL 2R. Cells without p55 are however still able to proliferate through signals induced
by IL 2 binding to p70, but only if IL 2 is added at high enough concentrations. This
would explain the increased proliferation seen when the IL 2 concentration was
increased while maintaining a constant C T L L density. Fujiwara et al (1987) have
reported that a factor in the 67-130 kDa size range produced by U937 cells inhibited
the expression of the p55 component of the IL 2R on P P D - or PHA-stimulated human T
cells. Expression dropped from 4 0 % to between 1 % and 2 4 % depending on the
dilution of inhibitor used. Although this influence w a s quite apart from any virusspecific action, these findings are relevant because they illustrate another system
wherein suppression of IL 2R expression can occur upon exposure to monocytederived soluble factors. Of further interest is the demonstration by Fujiwara and coworkers that a dilution of the 67-130 k D a inhibitor that suppressed T cell p55
expression to as low as between 2 and 6.5% did not affect the response of C T L L cells
to crude preparations of IL 2. Although such a proposal w a s not put forward by these
workers, it is possible that the level of IL 2 in the crude preparations they used was
sufficient to induce sufficient signal transduction via the p70 component. Although
smaller than fraction 4, a 60-70 kDa factor derived from THP-1 cells (Krauker
1985) has been shown to decrease IL 2-dependent T cell responses.
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Numazaki et al (1988) found that co-incubation of IL 2-dependent
lymphocytes with H C M V reduced their IL 2-responsiveness. This effect w a s related
to the observation that exposure to H C M V led to a 5 0 % decrease in the number of
cells expressing the p55 component of the IL 2R. Although the virus-cell interaction
system reported is distinct from the one used in the present study, what is of
relevence is the observation that doubling the IL 2 dose (from 1 0 % v/v to 2 0 % v/v)
had a restorative effect on the T cell proliferative response. Thus, this provides a
further example of an in vitro system wherein IL 2-unresponsiveness associated
with a reduction in p55 can be partially alleviated by increasing the concentration of
the exogenously supplied IL 2.

As opposed to affecting the actual expression of p55, another possible
mechanism to explain the reduction in p55 observed by M A B binding and F A C S
analysis is that fraction 4 interferes with the formation of high affinity IL 2R by
binding directly to p55, while still leaving p70 free to respond to IL 2 if levels are
sufficiently high. Such an explanation for the observed inhibition of anti C D 25 M A B
binding is feasible only if fraction 4 w a s not dislodged from p55 by the washing
protocol designed to remove endogenous IL 2 and presumably other potential IL 2Rbound proteins prior to M A B staining. Control experiments (Figure 24) suggested that
the washing protocol was'efficient in dislodging IL 2 prior to M A B binding. However,
if M A B binding were blocked by fraction 4, this observation could be extended to
suggest that fraction 4 binds more strongly to p55 than IL 2 and that in a competitive
binding situation, fraction 4 would have the advantage.

Measurement of p55 mRNA levels in fraction 4-treated T cells would be
necessary to ascertain if fraction 4 w a s inhibiting p55 expression or merely its
potential to bind IL 2. Irrespective of the exact m o d e of action on p55, the c o m m o n
feature in both these models is that the p70 component of the IL 2R remains

unaffected and that T cells retain the capacity to respond to IL 2, even though a higher
IL 2 concentration is required and the magnitude of the response is decreased. Oashi
et al (1989) report that while p55 and p70 are differentially expressed in resting
peripheral blood T cells, high levels of both sub-units are induceable upon P H A
activation. They propose that the mechanisms of induction of p55 and p70 are
different, and Bich Thuy et al (1987) state that the two sub units of the IL 2 R are
independently synthesized, transported and expressed on the cell surface. It is
therefore possible to envisage a mechanism whereby induction of one component is
suppressed while expression of the other remains unaffected. Both Bich Thuy et al
(1987) and Yagita et al (1989) have reported that resting C D 8 cells, which express
p70 constitutively, can be directly activated by high concentrations of IL 2 through
binding to p70 alone. The proposal is that because p70 alone has the capacity to
transduce intracellular signals, T cells that are only expressing p70 have the
potential to proliferate but, because of the intermediate binding affinity of p70, the IL
2 concentration must be higher than that required for stimulation of the p70-p55 high
affinity IL 2 R complex. This mechanism would explain the high exogenous IL 2
requirement demonstrated in the present study for induction of proliferation in
fraction-4 treated murine and h u m a n T cells. It m a y also help to explain the earlier
observation (Table 19) that although suppressive supernatants inhibited the
thymocyte response to both P H A and IL 2 and P H A and IL 1, thymocytes cultured with
P H A and IL 2 achieved a level of proliferation at least equivalent to that of control
cells cultured with P H A alone. Experiments showing that resting thymocytes were
resistant to the effect of suppressive supernatants (Table 22) are also compatible
with the proposal that the locus of inhibitor action (p55 expression or postexpression binding potential) is related to events associated with T cell activation.

In initial thymocyte assays, thymocytes primed for 24 h with IL 1 remained
sensitive to inhibition (Table 21) and in time course assays suppressive supernatants
remained active w h e n added as late as 24 h after induction of stimulation (Table 20;

Figures 15 & 16). Pockley et al (1989) report that in mitogen stimulated T cells, the
level of IL 2 production peaks at 24 h while IL 2 R expression only peaks at 48-72 h.
Collectively, this data is compatible with results obtained in this study where
suppression of p55 expression w a s still observed in T cells exposed to factor 4, 24 h
after initial P H A activation.

Gullberg et al (1987) state that there are 10 to 30 times more Tac (p55)
receptors on activated T cells than functional high affinity receptors. Thus, changes
in expression of the p55 sub-unit m a y not necessarily reflect functional alterations.
Similarly, Caillat-Zucman et al (1989) report that although 7 0 % inhibition of p55
expression can be achieved by cyclosporin treatment, the levels of the high affinity IL
2R are unaffected, suggesting that the remaining p55 is sufficient to associate with
p70 for functional IL 2 R expression. These reports both suggest that a decrease in
p55 and a decrease in IL 2 responsiveness should not be automatically correlated. As
further evidence of a lack of correlation between p55 expression and IL 2
responsiveness, Debatin et al (1989) have shown that malignant T cells from patients
with adult T cell leukaemia express higher levels of p55 after P H A induction than
control cells, but that they do not bind IL 2. Despite these reports, it is thought that
the depression of p55 seen in the present study would be severe enough to
compromise formation of high affinity IL 2R, even in the presence of normal levels of
p70.

As a further note of caution, there are reports that demonstrate inhibitors of
IL 2 production or responsiveness in normal h u m a n serum. Friemel et al (1987) for
example describe an 80 kDa activity that inhibits thymocyte IL 2 R expression, while
Fukushima et al (1987) describe a 70-220 kDa activity that affects C T L L IL 2
responsiveness. In the present study, 130-180 and 75-100 kDa fractions of culture
medium (containing 5 % h u m a n serum) were routinely included as controls when
testing the inhibitory potential of factor 2 and factor 4 respectively (Tables 28a,

242
28b, 29, 30, 34a, 34b & 34c). Hence it was conclusively demonstrated that the
suppressive influences recorded were not due to a non-specific contribution from
putative serum derived inhibitors.

A number of workers have implicated monocytes as the cell type responsible
for the decreased mitogen- and antigen-responsiveness of T cells in mixed populations
of peripheral blood mononuclear leukocytes (PBML) from C M V mononucleosis patients
(Carney et al 1981, 1983, Levin 1979, Rinaldo 1977, 1980). A similar suppressive
role for monocytes in mediating the reduced T cell reponsiveness that follows in vitro
infection of P B M L w a s proposed (Rice et al 1984 & Wahren et al 1986). The
suppressive role of the monocyte w a s confirmed by the demonstration (Carney and
Hirsch 1981 & Schrier et al 1986) that monocytes separately infected with H C M V
are suppressive for the proliferative response of normal autologous T cells. It is also
possible that the suppression of lymphocyte function reported by Kapasi and Rice
(1988), following direct infection of separated lymphocyte populations, may in fact
have been due to an influence supplied by a small population of contaminating
monocytes. It is possible that one of the mechanisms of monocyte-mediated
suppression is via the production of soluble monocyte factors with the capacity to
reduce T cell mitogen and/or antigen responsiveness, such as those described in the
present study

A virus-specific monocyte defect has also been implicated (Kapasi and Rice
1986, Rice et al 1984 & Schrier et al 1986) in the reduced cytotoxic T cell (CTC) and
natural killer cell (NK) activity associated with H C M V infection of peripheral blood T
cells. It has been shown that CD8-positive T cells and N K cells constitutively express
p70 (Phillips et al 1989 & Yagita et al 1989) and Phillips et al (1989) and Tvede et al
(1989) have further proposed that binding of IL 2 to p70 on N K and T cells induces p55
and subsequent complexing of sub-units for formation of high affinity receptors. A
possible mechanism whereby an HCMV-specific monocyte defect m a y reduce C T C and
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N K activity could be related to observations m a d e in the present study. If a population
of peripheral blood mononuclear cells is H C M V challenged, virus-specific monocytederived suppressor factors such as the one described here m a y have the capacity to
prevent induction of high affinity IL 2 R on C T C and N K cells through an effect on p55
expression or binding capacity, thus leading to decreased clonal expansion and a
reduced measure of C T C and N K activity.

The capacity of HCMV to influence p55 expression may be a mechanism
whereby H C M V is able to establish a persistent infection. Persistent viruses evolve
mechanisms that allow evasion of host surveillance systems; consequently the host
immune response is ineffective at recognizing or clearing virus and/or virusinfected cells. The action of C T C is central to clearing of virus infections. In the
HCMV-infected host, it is possible that virus-specific C T C , like virus-specific
antibody, m a y be m a d e but in s o m e way suppressed so that they are unable to detect
and clear infection. It is proposed that fraction 4 produced from virus-challenged
monocytes m a y serve to restrict the clonal expansion of HCMV-specific C T C through
downregulation of the p55 component of the IL 2R. Under normal circumstances, p55
would be induced via an M H C Class 1-restricted interaction between viral antigen on
A P C or virally infected cells and precursor C T C . This induced p55 would complex
with constitutively produced p70 for formation of the high affinity receptor and
consequent attainment of IL 2 responsiveness. Although this viral strategy m a y have
evolved for the selective suppression of H C M V - C T C generation, it can be envisaged
that such a mechanism has the potential to be generally immunosuppressive.

The existence of a mechanism involving soluble suppressor factors produced
by one cell type with the potential to affect another cell type could help to explain
why the aforementioned studies and others (Carney and Hirsch 1981, Dudding and
Garnett 1987 & Turtinen et al 1989) report a marked influence of H C M V on the
functional ability of a cell population while only a small percentage of cells express
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detectable viral antigen. It is possible that current detection systems do not
adequately predict the full extent of the virus interaction, but it has also been
suggested (Kapasi and Rice 1988) that H C M V infection of a small proportion of
peripheral blood mononuclear cells m a y directly affect the function of uninfected
cells.

In the present study too, despite using centrifugal infection techniques
(Hudson 1988) in an attempt to enhance the virus-monocyte interaction, no more than
1 2 % of a virus-challenged monocyte population stained positive for virus-specific
antigen (Table 35). However, the drop in the percentage of H L A DR-positive cells
seen after virus challenge is greater than can be attributable purely to direct
infection of susceptible cells. Evidence to date suggests that a low percentage of ceils
are infected. This implies that a small proportion of infected cells must be able to
exert an influence that :

1) downregulates HLA DR expression in adjacent uninfected cells, as well as
rendering them refractory to a DR-inducing stimulus. A factor that m a y be involved
in this mechanism is IFN a/3. The net result of a virus-induced decrease in H L A - D R
expression in uninfected cells would be that a large proportion of the local cell
population would be unable to initiate efficient monocyte-T cell contacts or partake in
the subsequent bi-directional interaction pathways that would lead ultimately to an
effector T cell response.

2) causes an increase in the IL 1 and TNF a activity in challenged cell
supernatants as a whole. This implies that infected cells would have to exert an
effect on adjacent uninfected cells in the challenged cell population, allowing for
cytokine upregulation from the general population. It m a y be that T N F a is produced
from infected cells only, and can then upregulate IL 1 (and T N F a) production by the

entire cell population. Alternatively, H C M V m a y directly affect the IL 1 response as
well.

3) induces production from virus-challenged monocytes of factors that are
suppressive for thymocyte and T cell proliferation. The possibility exists that such
factors are not only produced by monocytes directly infected with H C M V , but also by
uninfected monocytes in response to signals from infected monocytes in the same
challenged population. In the present study, exogenously added IL 1 appeared to
reduce endogenous IL 1 production, but no evidence was obtained for induction of the
suppressive factors produced in the virus-challenged monocyte system. Thus,
although IL 1 is enhanced with H C M V infection, it does not appear that it is a candidate
cytokine for induction of T cell suppressive factors from a monocyte population as a
whole. Future studies should evaluate the potential of exogenous T N F a to function as
a candidate for suppressor factor induction.

Whether production of suppressive factors occurs from uninfected monocytes
in response to signals from infected monocytes in the s a m e microenvironment
remains to be elucidated. A mechanism such as this would allow a suppressive
influence that w a s originally virus-induced to be secondarily mediated by a wider
range of cells than those directly infected. Such an influence could thus conceiveably
contribute to the immunological disturbances that characterize H C M V infection. In
primary H C M V infections such disturbances are generally localized, but as infection
progresses a more generalized immunosuppression becomes evident. Virus-induced
factors with the capacity to secondarily induce production of suppressive influences
from a broader cell range m a y contribute to the development of generalized
immunosuppression. The production of IFN 3 and possibly other cytokines by
productively infected cells such as endothelial cells m a y exacerbate this
immunosuppression.

5.0.0. GENERAL CONCLUSIONS

Challenge of peripheral blood monocytes with H C M V depresses their ability to
support antigen-specific T cell proliferation via an influence on the surface expression
of HLA-DR. T h e functional capacity of the antigen-presenting cell is further
compromised through a reduced ability to respond to T cell factors necessary for the
development of local amplification circuits. With time after virus challenge, the
accessory cell m a y also b e c o m e actively suppressive toward the contacted T cell
through the inappropriate upregulation of normal homeostatic mechanisms or the
induction of virus-specific suppressor factors.

As well as inhibiting antigen-specific T cell proliferation, suppressor factors
elaborated by HCMV-challenged monocytes have the capacity to suppress both the T
cell response induced by mitogen and that additionally augmented by cytokine
stimulation. Elevated levels of suppressor factors m a y thus have a more general
effect on cell-mediated immunity, influencing even the activation and/or clonal
expansion of T cells that are not in direct contact with affected monocytes.

HCMV challenge of peripheral blood monocytes elevates secretion of IL 1 and
T N F a under conditions of L P S stimulus and in the absence of such a specifically
applied stimulus. Because IL 1 and T N F a are potent mediators of the inflammatory
response, this m a y have important immunopathological consequences in vivo.

Monocyte-derived HCMV-induced suppressor factors act at the level of T cell
IL 2 responsiveness. This is associated with a decrease in the surface expression of
the a chain (Tac/p55 component) of the high affinity IL 2R. The degree of IL 2
unresponsiveness can be partly relieved by increasing the IL 2 dose and it is proposed
that this is due to retention of the ability of T cells to respond to high levels of IL 2
through the 3 chain (p70 component) of the high affinity IL 2R, which can alone bind IL

2 with intermediate affinity and initiate signal transduction. If such a mechanism of
alleviating HCMV-induced immunosuppression were shown to be operational in vivo ,it
would only have therapeutic potential if the IL 2 dose required did not cause a
generalized toxicity.
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7.0.0 APPENDIX
Tissue

i)

Culture

Media.

RPMI 1640

R P M I powder

1 sachet

NaHC03

2g

HEPES

2.383g

Penicillin

0.06g

Streptomycin

0.1g

In 1 litre glass distilled water.
Adjust to p H 7.2. Filter sterilize.
ii) CMRL 1969
C M R L powder

1 sachet

NaHC03

1.75g

Penicillin

0.3g

Streptomycin

0.5g

In 5 litres glass distilled water.
Adjust to p H 7.2. Filter sterilize.
iii) Hanks balanced salt solution (HBSS)
(calcium and magnesium free)
For 10 X stock:
Solution A:

NaCI

20g

KCI

10

Solution C:

M a k e each up to 100ml with glass distilled water.
Autoclave and store A and C separately.

KH2PO4

0.12g

Na2HP04

0.12g

Glucose

2g

Phenol red

0.04g
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For workinn solution (1 X):

B

Solution A
Solution C

5ml
5 ml

Distilled water
NaHC03

90ml
0.47ml of a 7.5% solution.

Preparation of h u m a n

serum

( H C M V seronegative donors; blood group A B or O).

Collect 100ml blood into a glass container without anticoagulant and allow up to 4h at
room temperature for coagulation to occur.
Place at 4°C overnight for clot contraction.
Harvest serum and remove residual erythrocytes by centrifugation at 700g for 5 min.
Heat-inactivate serum at 56°C for 30 min, aliquot into 10 ml volumes and store at 20°C.

C Preparation of Con A-activated spleen cell supernatant (con A
sup).
Culture mouse (CBA) spleen cells in Linbro 12 well trays (2x106 cells/ml) with
2pg/ml con A (Sigma, St. Louis, M O ) at 37°C in 4 ml volumes of RPMI 1640
supplemented with 1 0 % FCS, 2 m M glutamine, 2 M E , 100U/ml penicillin and 100pg/ml
streptomycin.
Harvest supernatant after 5 days and centrifuge at 400g for 5 min to remove residual
cells. Filter through a 0.45 p m filter, aliquot into 10ml volumes and store at -20°C.
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D

Mycoplasma testing using:
i) ThR DAPI stain
Grow cells to be tested on coverslips and wash with P B S prior to staining.

Incubate with a 1:50 dilution of DAPI solution in methanol for 15 min at 37°C. W a s h
cells with methanol, mount and view under a fluorescence microscope.
Extracellular and extranuclear fluorescence generally indicates the presence of
mycoplasma contamination.
If cells cannot be grown on coverslips they are cytospun onto slides prior to staining.
ii) Mvcotrim T C flasks
Aseptically inoculate the agar surface of a Mycotim T C flask allowing the
sample to flow down the agar and into the broth.
Incubate flasks agar-side up at 37°C for 4-7 days or until a colour change indicates a
possible positive result.
If a negative result is obtained, re-inoculate the agar by allowing the original broth to
wash over one half of the agar surface and reincubate as before.
Presumptive positives are confirmed by staining the agar with Dienes stain (Dienes
1960) for 30 min. Mycoplasma colonies stain deep blue.

E Preparation of nylon wool

Boil nylon wool in distilled water for 10 min and soak in 0.2N HCI overnight. Rinse in
distilled water and repeat boiling procedure 4 times with the final two washes being in
glass distilled water. Drain wool and allow to dry in a 37°C incubator or a laminar
flow hood. Weigh out the appropriate amount of nylon wool (using 0.5g for each 1 0 8
cells) and tease the strands apart using forceps until the wool is loosely connected and
free of knots or clumps. Pack wool loosely into a syringe (to the 6ml mark of a 10ml
syringe for 0.5g of wool) and autoclave sterilize.
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F.

IL 13 ELISA Assay
All reagents supplied by Cistron Biotechnology.

a) Add duplicate test samples, relevant controls and standards in 100pl volumes to
microtitration wells precoated with M A B specific for IL 13 and incubate at 37oC for
2h.
b) W a s h wells 3 times with wash buffer (PBS with 0.1% Triton X-100 and 0.02%
thimerosal)
c) Add 100pl rabbit IL 13 antiserum /well and incubate at 37°C for 2h.
d) W a s h as before and add 100pl anti-rabbit IgG - horse radish peroxidase (HRP)
conjugate to each well. Incubate at room temperature for 30 min.
e) W a s h as before and add 100pl freshly prepared substrate (o-Phenylenediamine and
hydrogen peroxide) to each well. Incubate the wells uncovered at room temperature
for 15 min. Add 50pl of 4N sulphuric acid to each well and read the O D 4go of each
well within 15 min of assay completion.
f) Calculate the average O D 4 9 0 for each set of duplicate wells, subtract the reading
obtained for non-specific binding controls and determine the amount of IL 13 in each
test sample by reference to the standard curve.

G Reagents for TNF a assay.

i) PBS: Dulbecco 'A' formulation; pH 7.0.
ii)

Stain:

0.5g crystal violet in 20 ml methanol and 80 ml H2O.

iii)

Elutant:

33 ml glacial acetic acid and 67 ml H2O

H Buffers for immunofluorescent staining

i) Fr.r fluorescence microscopy:
P B S (Dulbecco 'A' formulation) + 2 % B S A + 0.1% NaN 3 .
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ii) For flow cytometry:
P B S (Dulbecco 'A') + 0.5% B S A + 0.02% NaN 3 .
For blocking buffer, 1 0 % A B serum is included.

I

Paraformaldehyde

(2%)

Dissolve 2g paraformaldehyde in 100ml PBS (Dulbecco 'A'). Heat to between 70 °C
and 90 °C in a fume hood, adding 200 pi 10M N a O H to assist in dissolving. Cool, filter
and adjust to pH 7.4. Store for no longer than 2 weeks at 4°C in the dark.

J Preparation of endothelial cells

Process cord within an hour of collection. Flush vein with sterile PBS to remove
residual blood. Fill vein with collagenase (0.2%) and incubate at 37°C for 10-15 min.
Collect collagenase solution into a 50 ml centrifuge and flush with P B S into the same
centrifuge tube. Sediment cells at 250g for 5 min. Resuspend cells in endothelial
growth medium (see below) and seed onto gelatin-coated flasks. Incubate cells at
37°C in a 5 % C O 2 atmosphere.
Endothelial cell (EC) growth medium.
M 199 medium 69.55 ml
Glutamine (2 m M )
F C S (heat inactivated)

1 ml
25 ml

HEPES(25mM)
Penicillin

2.5 ml
0.006g

Streptomycin
Heparin

0.01 g
1 ml of 100x stock (100 pg/ml final)

E C growth factor

1 ml of 100X stock (100 pg/ml final)
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K.

Plaque assay for H C M V

titration

The following modification of the plaque assay method derived by Wentworth
and French (1970) was used:
a) Seed fibroblasts into 24 well trays (Flow) and, when confluent, infect cells with
200 pi aliquots of virus suitably diluted in growth medium (serum free C M R L 1969
supplemented as described in methods (section 2.2).
b) Centrifuge trays at 500g for 20 min to centrifugally enhance the infection. After a
further 60 min passive adsorbtion period at 37°C, remove virus inoculum and replace
with agarose (0.33% in C M R L containing 2 % FCS) and incubate at 37°C.
c) O n e week post-infection add further agarose and re-incubate.
d) W h e n foci of infection (plaques) are optimally observed by microscopic examination
of fibroblast monolayers (2-3 weeks post infection), fix and stain cell monolayer (Dip
Quick staining kit; Histo Labs, North Rocks N S W ) and enumerate plaques. Cells can
alternatively be stained with 1 % Gentian Violet solution or 1 % Neutral Red.

L Absorbance (280nm) profiles of monocyte supernatant fractions.

The A280 profiles of fractions (8ml/fraction) of monocyte supernatants (1
ml volumes) generated from LPS-stimulated (20 pg/ml), mock-and H C M V (p72; moi
10:1)-challenged monocytes (0-48, 48-96 and 96-144 h after initiation of culture)
and eluted from a Sephacryl S-200 H R column (90 x 1.5 cm; flow rate 8 ml/h) with
Tris-HCI buffer (as described in detail in section 2.4) are shown. Also shown is the
A280 profile of the corresponding medium only control. Void volume (V 0 ), total
volume (Vt) and the position of molecular weight standards: blue dextran 2000
(void), bovine serum albumin (67 kDa) and ribonuclease A (13.7 kDa) are indicated on
the medium only control profile. The relative positions of fractions with potential
biological suppressive activity (Fraction 2 and Fraction 4) are indicated on the
monocyte supernatant profiles.
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Elution profile of medium only control
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